
<link rel="stylesheet" href="https://api.manicmarket.com/static/annual-report/css/custom-bootstrap.css">
<link rel="stylesheet" href="https://api.manicmarket.com/static/annual-report/css/all.min.css">
<link rel="stylesheet" href="https://api.manicmarket.com/static/annual-report/css/app.css">
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/jquery-3.3.1.slim.min.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/popper.min.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/bootstrap.min.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/moment.js"></script>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/vanilla-picker.min.js"></script>
<style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style>
<script type="text/javascript" src="https://api.manicmarket.com/static/annual-report/js/he.js"></script>
<script type="text/javascript" defer="true" src="https://api.manicmarket.com/static/annual-report/js/production.min.js?d=22-10-2021"></script>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style>

 <div class="reboot main-container">
  <div class="reboot d-none" id="back-to-top">
  </div>
  <div class="position-relative" id="dynamic-xbrl-form">
   <!--?xml version="1.0" encoding="US-ASCII"?-->
   <!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
   <!-- Created: Tue Mar 30 13:44:32 EDT 2021 -->
   <title>
   </title>
   <meta content="text/html" http-equiv="Content-Type"/>
   <div style="font: 10pt Times New Roman, Times, Serif">
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="width: 100%">
     <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       UNITEDSTATES
       <br/>
       SECURITIES AND EXCHANGE COMMISSION
       <br/>
       WASHINGTON, DC 20549
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin: 3pt auto; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">
      FORM
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-0" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentType" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        10-K
       </ix:nonnumeric>
      </span>
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <span>
      <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:boolballotbox" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentAnnualReport" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <span style="font: 10pt Times New Roman, Times, Serif">
        ☒
       </span>
      </ix:nonnumeric>
     </span>
     <span style="font: 10pt Times New Roman, Times, Serif">
      <b>
       ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Forthe fiscal year ended:
      <b>
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayyearen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-2" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentPeriodEndDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         <span style="text-decoration:underline">
          <span>
           <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:datemonthdayen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-3" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:CurrentFiscalYearEndDate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            December 31
           </ix:nonnumeric>
          </span>
          ,
          <span>
           <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-4" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentFiscalYearFocus" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            2020
           </ix:nonnumeric>
          </span>
         </span>
        </ix:nonnumeric>
       </span>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OR
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <span>
      <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:boolballotbox" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-5" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentTransitionReport" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       ☐
      </ix:nonnumeric>
     </span>
     <span style="font: 10pt Times New Roman, Times, Serif">
      <b>
       TRANSITIONREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Forthe transition period from ______________________ to ______________________
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Commissionfile number:
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-6" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityFileNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <span style="text-decoration:underline">
         001-34673
        </span>
       </ix:nonnumeric>
      </span>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span>
      <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-7" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityRegistrantName" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 14pt">
        <b>
         <span style="text-decoration:underline">
          CORMEDIXINC.
         </span>
        </b>
       </span>
      </ix:nonnumeric>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font: 10pt Times New Roman, Times, Serif">
      (Exact name of Registrant as Specified in Its Charter)
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span>
          <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:stateprovnameen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-8" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityIncorporationStateCountryCode" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            Delaware
           </span>
          </ix:nonnumeric>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span>
          <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-9" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityTaxIdentificationNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            20-5894890
           </span>
          </ix:nonnumeric>
         </span>
        </p>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (State or Other Jurisdiction of
         <br/>
         Incorporation or Organization)
        </span>
       </td>
       <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (I.R.S. Employer
         <br/>
         Identification No.)
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif">
       <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 49%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <span>
           <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-10" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressAddressLine1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            300Connell Drive
           </ix:nonnumeric>
          </span>
          ,
          <span>
           <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-11" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressAddressLine2" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            Suite 4200
           </ix:nonnumeric>
          </span>
          ,
          <span>
           <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-12" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressCityOrTown" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            Berkeley Heights
           </ix:nonnumeric>
          </span>
          ,
          <span>
           <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-13" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressStateOrProvince" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            NJ
           </ix:nonnumeric>
          </span>
         </span>
        </p>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom; width: 49%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span>
          <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-14" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityAddressPostalZipCode" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            <b>
             07922
            </b>
           </span>
          </ix:nonnumeric>
         </span>
        </p>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif">
       <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (Address of Principal Executive Offices)
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (Zip Code)
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Registrant’stelephone number, including area code:
      <span style="text-decoration:underline">
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-15" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:CityAreaCode" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         (908)
        </ix:nonnumeric>
       </span>
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-16" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:LocalPhoneNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         517-9500
        </ix:nonnumeric>
       </span>
      </span>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Securitiesregistered pursuant to Section 12(b) of the Act:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Titleof each class
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          TradingSymbol
         </span>
        </p>
       </td>
       <td style="text-align: center; width: 2%; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Nameof each exchange on which registered
         </span>
        </p>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <span>
         <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-17" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:Security12bTitle" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
           Common Stock, $0.001 Par Value
          </span>
         </ix:nonnumeric>
        </span>
       </td>
       <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <span>
         <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-18" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:TradingSymbol" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
           CRMD
          </span>
         </ix:nonnumeric>
        </span>
       </td>
       <td style="text-align: center; vertical-align: top">
       </td>
       <td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">
        <span>
         <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:exchnameen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-19" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:SecurityExchangeName" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
           Nasdaq Global Market
          </span>
         </ix:nonnumeric>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Securitiesregistered pursuant to Section 12(g) of the Act: none
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Yes☐
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-20" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityWellKnownSeasonedIssuer" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        No
       </ix:nonnumeric>
      </span>
      ☒
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Yes☐
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-21" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityVoluntaryFilers" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        No
       </ix:nonnumeric>
      </span>
      ☒
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Indicateby check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-22" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityCurrentReportingStatus" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        Yes
       </ix:nonnumeric>
      </span>
      ☒   No ☐
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-23" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityInteractiveDataCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        Yes
       </ix:nonnumeric>
      </span>
      ☒   No ☐
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%; white-space: nowrap">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Large accelerated filer
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%; white-space: nowrap">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ☐
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%; white-space: nowrap">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Accelerated filer
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 25%; white-space: nowrap">
        ☐
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <span>
          <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:entityfilercategoryen" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-24" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityFilerCategory" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
           Non-accelerated filer
          </ix:nonnumeric>
         </span>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
        ☒
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Smaller reporting company
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
        <span>
         <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:boolballotbox" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-25" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntitySmallBusiness" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
           ☒
          </span>
         </ix:nonnumeric>
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
        Emerging growth company
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
        <span>
         <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:boolballotbox" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-26" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityEmergingGrowthCompany" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          ☐
         </ix:nonnumeric>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any news or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Indicateby check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report. ☐
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Yes☐
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt:booleanfalse" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-27" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityShellCompany" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        No
       </ix:nonnumeric>
      </span>
      ☒
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theaggregate market value of the registrant’s voting common equity held by non-affiliates of the registrant, based upon theclosing price of the registrant’s common stock on the last business day of the registrant’s most recently completedsecond fiscal quarter was approximately $
      <span style="-sec-ix-hidden: hidden-fact-0">
       <span>
        <ix:nonfraction contextref="c2" continued-taxonomy="false" data-original-id="hidden-fact-0" decimals="0" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-28" inside-table="false" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="dei:EntityPublicFloat" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd">
         208.4
        </ix:nonfraction>
       </span>
      </span>
      million. Solely for the purpose of this calculation, shares held by directors andexecutive officers of the registrant have been excluded.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     The number of outstanding shares of theregistrant’s common stock was
     <span>
      <ix:nonfraction contextref="c1" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-29" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="dei:EntityCommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
       38,024,194
      </ix:nonfraction>
     </span>
     as of March 25, 2021.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      DOCUMENTSINCORPORATED BY REFERENCE
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      None
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="width: 100%">
     <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 1 -->
    <div>
    </div>
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
     </p>
    </div>
    <div>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       CORMEDIXINC.
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_001" tabindex="18">
          PART    I
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         1
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 9%; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_002" tabindex="18">
          Item    1.
         </a>
        </span>
       </td>
       <td style="width: 1%; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_002" tabindex="18">
          Business
         </a>
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         1
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_003" tabindex="18">
          Item    1A.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_003" tabindex="18">
          Risk    Factors
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         17
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_004" tabindex="18">
          Item    1B.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_004" tabindex="18">
          Unresolved    Staff Comments
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         44
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_005" tabindex="18">
          Item    2.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_005" tabindex="18">
          Properties
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         44
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_006" tabindex="18">
          Item    3.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_006" tabindex="18">
          Legal    Proceedings
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         44
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_007" tabindex="18">
          Item    4.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_007" tabindex="18">
          Mine    Safety Disclosures
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         45
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_008" tabindex="18">
          PART    II
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         46
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_009" tabindex="18">
          Item    5.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_009" tabindex="18">
          Market    for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         46
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_010" tabindex="18">
          Item    6.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_010" tabindex="18">
          Selected    Financial Data
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         46
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_011" tabindex="18">
          Item    7.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_011" tabindex="18">
          Management’s    Discussion and Analysis of Financial Condition and Results of Operations
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         47
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_012" tabindex="18">
          Item    7A.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_012" tabindex="18">
          Quantitative    and Qualitative Disclosures About Market Risk
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         56
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_013" tabindex="18">
          Item    8.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_013" tabindex="18">
          Financial    Statements and Supplementary Data
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         56
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_014" tabindex="18">
          Item    9.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_014" tabindex="18">
          Changes    in and Disagreements With Accountants on Accounting and Financial Disclosure
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         57
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_015" tabindex="18">
          Item    9A.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_015" tabindex="18">
          Controls    and Procedures
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         57
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_016" tabindex="18">
          Item    9B.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_016" tabindex="18">
          Other    Information
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         57
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_017" tabindex="18">
          PART    III
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         58
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_018" tabindex="18">
          Item    10.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_018" tabindex="18">
          Directors,    Executive Officers, and Corporate Governance
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         58
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_019" tabindex="18">
          Item    11.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_019" tabindex="18">
          Executive    Compensation
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         63
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_020" tabindex="18">
          Item    12.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_020" tabindex="18">
          Security    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         73
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_021" tabindex="18">
          Item    13.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_021" tabindex="18">
          Certain    Relationships and Related Transactions and Director Independence
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         76
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_022" tabindex="18">
          Item    14.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_022" tabindex="18">
          Principal    Accounting Fees and Services
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         77
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_023" tabindex="18">
          PART    IV
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         78
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_024" tabindex="18">
          Item    15.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_024" tabindex="18">
          Exhibits,    Financial Statement Schedules
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         78
        </span>
       </td>
      </tr>
      <tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; ">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_025" tabindex="18">
          Item    16.
         </a>
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="padding-left: 0.125in; text-indent: -0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#a_025" tabindex="18">
          Form    10-K Summary
         </a>
        </span>
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif">
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         80
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      DefenCath™is our registered trademark. All other trade names, trademarks and service marks appearing in this report are the property oftheir respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, suchterms, when first mentioned in this report, appear with the trade name, trademark or service mark notice and then throughout theremainder of this report without trade name, trademark or service mark notices for convenience only and should not be construedas being used in a descriptive or generic sense.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
      <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->
      i
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <div>
     <a id="a_001">
     </a>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      PARTI
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Forward-LookingStatements
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thisreport contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that,if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied bysuch forward-looking statements. The statements contained in this report that are not purely historical are forward-lookingstatements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-lookingstatements are often identified by the use of words such as, but not limited to, “anticipate,”“believe,” “can,” “continue,” “could,” “estimate,”“expect,” “intend,” “may,” “will,” “plan,” “project,”“seek,” “should,” “target,” “will,” “would,” and similarexpressions or variations intended to identify forward-looking statements. These statements are based on the beliefs andassumptions of our management based on information currently available to management. Such forward-looking statements aresubject to risks, uncertainties and other important factors that could cause actual results and the timing of certain eventsto differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause orcontribute to such differences include, but are not limited to, those identified below in the section titled “Item 1A.Risk Factors.” The impact of COVID-19 may also exacerbate these risks, any of which could have a material effect on us.Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, weundertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of suchstatements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_002">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                                         1.
         </b>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Business
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Overview
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weare a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatmentof infectious and inflammatory diseases.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourprimary focus is on the development of our lead product candidate, DefenCath
      <sup>
       ™
      </sup>
      , for potential commercializationin the United States, or U.S., and other key markets. We have in-licensed the worldwide rights to develop and commercialize DefenCathand Neutrolin
      <sup>
       ®
      </sup>
      . The name DefenCath is the U.S. proprietary name conditionally approved by the U.S. Food and DrugAdministration (“FDA”). The name Neutrolin is currently used in the European Union (“EU”) and other territorieswhere the Company has received CE-Mark approval for the commercial distribution of Neutrolin as a catheter lock solution (“CLS”)regulated as a medical device.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     DefenCath is a novelanti-infective solution (a formulation of taurolidine 1.35% and heparin 1000 USP U/ml) intended for the reduction of catheter-relatedinfections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutritionand oncology. Infections represent key complications among hemodialysis, total parenteral nutrition and cancer patients with centralvenous catheters. These complications can lead to treatment delays and increased costs to the healthcare system when they occurdue to hospitalizations, need for intravenous, or IV, antibiotic treatment, removal/replacement of the central venous catheter(“CVC”), related treatment costs and increased mortality. We believe DefenCath addresses a significant unmet medicalneed and a potential large market opportunity.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <span style="text-decoration:underline">
       DefenCath– United States
      </span>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inlate 2013, we met with the FDA, to determine the pathway for U.S. marketing approval of DefenCath. We launched the Phase 3 clinicaltrial in patients with hemodialysis catheters in the U.S. in December 2015. The clinical trial, named Phase 3 Prospective, Multicenter,Double-blind, Randomized, Active Control Study to Demonstrate Safety and Effectiveness of DefenCath in Preventing Catheter-relatedBloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease, or LOCK-IT-100, was a prospective, multicenter,randomized, double-blind, active control trial which aimed to demonstrate the efficacy and safety of DefenCath in preventing catheter-relatedbloodstream infections, or CRBSI, in subjects receiving hemodialysis therapy as treatment for end stage renal disease. The primaryendpoint for the trial was time to CRBSI. The trial evaluated DefenCath relative to the active control heparin by documentingthe incidence of CRBSI and the time until the occurrence of CRBSI for each study subject. Secondary endpoints were catheter patency,which was defined as required use of tissue plasminogen activating factor, or tPA, or removal of catheter due to dysfunction,and removal of catheter for any reason.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      1
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Duringthe course of the study, in consultation with the FDA, we established the Clinical Adjudication Committee, or CAC, to criticallyand independently assess CRBSI while being blinded to treatment assignment. As announced in July 2018, the CAC reviewed potentialcases of CRBSI in our LOCK-IT-100 study that occurred through early December 2017 and identified 28 such cases. As previouslyagreed with the FDA, an interim efficacy analysis was performed when the first 28 CRBSIs were identified. On July 25, 2018, weannounced that the independent Data Safety Monitoring Board, or DSMB, had completed its review of the interim analysis of thedata from the LOCK-IT-100 study. Based on the first 28 cases, there was a highly statistically significant 72% reduction in CRBSIrelative to the control (p=0.0034). Because the pre-specified level of statistical significance was reached for the primary endpointand efficacy had been demonstrated with no safety concerns, the DSMB recommended the study be terminated early.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Followingdiscussions with the FDA, we proceeded with an orderly termination of LOCK-IT-100. In late January 2019, we announced the toplineresults of the full data set of the LOCK-IT-100 study. The study continued enrolling and treating subjects until study termination,and the final efficacy analysis was based on a total of 795 subjects.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theprimary endpoint of the Phase 3 LOCK-IT-100 study was the reduction of the risk of occurrence of CRBSI by DefenCath relative tothe active control of heparin. In the analysis of the full data set, a total of 41 CRBSI events were determined by the CAC. Therewas a 71% reduction in the risk of occurrence of CRBSIs compared with the active control of heparin, which was well in excessof the study’s assumed treatment effect size of a 55% reduction. In the DefenCath arm, the CRBSI event rate was 0.13 per1000 catheter days, which is significantly lower than the event rate of 0.46 per 1000 catheter days in the control arm. The statisticalsignificance of the primary endpoint in the full data set (p=0.0006) was even more impressive than that of the interim analysis(p=0.0034).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Therewere no statistically significant differences between the results in the DefenCath arm compared with the control arm in the finalanalysis for the secondary endpoints. The event rate for one of the secondary endpoints, catheter removal for any reason, was3.48 per 1000 catheter-days (236 out of 397 subjects) in the DefenCath arm and 3.23 per 1000 catheter-days (225 out of 398 subjects)in the control arm (p=0.416). The loss of catheter patency, which was defined either as catheter removal due to loss of catheterpatency or the administration of tPA, was also a secondary endpoint. The event rate for loss of catheter patency was 0.99 per1000 catheter-days (63 out of 397 subjects) in the DefenCath arm and 0.74 per 1000 catheter-days (48 out of 398 subjects) in thecontrol arm (p=0.12). In the top-line safety analysis, the observed rate of treatment-emergent adverse events was lower in theDefenCath arm. The rate of adverse events per patient was 5.1 in the DefenCath arm and 5.8 in the control arm.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Althoughthe FDA usually requires two pivotal clinical trials to provide substantial evidence of safety and effectiveness for approvalof a New Drug Application, or NDA, the FDA will in some cases accept one adequate and well-controlled trial, where it is a largemulticenter trial with a broad range of subjects and investigation sites with procedures to include trial quality that has demonstrateda clinically meaningful and statistically very persuasive effect on prevention of a disease with potentially serious outcome.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In March 2020, webegan the modular submission process for the NDA for DefenCath for the prevention of CRBSI in hemodialysis patients, and inAugust 2020, the FDA accepted for filing the DefenCath NDA. The FDA also granted our request for priority review, whichprovides for a six-month review period instead of the standard ten-month review period. As we announced in March 2021, theFDA informed us that it will not approve the NDA for DefenCath in its present form. The FDA noted concerns at the third-partymanufacturing facility after a review of records requested by the FDA and provided by the manufacturing facility. We areworking with the manufacturing facility to develop plans for resolution of the deficiencies. Additionally, the FDA isrequiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vialsdespite an existing in-process control to demonstrate fill volume within specifications. We expect to be able to completethis requirement expeditiously. Satisfactory resolution of these issues is required for approval of the DefenCath NDA by apre-approval inspection and/or adequate manufacturing facility responses addressing these concerns. If an inspection isrequired, we may encounter delays in obtaining FDA approval because the FDA is currently facing a backlog due to the pandemicand is actively working to define an approach for scheduling outstanding inspections once safe travel may resume. We willrequest a meeting with the FDA, which we estimate will occur in mid-April, to obtain agreement with the FDA on the proposedresolutions of the deficiencies.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 4; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      2
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA did not request additional clinical data and did not identify any deficiencies related to the data submitted on the efficacyor safety of DefenCath from LOCK-IT-100. In draft labeling discussed with the FDA, the FDA added that the initial approval willbe for the limited population of patients with kidney failure receiving chronic hemodialysis through a central venous catheter.This is consistent with our request for approval pursuant to the Limited Population Pathway for Antibacterial and Antifungal Drugs,or LPAD. LPAD, passed as part of the 21
      <sup>
       st
      </sup>
      Century Cures Act, is a new program intended to expedite the developmentand approval of certain antibacterial and antifungal drugs to treat serious or life-threatening infections in limited populationsof patients with unmet needs. LPAD provides for a streamlined clinical development program involving smaller, shorter, or fewerclinical trials and is intended to encourage the development of safe and effective products that address unmet medical needs ofpatients with serious bacterial and fungal infections. We believe that LPAD will provide additional flexibility for the FDA toapprove DefenCath to reduce CRBSIs in the limited population of patients with kidney failure receiving hemodialysis through acentral venous catheter.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InJanuary 2015, the FDA granted Fast Track designation to DefenCath, a designation intended to facilitate development and expeditereview of drugs that treat serious and life-threatening conditions so that the approved drug can reach the market expeditiously.Also in January 2015, the FDA designated DefenCath as a Qualified Infectious Disease Product, or QIDP, for prevention of catheter-relatedblood stream infections in patients with end stage renal disease receiving hemodialysis through a central venous catheter. Catheter-relatedblood stream infections can be life-threatening. The QIDP designation provides five years of marketing exclusivity in additionto the five years granted for a New Chemical Entity upon approval of the NDA. We received a deferral from FDA for the requirementof submitting data in the NDA for use of DefenCath in pediatric hemodialysis patients as a catheter lock solution. When the pediatricstudy is completed as a post-approval commitment, DefenCath will be eligible for an additional six months of marketing exclusivity.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <span style="text-decoration:underline">
       Neutrolin– International
      </span>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe European Union, or EU, Neutrolin is regulated as a Class 3 medical device. In July 2013, we received CE Mark approval forNeutrolin. In December 2013, we commercially launched Neutrolin in Germany for the prevention of CRBSI, and maintenance of catheterpatency in hemodialysis patients using a tunneled, cuffed central venous catheter for vascular access. To date, Neutrolin is registeredand may be sold in certain European Union and Middle Eastern countries for such treatment.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InSeptember 2014, the TUV-SUD and The Medicines Evaluation Board of the Netherlands, or MEB, granted a label expansion for Neutrolinfor these same expanded indications for the EU. In December 2014, we received approval from the Hessian District President inGermany to expand the label to include use in oncology patients receiving chemotherapy, IV hydration and IV medications via centralvenous catheters. The expansion also adds patients receiving medication and IV fluids via central venous catheters in intensiveor critical care units (cardiac care unit, surgical care unit, neonatal critical care unit, and urgent care centers). An indicationfor use in total parenteral nutrition was also approved.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <span style="text-decoration:underline">
       AdditionalDevelopment Possibilities
      </span>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition to developing the use of taurolidine as a catheter lock solution, we are sponsoring a pre-clinical research collaborationfor the use of taurolidine as a possible treatment for rare pediatric tumors. In February 2018, the FDA granted orphan drug designationto taurolidine for the treatment of neuroblastoma in children. We may seek one or more strategic partners or other sources ofcapital to help us develop and commercialize taurolidine for the treatment of neuroblastoma in children. We are also evaluatingopportunities for the possible expansion of taurolidine as a platform compound for use in certain medical devices. Patent applicationshave been filed in several indications, including wound closure, surgical meshes, and wound management. Based on initial feasibilitywork, we are advancing pre-clinical studies for taurolidine-infused surgical meshes, suture materials and hydrogels. We will seekto establish development/commercial partnerships as these programs advance.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA regards taurolidine as a new chemical entity and therefore it is currently regulated as an unapproved new drug. We might inthe future pursue product candidates that would involve devices impregnated with taurolidine, and we believe that at the currenttime such products would be combination products subject to both device premarket submission requirements and drug regulations.Consequently, given that there is no appropriate predicate medical device currently marketed in the U.S. on which a 510(k) clearanceprocess could be based and that taurolidine is not yet approved in any application, we anticipate that we would be required tosubmit a premarket approval application, or PMA, for marketing authorization for any medical device indications that we may pursuefor devices containing taurolidine. In the event that an NDA for DefenCath is approved by the FDA, the regulatory pathway forthese medical device product candidates may be revisited with the FDA. Although there may be no appropriate predicate, de novoClass II designation can be proposed, based on a risk assessment and a reasonable assurance of safety and effectiveness.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 5; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      3
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">
      DefenCath
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       MarketOpportunity
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Central venous cathetersand peripherally inserted central catheters (“Central Catheters”) are an important and frequently used method for accessingthe vasculature in hemodialysis (a form of dialysis where the patient’s blood is circulated through a dialysis filter), administeringchemotherapy and basic fluids in cancer patients and for cancer chemotherapy, long term antibiotic therapy, total parenteral nutrition(complete or partial dietary support via intravenous nutrients).
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Accordingto the 2015 United States Renal Disease System, there were 660,000 patients on hemodialysis in the U.S. Hemodialysis NationalKidney Foundation has reported that patients requiring Central Catheters represent over 63 million catheter/dialysis treatmentdays per year. In 2019, the estimated number of patients with cancer is approximately 6 million, and between 25-60% require CentralCatheters, and represents about 136 million catheter days per year, based on market research by a third-party commissioned byus.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Oneof the major and common complications for all patients requiring CVCs is CRBSI and the clinical complications associated withthem. The total annual cost for treating CRBSI episodes and their related complications in the U.S. is up to $2.7 billion, withapproximately 250,000 CRBSI episodes per year (Becker’s Hospital Review).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Biofilmbuild up is the pathogenesis of both infections and thrombotic complications in central venous catheters. Prevention of CRBSIand inflammatory complications requires both removal of pathogens from the internal surface of the catheter to prevent the systemicdissemination of organisms contained within the biofilm as well as an anticoagulant to retain blood flow during dialysis. Biofilmforms when bacteria adhere to surfaces in aqueous environments and begin to excrete a slimy, glue-like substance that can anchorthem to various types of materials, including intravenous catheters. The presence of biofilm has many adverse effects, includingthe ability to release bacteria into the blood stream. The current standard of catheter care is to instill a heparin lock solutionat a concentration of 1000 u/mL into each catheter lumen immediately following treatment, in order to prevent clotting betweendialysis treatments. However, a heparin lock solution provides no protection from the risk of infection.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Currently, there areno pharmacologic agents approved in the U.S. for the prevention of CRBSI in CVCs. As noted above, we received the CE Mark approvalfor Neutrolin from the MEB of the EU in July 2013. We believe there is a significant need for prevention of CRBSI in the hemodialysispatient population as well as for other patient populations utilizing central venous catheters and peripherally inserted centralcatheters, such as oncology/chemotherapy, and total parenteral nutrition.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      DefenCathis a broad-spectrum antibacterial, antifungal and anticoagulant combination that is active against common microbes including antibiotic-resistantstrains and in addition may prevent biofilm formation. We believe that using DefenCath as an anti-infective solution will significantlyreduce the incidence of life-threatening catheter-related blood stream infections, thus reducing the need for local and systemicantibiotics while prolonging catheter function.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Initially, we expectto sell DefenCath in the U.S. primarily to key operators of dialysis centers. We anticipate that Medicare reimbursement could beavailable for DefenCath in hemodialysis and other catheter indications such as oncology patients and total parenteral nutritionpatients through relevant hospital inpatient diagnosis-related groups, or DRGs, or outpatient ambulatory payment classifications,or APCs, the End-Stage Renal Disease Prospective Payment System, or ESRD PPS, base payment, or under the Durable Medical Equipment,Prosthetics, Orthotics, and Supplies, or DMEPOS, Fee Schedule, depending on the setting of care. We also plan to seek separatereimbursement as a drug, where available under Medicare, through mechanisms such as pass-through status under the Hospital OutpatientProspective Payment System, the transitional drug add-on payment adjustment, or TDAPA, under the ESRD PPS, or reimbursement asa drug used with a DMEPOS infusion pump. We have engaged the U.S. Centers for Medicare &amp; Medicaid Services, or CMS, in preliminarydiscussions concerning the reimbursement for DefenCath under TDAPA, however, qualifications cannot be determined until after FDAapproval and CMS evaluates the request for coverage in a quarterly review. If approved under TDAPA, reimbursement of DefenCathwould be calculated based on its average selling price. To be eligible for TDAPA, a new renal drug or biologic must be:
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Approved                                         by FDA pursuant to Section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Commercially                                         available
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 6; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      4
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Assigned                                         a Healthcare Common Procedure Coding System code
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Identified                                         as having an end action effect that treats or manages a condition or conditions associated                                         with ESRD
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Identified                                         as not fitting into an established ESRD PPS functional category
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Designated                                         by CMS as a renal dialysis service.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Althoughwe cannot fully anticipate changes in reimbursement requirements and mechanisms in the coming years, we expect DefenCath wouldbe eligible for and would obtain TDAPA. DefenCath meets the criterion of being a new renal dialysis product used to treat or managea condition associated with ESRD, since infections are the second leading cause of death in patients with ESRD and CVCs are asignificant risk factor for infection-associated mortality.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Furthermore,we anticipate that the CMS, and private payers will increasingly demand that manufacturers demonstrate the cost effectivenessof their product as part of the reimbursement review and approval process. With this in mind, we are performing health economicevaluations to support this review in the context of the prospective use of DefenCath in dialysis, and other settings, such asoncology. Our studies may not be sufficient to support coverage or reimbursement at levels that allow providers to use DefenCath.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       CompetitiveLandscape
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thedrug and medical device industries are highly competitive and subject to rapid and significant technological change. DefenCath’scurrent and future competitors include large as well as specialty pharmaceutical and biotechnology companies. Many of our competitorshave substantially greater financial, technical and human resources than we do and significantly more experience in the developmentand commercialization of drugs and medical devices. Further, the development of new treatment methods could render DefenCath non-competitiveor obsolete.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We believe that thekey competitive factors that will affect the development and commercial success of DefenCath are efficacy and safety, as well aspricing and reimbursement. Given that there are no approved catheter lock solutions with antimicrobial properties in the U.S.,and that the current standard of care is heparin, we believe there is an opportunity for DefenCath to become the new standard ofcare as a CLS in the U.S. market, if approved by FDA. We are not aware of any potentially competitive CLS which are approved orunder development by other companies in the U.S. A development stage product from Citius is being studied for salvage of CVCs oncea patient becomes diagnosed with a catheter related blood stream infection.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In the EU, severalcatheter lock solutions have received a CE Mark, in addition to Neutrolin. For example, TauroLock contains a combination of citrate4% with (cyclo)-taurolidine and heparin or urokinase, but it is not approved for use in the U.S. Some device companies have launchedantibiotic or antimicrobial-coated catheters as short-term prevention of catheter infections. We believe these are not effectivefor hemodialysis catheters due to the long-term use and high blood flow associated with hemodialysis.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Manufacturing/SupplyChain
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wedo not own or operate any manufacturing facilities related to the production of our products. All our manufacturing processescurrently are, and we expect them to continue, to be outsourced to third parties. We rely on third-party manufacturers to producesufficient quantities of drug product for use both commercially and in clinical trials. We intend to continue this practice inthe future.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Withregards to taurolidine, an active drug ingredient, or API, of DefenCath, we have a Drug Master File filed with the FDA. Thereis a master commercial supply agreement between the third-party manufacturer, Alcami, and us in place from August 2018. We havetwo sources for the other key API, Heparin sodium.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We have utilized twodrug product contract manufacturing organizations, or CMOs. One CMO manufactures for the EU and Middle East markets and the otheris for U.S. production. In order to assure supply, we are in the process of beginning to qualify a second CMO for U.S. vial production.All API and drug products are validated at commercial scale.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We are confident thatthese CMO’s have adequate capacity to produce the volumes needed, and that there exists a sufficient number of potentialalternate sources for the drug substances required to produce our products, as well as third-party manufacturers, that we willbe able to find alternate suppliers and third-party manufacturers in the event that our relationship with any supplier or third-partymanufacturer deteriorates. The process for selecting and qualifying an alternative contract manufacturer and for completing thetechnology transfer to such a manufacturer to the point of enabling commercialization of the product would take several years.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 7; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      5
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      UnitedStates Government Regulation
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theresearch, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things,of our products are extensively regulated by governmental authorities in the U.S. and other countries. Our products may be classifiedby the FDA as a drug or a medical device depending upon the indications for use or claims. Because certain of our product candidatesare considered as medical devices and others are considered as drugs for regulatory purposes, we intend to submit applicationsto regulatory agencies for approval or clearance of both medical devices and pharmaceutical product candidates.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe U.S., the FDA regulates drugs and medical devices under the Federal Food, Drug, and Cosmetic Act (FDCA) and the Agency’simplementing regulations. If we fail to comply with the applicable U.S. requirements at any time during the product developmentprocess, clinical testing, and during the approval process or after approval, we may become subject to administrative or judicialsanctions. These sanctions could include the FDA’s refusal to approve pending applications, license suspension or revocation,withdrawal of an approval, warning letters, adverse publicity, product recalls, product seizures, total or partial suspensionof production or distribution, injunctions, fines, civil penalties or criminal prosecution, among other actions. Any agency enforcementaction and/or any related impact could have a material adverse effect on us.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      DrugApproval Process
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theresearch, development, and approval process in the United States and elsewhere is intensive and rigorous and generally takes manyyears to complete. The typical process required by the FDA before a therapeutic drug may be marketed in the United States includes:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Pre-clinical                                         laboratory and animal tests performed under the FDA’s Good Laboratory Practices,                                         or GLP, regulations;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         submission                                         to the FDA of an investigational new drug application, or IND, which must become effective                                         before human clinical trials may commence;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         human                                         clinical studies to evaluate the drug’s safety and effectiveness for its intended                                         uses;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         FDA                                         review of whether the facility in which the drug is manufactured, processed, packaged,                                         or held meets standards designed to assure the product’s continued quality and                                         FDA review of clinical trial sites to determine whether the clinical trials were conducted                                         in accordance with Good Clinical Practices, or GCPs; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         submission                                         of a new drug application, or NDA, to the FDA, and approval of the application by the                                         FDA to allow sales of the drug.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Duringpre-clinical testing, studies are performed with respect to the chemical and physical properties of candidate formulations. Thesestudies are subject to GLP requirements. Biological testing is typically done in animal models to demonstrate the activity ofthe compound against the targeted disease or condition and to assess the apparent effects of the new product candidate on variousorgan systems, as well as its relative therapeutic effectiveness and safety. An IND application must be submitted to the FDA andbecome effective before studies in humans may commence.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Clinicaltrial programs in humans generally follow a three-phase process. Typically, Phase 1 studies are conducted in small numbers ofhealthy volunteers or, on occasion, in patients afflicted with the target disease. Phase 1 studies are conducted to determinethe metabolic and pharmacological action of the product candidate in humans and the side effects associated with increasing doses,and, if possible, to gain early evidence of effectiveness. In Phase 2, studies are generally conducted in larger groups of patientshaving the target disease or condition in order to validate clinical endpoints, and to obtain preliminary data on the effectivenessof the product candidate and optimal dosing. This phase also helps determine further the safety profile of the product candidate.In Phase 3, large-scale clinical trials are generally conducted in patients having the target disease or condition to providesufficient data for the statistical proof of effectiveness and safety of the product candidate as required by United States andforeign regulatory agencies. Typically, two Phase 3 trials are required for marketing approval.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 8; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      6
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe case of products for certain serious or life-threatening diseases, the initial human testing may be done in patients withthe disease rather than in healthy volunteers. Because these patients are already afflicted with the target disease or condition,it is possible that such studies will also provide results traditionally obtained in Phase 2 studies. These studies are oftenreferred to as “Phase 1/2” studies. However, even if patients participate in initial human testing and a Phase 1/2study is carried out, the sponsor is still responsible for obtaining all the data usually obtained in both Phase 1 and Phase 2studies.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Beforeproceeding with a study, sponsors may seek a written agreement known as a Special Protocol Assessment, or SPA, from the FDA regardingthe design, size, and conduct of a clinical trial. Among other things, SPAs can cover clinical studies for pivotal trials whosedata will form the primary basis to establish a product’s efficacy. SPAs help establish up-front agreement with the FDAabout the adequacy of a clinical trial design to support a regulatory approval, but the agreement is not binding on the FDA ifnew circumstances arise. An SPA may only be modified with the agreement of the FDA and the trial sponsor or if the director ofthe FDA reviewing division determines that a substantial scientific issue essential to determining the safety or efficacy of thedrug was identified after the testing began. There is no guarantee that a study will ultimately be adequate to support an approvaleven if the study is subject to an SPA.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Additionally,some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, knownas a data safety monitoring board or committee. This group regularly reviews accumulated data and advises the study sponsor regardingthe continuing safety of trial subjects, and the continuing validity and scientific merit of the clinical trial. The data safetymonitoring board receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinicaltrial if it determined there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy.The committee can also stop a clinical trial for an overwhelming demonstration of efficacy, based on pre-defined, stringent statisticalparameters and ethical considerations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Themanufacture of investigational drugs for the conduct of human clinical trials is subject to current Good Manufacturing Practice,or cGMP, requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subjectto regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug products outsideof the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements underthe FDCA.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      INDsponsors are required to submit a number of reports to the FDA during the course of a development program. For instance, sponsorsare required to make annual reports to the FDA concerning the progress of their clinical trial programs as well as more frequentreports for certain serious adverse events. Sponsors must submit a protocol for each clinical trial, and any subsequent protocolamendments to the FDA. Investigators must also provide certain information to the clinical trial sponsors to allow the sponsorsto make certain financial disclosures to the FDA. Information about certain clinical trials, including a description of the studyand study results, must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public disseminationon their clinicaltrials.gov website. Moreover, under the 21st Century Cures Act, manufacturers or distributors of investigationaldrugs for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must have a publicly availablepolicy concerning expanded access to investigational drugs.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      UnitedStates law requires that studies conducted to support approval for product marketing be “adequate and well controlled.”In general, this means that either a placebo or a product already approved for the treatment of the disease or condition understudy must be used as a reference control. The recently passed 21st Century Cures Act, however, provides for FDA acceptance ofnew kinds of data such as patient experience data, real world evidence, and, for appropriate indications sought through supplementalmarketing applications, data summaries. Studies must also be conducted in compliance with good clinical practice requirements,and informed consent must be obtained from all study subjects.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA for a new active ingredient, indication,dosage form, dosage regimen, or route of administration must contain data that are adequate to assess the safety and effectivenessof the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration foreach pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the requestof the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use inadults, or full or partial waivers from the pediatric data requirements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 9; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      7
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA also may require submission of a risk evaluation and mitigation strategy, or REMS, to ensure that the benefits of the drugoutweigh the risks of the drug. The REMS plan could include medication guides, physician communication plans, and elements toassure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. An assessmentof the REMS must also be conducted at set intervals. Following product approval, a REMS may also be required by the FDA if newsafety information is discovered and the FDA determines that a REMS is necessary to ensure that the benefits of the drug outweighthe risks of the drug.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theclinical trial process for a new compound can take ten years or more to complete. The FDA may prevent clinical trials from beginningor may place clinical trials on hold at any point in this process if, among other reasons, it concludes that study subjects arebeing exposed to an unacceptable health risk. Trials may also be prevented from beginning or may be terminated by institutionalreview boards, or IRBs, who must review and approve all research involving human subjects and amendments thereto. The IRB mustcontinue to oversee the clinical trial while it is being conducted. This includes the IRB receiving information concerning unanticipatedproblems involving risk to subjects. Side effects or adverse events that are reported during clinical trials can delay, impede,or prevent marketing authorization. Similarly, adverse events that are reported after marketing authorization can result in additionallimitations being placed on a product’s use and, potentially, withdrawal of the product from the market.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Followingthe completion of a clinical trial, the data are analyzed by the sponsoring company to determine whether the trial successfullydemonstrated safety and effectiveness and whether a product approval application may be submitted. In the United States, if theproduct is regulated as a new drug, an NDA must be submitted and approved by the FDA before commercial marketing may begin. TheNDA must include a substantial amount of data and other information concerning the safety and effectiveness of the compound fromlaboratory, animal, and human clinical testing, as well as data and information on manufacturing, product quality and stability,and proposed product labeling.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Eachdomestic and foreign manufacturing establishment, including any contract manufacturers that we may decide to use, must be listedin the NDA and must be registered with the FDA. The application generally will not be approved until the FDA conducts a manufacturinginspection, approves the applicable manufacturing process for the drug product, and determines that the facility is in compliancewith current cGMP requirements. Moreover, FDA will also typically inspect one or more clinical trial sites to confirm that theapplicable clinical trials were conducted in accordance with GCPs.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Underthe Prescription Drug User Fee Act (PDUFA), as amended, the FDA assesses and receives application user fees for reviewing an NDA,as well as annual program fees for commercial manufacturing establishments and for approved products. These fees can be significant.Fee waivers, reductions or refunds are available in certain circumstances. One basis for a waiver or refund of the applicationuser fee is if the applicant is a “small business” generally defined as employing fewer than 500 employees, includingemployees of affiliates, no approved marketing application for a product that has been introduced or delivered for introductioninto interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application. Productcandidates that are designated as orphan drugs, which are further described below, are also not subject to application user feesunless the application includes an indication other than the orphan indication. Under certain circumstances, orphan products mayalso be exempt from product and establishment fees.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      EachNDA submitted for FDA approval is usually reviewed for administrative completeness and reviewability. Following this review, theFDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmittedwith the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Onceaccepted for filing, the FDA’s review of an application may involve review and recommendations by an independent FDA advisorycommittee. The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the activeingredients that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summaryfor not referring it to an advisory committee. The FDA may also refer drugs to advisory committees when it is determined thatan advisory committee’s expertise would be beneficial to the regulatory decision-making process, including the evaluationof novel products and the use of new technology. An advisory committee is typically a panel that includes clinicians and otherexperts, which review, evaluate, and make a recommendation as to whether the application should be approved and under what conditions.The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when makingdecisions.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 10; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      8
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Afterevaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reportsregarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a CompleteResponse Letter, or CRL. If a CRL is issued, the applicant may either resubmit the NDA, addressing all the deficiencies identifiedin the letter; withdraw the application; or request an opportunity for a hearing. A CRL indicates that the review cycle of theapplication is complete, and the application is not ready for approval and describes all the specific deficiencies that the FDAidentified in the NDA. A CRL generally contains a statement of specific conditions that must be met in order to secure final approvalof the NDA and may require additional clinical or pre-clinical testing in order for the FDA to reconsider the application. Thedeficiencies identified may be minor, for example, requiring labeling changes; or major, for example, requiring additional clinicaltrials. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfythe regulatory criteria for approval. If and when those conditions have been met to the FDA’s satisfaction, the FDA mayissue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing informationfor specific indications.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Evenif the FDA approves a product, it may limit the approved therapeutic uses for the product as described in the product labeling,require that warning statements be included in the product labeling, require that additional studies be conducted following approvalas a condition of the approval, impose restrictions and conditions on product distribution, prescribing, or dispensing in theform of a REMS or otherwise limit the scope of any approval.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        SpecialFDA Expedited Review and Approval Programs
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA has various programs, including Fast Track designation, priority review and breakthrough designation, that are intended toexpedite or simplify the process for the development and FDA review of certain drug products that are intended for the treatmentof serious or life threatening diseases or conditions, and demonstrate the potential to address unmet medical needs or presenta significant improvement over existing therapy. The purpose of these programs is to provide important new drugs to patients earlierthan under standard FDA review procedures.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Tobe eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a product is intendedto treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. TheFDA will determine that a product will fill an unmet medical need if the product will provide a therapy where none exists or providea therapy that may be potentially superior to existing therapy based on efficacy, safety, or public health factors. If Fast Trackdesignation is obtained, drug sponsors may be eligible for more frequent development meetings and correspondence with the FDA.In addition, the FDA may initiate review of sections of an NDA before the application is complete. This “rolling review”is available if the applicant provides and the FDA approves a schedule for the remaining information. A Fast Track product isalso eligible to apply for accelerated approval and priority review.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA may give a priority review designation to drugs that are intended to treat serious conditions and, if approved, would providesignificant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. A priorityreview means that the goal for the FDA is to review an application within six months, rather than the standard review of ten monthsunder current PDUFA guidelines, of the 60-day filing date for new molecular entities.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Moreover,under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted in 2012, a sponsor canrequest designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drugthat is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition,and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on oneor more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugsdesignated as breakthrough therapies are eligible for the Fast Track designation features as described above, intensive guidanceon an efficient drug development program beginning as early as Phase 1 trials, and a commitment from the FDA to involve seniormanagers and experienced review staff in a proactive collaborative, cross-disciplinary review.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Evenif a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditionsfor qualification or decide that the time period for FDA review or approval will not be shortened.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 11; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      9
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Afinal new program to expedite the development of drug products is the LPAD, which was passed as part of the 21
      <sup>
       st
      </sup>
      CenturyCures Act. LPAD allows for the FDA’s determination of safety and effectiveness to reflect the risk-benefit profile of thedrug in the intended limited population, taking into account the severity, rarity, or prevalence of the infection and the availabilityof alternative treatments in the limited population. Under LPAD, a sponsor may request drug approval for an antibacterial or antifungaldrug if the drug is intended to treat a serious life-threatening infection in a limited population of patients with unmet needs.The drug may be approved for the limited population notwithstanding a lack of evidence to fully establish a favorable benefit-riskprofile in a broader population. The FDA must provide prompt advice to sponsors seeking approval under LPAD to enable them toplan a development program. If approved under LPAD, certain post-marketing requirements would apply, such as required labelingand advertising statements and pre-distribution submission of promotional materials to FDA. If after approval for a limited population,a product receives a broader approval, the FDA may remove such post-marketing restrictions. While a drug may only be approvedfor a limited population under this program, the 21
      <sup>
       st
      </sup>
      Century Cures Act states that it is not intended to restrictthe prescribing of antimicrobial drugs or other products by healthcare professionals.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Exclusivity
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Forapproved drug products, market exclusivity provisions under the FDCA provide periods of regulatory exclusivity, which gives theholder of an approved NDA limited protection from new competition in the marketplace for the innovation represented by its approveddrug.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Section505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorizationfor a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy.A Section 505(b)(2) NDA is an application in which the applicant, in part, relies on investigations that were not conducted byor for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom theinvestigations were conducted. Section 505(j) establishes an abbreviated approval process for a generic version of approved drugproducts through the submission of an Abbreviated New Drug Application, or ANDA. An ANDA provides for marketing of a generic drugproduct that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics,and intended use, among other things, to a previously approved product. Limited changes must be pre-approved by the FDA via asuitability petition.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Fiveyears of exclusivity are available to New Chemical Entities, or NCEs. A NCE is a drug that contains no active moiety that hasbeen approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions of the molecule,that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent derivatives,such as a complex, chelate, or clathrate, of the molecule, responsible for the therapeutic activity of the drug substance. Duringthe exclusivity period, the FDA may not accept for review and make an ANDA or a 505(b)(2) NDA approval effective for an applicationsubmitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, maybe submitted one year before NCE exclusivity expires if the applicant submits a certification stating that the patents listedby the NCE sponsor in FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, areinvalid or will not be infringed by the manufacture, use, or sale of the drug product for which approval is sought. Five-yearexclusivity will also not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would berequired to conduct or obtain a right of reference to all the pre-clinical studies and adequate and well-controlled clinical trialsnecessary to demonstrate safety and efficacy.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Pediatricexclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachmentof an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patentexclusivity period described above. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairlyrespond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatricpopulation studied; rather, if the clinical trial is deemed to fairly respond to the FDA’s request, the additional protectionis granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the required time frames,whatever statutory or regulatory periods of exclusivity or Orange Book listed patent protection cover the drug are extended bysix months. Moreover, pediatric exclusivity attaches to all formulations, dosage forms, and indications for products with existingmarketing exclusivity or patent life that contain the same active moiety as that which was studied.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 12; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      10
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheOrphan Drug Act also provides incentives for the development of drugs intended to treat rare diseases or conditions, which generallyare diseases or conditions affecting fewer than 200,000 individuals annually in the United States, or affecting more than 200,000in the United States and for which there is no reasonable expectation that the cost of developing and making the drug availablein the United States will be recovered from sales in the United States. Additionally, sponsors must present a plausible hypothesisfor clinical superiority to obtain orphan designation if there is a drug already approved by the FDA that is intended for thesame indication and that is considered by the FDA to be the same drug as the already approved drug. This hypothesis must be demonstratedto obtain orphan drug exclusivity. If granted, prior to product approval, Orphan Drug Designation entitles a party to financialincentives such as opportunities for grant funding towards clinical study costs, tax advantages, and user-fee waivers. In addition,if a product receives FDA approval for the indication for which it has orphan designation, the product is generally entitled toorphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indicationfor a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product withorphan exclusivity.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Forcertain infectious disease products, the above discussed exclusivity periods may be further extended under the FDA’s qualifiedinfectious disease product program. A qualified infectious disease product, or QIDP, is an antibacterial or antifungal drug forhuman use intended to treat serious or life-threatening infections, including those caused by an antibacterial or antifungal resistantpathogen, including novel or emerging infectious pathogens; or qualifying pathogens designated by the FDA that have the potentialto pose a serious threat to public health. Subject to the specified statutory limitations, a drug that is designated as a QIDPand is approved for the use for which the QIDP designation was granted will receive a 5-year extension to any exclusivity forwhich the application qualifies upon approval. For example, if the FDA approves an NDA for a drug designated as a QIDP, the NCEexclusivity period is extended to ten years and the FDA may not accept applications for nine years. Moreover, if a product isdesignated as a QIDP and an orphan product, the orphan product exclusivity period is extended to twelve years. These extensionsare in addition to any extension that an application may be entitled to under the pediatric exclusivity provisions. To receivea QIDP designation, the sponsor must request that the FDA designate the product as such prior to the submission of an NDA. Thisdesignation may not be withdrawn except if the FDA finds that the request for designation contained an untrue statement of materialfact. QIDPs are also eligible for fast track status and priority review.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        PostApproval Requirements
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Significantlegal and regulatory requirements also apply after FDA approval to market under an NDA. These include, among other things, requirementsrelated to adverse event and other reporting, product tracking and tracing, suspect and illegitimate product investigations andnotifications, product advertising and promotion and ongoing adherence to cGMPs, as well as the need to submit appropriate newor supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturingprocess. The FDA also enforces the requirements of the Prescription Drug Marketing Act which, among other things, imposes variousrequirements in connection with the distribution of product samples to physicians. The FDA enforces these requirements through,among other ways, periodic announced and unannounced facility inspections.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A companycan make only those claims relating to safety and efficacy that are approved by the FDA. Physicians, in their independent professionalmedical judgment, may prescribe legally available products for unapproved indications that are not described in the product’slabeling and that differ from those tested and approved by the FDA. Pharmaceutical companies, however, are allowed to promotetheir drug products only for the approved indications and in accordance with the provisions of the approved label. The FDA andother agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is foundto have improperly promoted off-label uses may be subject to significant liability, including, but not limited to, criminal andcivil penalties under the FDCA and the civil False Claims Act, or FCA, exclusion from participation in federal healthcare programs,mandatory compliance programs under corporate integrity agreements, debarment, and refusal of government contracts.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theregulatory framework applicable to the production, distribution, marketing, and/or sale, of our product candidates may changesignificantly from the current descriptions provided herein in the time that it may take for any of our product candidates toreach a point at which an NDA is approved. Moreover, individual states may have laws and regulations that we must comply with,such as laws and regulations concerning licensing, promotion, sampling, distribution, and reporting.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 13; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      11
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Overallresearch, development, and approval times depend on a number of factors, including the period of review at the FDA, the numberof questions posed by the FDA during review, how long it takes to respond to the FDA’s questions, the severity or life-threateningnature of the disease in question, the availability of alternative treatments, the availability of clinical investigators andeligible patients, the rate of enrollment of patients in clinical trials, and the risks and benefits demonstrated in the clinicaltrials.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        MedicalDevice Approval Process
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition to our lead product candidate DefenCath, which is subject to regulation by the FDA as a drug, we may be developing otherproducts that may be regulated as medical devices in the United States. The FDA considers a product to be a device, and subjectto the FDA regulation, if it meets the definition of a medical device in the FDCA, which states that a device is an instrument,apparatus, implement, machine, contrivance, implant,
      <i>
       in vitro
      </i>
      reagent, or other similar or related article, including acomponent part, or accessory which is:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         recognized                                         in the official National Formulary, or the United States Pharmacopoeia, or any supplement                                         to them,
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         intended                                         for use in the diagnosis of disease or other conditions, or in the cure, mitigation,                                         treatment, or prevention of disease, in man or other animals, or
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         intended                                         to affect the structure or any function of the body of man or other animals, and which                                         does not achieve its primary intended purposes through chemical action within or on the                                         body of man or other animals and which does not achieve its primary intended purposes                                         through chemical action within or on the body of man or other animals and which is not                                         dependent upon being metabolized for the achievement of its primary intended purposes.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA regulates the design, development, clinical testing, manufacture, labeling, distribution, import and export, sale and promotionof medical devices. Unless an exemption applies or a product is a Class I device, all medical devices must receive either 510(k)clearance or an approved pre-market application, or PMA, from the FDA before they may be commercially distributed in the U.S.In addition, certain modifications made to marketed devices also may require 510(k) clearance or approval of a PMA supplement.Unlike approved drug products, there are no market exclusivity provisions under the FDCA for products regulated as medical devices.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Toobtain a 510(k) clearance for a device, a pre-market notification to the FDA must be submitted demonstrating that the device issubstantially equivalent to a legally marketed predicate device. For a new device to be found “substantially equivalent”to one or other legally marketed predicate devices, the new device must have: 1) the same intended use as a predicate; and 2)either a) the same technological characteristics as the predicate device or b) different technological characteristics, but theinformation submitted must not raise new questions of safety and effectiveness and must demonstrate substantial equivalence. TheFDA attempts to respond to a 510(k) pre-market notification within 90 days of submission, but as a practical matter, pre-marketclearance can take significantly longer, potentially up to one year or more.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      ThePMA process is much more demanding and uncertain than the 510(k) pre-market notification process and must be supported by extensiveclinical, laboratory, technical and other information, including at least one adequate and well-controlled clinical investigationconducted under an investigational device exemption (IDE). The FDA has 180 days to review an accepted PMA, although the reviewgenerally occurs over a significantly longer period of time and can take up to several years.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA has informed us that it regards taurolidine as a new chemical entity and therefore an unapproved new drug. Consequently, forany other products that we intend to develop as a medical device, there is currently no appropriate predicate device currentlymarketed in the U.S. on which a 510(k) approval process could be based. As a result, we will be required to submit a premarketapproval application for marketing authorization for these indications. In the event that the NDA for DefenCath is approved bythe FDA, the regulatory pathway for these taurolidine product candidates can be revisited with the FDA. Although there will presumablystill be no appropriate predicate,
      <i>
       de novo
      </i>
      Class II designation can be proposed, a process that provides a pathway to classifynovel medical device for which there is no legally marketed predicate device, based on a risk assessment and a reasonable assuranceof safety and effectiveness.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 14; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      12
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Aftera device is placed on the market, numerous regulatory requirements apply, including:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Quality                                         System Regulations, or QSRs, which require manufacturers to have a quality system for                                         the design, manufacture, packaging, labeling, storage, installation, and servicing of                                         finished medical devices;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         labeling                                         regulations, which govern product labels and labeling, prohibit the promotion of products                                         for unapproved, or off-label, uses and impose other restrictions on labeling and promotional                                         activities;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         medical                                         device listing and establishment registration;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         post-approval                                         restrictions or conditions, including post-approval study commitments;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         post-market                                         surveillance requirements;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         medical                                         device reporting, or MDR, regulations, which require that manufacturers evaluate and                                         investigate potential adverse events and malfunctions, and report to the FDA if their                                         device may have caused or contributed to a death or serious injury or malfunctioned in                                         a way that would likely cause or contribute to a death or serious injury if it were to                                         recur;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         regulations                                         requiring the reporting of any device corrections or removals if the correction or removal                                         was initiated to reduce a risk to health posed by the device or remedy a violation of                                         the FDCA which may present a risk to health; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the                                         FDA’s recall authority, whereby it can ask, or under certain conditions order,                                         device manufacturers to recall from the market a product that is a risk to health.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourmanufacturing facilities, as well as those of certain of our suppliers, are subject to periodic and for-cause inspections by theFDA and other governmental authorities to verify compliance with the QSR and other regulatory requirements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Reimbursementand Pricing Controls
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inmany of the markets where we or the parties we collaborate with have targeted or will target DefenCath for sale, laws controlthe prices charged to certain purchasers of pharmaceutical products and the prices paid by drug reimbursement programs throughvarying price control mechanisms. Public and private health care payors control costs and influence drug pricing through a varietyof mechanisms, including through negotiating rebates with the manufacturers, limiting the reimbursement rate paid to providers,and using tiered formularies, co-payment structures that incentivize beneficiaries to request lower cost alternatives, and othermechanisms that provide preferential access to certain drugs over others within a therapeutic class. Federal and commercial payorsuse competition for health plan coverage and market share as leverage to obtain rebates on products they reimburse, which impactsthe manufacturer’s net realization on the sale of the products. These rebates may be paid on drugs sold at a mandatory discount.Additionally, federal and commercial health plans may choose to reimburse dialysis providers for dialysis services and drugs usedin the provision of those services through a single bundled payment rate, which tends to make cost a more important factor forproviders when making drug purchase decisions than it would otherwise be if the providers were reimbursed for drugs on a stand-alonebasis. Payors also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursedor otherwise covered. In particular, many public and private health care payors limit reimbursement and coverage to the uses ofa drug that are either approved by the FDA or that are supported by other appropriate evidence (for example, published medicalliterature) and appear in a recognized drug compendium. Drug compendia are publications that summarize the available medical evidencefor particular drug products and identify which uses of a drug are supported or not supported by the available evidence, whetheror not such uses have been approved by the FDA.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal">
      <b>
       ForeignRegulatory Requirements
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weand our collaborative partners may be subject to widely varying foreign regulations, which may be quite different from those ofthe FDA, governing clinical trials, manufacture, product registration and approval, and pharmaceutical sales. Whether or not FDAapproval has been obtained, we or our collaboration partners must obtain a separate approval for a product by the comparable regulatoryauthorities of foreign countries prior to the commencement of product marketing in those countries. In certain countries, regulatoryauthorities also establish pricing and reimbursement criteria. The approval process varies from country to country, and the timemay be longer or shorter than that required for FDA approval. In addition, under current United States law, there are restrictionson the export of products not approved by the FDA, depending on the country involved and the status of the product in that country.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 15; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      13
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Internationalsales of medical devices manufactured in the U.S. that are not approved by the FDA for use in the U.S., or are banned or deviatefrom lawful performance standards, are subject to FDA export requirements. Exported devices are subject to the regulatory requirementsof each country to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries,medical devices are regulated. Frequently, regulatory approval may first be obtained in a foreign country prior to applicationin the U.S. to take advantage of differing regulatory requirements. Most countries outside of the U.S. require that product approvalsbe recertified on a regular basis, generally every five years. The recertification process requires that we evaluate any devicechanges and any new regulations or standards relevant to the device and conduct appropriate testing to document continued compliance.Where recertification applications are required, they must be approved in order to continue selling our products in those countries.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe European Union, in order for our product candidates to be marketed and sold, we are required to comply with the Medical DevicesDirective and obtain CE Mark certification. The CE Mark certification encompasses an extensive review of our quality managementsystem which is inspected by a notified body’s auditor as part of a Stage 1 and 2 International Organization for Standardization,or ISO, 13485:2003 audit, in accordance with worldwide recognized ISO standards and applicable European Medical Devices Directivesfor quality management systems for medical device manufacturers. Once the quality management system and design dossier has beensuccessfully audited by a notified body and reviewed and approved by a competent authority, a CE certificate for the medical devicewill be issued. We are also required to comply with other foreign regulations such as the requirement that we obtain Ministryof Health, Labor and Welfare approval before we can launch new products in Japan. The time required to obtain these foreign approvalsto market our products may vary from U.S. approvals, and requirements for these approvals may differ from those required by theFDA.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Medicaldevice laws and regulations are in effect in many of the countries in which we may do business outside the United States. Theselaws and regulations range from comprehensive device approval requirements for our medical device product to requests for productdata or certifications. The number and scope of these requirements can be complex and could increase. We may not be able to obtainor maintain regulatory approvals in such countries and we may be required to incur significant costs in obtaining or maintainingour foreign regulatory approvals. In addition, the export of certain of our products which have not yet been cleared for domesticcommercial distribution may be subject to FDA export restrictions. Any failure to obtain product approvals in a timely fashionor to comply with state or foreign medical device laws and regulations may have a serious adverse effect on our business, financialcondition or results of operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      IntellectualProperty
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnJanuary 30, 2008, we entered into a License and Assignment Agreement, or the NDP License Agreement, with ND Partners, LLC, orNDP. Pursuant to the NDP License Agreement, NDP granted us exclusive, worldwide licenses for certain antimicrobial catheter locksolutions, processes for treating and inhibiting infections, a biocidal lock system and a taurolidine delivery apparatus, andthe corresponding United States and foreign patents and applications (the “NDP Technology”). We acquired such licensesand patents through our assignment and assumption of NDP’s rights under certain separate license agreements by and betweenNDP and Dr. Hans-Dietrich Polaschegg, Dr. Klaus Sodemann, and Dr. Johannes Reinmueller. NDP also granted us exclusive licenses,with the right to grant sublicenses, to use and display certain trademarks in connection with the NDP Technology. As considerationin part for the rights to the NDP Technology, we paid NDP an initial licensing fee of $325,000 and granted NDP an equity interestin our company consisting of 73,107 shares of common stock as of December 31, 2010. In addition, we are required to make paymentsto NDP upon the achievement of certain regulatory and sales-based milestones. Certain of the milestone payments are to be madein the form of shares of common stock currently held in escrow for NDP, and other milestone payments are to be paid in cash. Themaximum aggregate number of shares issuable upon achievement of milestones and the number of shares held in escrow is 29,109 sharesof common stock. The maximum aggregate amount of cash payments upon achievement of milestones is $3,000,000 with $2,500,000 remainingat December 31, 2020. Events that trigger milestone payments include but are not limited to the reaching of various stages ofregulatory approval processes and certain worldwide net sales amounts.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     During the year endedDecember 31, 2013, a milestone payment of $500,000 was earned by NDP upon the first issuance of the CE Mark for Neutrolin. UnderArticle 6 of the NDP License Agreement, we were obligated to make a milestone payment of $500,000 to NDP upon the first issuanceof a CE Mark for a licensed product, which payment was payable to NDP within 30 days after such issuance. On April 11, 2013, weentered into an amendment to the NDP License Agreement which extended the milestone payment from within 30 days after such issuanceto within twelve months after the achievement of such issuance. As consideration for the amendment, we issued NDP a five-year warrantto purchase 25,000 shares of our common stock at an exercise price of $7.50 per share. The warrant was exercisable immediatelyupon issuance and expired in April 2018. In January 2014, the $500,000 milestone payment due to NDP was converted into 10,000 SeriesC-3 non-voting preferred stock and a warrant to purchase 50,000 shares of our common stock at an exercise price of $4.50 per share.The warrants expired during the year ended December 31, 2020.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 16; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      14
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     During the year ended December 31, 2014, a certain milestonewas achieved resulting in the release of 7,277 shares held in escrow. The number of shares held in escrow as of December 31, 2020is 21,832 shares of common stock. There were no milestones achieved in 2020 or 2019.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheNDP License Agreement will expire on a country-by-country basis upon the earlier of (i) the expiration of the last patent claimunder the NDP License Agreement in a given country, or (ii) the payment of all milestone payments and release of all shares ofour common stock held in escrow under the NDP License Agreement. Upon the expiration of the NDP License Agreement in each country,we will have an irrevocable, perpetual, fully paid-up, royalty-free exclusive license to the NDP Technology in such country. TheNDP License Agreement also may be terminated by NDP if we materially breach or default under the NDP License Agreement and thatbreach is not cured within 60 days following the delivery of written notice to us, or by us on a country-by-country basis upon60 days prior written notice. If the NDP License Agreement is terminated by either party, our rights to the NDP Technology willrevert back to NDP.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Webelieve that the patents and patent applications we have licensed pursuant to the NDP License Agreement cover effective solutionsto the various medical problems discussed previously when using taurolidine in clinical applications, and specifically in hemodialysisapplications. Our patent portfolio consists of 5 issued U.S. patents and 13 pending U.S. patent applications; 15 issued foreignpatents and 44 pending foreign patent applications. Additional patent applications will be filed to cover any additional relatedsubject matter developed. The patents cover additional applications using taurolidine in, among others, sutures, hydrogels, meshes,transdermal and biofilm products.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     Employees and Human Capital Resources
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     As of March 19, 2021, we employed 35 full-time employees, who work out of our corporate offices in Berkeley Heights NJ or work remotely in variouslocations throughout the United States and Europe. We are committed to diversity, equity and inclusion, regardless of gender orrace/ethnicity, and conduct training to reflect our commitment as an organization and build awareness.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     We invest in our workforceby offering competitive salaries and benefits. We endeavor to foster a strong sense of ownership by offering stock options underour stock incentive program. We also offer comprehensive and locally relevant benefits for all eligible employees. We recognizeand support the growth and development of our employees.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We have implementedCOVID-19 policies designed to ensure the safety and well-being of all employees and the people associated with them. As a resultof the COVID-19 pandemic, to reduce risk, our employees have been asked to work remotely, and all employees have been asked toavoid all non-essential travel, adhere to good hygiene practices, and engage in physical distancing.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     None of our employeesare subject to a collective bargaining agreement. We consider our relationship with our employees to be good.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      CorporateInformation
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wewere organized as a Delaware corporation on July 28, 2006 under the name “Picton Holding Company, Inc.” and we changedour corporate name to “CorMedix Inc.” on January 18, 2007. Our principal executive offices are located at 300 ConnellDrive, Suite 4200, Berkeley Heights, New Jersey 07922. Our telephone number is (908) 517-9500.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnMarch 26, 2019, we effected a 1-for-5 reverse stock split of our issued and outstanding shares of common stock, par value $0.001,per share (“Common Stock”), by combining, reclassifying and changing each authorized and outstanding five shares of“old” common stock into one share of “new” common stock. No fractional shares were issued, and, in lieuthereof, where applicable, one whole share was issued. To reflect the reverse stock split, reclassification, combination and change,proportional adjustments were also made to the number of shares of our common stock issuable upon conversion of outstanding preferredshares and the convertible note payable, warrants and options and other equity awards. The reverse stock split did not affectthe par value per share of our common stock (which remains at $0.001 per share) or the total number of shares of common stockthat are authorized to be issued pursuant to our Amended and Restated Certificate of Incorporation, as amended, which remainsat 160 million shares. All issued and outstanding share and per share amounts included in the accompanying consolidated financialstatements and in this report have been adjusted to reflect the reverse stock split, reclassification, combination and changefor all periods presented.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In April 2020, we receivedapproximately $5.2 million, net of expenses, from the sale of most of our remaining unused New Jersey net operating losses (“NOL”)eligible for sale under the State of New Jersey’s Economic Development Authority’s New Jersey Technology Business TaxCertificate Transfer program (“NJEDA Program”). The NJEDA Program allowed us to sell approximately $5.5 million ofour total $6.0 million in available NOL tax benefits for the state fiscal year 2019.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     As previously announced,the NJEDA has approved our application to participate in the NJEDA Program for the state fiscal year 2020. The approval will allowus to sell approximately $1.3 million of the total $1.3 million in available tax benefits to an unrelated, profitable New Jerseycorporation in return for approximately $1.3 million in cash. Closing is subject to NJEDA’s typical closing conditions, whichare in process of completion.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 17; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      15
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In April 2020, we receivedfrom the FDA a refund for the NDA application fee in the amount of $2.9 million, which was paid in the first quarter of 2020. Wemet the conditions of the Federal Food, Drug, and Cosmetic Act for the small business waiver of the user fees and our request fora waiver of an application user fee was granted by the FDA.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     In May 2020, we formed a wholly-owned Spanish subsidiary, CorMedixSpain, S.L.U. for which no substantial operations had occurred during the year 2020.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     On July 30, 2020, wecompleted an underwritten public offering of our common stock, par value $0.001 per share, which yielded gross proceeds, beforeunderwriting commissions and estimated expenses, of approximately $23.0 million. The public offering was made pursuant to an underwritingagreement with SunTrust Robinson Humphrey, Inc. and JMP Securities LLC (collectively, the “Underwriters”), relatingto the issuance and sale of an aggregate of 5,111,110 shares of common stock, including 666,666 shares of common stock pursuantto the full exercise of the Underwriters’ option, at a public offering price of $4.50 per share. The offering was made pursuantto our effective registration statement on Form S-3 Registration Statement No. 333-223562 previously filed with and declared effectiveby the SEC and a prospectus supplement and accompanying prospectus filed with the SEC.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In November 2020, wefiled a new registration statement, under which we could issue and sell up to an aggregate of $100.0 million of shares of our commonstock, $0.001 par value per share. On November 27, 2020, we entered into an Amended and Restated At Market Issuance Sales Agreement(“Amended Sales Agreement”) with B. Riley and Needham &amp; Company, LLC (“Needham”), together with B.Riley, acting as sales agents (“Sales Agent”). The Amended Sales Agreement relates to the sale of shares of up to $25.0million of our common stock under our ATM program, of which we may issue and sell common stock from time to time through the SalesAgent, subject to limitations imposed by us and subject to Sales Agent’s acceptance, such as the number or dollar amountof shares registered under the registration statement to which the offering relates. Sales Agent is entitled to a commission ofup to 3% of the gross proceeds from the sale of common stock sold under the ATM program. During the year ended December 31, 2020,we sold 832,676 shares of common stock under the Amended Sales Agreement at the weighted average price of $8.69 per share and realizednet proceeds of approximately $7.0 million. At December 31, 2020, we have approximately $17.8 million available under the AmendedSales Agreement and $75.0 million available under our current shelf registration for the issuance of equity, debt or equity-linkedsecurities unrelated to the Amended Sales Agreement. On February 5, 2021, we allocated to our ATM program an additional $25.0 millionof the remaining $75.0 million available under our shelf registration statement. Giving effect to the additional $25.0 million,plus the $17.8 million available at December 31, 2020, we had a total of $42.8 million available under the ATM program. DuringJanuary and February 2021, we sold an aggregate of 3,737,862 shares of our common stock under the ATM program and realized netproceeds of approximately $41.5 million. As of the filing of this Annual Report on Form 10-K, we have no available balance underour ATM program and we have $50.0 million available under our current shelf registration for the issuance of equity, debt or equity-linkedsecurities.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We maintain a websiteat www.cormedix.com; however, the information on, or that can be accessed through, our website or certain information in our websiteis not part of this report. This report and all of our filings under the Exchange Act, including copies of annual reports on Form10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, are available free of chargethrough our website on the date we file those materials with, or furnish them to, the Securities and Exchange Commission (the “SEC”).Such filings are also available to the public on the internet at the SEC’s website at www.sec.gov.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 18; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      16
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <div>
     <a id="a_003">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                                         1A.
         </b>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
         <span style="font-family: Times New Roman, Times, Serif">
          <b>
           Risk                                         Factors
          </b>
         </span>
        </p>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 7pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <span style="text-decoration:underline">
       Summary Risk Factors
      </span>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <span style="font-size: 7pt">
      <b>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     The following is a summary of material risks that could affectour business. This summary may not contain all of our material risks, and it is qualified in its entirety by the more detailedrisk factors set forth below.
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <span style="font-size: 7pt">
     </span>
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <span style="text-decoration:underline">
       Risks Related to our Financial Position and Need for AdditionalCapital
      </span>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="width: 0.25in; text-align: justify">
        1.
       </td>
       <td style="text-align: justify">
        We have a history of operating losses, expect to incuradditional operating losses in the future and may never be profitable.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        2.
       </td>
       <td style="text-align: justify">
        Our cost of operations could increase significantly more than what we expect depending on the costs to complete our developmentprogram for DefenCath/Neutrolin.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        3.
       </td>
       <td style="text-align: justify">
        We will need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaborationand licensing arrangements. Any additional funds that we obtain may not be on terms favorable to us or our stockholders and mayrequire us to relinquish valuable rights.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <span style="text-decoration:underline">
       Risks Related to the Development and Commercializationof Our Product Candidates
      </span>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0.25in">
       </td>
       <td style="width: 0.25in">
        1.
       </td>
       <td style="text-align: justify">
        Defencath, our lead product candidate, has received Fast Track designation and Qualified Infectious Disease Product designationfrom FDA, but we cannot provide assurances that these designations will not be rescinded.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        2.
       </td>
       <td style="text-align: justify">
        If the FDA requires a second clinical trial for DefenCath or imposes additional manufacturing requirementsto approve the New Drug Application, the development of DefenCath will take longer and cost more to complete, and we will needsignificant additional funds to undertake a second trial, if required.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        3.
       </td>
       <td style="text-align: justify">
        Our only product Neutrolin is only approved in Europe and is still in development in the United States.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        4.
       </td>
       <td style="text-align: justify">
        Final approval by regulatory authorities of our product candidates for commercial use may be delayed, limited or prevented,any of which would adversely affect our ability to generate operating revenues.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        5.
       </td>
       <td style="text-align: justify">
        Successful development and commercialization of our other products is uncertain.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        6.
       </td>
       <td style="text-align: justify">
        If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penaltiesor incur costs that could harm our business.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        7.
       </td>
       <td style="text-align: justify">
        The successful commercialization of Neutrolin will depend on obtaining coverage and reimbursement for use of Neutrolin fromthird-party payors.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        8.
       </td>
       <td style="text-align: justify">
        Physician and patients may not accept and use our products.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        9.
       </td>
       <td style="text-align: justify">
        Changes in funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delaysin the submission and regulatory review of marketing applications, which could negatively impact our business or prospects.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        10.
       </td>
       <td style="text-align: justify">
        The outbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease maymaterially and adversely impact our business, including our preclinical studies and clinical trials.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        11.
       </td>
       <td style="text-align: justify">
        Clinical trials required for our product candidates may be expensive and time-consuming, and their outcome is uncertain.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        12.
       </td>
       <td style="text-align: justify">
        If we fail to comply with international regulatory requirements, we could be subject to regulatory delays, fines or other penalties.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        13.
       </td>
       <td style="text-align: justify">
        We do not have, and may never obtain, the regulatory approvals we need to market our product candidates outside of the EuropeanUnion.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        14.
       </td>
       <td style="text-align: justify">
        Even if approved, our products will be subject to extensive post-approval regulation.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <span style="text-decoration:underline">
       Risks Related to Our Business and Industry
      </span>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        1.
       </td>
       <td style="text-align: justify">
        Competition and technological change may make our product candidates and technologies less attractive or obsolete.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        2.
       </td>
       <td style="text-align: justify">
        Healthcare policy changes, including reimbursement policies for drugs and medical devices, may have an adverse effect on ourbusiness, financial condition and results of operations.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        3.
       </td>
       <td style="text-align: justify">
        If we lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other personnelor experience increases in compensation costs, our business may materially suffer.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        4.
       </td>
       <td style="text-align: justify">
        If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        5.
       </td>
       <td style="text-align: justify">
        We may not successfully manage our growth.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        6.
       </td>
       <td style="text-align: justify">
        We face the risk of product liability claims and the amount of insurance coverage we hold now or in the future may not be adequateto cover all liabilities we might incur.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        7.
       </td>
       <td style="text-align: justify">
        We may be exposed to liability claims associated with the use of hazardous materials and chemicals.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        8.
       </td>
       <td style="text-align: justify">
        Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from thefinancial markets or collaborators.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 19; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      17
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <span style="text-decoration:underline">
       Risks Related to Our Intellectual Property
      </span>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0.25in">
       </td>
       <td style="width: 0.25in">
        1.
       </td>
       <td style="text-align: justify">
        If we materially breach or default under any of our license agreements, the licensor party to such agreement will have theright to terminate the license agreement, which termination may materially harm our business.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        2.
       </td>
       <td style="text-align: justify">
        If we and our licensors do not obtain protection for and successfully defend our respective intellectual property rights, competitorsmay be able to take advantage of our research and development efforts to develop competing products.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        3.
       </td>
       <td style="text-align: justify">
        Ongoing and future intellectual property disputes could require us to spend time and money to address such disputes and couldlimit our intellectual property rights.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        4.
       </td>
       <td style="text-align: justify">
        The decisions by the European and German patent offices may affect patent rights in other jurisdictions.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        5.
       </td>
       <td style="text-align: justify">
        If we infringe the rights of third parties we could be prevented from selling products and forced to pay damages and defendagainst litigation.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
     </b>
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <span style="text-decoration:underline">
       Risks Related to Dependence on Third Parties
      </span>
     </b>
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        1.
       </td>
       <td style="text-align: justify">
        We currently have no internal marketing and sales organization and currently rely and intend to continue to rely on third partiesto market, sell, and distribute Neutrolin outside of the U.S. We may seek a sales partner in the U.S. if DefenCath receives FDAapproval or we may undertake marketing and sales of DefenCath in the U.S. on our own. If we are unable to enter into or maintainagreements with third parties to market and sell DefenCath or any other product after approval or are unable to find a sales partneror establish our own marketing and sales capabilities, we may not be able to generate significant or any product revenues.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        2.
       </td>
       <td style="text-align: justify">
        If we or our collaborators are unable to manufacture our products in sufficient quantities or areunable to obtain regulatory approvals for a manufacturing facility, we may be unable to meet demand for our products and we maylose potential revenues.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        3.
       </td>
       <td style="text-align: justify">
        Corporate and academic collaborators may take actions that delay, prevent, or undermine the success of our products.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        4.
       </td>
       <td style="text-align: justify">
        Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to befalse, misleading, or incomplete.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        5.
       </td>
       <td style="text-align: justify">
        We rely on third parties to conduct our clinical trials and pre-clinical studies. If those parties do not successfully carryout their contractual duties or meet expected deadlines, our product candidates may not advance in a timely manner or at all.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        6.
       </td>
       <td style="text-align: justify">
        We will depend on third party suppliers and contract manufacturers for the manufacturing of our product candidates and haveno direct control over the cost of manufacturing our product candidates. Increases in the cost of manufacturing our product candidateswould increase our costs of conducting clinical trials and could adversely affect our future profitability.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <span style="text-decoration:underline">
       Risks Related to Our Common Stock
      </span>
     </b>
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        1.
       </td>
       <td style="text-align: justify">
        We will need additional financing to fund our activities in the future, which likely will dilute our stockholders.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        2.
       </td>
       <td style="text-align: justify">
        Our executive officers and directors may sell shares of their stock, and these sales could adversely affect our stock price.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        3.
       </td>
       <td style="text-align: justify">
        Our common stock price has fluctuated considerably and is likely to remain volatile, in part due to the limited market forour common stock and you could lose all or a part of your investment.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        4.
       </td>
       <td style="text-align: justify">
        A significant number of additional shares of our common stock may be issued at a later date, and their sale could depress themarket price of our common stock.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        5.
       </td>
       <td style="text-align: justify">
        Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficialto our stockholders, more difficult.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        6.
       </td>
       <td style="text-align: justify">
        If we fail to comply with the continued listing standards of the Nasdaq Global Market, it may result in a delisting of ourcommon stock from the exchange.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        7.
       </td>
       <td style="text-align: justify">
        Laws, rules and regulations relating to public companies may be costly and impact our ability to attract and retain directorsand executive officers.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        8.
       </td>
       <td style="text-align: justify">
        Our internal control over financial reporting and our disclosure controls and procedures may not prevent all possible errorsthat could occur.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        9.
       </td>
       <td style="text-align: justify">
        Security breaches and other disruptions could compromise our information and expose us to liability, which would cause ourbusiness and reputation to suffer.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        10.
       </td>
       <td style="text-align: justify">
        We do not intend to pay dividends on our common stock so any returns on our common stock will be limited to the value of ourcommon stock.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 20; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      18
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      RisksRelated to Our Financial Position and Need for Additional Capital
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wehave a history of operating losses, expect to incur additional operating losses in the future and may never be profitable.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourprospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companiesin the early stages of operation. We incurred net losses of approximately $22.0 million and $16.4 million for the years endedDecember 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of approximately $217.4 million.We expect to incur substantial additional operating expenses over the next several years as our research, development, pre-clinicaltesting, clinical trial and commercialization activities increase as we develop and commercialize DefenCath and our other productcandidates. As a result, we expect to experience negative cash flow as we fund our operating losses and capital expenditures.The amount of future losses and when, if ever, we will achieve profitability are uncertain. Neutrolin was launched in December2013 and is currently available for distribution in certain European Union and Middle East countries. We have not generated anysignificant commercial revenue and do not expect to generate substantial revenues from DefenCath unless and until it is approvedby the United States Food and Drug Administration (“FDA”) and launched in the United States (“U.S.”) market,and we might never generate significant revenues from the sale of DefenCath or any other products. Our ability to generate revenueand achieve profitability will depend on, among other things, the following: obtaining FDA approval of DefenCath for the preventionof catheter-related bloodstream infections (“CRBSIs”) in patients with kidney failure receiving hemodialysis througha central venous catheter; successfully launching and marketing DefenCath in the U.S., if approved by the FDA; successfully marketingNeutrolin in foreign countries in which it is approved for sale; obtaining necessary regulatory approvals for our other productcandidates from the FDA and, if sought, international regulatory agencies; establishing manufacturing, sales, and marketing arrangements,either alone or with third parties; and raising sufficient funds to finance our activities. We might not succeed at any of theseundertakings. If we are unsuccessful at some or all of these undertakings, our business, prospects, and results of operationsmay be materially adversely affected.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ourcost of operations could increase significantly more than what we expect depending on the costs to complete our development programfor DefenCath.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ouroperations are subject to a number of factors that can affect our operating results and financial condition. Such factors include,but are not limited to: the results of clinical testing and trial activities of our product candidates; the ability to obtainregulatory approval to market our products; ability to manufacture successfully; competition from products manufactured and soldor being developed by other companies; the price of, and demand for, our products; our ability to negotiate favorable licensingor other manufacturing and marketing agreements for our products; and our ability to raise capital to support our operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     To date, our commercial operations have not generated sufficientrevenues to enable profitability. As of December 31, 2020, we had an accumulated deficit of $217.4 million, and incurred net lossesof $22.0 million for the year then ended. Based on the current development plans for DefenCath and Neutrolin in both the U.S. andforeign markets (including the concluded hemodialysis Phase 3 clinical trial in the U.S.) and our other operating requirements,management believes that the existing cash at December 31, 2020, after taking into consideration the $41.5 million of net proceedsreceived in January and February 2021 from the at-the-market program, will be sufficient to fund operations at least into the secondhalf of 2022. We will need additional funding for the commercialization of DefenCath upon FDA approval and funding for the labelexpansion studies for DefenCath into oncology and total parenteral nutrition.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourcontinued operations will ultimately depend on our ability to raise additional capital through various potential sources, suchas equity and/or debt financings, strategic relationships, potential strategic transactions or out-licensing of our products inorder to complete the development of DefenCath and until we achieve profitability, if ever. We can provide no assurances thatsuch financing or strategic relationships will be available on acceptable terms, or at all. Without this funding, we could berequired to delay, scale back or eliminate some or all of our research and development programs which would likely have a materialadverse effect on our business.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 21; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      19
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wewill need to finance our future cash needs through public or private equity offerings, debt financings or corporate collaborationand licensing arrangements. Any additional funds that we obtain may not be on terms favorable to us or our stockholders and mayrequire us to relinquish valuable rights.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wehave launched Neutrolin in certain European Union and Middle East countries, but to date have no other approved product on themarket and have not generated significant product revenue from Neutrolin to date. Unless and until we receive applicable regulatoryapproval for DefenCath in the U.S., we cannot sell DefenCath in the U.S. Therefore, for the foreseeable future, we will have tofund all of our operations and capital expenditures from Neutrolin sales in Europe and other foreign markets, if approved, cashon hand, additional financings, licensing fees and grants.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We believe that our cash resources as of December 31, 2020,after taking into consideration the $41.5 million of net proceeds received in January and February 2021 from the at-the-marketprogram, will be sufficient to fund operations at least into the second half of 2022. Nevertheless, we may need to raise additionalfunds through financings or strategic relationships if our costs exceed our expectations, as well as funds for our operations beyondthe second half of 2022. We can provide no assurances that any financing or strategic relationships will be available to us onacceptable terms, or at all. We expect to continue to use significant cash to fund our operations as we seek FDA approval of DefenCathin the U.S., commercialize Neutrolin in Europe and other markets, pursue development of our medical devices and other businessdevelopment activities, and incur additional legal costs to defend our intellectual property.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Toraise needed capital, we may sell additional equity or debt securities, obtain a bank credit facility, or enter into a corporatecollaboration or licensing arrangement. The sale of additional equity or debt securities, if convertible, could result in dilutionto our stockholders. The incurrence of indebtedness would result in fixed obligations and could also result in covenants thatwould restrict our operations. Raising additional funds through collaboration or licensing arrangements with third parties mayrequire us to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates,or to grant licenses on terms that may not be favorable to us or our stockholders.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 22; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      20
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <span style="text-decoration:underline">
        RisksRelated to the Development and Commercialization of Our Product Candidates
       </span>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        DefenCath,our lead product candidate, has received Fast Track designation and Qualified Infectious Disease Product designation from FDA,but we cannot provide assurances that these designations will not be rescinded.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      DefenCathis being developed as a catheter lock solution for the reduction of CRBSIs in patients with kidney failure receiving hemodialysisthrough a central venous catheter. The FDA has determined that DefenCath will be regulated as a New Drug, because it containsthe new chemical entity taurolidine as a novel antimicrobial agent. After we filed the Investigational New Drug Application (“IND”),FDA granted designations as Fast Track and a Qualified Infectious Disease Product (“QIDP”) in January 2015. Fast Trackis designed to facilitate development of a drug that is intended to treat a serious or life-threatening condition and addressan unmet medical need. Fast Track confers eligibility to request priority review of an NDA, with FDA’s decision regardingpotential priority review to be made after receipt of a complete application. QIDP was established pursuant to the GeneratingAntibiotic Incentives Now (“GAIN”) Act and creates incentives for the development of antibacterial and antifungaldrug products that treat serious or life-threatening infections. Subject to the specified statutory limitations, a drug that isdesignated as QIDP and is approved for the use for which the QIDP designation was granted will receive a 5-year extension to anyexclusivity for which the application qualifies upon approval, such as the 5 year exclusivity for a new chemical entity. We cannotprovide assurances that DefenCath will retain these designations and continue to receive the benefits conferred.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifthe FDA requires a second clinical trial for DefenCath or imposes additional manufacturing requirements to approve the New DrugApplication, the development of DefenCath will take longer and cost more to complete, and we will need significant additionalfunds to undertake a second trial, if required.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Although two pivotalclinical trials to demonstrate safety and effectiveness of DefenCath are generally required by the FDA to secure marketing approvalin the U.S., FDA will in some cases accept one adequate and well-controlled trial, where it is a large multicenter trial with abroad range of subjects and investigation sites with procedures to include trial quality that has demonstrated a clinically meaningfuland statistically very persuasive effect on prevention of a disease with potentially serious outcome. We discussed submission ofthe NDA with the FDA based on the data from LOCK-IT-100 and were granted our request for rolling submission and review of the NDAfor DefenCath as a catheter lock solution for the prevention of CRBSIs in patients with end stage renal disease receiving hemodialysisthrough a central venous catheter. In August 2020, the FDA accepted the DefenCath NDA for filing and granted our request for priorityreview, with a PDUFA date of February 28, 2021. As we announced in March 2021, the FDA informed us in a Complete Response Letterthat it will not approve the NDA in its present form, because of concerns at the third-party manufacturing facility and a requirementto conduct a manual extraction study to demonstrate that the labeled volume can be consistently withdrawn from the vials. We planto meet with the FDA to obtain agreement on the proposed resolutions of the deficiencies. The FDA did not request additional clinicaldata and did not identify any deficiencies related to the data submitted on the efficacy and safety of DefenCath from LOCK-IT-100.In draft labeling discussed with FDA, the FDA added that the initial approval will be for the limited population of patients withkidney failure receiving hemodialysis through a central venous catheter. This is consistent with our request for approval of theNDA pursuant to the Limited Population Pathway for Antibacterial and Antifungal Drugs (“LPAD”) pathway, which was passedas part of the 21st Century Cures Act. LPAD is intended to expedite the development and approval of certain antibacterial and antifungaldrugs which meet three criteria: intended to treat serious or life-threatening infections; in limited populations of patients;and with unmet needs. The LPAD pathway provides for a streamlined clinical development program for a limited population that mayinvolve smaller, shorter or fewer clinical trials. Labeling of an LPAD approved product will specify the use in the limited population.However, until the NDA is approved, if we experience issues related to the clinical trial results, we may incur additional costsand delays in the trial, and may not be able to complete the clinical trial in a cost-effective or timely manner, which would havean adverse effect on our development program for DefenCath as a treatment for catheter-related bloodstream infections.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ouronly product Neutrolin is only approved in Europe and is still in development in the United States.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Neutrolincurrently and for at least the near future is our only current product as well as product candidate. Neutrolin has received CEMark approval in Europe, and we started sales in Germany in December 2013. We also are pursuing development of DefenCath in theU.S. Our product commercialization and development efforts may not lead to commercially viable products for any of several reasons.For example, our product candidates may fail to be proven safe and effective in clinical trials, or we may have inadequate financialor other resources to pursue development efforts for our product candidates. Even if approved, our product may not be acceptedin the marketplace. DefenCath will require significant additional development, including the preparation and filing of an NDA,possibly a second clinical trial, and/or investment by us or our collaborators as we continue its commercialization, as will anyother product candidates.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 23; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      21
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In April 2017, we enteredinto a commercial collaboration with Hemotech SAS covering France and certain overseas territories. We have an agreement with aSouth Korean company to market, sell and distribute Neutrolin in South Korea upon receipt of regulatory approval in that country,which requires approval by the U.S. FDA. We also have commercial sales in Germany and a distributor agreement for the United ArabEmirates, which is pursuant to the EU CE Mark. Consequently, we will be dependent on these companies and individuals for the successof sales in those countries and any other countries in which we receive regulatory approval and in which we contract with thirdparties for the marketing, sale and/or distribution of Neutrolin. If these companies or individuals do not perform for whateverreason, our business, prospects and results of operations will be adversely affected. Finding a suitable replacement organizationor individual for these or any other companies or individuals with whom we might contract could be difficult, which would furtherharm our business, prospects and results of operations. The negotiation and consummation of collaboration agreements typicallyinvolve simultaneous discussions with multiple potential collaborators and require significant time and resources. In addition,in attracting the attention of pharmaceutical and biotechnology company collaborators, we compete with numerous other third partieswith product opportunities as well as the collaborators’ own internal product opportunities. We may not be able to consummatecollaborative agreements, or we may not be able to negotiate commercially acceptable terms for these agreements.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <b>
      <i>
       Final approval by regulatory authoritiesof our product candidates for commercial use may be delayed, limited or prevented, any of which would adversely affect our abilityto generate operating revenues.
      </i>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Our ability to generateoperating revenue will be severely limited until we, a licensee, or a potential collaborator successfully commercializes DefenCathin the United States. We may experience unforeseen events during product development that may substantially delay or prevent productapproval. For example, in the course of conducting a clinical trial, the FDA could order the temporary, or permanent, discontinuationat any time if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presentsan unacceptable risk to the clinical trial patients. An Institutional Review Board (“IRB”) may also require the clinicaltrial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements or ifthe trial poses an unexpected serious harm to clinical trial patients. The FDA or an IRB may also impose conditions on the conductof a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to clinical trialpatients, a lack of favorable results, or changing business priorities.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     The clinical development,manufacturing, labeling, packaging, storage, recordkeeping, export, marketing, promotion and distribution, and other possible activitiesrelating to our product candidates are subject to extensive regulation by the FDA and other regulatory agencies. Failure to complywith applicable regulatory requirements may, either before or after product approval, subject us to administrative or judiciallyimposed sanctions that may negatively impact the approval of one or more of our product candidates or otherwise negatively impactour business. Compliance with such regulations may consume substantial financial and management resources and expose us and ourcollaborators to the potential for other adverse circumstances. For example, a regulatory authority can place restrictions on thesale or marketing of a drug in order to manage the risks identified during initial clinical trials or after the drug is on themarket. A regulatory authority can condition the approval for a drug on costly post-marketing follow-up studies. Based on thesestudies, if a regulatory authority does not believe that the drug demonstrates a clinical benefit to patients or an acceptablesafety profile, it could limit the indications for which a drug may be sold or revoke the drug’s marketing approval. In addition,identification of certain side effects either during clinical trials or after a drug is on the market may result in reformulationof a drug, additional pre-clinical and clinical trials, labeling changes, termination of ongoing clinical trials or withdrawalof approval. Any of these events could delay or prevent us from generating revenue from the commercialization of these drugs andcause us to incur significant additional costs.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Neither collaborators,licensees nor we are permitted to market a product candidate in the United States until the particular product candidate is approvedfor marketing by the FDA. Specific pre-clinical data, chemistry, manufacturing and controls data, a proposed clinical trial protocoland other information must be submitted to the FDA as part of an IND application, and clinical trials may commence only after theIND application becomes effective. To market a new drug in the United States, we must submit to the FDA and obtain FDA approvalof an NDA. An NDA must be supported by extensive clinical and pre-clinical data, as well as extensive information regarding chemistry,manufacturing and controls, to demonstrate the safety and effectiveness of the product candidate, and the FDA will also assesswhether the manufacturing processes and facilities are suitable to support the application. Approval of an NDA may be delayed dueto delays in FDA’s review of the manufacturing facility, which may require an onsite inspection.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Obtaining approvalof an NDA can be a lengthy, expensive and uncertain process. Review time can be impacted by the quality of the information includedin the application, FDA’s internal resources such as the availability of reviewers, or requests from the FDA for additionalinformation. Regulatory approval of an NDA is not guaranteed. The number and types of pre-clinical studies and clinical trialsthat will be required for FDA approval varies depending on the product candidate, the disease or condition that the product candidateis designed to target and the regulations applicable to any particular product candidate. Despite the time and expense exertedin pre-clinical and clinical studies, failure can occur at any stage, and we could encounter problems that delay our product candidatedevelopment or that cause us to abandon clinical trials or to repeat or perform additional pre-clinical studies and clinical trials.The FDA can delay, limit or deny approval of a product candidate for many reasons, and product candidate development programsmay be delayed or may not be successful for many reasons including but not limited to, the following:
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         The FDA or IRBs may not authorize us to commence, amend, or continue clinical studies;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         we may not be able to enroll a sufficient number of qualified patients for clinical trials in a timely manner or at all, patients may drop out of our clinical trials or be lost to follow-up at a higher rate than we anticipate, patients may not follow the clinical trial procedures, or the number of patients required for clinical trials may be larger than we anticipate;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA may not accept an NDA or other submission due to, among other reasons, the content or formatting of the submission;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         a product candidate may not be deemed adequately safe or effective for an intended use;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 24; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      22
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA may not find the data from pre-clinical studies and clinical trials sufficient;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA may require that we conduct additional pre-clinical or clinical studies, change our manufacturing process, or gather additional manufacturing information above what we currently have planned for;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA’s interpretation and our interpretation of data from pre-clinical studies and clinical trials or chemistry, manufacturing and controls data may differ significantly;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA may not agree with our intended indications, the design of our clinical or pre-clinical studies, or there may be a flaw in the design that does not become apparent until the studies are well advanced;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         we may not be able to establish agreements with contractors or collaborators or they or we may fail to comply with applicable FDA and other regulatory requirements, including those identified in other risk factors;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA may not accept aspects of our proposed labeling, or may impose specific limitations in the labeling and require post-marking commitments or Phase 4 clinical trials before the labeling can be expanded;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA may determine that the manufacturing processes and facilities for our product candidate do not have sufficient good manufacturing practice (GMP) controls in place to support approval; or
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the FDA may change its approval policies or adopt new regulations.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Our pre-clinical andclinical data, other information and procedures relating to a product candidate may not be sufficient to support approval by theFDA or any other U.S. or foreign regulatory authority, or regulatory interpretation of these data and procedures may be unfavorable.Failure to conduct required post-approval studies, or confirm a clinical benefit, will allow the FDA to withdraw the drug fromthe market on an expedited basis. Our business and reputation may be harmed by any failure or significant delay in receiving regulatoryapproval for the sale of any drugs resulting from our product candidates. As a result, we cannot predict when or whether regulatoryapproval will be obtained for any drug we develop.
    </p>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Additionally, otherfactors may serve to delay, limit or prevent the final approval by regulatory authorities of our product candidates for commercialuse, including, but not limited to:
    </p>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         we or our licensees will need to conduct significant clinical testing and development work to demonstrate the quality, safety, and efficacy of these product candidates before applications for marketing can be filed with the FDA, or with the regulatory authorities of other countries;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         development and testing of product formulation, including identification of suitable excipients, or chemical additives intended to facilitate delivery of our product candidates;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="font: 6pt Times New Roman, Times, Serif; width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         it may take us many years to complete the testing of our product candidates, and failure can occur at any stage of this process; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         negative or inconclusive results or adverse medical events during a clinical trial could cause us to delay or terminate our development efforts.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     The successful developmentof any of these product candidates is uncertain and, accordingly, we may never commercialize any of these product candidates orgenerate significant revenue.
    </p>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 6pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Successfuldevelopment and commercialization of our products is uncertain.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourdevelopment and commercialization of current and future product candidates is subject to the risks of failure and delay inherentin the development of new pharmaceutical products, including but not limited to the following:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         inability                                         to produce positive data in pre-clinical and clinical trials;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 6pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 6pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         delays                                         in product development, pre-clinical and clinical testing, or manufacturing;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         unplanned                                         expenditures in product development, clinical testing, or manufacturing;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         challenges                                         with securing the heparin supply chain;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         uncertainties                                         relating to, or changes in FDA view of, the appropriate product approval pathway;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         failure                                         to obtain treatment of a drug or application under expedited development and review programs                                         or to obtain marketing exclusivities;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         failure                                         to receive or maintain regulatory approvals;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         emergence                                         of superior or equivalent products;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         inability                                         to manufacture our product candidates on a commercial scale on our own, or in collaboration                                         with third parties;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         failure                                         to comply with a broad range of post-marketing requirements including those related to                                         labeling, promotion and advertising, manufacturing and quality, pharmacovigilance and                                         adverse event reporting, commercial distribution and supply chain requirements, and drug                                         sample distribution requirements; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         failure                                         to achieve market acceptance.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Becauseof these risks, our development efforts may not result in any commercially viable products. If a significant portion of thesedevelopment efforts are not successfully completed, required regulatory approvals are not obtained or any approved products arenot commercialized successfully, our business, financial condition, and results of operations will be materially harmed.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 25; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      23
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <b>
      <i>
       If we fail to comply with environmental,health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
      </i>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     From time to time andin the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials,and may also produce hazardous waste. Even if we contract with third parties for the disposal of these materials and waste, wecannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination orinjury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and anyliability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penaltiesfor failure to comply with such laws and regulations.
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In addition, we mayincur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Currentor future environmental laws and regulations may impair our research, development or production efforts. In addition, failure tocomply with these laws and regulations may result in substantial fines, penalties or other sanctions.
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <b>
      <i>
       The successful commercializationof DefenCath will depend on obtaining coverage and reimbursement for use of DefenCath from third-party payors.
      </i>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Sales of pharmaceuticalproducts largely depend on the reimbursement of patients’ medical expenses by government health care programs and/or privatehealth insurers, both in the U.S. and abroad. Further, significant uncertainty exists as to the reimbursement status of newly approvedhealth care products. We initially expect to sell DefenCath directly to hospitals and key dialysis center operators, but also planto expand its usage into oncology and total parenteral nutrition patients requiring catheters. All of these potential customersare healthcare providers who depend upon reimbursement by government and commercial insurance payors for dialysis and other treatments.Depending on the treatment setting, we believe that DefenCath would be eligible for coverage under various reimbursement programs,such as the End Stage Renal Disease (“ESRD”) Prospective Payment System and ESRD Quality Incentive Program; however,coverage by any of these reimbursement programs is not assured, and even if coverage is granted, it could later be revoked or modifiedunder future regulations. Further, the U.S. Centers for Medicare &amp; Medicaid Services (“CMS”), which administersMedicare, and works with states to administer Medicaid, has adopted and will continue to adopt and/or amend rules governing reimbursementfor specific treatments. We anticipate that CMS and private insurers will increasingly demand that manufacturers demonstrate thecost effectiveness of their products as part of the reimbursement review and approval process. Rising healthcare costs have alsoled many European and other foreign countries to adopt healthcare reform proposals and medical cost containment measures. Similarlegislation could be introduced in the U.S. Any measures affecting the reimbursement programs of these governmental and privateinsurance payors, including any uncertainty in the medical community regarding their nature and effect on reimbursement programs,could have an adverse effect on purchasing decisions regarding DefenCath, as well as limit the prices we may charge for DefenCath.The failure to obtain or maintain reimbursement coverage for DefenCath or any other products could materially harm our operations.
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In anticipation thatthe CMS and private payers will demand that we demonstrate the cost effectiveness of DefenCath as part of the reimbursement reviewand approval process, we will incorporate health economic evaluations into our clinical studies to support this review in the contextof the prospective use of DefenCath in dialysis, oncology and total parenteral nutrition settings. However, our studies might notbe sufficient to support coverage or reimbursement at levels that allow providers to use DefenCath.
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <b>
      <i>
       Physicians and patients may not accept and useour products.
      </i>
     </b>
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Even with the CE Markapproval of Neutrolin, and even if we receive FDA or other foreign regulatory approval for DefenCath/Neutrolin or other productcandidates, physicians and patients may not accept and use our products. Acceptance and use of our products will depend upon anumber of factors including the following:
    </p>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         perceptions by members of the health care community, including physicians, about the safety and effectiveness of our drug or device product;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         prevalence of the disease to be treated;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         prevalence and severity of any side effects;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         cost-effectiveness of our product relative to competing products;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         availability of coverage and reimbursement from government and other third-party payers;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         timing of market introduction of our drugs and competitive drugs;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         potential or perceived advantages or disadvantages over alternative treatments;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         potential post-marketing commitments imposed by regulatory authorities, such as patient registries;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         price of our future products, both in absolute terms and relative to alternative treatments; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 48px">
       </td>
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the effect of current and future healthcare laws and regulations on our product candidates.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Because we expect salesof DefenCath to generate substantially all of our product revenues for the foreseeable future, the failure of DefenCath to findmarket acceptance would harm our business and would require us to seek additional financing.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 26; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      24
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Changesin funding for the FDA and other government agencies or future government shutdowns or disruptions could cause delays in the submissionand regulatory review of marketing applications, which could negatively impact our business or prospects.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theability of the FDA to review and approve new products can be affected by a variety of factors, including government budget andfunding levels, ability to hire and retain key personnel and accept submission, applications, and the payment of user fees, andstatutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research anddevelopment activities is subject to the political process, which is inherently fluid and unpredictable. The impact of globalevents, including terrorism, natural disasters and pandemics, including the ongoing COVID-19 pandemic or other health emergencies,may also cause disruptions in the normal functioning of the FDA or other government agencies.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Disruptions at theFDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, had to furlough criticalFDA employees and stop critical activities. In addition, in March 2020, the FDA announced the postponement of most foreign inspectionsdue to the global impact of COVID-19, which has continued for more than a year. If a prolonged government shutdown or other disruptionto the normal functioning of government agencies occurs, it could significantly impact the ability of the FDA to timely reviewand process our regulatory submissions, which could have a material adverse effect on our business or prospects. At this time,there is a backlog at FDA in conducting pre-approval inspections of manufacturing facilities, because of travel restrictions imposedby COVID-19. Such backlog has prevented the FDA from inspecting the facilities of our CMO for the manufacturing of DefenCath, whichis located outside the United States. If FDA deems a pre-approval inspection to be necessary for approval of the DefenCath NDA,there will be a delay until FDA inspectors can resume travel.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Theoutbreak of the novel coronavirus disease, COVID-19, or other pandemic, epidemic or outbreak of an infectious disease may materiallyand adversely impact our business, including our preclinical studies and clinical trials.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In December 2019, thenovel coronavirus disease, COVID-19, was identified in Wuhan, China. This virus has been declared a pandemic and has spread tomultiple global regions. The outbreak and government measures taken in response have also had a significant impact, both directand indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities andproduction have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, whiledemand for other goods and services, such as travel, has fallen. In response to the COVID-19 outbreak, “shelter in place”orders and other public health guidance measures have been implemented across much of the United States, Europe and Asia, includingin the locations of our offices, clinical trial sites, key vendors and partners. Such “shelter in place” orders werepreviously lifted, at least partially, in many locations. However, an increase in the spread of COVID-19 and variants, which mayreflect the spread of one or more successive waves of the virus, has led to the re-imposition by many states of quarantine requirementsfor out-of-state travelers and may lead to the re-imposition of “shelter-in-place” or other similar orders. Althoughseveral vaccines for prevention or mitigation of the severity of the virus have been granted Emergency Use Authorization by theFDA and foreign regulatory authorities, the timely distribution and public acceptance thereof in reducing the pandemic remain uncertain.Our clinical development program timelines may be negatively affected by COVID-19, which could materially and adversely affectour business, financial condition and results of operations. Further, due to “shelter in place” orders and other publichealth guidance measures, we have implemented a work-from-home policy for all staff members excluding those necessary to maintainminimum basic operations. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt,delay or otherwise adversely impact our business.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Asa result of the COVID-19 outbreak, or similar pandemics, and related travel restrictions and “shelter in place” ordersand other public health guidance measures, we have and may in the future experience disruptions that could materially and adverselyimpact our clinical trials, business, financial condition and results of operations. Potential disruptions include but are notlimited to:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         delays                                         or difficulties at our third-party vendors on whom we are dependent for manufacturing                                         activities;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         delays                                         or difficulties in enrolling patients in our clinical trials;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         delays                                         or difficulties in initiating or expanding clinical trials, including delays or difficulties                                         with clinical site initiation and recruiting clinical site investigators and clinical                                         site staff;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 27; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      25
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         increased                                         rates of patients withdrawing from our clinical trials following enrollment as a result                                         of contracting COVID-19 or other health conditions or being forced to quarantine;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         diversion                                         of healthcare resources away from the conduct of clinical trials, including the diversion                                         of hospitals serving as our clinical trial sites and hospital staff supporting the conduct                                         of our clinical trials;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         interruption                                         of key clinical trial activities, such as clinical trial site data monitoring, due to                                         limitations on travel imposed or recommended by federal or state governments, employers                                         and others or interruption of clinical trial subject visits and study procedures, which                                         may impact the integrity of subject data and clinical study endpoints;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         interruption                                         or delays in the operations of the FDA or other regulatory authorities, which may impact                                         review and approval timelines for our NDA;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         delays                                         or disruptions in preclinical experiments and investigational new drug application-enabling                                         studies due to restrictions of on-site staff and unforeseen circumstances at contract                                         research organizations and vendors;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         interruption                                         of, or delays in receiving supplies of our product candidates from our contract manufacturing                                         organizations due to staffing shortages, production slowdowns or stoppages and disruptions                                         in delivery systems;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         limitations                                         on our ability to recruit and hire key personnel due to our inability to meet with candidates                                         because of travel restrictions and “shelter in place” orders;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         limitations                                         on employee resources that would otherwise be focused on the conduct of our preclinical                                         studies and clinical trials, including because of sickness of employees or their families                                         or the desire of employees to avoid contact with large groups of people; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         interruption                                         or delays to our sourced discovery and clinical activities.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheCOVID-19 pandemic continues to rapidly evolve. The extent to which the outbreak impacts our business, preclinical studies andclinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such asthe ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in theUnited States and other countries, business closures or business disruptions and the effectiveness of actions taken in the UnitedStates and other countries to contain and treat the disease. If we or any of the third parties with whom we engage were to experienceshutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently plannedcould be materially and negatively impacted.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a resultof the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our common stock or such salesmay be on unfavorable terms.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Clinicaltrials required for our product candidates may be expensive and time-consuming, and their outcome is uncertain.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inorder to obtain FDA or foreign approval to market a new drug or device product, we must demonstrate proof of safety and effectivenessin humans. Foreign regulations and requirements are similar to those of the FDA. To meet FDA requirements, we must conduct “adequateand well-controlled” clinical trials. Conducting clinical trials is a lengthy, time-consuming, and expensive process. Thelength of time may vary substantially according to the type, complexity, novelty, and intended use of the product candidate, andoften can be several years or more per trial. Delays associated with the DefenCath development program or the development plansfor any other product candidates may cause us to incur additional operating expenses. The commencement and rate of completionof clinical trials may be delayed by many factors, including, for example:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         inability                                         to manufacture sufficient quantities of qualified materials under the FDA’s cGMP                                         requirements for use in clinical trials;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         slower                                         than expected rates of patient recruitment;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 28; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      26
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         failure                                         to recruit a sufficient number of patients;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         modification                                         of clinical trial protocols;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         changes                                         in regulatory requirements for clinical trials;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         lack                                         of effectiveness during clinical trials;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         emergence                                         of unforeseen safety issues;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         delays,                                         suspension, or termination of clinical trials due to the IRB responsible for overseeing                                         the study at a particular study site; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         government                                         or regulatory delays or “clinical holds” requiring suspension or termination                                         of the trials.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Further,the results from early pre-clinical and clinical trials are not necessarily predictive of results to be obtained in later clinicaltrials. Accordingly, even if we obtain positive results from early pre-clinical or clinical trials, we may not achieve the samesuccess in later clinical trials. Moreover, comparisons of results across different studies should be viewed with caution as suchcomparisons are limited by a number of factors, including differences in study designs and populations. Such comparisons alsowill not provide a sufficient basis for any comparative claims following product approval. Clinical results are frequently susceptibleto varying interpretations that may delay, limit or prevent regulatory approvals or commercialization. Negative or inconclusiveresults or adverse medical events during a clinical trial could cause a clinical trial to be delayed, repeated or terminated,or a clinical program to be abandoned.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourclinical trials may be conducted in patients with serious or life-threatening diseases for whom conventional treatments have beenunsuccessful or for whom no conventional treatment exists, and in some cases, our product is expected to be used in combinationwith approved therapies that themselves have significant adverse event profiles. During the course of treatment, these patientscould suffer adverse medical events or die for reasons that may or may not be related to our products. We cannot ensure that safetyissues will not arise with respect to our products in clinical development.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Clinicaltrials may not demonstrate statistically significant safety and effectiveness to obtain the requisite regulatory approvals forproduct candidates. The failure of clinical trials to demonstrate safety and effectiveness for the desired indications could harmthe development of our product candidates. Such a failure could cause us to abandon a product candidate and could delay developmentof other product candidates. Any delay in, or termination of, our clinical trials would delay the filing of any NDA or any PremarketApproval Application, or PMA, with the FDA and, ultimately, our ability to commercialize our product candidates and generate productrevenues. Any change in, or termination of, our clinical trials could materially harm our business, financial condition, and resultsof operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe fail to comply with international regulatory requirements, we could be subject to regulatory delays, fines or other penalties.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Regulatoryrequirements in foreign countries for international sales of medical devices often vary from country to country. The occurrenceand related impact of the following factors would harm our business:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         delays                                         in receipt of, or failure to receive, foreign regulatory approvals or clearances;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the                                         loss of previously obtained approvals or clearances; or
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the                                         failure to comply with existing or future regulatory requirements.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 29; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      27
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheCE Mark is a mandatory conformity mark for products to be sold in the European Economic Area. Currently, 28 countries in Europerequire products to bear CE Marking. To market in Europe, a product must first obtain the certifications necessary to affix theCE Mark. The CE Mark is an international symbol of adherence to the Medical Device Regulations, previously the Medical DeviceDirectives, and the manufacturer’s declaration that the product complies with essential requirements. Compliance with theserequirements is ascertained within a certified Quality Management System (QMS) pursuant to ISO 13485. In order to obtain and tomaintain a CE Mark, a product must be in compliance with the applicable quality assurance provisions of the aforementioned ISOand obtain certification of its quality assurance systems by a recognized European Union notified body. We received CE Mark approvalfor Neutrolin on July 5, 2013. However, certain individual countries within the European Union require further approval by theirnational regulatory agencies. Additionally, implementation of the new European Union Medical Device Regulations may pose challengesin demonstrating continued conformity to the new medical device regulatory paradigm. Failure to receive or maintain these otherrequisite approvals could prohibit us from marketing and selling Neutrolin in the entire European Economic Area or elsewhere.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wedo not have, and may never obtain, the regulatory approvals we need to market our product candidates outside of the European Union.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Whilewe have received the CE Mark approval for Neutrolin in Europe, certain individual countries within the European Union requirefurther approval by their national regulatory agencies. Failure to receive or maintain these other requisite approvals could prohibitus from marketing and selling Neutrolin in the entire European Economic Area. In addition, we will need regulatory approval tomarket and sell Neutrolin in foreign countries outside of Europe.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In the United States,we have not received the regulatory approvals required for the commercial sale of any of our product candidates. The NDA for DefenCathcould not be approved by FDA in its present form and resolution of deficiencies at our third-party manufacturing facility is required.Additionally, the FDA is requiring a manual extraction study to demonstrate that the labeled volume can be consistently withdrawnfrom the vials despite an existing in-process control to demonstrate fill volume within specifications. We plan to meet with theFDA to discuss proposed resolutions to the deficiencies, but we may not be able to obtain regulatory approval for commercial distribution.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wealso are pursuing development of taurolidine-based devices for several indications, including wound closure, surgical meshes,and wound management. The FDA regards taurolidine as a new chemical entity and therefore an unapproved new drug. Consequently,there is no appropriate predicate device currently marketed in the U.S. on which a 510(k) approval process for these devices couldbe based. As a result, we will be required to submit a premarket approval application for marketing authorization for these indications.In the event that the NDA for DefenCath is approved by the FDA, the regulatory pathway for these devices can be revisited withthe FDA. Although there will presumably still be no appropriate predicate,
      <i>
       de novo
      </i>
      Class II designation can be proposed,based on a risk assessment and a reasonable assurance of safety and effectiveness.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Itis possible that DefenCath will not receive any further approval or that any of our other product candidates will be approvedfor marketing. Failure to obtain regulatory approvals, or delays in obtaining regulatory approvals, would adversely affect thesuccessful commercialization of DefenCath or any other drugs or products that we or our partners develop, impose additional costson us or our collaborators, diminish any competitive advantages that we or our partners may attain, and/or adversely affect ourcash flow, financial condition and results of operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Evenif approved, our products will be subject to extensive post-approval regulation.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Oncea product is approved, numerous post-approval requirements apply in the United States and abroad. These include, among other things,requirements related to pharmacovigilance and adverse event and other reporting, supply chain security requirements, suspect andillegitimate product investigations and notifications, limitations on product advertising and promotion and on the distributionof product samples, and ongoing adherence to cGMPs, as well as the need to submit appropriate new or supplemental applicationsand obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Establishingand maintaining systems and procedures for compliance with these requirements, and for training and monitoring personnel relativeto their compliance, is expensive, time consuming, and an ongoing effort. Depending on the circumstances, failure to meet thesepost-approval requirements can result in criminal prosecution, fines, injunctions, recall or seizure of products, total or partialsuspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supplycontracts, including government contracts. In addition, even if we comply with FDA, foreign and other requirements, new informationregarding the safety or effectiveness of a product could lead the FDA or a foreign regulatory body to modify or withdraw productapproval.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 30; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      28
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <span style="text-decoration:underline">
        RisksRelated to Our Business and Industry
       </span>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Competitionand technological change may make our product candidates and technologies less attractive or obsolete.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wecompete with established pharmaceutical and medical device companies that are pursuing other forms of prevention or treatmentfor the same or similar indications we are pursuing and that have greater financial and other resources. Other companies may succeedin developing products earlier than we do, obtaining FDA or any other regulatory agency approval for products more rapidly, ordeveloping products that are more effective than our product candidates. Research and development by others may render our technologyor product candidates obsolete or noncompetitive, or result in processes, treatments or cures superior to any therapy we develop.We face competition from companies that internally develop competing technology or acquire competing technology from universitiesand other research institutions. As these companies develop their technologies, they may develop competitive positions that mayprevent, make futile, or limit our product commercialization efforts, which would result in a decrease in the revenue we wouldbe able to derive from the sale of any products.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Therecan be no assurance that DefenCath or any other product candidate will be accepted by the marketplace as readily as these or othercompeting treatments. Furthermore, if our competitors’ products are approved before ours, it could be more difficult forus to obtain approval from the FDA or any other regulatory agency. Even if our products are successfully developed and approvedfor use by all governing regulatory bodies, there can be no assurance that physicians and patients will accept any of our productsas a treatment of choice.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Furthermore,the pharmaceutical and medical device industry is diverse, complex, and rapidly changing. By its nature, the business risks associatedwith the industry are numerous and significant. The effects of competition, intellectual property disputes, market acceptance,and FDA or other regulatory agency regulations preclude us from forecasting regulatory approval, product acceptance, revenuesor income with certainty or even confidence.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Healthcarepolicy changes, including reimbursement policies for drugs and medical devices, may have an adverse effect on our business, financialcondition and results of operations.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourfuture revenues, profitability and access to capital will be affected by the continuing efforts of governmental and private third-partypayors to manage, contain or reduce the costs of health care through various means, such as capping prices, limiting price increases,reducing reimbursement, and requiring rebates. Market acceptance and sales of DefenCath or any other product candidates that wedevelop will depend on reimbursement policies and may be affected by health care reform measures in the U.S. and abroad. Governmentauthorities and other third-party payors, such as private health insurers, decide which drugs they will pay for and establishreimbursement levels. We cannot be sure that reimbursement will be available for DefenCath or any other product candidates thatwe develop. Also, we cannot be sure that the amount of reimbursement available, if any, will not reduce the demand for, or theprice of, our products. If reimbursement is not available or is available only at limited levels, we may not be able to successfullycommercialize DefenCath or any other product candidates that we develop.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inboth the U.S. and certain foreign jurisdictions, there have been and we expect there will continue to be a number of legislativeand regulatory changes to the health care system that could affect our ability to sell our approved products profitably. The U.S.government and other governments have shown significant interest in pursuing healthcare reform. In particular, the Medicare ModernizationAct of 2003 revised the payment methodology for many products under the Medicare program in the United States. This has resultedin lower rates of reimbursement. In 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and EducationReconciliation Act (collectively, the “Affordable Care Act”), was enacted. The Affordable Care Act substantially changedthe way healthcare is financed by both governmental and private insurers. Such government-adopted reform measures may adverselyaffect the pricing of healthcare products and services in the U.S. or internationally and the amount of reimbursement availablefrom governmental agencies or other third-party payors.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inrecent years, the U.S. Congress has sought to repeal and has significantly amended the Affordable Care Act. We expect that therewill continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to keep healthcarecosts down while expanding individual healthcare benefits. Certain of these changes could impose limitations on the prices wewill be able to charge for any products that are approved or the amounts of reimbursement available for these products from governmentalagencies or other third-party payors or may increase the tax requirements for life sciences companies such as ours. Any such legislationcould have an adverse effect on our business, financial condition and results of operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 31; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      29
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Therehas been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, whichhave resulted in several recent Congressional inquiries and proposed and enacted bills by Congress and the states designed to,among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patientprograms, and reform government program reimbursement methodologies for products. In addition, the U.S. government, state legislatures,and foreign governments have shown significant interest in implementing cost containment programs, including price-controls, restrictionson reimbursement and requirements for substitution of generic products for branded prescription drugs to limit the growth of governmentpaid health care costs. For example, the U.S. government has passed legislation requiring pharmaceutical manufacturers to providerebates and discounts to certain entities and governmental payors to participate in federal healthcare programs. Further, Congressand the current administration have each indicated that it will continue to seek new legislative and/or administrative measuresto control drug costs, and the current administration recently released a “Blueprint”, or plan, to reduce the costof drugs. The current administration’s Blueprint contains certain measures that the U.S. Department of Health and HumanServices is already working to implement. Individual states in the United States have also been increasingly passing legislationand implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints,discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,designed to encourage importation from other countries and bulk purchasing.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Healthadministration authorities in countries other than the U.S. may not provide reimbursement for Neutrolin or any of our other productcandidates at rates sufficient for us to achieve profitability, or at all. Like the U.S., these countries could adopt health carereform proposals and could materially alter their government-sponsored health care programs by reducing reimbursement rates.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Anyreduction in reimbursement rates under Medicare or private insurers or foreign health care programs could negatively affect thepricing of our products. If we are not able to charge a sufficient amount for our products, then our margins and our profitabilitywill be adversely affected.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe lose key management or scientific personnel, cannot recruit qualified employees, directors, officers, or other personnel orexperience increases in compensation costs, our business may materially suffer.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weare highly dependent on the principal members of our management and scientific staff, specifically, Khoso Baluch, a director andour Chief Executive Officer, Dr. Matthew David, our Executive Vice President and Chief Financial Officer, Phoebe Mounts, our ExecutiveVice President and General Counsel, Paul Chew, our Acting Chief Medical Officer, Elizabeth Masson-Hurlburt, our Executive VicePresident and Head of Clinical Operations, and John Armstrong, our Executive Vice President for Technical Operations. Our futuresuccess will depend in part on our ability to identify, hire, and retain current and additional personnel. We experience intensecompetition for qualified personnel and may be unable to attract and retain the personnel necessary for the development of ourbusiness. Moreover, our work force is located in the New York metropolitan area, where competition for personnel with the scientificand technical skills that we seek is extremely high and is likely to remain high. Because of this competition, our compensationcosts may increase significantly. In addition, we have only limited ability to prevent former employees from competing with us.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe are unable to hire additional qualified personnel, our ability to grow our business may be harmed.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Overtime, we expect to hire additional qualified personnel with expertise in government regulation, formulation and manufacturing,and sales and marketing, among others. We compete for qualified individuals with numerous pharmaceutical companies, universitiesand other research institutions. Competition for such individuals is intense, and we cannot be certain that our search for suchpersonnel will be successful. Attracting and retaining such qualified personnel will be critical to our success.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wemay not successfully manage our growth.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Oursuccess will depend upon the expansion of our operations to commercialize DefenCath and the effective management of any growth,which could place a significant strain on our management and our administrative, operational and financial resources. To managethis growth, we may need to expand our facilities, augment our operational, financial and management systems and hire and trainadditional qualified personnel. If we are unable to manage our growth effectively, our business may be materially harmed.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 32; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      30
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Weface the risk of product liability claims and the amount of insurance coverage we hold now or in the future may not be adequateto cover all liabilities we might incur.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourbusiness exposes us to the risk of product liability claims that are inherent in the development of drugs. If the use of one ormore of our or our collaborators’ drugs or devices harms people, we may be subject to costly and damaging product liabilityclaims brought against us by clinical trial participants, consumers, health care providers, pharmaceutical companies or othersselling our products.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wecurrently carry product liability insurance. We cannot predict all of the possible harms or side effects that may result and,therefore, the amount of insurance coverage we hold may not be adequate to cover all liabilities we might incur. Our insurancecovers bodily injury and property damage arising from our clinical trials, subject to industry-standard terms, conditions andexclusions. Our coverage also includes the sale of commercial products. We have expanded our insurance coverage to include thesale of commercial products due to the receipt of the CE Mark approval, but we may be unable to maintain such coverage or obtaincommercially reasonable product liability insurance for any other products approved for marketing.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifwe are unable to obtain insurance at an acceptable cost or otherwise protect against potential product liability claims, we maybe exposed to significant liabilities, which may materially and adversely affect our business and financial position. If we aresued for any injury allegedly caused by our or our collaborators’ products and do not have sufficient insurance coverage,our liability could exceed our total assets and our ability to pay the liability. A successful product liability claim or seriesof claims brought against us would decrease our cash and could cause the value of our capital stock to decrease.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wemay be exposed to liability claims associated with the use of hazardous materials and chemicals.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourresearch, development and manufacturing activities and/or those of our third-party contractors may involve the controlled useof hazardous materials and chemicals. Although we believe that our safety procedures for using, storing, handling and disposingof these materials comply with federal, state and local, as well as foreign, laws and regulations, we cannot completely eliminatethe risk of accidental injury or contamination from these materials. In the event of such an accident, we and the third-partycould be held liable for any resulting damages and any liability could materially adversely affect our business, financial conditionand results of operations. In addition, the federal, state and local, as well as foreign, laws and regulations governing the use,manufacture, storage, handling and disposal of hazardous or radioactive materials and waste products may require us to incur substantialcompliance costs that could materially adversely affect our business, financial condition and results of operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        NegativeU.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial marketsor collaborators.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Negativeconditions in the U.S. or global economy, including financial markets, may adversely affect our business and the business of currentand prospective vendors, licensees and collaborators, and others with whom we do or may conduct business. The U.S. or global economymay experience disruptions as the result of international hostilities, natural disasters, pandemics, other international healthemergencies, or weather-related or similar events (such as fires, hurricanes, earthquakes, floods, landslides and other naturalconditions including the effects of climate change), political instability, labor strikes or turmoil, or terrorist attacks. Inparticular, countries around the world have experienced the spread of the COVID-19 pandemic, resulting in quarantines, supplychain disruptions, reduction in travel, increased demand for medical services and a general decline in economic activity and marketconfidence. Similar potential disruptions may occur in the future in any of the locations in which we or our collaborators dobusiness. We continue to assess the potential impact on our counterparties and customers of such events, and what impact, if any,these events could have on our business.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theduration and severity of these conditions is uncertain. If negative economic conditions occur, we may be unable to secure fundingon terms satisfactory to us to sustain our operations or to find suitable collaborators to advance our internal programs, evenif we achieve positive results from our drug development programs.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 33; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      31
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <span style="text-decoration:underline">
        RisksRelated to Our Intellectual Property
       </span>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe materially breach or default under any of our license agreements, the licensor party to such agreement will have the rightto terminate the license agreement, which termination may materially harm our business.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourcommercial success will depend in part on the maintenance of our license agreements. Each of our license agreements provides thelicensor with a right to terminate the license agreement for our material breach or default under the agreement, including thefailure to make any required milestone or other payments. Should the licensor under any of our license agreements exercise sucha termination right, we would lose our right to the intellectual property under the respective license agreement, which loss maymaterially harm our business.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe and our licensors do not obtain protection for and successfully defend our respective intellectual property rights, competitorsmay be able to take advantage of our research and development efforts to develop competing products.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourcommercial success will depend in part on obtaining further patent protection for our products, product candidates and other technologiesand successfully defending any patents that we currently have or will obtain against third-party challenges. The patents whichwe currently believe are most material to our business are as follows:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         U.S.                                         Patent No. 8,541,393 (expiring November 2, 2024) (the “Prosl Patent”) - use                                         of Neutrolin for preventing infection and maintenance of catheter patency in hemodialysis                                         catheters;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         U.S.                                         Patent No. 9,339,036 (expiring November 2, 2024);
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         U.S.                                         Patent No. 7,696,182 (expiring May 16, 2025); and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         European                                         Patent EP 1 814 562 B1 (expiring October 12, 2025) (the “Prosl European Patent”)                                         - a low heparin catheter lock solution for maintaining and preventing infection in a                                         hemodialysis catheter. The European Patent Office has found the Prosl European Patent                                         to be invalid and has revoked it. An appeal to that decision is pending.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weare currently seeking further patent protection for our compounds and methods of treating diseases. However, the patent processis subject to numerous risks and uncertainties, and there can be no assurance that we will be successful in protecting our productsby obtaining and defending patents. These risks and uncertainties include the following:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         patents                                         that may be issued or licensed may be challenged, invalidated, or circumvented, or otherwise                                         may not provide any competitive advantage;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         our                                         competitors, many of which have substantially greater resources than we have and many                                         of which have made significant investments in competing technologies, may seek, or may                                         already have obtained, patents that will limit, interfere with, or eliminate our ability                                         to make, use, and sell our potential products either in the United States or in international                                         markets;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         there                                         may be significant pressure on the United States government and other international governmental                                         bodies to limit the scope of patent protection both inside and outside the United States                                         for treatments that prove successful as a matter of public policy regarding worldwide                                         health concerns; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         countries                                         other than the United States may have less restrictive patent laws than those upheld                                         by United States courts, allowing foreign competitors the ability to exploit these laws                                         to create, develop, and market competing products.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition, the United States Patent and Trademark Office (“PTO”), and patent offices in other jurisdictions have oftenrequired that patent applications concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantiallyto cover only the specific innovations exemplified in the patent application, thereby limiting the scope of protection againstcompetitive challenges. Thus, even if we or our licensors are able to obtain patents, the patents may be substantially narrowerthan anticipated. Additionally, the breadth of claims allowed in biotechnology and pharmaceutical patents or their enforceabilitycannot be predicted. We cannot be sure that, should any patents issue, we will be provided with adequate protection against potentiallycompetitive products. Furthermore, we cannot be sure that should patents issue, they will be of commercial value to us, or thatprivate parties, including competitors, will not successfully challenge our patents or circumvent our patent position in the U.S.or abroad.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 34; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      32
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theabove-mentioned patents are exclusively licensed to us. To support our patent strategy, we have engaged in a review of patentabilityand certain freedom to operate issues, including performing certain searches. However, patentability and certain freedom to operateissues are inherently complex, and we cannot provide assurances that a relevant patent office and/or relevant court will agreewith our conclusions regarding patentability issues or with our conclusions regarding freedom to operate issues, which can involvesubtle issues of claim interpretation and/or claim liability. Furthermore, we may not be aware of all patents, published applicationsor published literature that may affect our business either by blocking our ability to commercialize our product candidates, preventingthe patentability of our product candidates to us or our licensors, or covering the same or similar technologies that may invalidateour patents, limit the scope of our future patent claims or adversely affect our ability to market our product candidates. Additionally,it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability ofa claim, may, nonetheless, ultimately be found by a court of law or an administration panel to affect the validity or enforceabilityof a claim. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at leastpart, and perhaps all, of the patent protection on our product candidates. Such loss of patent protection could have a materialadverse impact on our business. Additionally, since patent applications in the United States are maintained in secrecy until publishedor issued and as publication of discoveries in the scientific or patent literature often lag behind the actual discoveries, wecannot be certain that we were the first to make the inventions covered by the pending patent applications or issued patents referredto above or that we were the first to file patent applications for such inventions.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition to patents, we also rely on trade secrets and proprietary know-how. Although we take measures to protect this informationby entering into confidentiality and inventions agreements with our employees, and some but not all of our scientific advisors,consultants, and collaborators, we cannot provide any assurances that these agreements will not be breached, that we will be ableto protect ourselves from the harmful effects of disclosure or dispute ownership if they are breached, or that our trade secretswill not otherwise become known or be independently discovered by competitors. We may also be unsuccessful in executing such anagreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims byor against us related to the ownership of such intellectual property. If any of these events occurs, or we otherwise lose protectionfor our trade secrets or proprietary know-how, the value of our intellectual property may be greatly reduced. Even if we are successfulin prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our seniormanagement and scientific personnel.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ongoingand future intellectual property disputes could require us to spend time and money to address such disputes and could limit ourintellectual property rights.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thebiotechnology and pharmaceutical industries have been characterized by extensive litigation regarding patents and other intellectualproperty rights, and companies have employed intellectual property litigation to gain a competitive advantage. We may initiateor become subject to infringement claims or litigation arising out of patents and pending applications of our competitors, orwe may become subject to proceedings initiated by our competitors or other third parties or the PTO or applicable foreign bodiesto reexamine the patentability of our licensed or owned patents. In addition, litigation may be necessary to enforce our issuedpatents, to protect our trade secrets and know-how, or to determine the enforceability, scope, and validity of the proprietaryrights of others. If we are required to defend patent infringement actions brought by third parties, or if we sue to protect ourown patent rights, we may be required to pay substantial litigation costs and managerial attention may be diverted from businessoperations even if the outcome is not adverse to us. In addition, any legal action that seeks damages or an injunction to stopus from carrying on our commercial activities relating to the affected technologies could subject us to monetary liability andrequire us or any third party licensors to obtain a license to continue to use the affected technologies. We cannot predict whetherwe would prevail in any of these types of actions or that any required license would be made available on commercially acceptableterms or at all. Furthermore, to the extent that we or our consultants or research collaborators use intellectual property ownedby others in work performed for us, disputes may also arise as to the rights in such intellectual property or in resulting know-howand inventions. An adverse claim could subject us to significant liabilities to such other parties and/or require disputed rightsto be licensed from such other parties.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weinitiated court proceedings in Germany for patent infringement and unfair use of our proprietary information related to Neutrolin(as described below). We also have had opposition proceedings brought against the European Patent and the German utility modelpatent which are the basis of our infringement proceedings (as described below). The defense and prosecution of these ongoingand any future intellectual property suits, PTO or foreign proceedings, and related legal and administrative proceedings are costlyand time-consuming to pursue, and their outcome is uncertain. An adverse determination in litigation or PTO or foreign proceedingsto which we may become a party could subject us to significant liabilities, including damages, require us to obtain licenses fromthird parties, restrict or prevent us from selling our products in certain markets, or invalidate or render unenforceable ourlicensed or owned patents. Although patent and intellectual property disputes might be settled through licensing or similar arrangements,the costs associated with such arrangements may be substantial and could include our paying large fixed payments and ongoing royalties.Furthermore, the necessary licenses may not be available on satisfactory terms or at all.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 35; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      33
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnSeptember 9, 2014, we filed in the District Court of Mannheim, Germany a patent infringement action against TauroPharm GmbH andTauro-Implant GmbH as well as their respective CEOs (the “Defendants”) claiming infringement of our European PatentEP 1 814 562 B1, which was granted by the European Patent Office (the “EPO”) on January 8, 2014 (the “ProslEuropean Patent”). The Prosl European Patent covers a low dose heparin catheter lock solution for maintaining patency andpreventing infection in a hemodialysis catheter. In this action, we claim that the Defendants infringe on the Prosl European Patentby manufacturing and distributing catheter locking solutions to the extent they are covered by the claims of the Prosl EuropeanPatent. We believe that our patent is sound and are seeking injunctive relief and raising claims for information, rendering ofaccounts, calling back, destruction and damages. Separately, TauroPharm has filed an opposition with the EPO against the ProslEuropean Patent alleging that it lacks novelty and inventive step. We cannot predict the ultimate outcome of either of these relatedmatters. At present, the EPO has revoked the Prosl European Patent as invalid, and we have filed an appeal, which is currentlypending.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe same complaint against the same Defendants, we also alleged an infringement (requesting the same remedies) of NDP’sutility model DE 20 2005 022 124 U1 (the “Utility Model”), which we believe is fundamentally identical to the ProslEuropean Patent in its main aspects and claims. The Court separated the two proceedings and the Prosl European Patent and theUtility Model were being tried separately. TauroPharm has filed a cancellation action against the Utility Model before the GermanPatent and Trademark Office (the “German PTO”) based on the similar arguments as those in the opposition against theProsl European Patent.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheCourt issued its decisions on May 8, 2015 staying both proceedings. In its decisions, the Court found that the commercializationby TauroPharm in Germany of its TauroLock catheter lock solutions Hep100 and Hep500 infringes both the Prosl European Patent andthe Utility Model and further that there is no prior use right that would allow TauroPharm to continue to make, use or sell itsproduct in Germany. However, the Court declined to issue an injunction in favor of us that would preclude the continued commercializationby TauroPharm based upon its finding that there is a sufficient likelihood that the EPO, in the case of the Prosl European Patent,or the German PTO, in the case of the Utility Model, may find that such patent or utility model is invalid. Specifically, theCourt noted the possible publication of certain instructions for product use that may be deemed to constitute prior art. As such,the District Court determined that it will defer any consideration of the request by us for injunctive and other relief untilsuch time as the EPO or the German PTO has ruled on the underlying validity of the Prosl European Patent and the Utility Model.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theopposition proceeding against the Prosl European Patent before the EPO is ongoing. Oral proceedings before the Opposition Divisionat the EPO were held on November 25, 2015, at which the three-judge patent examiner panel considered arguments related to thevalidity of the Prosl European Patent. The hearing was adjourned due to the fact that the panel was of the view that Claus Herdeis,one of the managing directors of TauroPharm, has to be heard as a witness in a further hearing in order to close some gaps inthe documentation presented by TauroPharm as regards the publication of prior art.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheGerman PTO held a hearing in the validity proceedings relating to the Utility Model on June 29, 2016, at which the panel affirmedits preliminary finding that the Utility Model was invalid based upon prior publication of a reference to the benefits that maybe associated with adding heparin to a taurolidine based solution. The Company filed an appeal against the ruling on September7, 2016. An oral hearing was held on September 17, 2019 in which the German Federal Patent affirmed the first instance decisionthat the Utility Model was invalid. The decision has only a declaratory effect, as the Utility Model had expired in November 2015.On April 28, 2020, we filed a withdrawal of the complaint on the German utility model, thereby waiving our claims on these proceedings.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnNovember 22, 2017, the EPO in Munich, Germany held a further oral hearing in this matter. At the hearing, the panel held thatthe Prosl European Patent would be invalidated because it did not meet the requirements of novelty based on a technical aspectof the European intellectual property law. We disagree with this decision and have appealed the decision. We continue to believethat the Prosl European Patent is indeed novel and that its validity should be maintained. There can be no assurance that we willprevail in this matter. In addition, the ongoing Unfair Competition litigation against TauroPharm is not affected and will continue.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 36; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      34
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnJanuary 16, 2015, we filed a complaint against TauroPharm GmbH and its managing directors in the District Court of Cologne, Germany.In the complaint, we allege violation of the German Unfair Competition Act by TauroPharm for the unauthorized use of its proprietaryinformation obtained in confidence by TauroPharm. We allege that TauroPharm is improperly and unfairly using its proprietary informationrelating to the composition and manufacture of Neutrolin, in the manufacture and sale of TauroPharm’s products TauroLockTM,TauroLock-HEP100 and TauroLock-HEP500. We seek a cease and desist order against TauroPharm from continuing to manufacture andsell any product containing taurolidine (the active pharmaceutical ingredient (“API”) of Neutrolin) and citric acidin addition to possible other components, damages for any sales in the past and the removal of all such products from the market.An initial hearing in the District Court of Cologne, Germany was held on November 19, 2015 to consider our claims. On January14, 2016, the court issued an interim decision in the form of a court order outlining several issues of concern that relate primarilyto court’s interest in clarifying the facts and reviewing any and all available documentation, in particular with regardto the question which specific know-how was provided to TauroPharm by whom and when. A further oral hearing in this matter washeld on November 15, 2016. In this hearing, the court heard arguments from us and TauroPharm concerning the allegations of unfaircompetition. On March 7, 2017, the court issued another interim decision in the form of a court order outlining again severalissues relating to the argumentation of both sides in the proceedings. Both parties submitted further writs in this matter andthe court scheduled a further hearing for May 8, 2018. After having been rescheduled several times, the hearing took place onNovember 20, 2018. A decision was rendered by the court on December 11, 2018, dismissing the complaint in its entirety. However,we intend to continue to pursue this matter, and still believe that our claims are well-founded. We have therefore appealed inJanuary 2019 and filed our grounds of appeal in March 2019. An oral hearing was held on September 6, 2019 in which our legal counselbrought forward further arguments for the fact that the manufacturing process of the respective catheter locking solution is indeedprotectable as a trade secret. In view of these new arguments, the court issued an evidentiary order on September 27, 2019 orderingan expert opinion. The expert opinion was not in our favor, but we have filed a response to the expert opinion in reaction towhich the Court asked the expert to supplement his opinion to address the issues brought forward in our submission. In the supplementaryexpert opinion, the expert confirmed his view. We have filed another response and an oral hearing has been scheduled for February5, 2021 but was postponed to June 18, 2021 due to the COVID-19 situation in Germany.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Thedecisions by the European and German patent offices may affect patent rights in other jurisdictions.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theprior art on the basis of which the Prosl European Patent and the German Utility Model have been found to be invalid may beused to challenge the validity of issued United States and/or other foreign patents that are directed to the same or similarsubject matter, in a court action or in an administrative proceeding before the USPTO. Pending United States and/or foreignpatent applications may be denied on that basis of that prior art as well. Such patents and patent applications include: US7,696,182; US 8,541,393; US 9,339,036; US 17/176,718; and EP 14150248.4.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe infringe the rights of third parties, we could be prevented from selling products and forced to pay damages and defend againstlitigation.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifour products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantialcosts and we may have to do one or more of the following:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         obtain                                         licenses, which may not be available on commercially reasonable terms, if at all;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         abandon                                         an infringing product candidate;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         redesign                                         our products or processes to avoid infringement;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         stop                                         using the subject matter claimed in the patents held by others;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         pay                                         damages; or
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         defend                                         litigation or administrative proceedings, which may be costly whether we win or lose,                                         and which could result in a substantial diversion of our financial and management resources.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 37; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      35
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <span style="text-decoration:underline">
        RisksRelated to Dependence on Third Parties
       </span>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wecurrently have no internal marketing and sales organization and currently rely and intend to continue to rely on third partiesto market, sell, and distribute Neutrolin outside of the U.S. We may seek a sales partner in the U.S. if DefenCath receives FDAapproval or we may undertake marketing and sales of DefenCath in the U.S. on our own. If we are unable to enter into or maintainagreements with third parties to market and sell DefenCath or any other product after approval or are unable to find a sales partneror establish our own marketing and sales capabilities, we may not be able to generate significant or any product revenues.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We currently haveno sales, marketing, or distribution infrastructure in the EU and have only started to build necessary functions in the U.S. Ourbusiness strategy for Neutrolin relies on collaborating with larger firms with experience in marketing and selling medical devicesand pharmaceutical products; for other products we may also rely on such marketing collaborations or out-licensing of our productcandidates. Specifically, for Neutrolin, we have a distributor agreement with each of an Emirati, and a South Korean company forsales and marketing (upon receipt of approval to market in the U.S., which is required for approval to market in South Korea).We have a commercial collaboration with Hemotech SAS covering France and certain overseas territories. Assuming we receive applicableregulatory approval for other markets, we plan to enter into distribution agreements with one or more third parties for the saleof Neutrolin in various European, Middle East and other markets. We will be dependent on the firms and individuals with whom wecontract for the success of sales in the countries in which they operate. However, there can be no assurance that we will be ableto successfully maintain those relationships or establish and maintain additional marketing, sales, or distribution relationships,nor can there be assurance that such relationships will be successful, or that we will be successful in gaining market acceptancefor our products. If these firms or individuals do not perform for whatever reason, our business, prospects and results of operationsmay be materially adversely affected. Finding a new or replacement organization for sales and marketing could be difficult, whichwould further harm our business, prospects and results of operations. To the extent that we enter into any marketing, sales, ordistribution arrangements with third parties, our product revenues will be lower than if we marketed and sold our products directly,and any revenues we receive will depend upon the efforts of such third parties.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifwe are unable to establish and maintain such third-party sales and marketing relationships, or choose not to do so, we will haveto establish our own in-house capabilities. To market any of our products directly, we would need to develop a marketing, sales,and distribution force that has both technical expertise and the ability to support a distribution capability. The establishmentof a marketing, sales, and distribution capability would take time and significantly increase our costs, possibly requiring substantialadditional capital. In addition, there is intense competition for proficient sales and marketing personnel, and we may not beable to attract individuals who have the qualifications necessary to market, sell, and distribute our products. There can be noassurance that we will be able to establish internal marketing, sales, or distribution capabilities. If we are unable to, or choosenot to establish these capabilities, or if the capabilities we establish are not sufficient to meet our needs, we will be requiredto establish collaborative marketing, sales, or distribution relationships with third parties, which we might not be able to doon acceptable terms or at all. The failure to successfully develop our own marketing and sales infrastructure would have a negativeadverse effect on our business and results of operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe or our collaborators are unable to manufacture our products in sufficient quantities or are unable to obtain regulatory approvalsfor a manufacturing facility, we may be unable to meet demand for our products and we may lose potential revenues.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Completion of ourclinical trials and commercialization of DefenCath and any other product candidate require access to, or development of, facilitiesto manufacture sufficient supplies. All of our manufacturing processes currently are, and we expect them to continue to be, outsourcedto third parties. Specifically, we will rely on one or more manufacturers to supply us and/or our distribution partners with commercialquantities of DefenCath. If, for any reason, we become unable to rely on our current sources for the manufacture of DefenCathor any other product candidates or for active pharmaceutical ingredient (“API”), either for clinical trials or forcommercial quantities, then we would need to identify and contract with additional or replacement third-party manufacturers tomanufacture compounds for pre-clinical, clinical, and commercial purposes. We may not be successful in identifying such additionalor replacement third-party manufacturers, or in negotiating acceptable terms with any that we do identify. Such third-party manufacturersmust receive FDA or applicable foreign approval before they can produce clinical material or commercial product, and any thatare identified may not receive such approval or may fail to maintain such approval. We were recently informed by FDA that theDefenCath NDA cannot be approved in its present form, because of concerns at the third-party manufacturing facility, which mustbe resolved to FDA’s satisfaction before the NDA can be approved. In addition, we may be in competition with other companiesfor access to these manufacturers’ facilities and may be subject to delays in manufacturing if the manufacturers give otherclients higher priority than they give to us. If we are unable to secure and maintain third-party manufacturing capacity, thedevelopment and sales of our products and our financial performance may be materially adversely affected.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 38; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      36
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Beforewe could begin to commercially manufacture DefenCath or any other product candidate on our own, we must obtain regulatory approvalof the manufacturing facility and process. The manufacture of drugs for clinical and commercial purposes must comply with cGMPand applicable non-U.S. regulatory requirements. The cGMP requirements govern quality control and documentation policies and procedures.Complying with cGMP and non-U.S. regulatory requirements would require that we expend time, money, and effort in production, recordkeeping,and quality control to assure that the product meets applicable specifications and other requirements. We would also have to passa pre-approval inspection prior to FDA or non-U.S. regulatory agency approval. Failure to pass a pre-approval inspection may significantlydelay regulatory approval of our products. If we fail to comply with these requirements, we would be subject to possible regulatoryaction and may be limited in the jurisdictions in which we are permitted to sell our products. As a result, our business, financialcondition, and results of operations could be materially adversely affected.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Corporateand academic collaborators may take actions that delay, prevent, or undermine the success of our products.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ouroperating and financial strategy for the development, clinical testing, manufacture, and commercialization of our product candidatesis heavily dependent on our entering into collaborations with corporations, academic institutions, licensors, licensees, and otherparties. Our current strategy assumes that we will successfully establish and maintain these collaborations or similar relationships.However, there can be no assurance that we will be successful establishing or maintaining such collaborations. Some of our existingcollaborations, such as our licensing agreements, are, and future collaborations may be, terminable at the sole discretion ofthe collaborator in certain circumstances. Replacement collaborators might not be available on attractive terms, or at all.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition, the activities of any collaborator will not be within our control and may not be within our power to influence. Therecan be no assurance that any collaborator will perform its obligations to our satisfaction or at all, that we will derive anyrevenue or profits from such collaborations, or that any collaborator will not compete with us. If any collaboration is not pursued,we may require substantially greater capital to undertake on our own the development and marketing of our product candidates andmay not be able to develop and market such products successfully, if at all. In addition, a lack of development and marketingcollaborations may lead to significant delays in introducing product candidates into certain markets and/or reduced sales of productsin such markets.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Dataprovided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading,or incomplete.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Werely on third-party vendors, scientists, and collaborators to provide us with significant data and other information related toour projects, clinical trials, and business. If such third parties provide inaccurate, misleading, or incomplete data, our business,prospects, and results of operations could be materially adversely affected.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Werely on third parties to conduct our clinical trials and pre-clinical studies. If those parties do not successfully carry outtheir contractual duties or meet expected deadlines, our product candidates may not advance in a timely manner or at all.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe course of our pre-clinical testing and clinical trials, we rely on third parties, including laboratories, investigators, clinicalcontract research organizations (“CROs”), and manufacturers, to perform critical services for us. For example, werely on third parties to conduct our clinical trials and many of our pre-clinical studies, which are required to be conductedconsistent with regulations on Good Laboratory Practice (“GLP”). CROs and study sites are responsible for many aspectsof the trials, including finding and enrolling subjects for testing and administering the trials. Although we rely on these thirdparties to conduct our pre-clinical and clinical trials, we are responsible for ensuring that each of our trials is conductedin accordance with its investigational plan and protocol and that the integrity of the studies and resulting data is protected.Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, commonly referred toas Good Clinical Practices (“GCPs”), for conducting, monitoring, recording, and reporting the results of clinicaltrials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequatelyinformed of the potential risks of participating in clinical trials. Our reliance on third parties does not relieve us of theseresponsibilities and requirements. These third parties may not be available when we need them or, if they are available, may notcomply with all regulatory and contractual requirements or may not otherwise perform their services in a timely or acceptablemanner, and we may need to enter into new arrangements with alternative third parties and our clinical trials may be extended,delayed or terminated. These independent third parties may also have relationships with other commercial entities, some of whichmay compete with us. In addition, if such third parties fail to perform their obligations in compliance with our protocols orthe applicable regulatory requirements, our trials may not meet regulatory requirements or may need to be repeated, we may notreceive marketing approvals, or we or such third parties may face regulatory enforcement. As a result of our dependence on thirdparties, we may face delays, failures or cost increases outside of our direct control. These risks also apply to the developmentactivities of collaborators, and we do not control their research and development, clinical trial or regulatory activities.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 39; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      37
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wewill depend on third party suppliers and contract manufacturers for the manufacturing of our product candidates and have no directcontrol over the cost of manufacturing our product candidates. Increases in the cost of manufacturing our product candidates wouldincrease our costs of conducting clinical trials and could adversely affect our future profitability.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wedo not intend to manufacture our product candidates ourselves, and we will rely on third parties for our drug supplies both forclinical trials and for commercial quantities in the future. We have taken the strategic decision not to manufacture API for ourproduct candidates, as these can be more economically supplied by third parties with particular expertise in this area. We haveidentified contract facilities that are registered with the FDA, have a track record of large-scale API manufacture, and havealready invested in capital and equipment. We have no direct control over the manufacturing of our product candidates, or thecost thereof. If the contract manufacturers are unable to produce sufficient quantities of our product candidates, as a resultof a lack of available materials or otherwise, our ability to complete product candidate development and our future profitabilitywould be adversely affected. If the cost of manufacturing increases, or if the cost of the materials used increases, these costswill be passed on to us, making the cost of conducting clinical trials more expensive. For example, there could be issues securingthe API heparin for our product as a result of the outbreak of African swine fever in China in 2019, which threatened the globalheparin supply. The United States is largely dependent on China for its heparin, because almost half of the global pig supply,the main animal source for heparin, is in China. Increases in manufacturing costs could adversely affect our future profitabilityif we are unable to pass all of the increased costs along to our customers.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Further,we, along with our contract manufacturers, are required to comply with FDA requirements for cGMPs, related to product testing,quality assurance, manufacturing and documentation. Our contract manufacturers may not be able to comply with the applicable FDAregulatory requirements, which could result in delays to our product development programs, could result in adverse regulatoryactions against them or us, and could prevent us from ultimately receiving product marketing approval. They also generally mustpass an FDA preapproval inspection for conformity with cGMPs before we can obtain approval to manufacture our product candidatesand will be subject to ongoing, periodic, unannounced inspection by the FDA and corresponding state agencies to ensure strictcompliance with cGMP, and other applicable government regulations and corresponding foreign standards. If we and our contractmanufacturers fail to achieve and maintain high manufacturing standards in compliance with cGMP, we may experience manufacturingerrors resulting in defective products that could be harmful to patients, product recalls or withdrawals, delays or interruptionsof production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applicationsfor our products, cost overruns or other problems that could seriously harm our business. Not complying with FDA requirementscould result in a product recall or prevent commercialization of our product candidates and delay our business development activities.In addition, such failure could be the basis for the FDA to issue a warning or untitled letter or take other regulatory or legalenforcement action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials,refusal to approve pending applications or supplemental applications, and potentially civil and/or criminal penalties dependingon the matter.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 40; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      38
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <span style="text-decoration:underline">
        RisksRelated to our Common Stock
       </span>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wewill need additional financing to fund our activities in the future, which likely will dilute our stockholders.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     To date, ourcommercial operations have not generated sufficient revenues to enable profitability. As of December 31, 2020, we had anaccumulated deficit of $217.4 million, and incurred net losses of $22.0 million for the year then ended. Based on the currentdevelopment plans for DefenCath/Neutrolin in both the U.S. and foreign markets (including the preparation of an NDA forDefenCath in hemodialysis catheters) and our other operating requirements, management believes that the existing cash atDecember 31, 2020, will be sufficient to fund operations at least into the second half of 2022, after taking intoconsideration the $41.5 million of net proceeds received in January and February 2021 from the at-the-market program.Further, we will need additional funding for DefenCath’s commercial launch. We anticipate that we will incur operatinglosses for the foreseeable future. Additionally, we will require substantial funds in the future to support our operations.Accordingly, we will need to obtain additional financing, including through issuances of equity securities.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Tothe extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. Wemay, as we have in the past, sell common stock, convertible securities or other equity securities in one or more transactionsat prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securitiesin more than one transaction, investors may be further diluted by subsequent sales. Such sales may also result in material dilutionto our existing stockholders, and new investors could gain rights superior to existing stockholders.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ourexecutive officers and directors may sell shares of their stock, and these sales could adversely affect our stock price.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Salesof our common stock by our executive officers and directors, or the perception that such sales may occur, could adversely affectthe market price of our common stock. Our executive officers and directors may sell stock in the future, either as part, or outside,of trading plans under Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ourcommon stock price has fluctuated considerably and is likely to remain volatile, in part due to the limited market for our commonstock and you could lose all or a part of your investment.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Duringthe period from the completion of our initial public offering (“IPO”), on March 30, 2010 through December 31, 2020,the high and low sales prices for our common stock were $52.00 and $0.75, respectively. There is a limited public market for ourcommon stock and we cannot provide assurances that an active trading market will develop or continue. As a result of low tradingvolume in our common stock, the purchase or sale of a relatively small number of shares could result in significant share pricefluctuations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Additionally,the market price of our common stock may continue to fluctuate significantly in response to a number of factors, some of whichare beyond our control, including the following:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         the                                         receipt of or failure to obtain additional regulatory approvals for DefenCath, including                                         FDA approval in the U.S.;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         market                                         acceptance of Neutrolin in those markets in which it is approved for sale;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         our                                         need for additional capital;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         results                                         of clinical trials of our product candidates, including any other Phase 3 trial for DefenCath                                         in the U.S., if required, or those of our competitors;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         our                                         entry into or the loss of a significant collaboration, or expiration or termination of                                         licenses;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         regulatory                                         or legal developments in the United States and other countries, including changes in                                         the healthcare payment systems;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         changes                                         in financial estimates or investment recommendations by securities analysts relating                                         to our common stock;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 41; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      39
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         future                                         sales or anticipated sales of our securities by us or our stockholders;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         announcements                                         by our competitors of significant developments, technological innovations, strategic                                         partnerships, joint ventures or capital commitments;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         changes                                         in key personnel;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         variations                                         in our financial results or those of companies that are perceived to be similar to us;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         actual                                         or anticipated variations in operating results;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         market                                         conditions in the pharmaceutical and medical device sectors and issuance of new or changed                                         securities analysts’ reports or recommendations;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         instability                                         in the stock market as a result of current or future domestic and global events;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         liquidity                                         of any market for our securities;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         threatened                                         or actual delisting of our common stock from a national stock exchange;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         general                                         economic, industry and market conditions;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         developments                                         or disputes concerning patents or other proprietary rights; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         any                                         other factors described in this “Risk Factors” section.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inaddition, the stock markets in general, and the stock of pharmaceutical and medical device companies in particular, have experiencedextreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of thesecompanies. In addition, changes in economic conditions in the U.S., the European Union or globally, particularly in the contextof current global events, could impact upon our ability to grow profitably. Adverse economic changes are outside our control andmay result in material adverse impacts on our business or our results of operations. Broad market and industry factors may negativelyaffect the market price of our common stock, regardless of our actual operating performance. In the past, following periods ofvolatility in the market price of a company’s securities, securities class-action litigation has often been instituted againstthat company. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management’sattention and resources.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Forthese reasons and others, an investment in our securities is risky and you should invest only if you can withstand wide fluctuationsin and a significant or complete loss of the value of your investment.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Asignificant number of additional shares of our common stock may be issued at a later date, and their sale could depress the marketprice of our common stock.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Asof December 31, 2020, we had outstanding the following securities that are convertible into or exercisable for shares of our commonstock:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 38.25pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         options                                         to purchase an aggregate of 15,334 shares of our common stock issued to our officers,                                         directors, employees and non-employee consultants under our 2006 Stock Plan, with a weighted                                         average exercise price of $6.18 per share;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         options                                         to purchase an aggregate of 1,325,369 shares of our common stock issued to our officers,                                         directors and non-employee consultants under our 2013 Stock Plan, with a weighted average                                         exercise price of $8.99 per share;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         options                                         to purchase an aggregate of 1,106,984 shares of our common stock issued to our officers,                                         directors and non-employee consultants under our 2019 Stock Plan, with a weighted average                                         exercise price of $5.11 per share;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 42; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      40
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         52,000                                         shares of Series C-3 Preferred Stock, which are convertible into 104,000 shares of common                                         stock;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         89,623                                         shares of Series E Preferred Stock, which are convertible into 391,953 shares of common                                         stock;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         100,000                                         shares of Series G Preferred Stock, which are convertible into 5,560,137 shares of common                                         stock; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         warrants                                         to purchase an aggregate of 183,148 shares of common stock with a weighted average exercise                                         price of $4.96 per share.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Additionally, thereare 2,490,903 shares of common stock available for grants under the 2019 Stock Plan (adopted on November 26, 2019).
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thepossibility of the issuance of these shares, as well as the actual sale of such shares, could substantially reduce the marketprice for our common stock and impede our ability to obtain future financing.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Provisionsin our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders,more difficult.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Provisionsin our Amended and Restated Certificate of Incorporation, as amended, and our Amended and Restated Bylaws, as well as provisionsof the General Corporation Law of the State of Delaware, or DGCL, may discourage, delay or prevent a merger, acquisition or otherchange in control of our company, even if such a change in control would be beneficial to our stockholders. These provisions includethe following:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         authorizing                                         the issuance of “blank check” preferred stock, the terms of which may be                                         established and shares of which may be issued without stockholder approval;
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         prohibiting                                         our stockholders from fixing the number of our directors; and
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         establishing                                         advance notice requirements for stockholder proposals that can be acted on at stockholder                                         meetings and nominations to our Board of Directors.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theseprovisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making itmore difficult for stockholders to replace members of our board of directors, which is responsible for appointing the membersof our management. In addition, we are subject to Section 203 of the DGCL, which generally prohibits a Delaware corporation fromengaging in any of a broad range of business combinations with an interested stockholder for a period of three years followingthe date on which the stockholder became an interested stockholder, unless such transactions are approved by the board of directors.This provision could have the effect of discouraging, delaying or preventing someone from acquiring us or merging with us, whetheror not it is desired by, or beneficial to, our stockholders. Any provision of our Amended and Restated Certificate of Incorporation,as amended, or Amended and Restated Bylaws or Delaware law that has the effect of delaying or deterring a change in control couldlimit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect theprice that some investors are willing to pay for our common stock.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ifwe fail to comply with the continued listing standards of the Nasdaq Global Market, it may result in a delisting of our commonstock from the exchange.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     Our common stockis currently listed for trading on the Nasdaq Global Market under the symbol “CRMD”, and the continued listing ofour common stock on the Nasdaq Global Market is subject to our compliance with a number of listing standards. If we fail to satisfythe continued listing requirements of The Nasdaq Capital Market such as the corporate governance requirements, the stockholder’sequity requirement or the minimum closing bid price requirement, The Nasdaq Capital Market may take steps to de-list our commonstock. Such a de-listing or even notification of failure to comply with such requirements would likely have a negative effecton the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. Inaddition, the delisting of our common stock could materially adversely impact our ability to raise capital on acceptable termsor at all. Delisting from Nasdaq could also have other negative results, including the potential loss of confidence by our currentor prospective third-party providers and collaboration partners, the loss of institutional investor interest, and fewer licensingand partnering. In the event of a de-listing, we would take actions to restore our compliance with The Nasdaq Capital Market’slisting requirements, but we can provide no assurance that any such action taken by us would allow our common stock to becomelisted again, stabilize the market price or improve the liquidity of our common stock.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 43; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      41
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifour common stock were no longer listed on the Nasdaq Global Market, investors might only be able to trade on one of the over-the-countermarkets, including the OTC Bulletin Board
      <sup>
       ®
      </sup>
      or in the Pink Sheets
      <sup>
       ®
      </sup>
      (a quotation medium operatedby Pink Sheets LLC). This would impair the liquidity of our common stock not only in the number of shares that could be boughtand sold at a given price, which might be depressed by the relative illiquidity, but also through delays in the timing of transactionsand reduction in media coverage.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Laws,rules and regulations relating to public companies may be costly and impact our ability to attract and retain directors and executiveofficers.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Lawsand regulations affecting public companies, including rules adopted by the Securities and Exchange Commission (“SEC”)and by the Nasdaq Global Market, may result in increased costs to us. These laws, rules and regulations could make it more difficultor costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forcedto accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impactof these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors,on our board committees or as executive officers. We cannot estimate accurately the amount or timing of additional costs we mayincur to respond to these laws, rules and regulations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Ourinternal control over financial reporting and our disclosure controls and procedures may not prevent all possible errors thatcould occur.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonableassurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposesin accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Ensuringthat we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statementson a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Failure on our part to haveeffective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a materialadverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stockto fall dramatically.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Acontrol system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the controlsystem’s objectives will be satisfied. Internal control over financial reporting and disclosure controls and proceduresare designed to give a reasonable assurance that they are effective to achieve their objectives. We cannot provide absolute assurancethat all of our possible future control issues will be detected. These inherent limitations include the possibility that judgmentsin our decision making can be faulty, and that isolated breakdowns can occur because of simple human error or mistake. The designof our system of controls is based in part upon assumptions about the likelihood of future events, and there can be no assurancethat any design will succeed absolutely in achieving our stated goals under all potential future or unforeseeable conditions.Because of the inherent limitations in a cost-effective control system, misstatements due to error could occur and not be detected.This and any future failures could cause investors to lose confidence in our reported financial information, which could havea negative impact on our financial condition and stock price.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Infuture periods, if the process required by Section 404 of the Sarbanes-Oxley Act reveals any material weaknesses or significantdeficiencies, the correction of any such material weaknesses or significant deficiencies could require remedial measures whichcould be costly and time-consuming. In addition, in such a case, we may be unable to produce accurate financial statements ona timely basis. Any associated accounting restatement could create a significant strain on our internal resources and cause delaysin our release of quarterly or annual financial results and the filing of related reports, increase our costs and cause managementdistraction. Any of the foregoing could cause investors to lose confidence in the reliability of our financial statements, whichcould cause the market price of our common stock to decline and make it more difficult for us to finance our operations and growth.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 44; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      42
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Securitybreaches and other disruptions could compromise our information and expose us to liability, which would cause our business andreputation to suffer.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe ordinary course of our business, we collect and store sensitive data, including intellectual property, our proprietary businessinformation and that of our suppliers, as well as personally identifiable information of clinical trial participants and employees.Similarly, our third-party providers possess certain of our sensitive protected health data. The secure maintenance of this informationis critical to our operations and business strategy. Despite our security measures, our information technology and infrastructuremay be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Attacks of this natureare increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticatedand organized groups and individuals with a wide range of motives and expertise. Although we develop and maintain systems andcontrols designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the developmentand maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologieschange and efforts to overcome security measures become more sophisticated, and such systems, controls and processes may not besuccessful in preventing a breach. Any such breach could compromise our networks and the information stored there could be accessed,publicly disclosed, lost or stolen. We could be required to expend significant amounts of money and other resources to repairor replace information systems or networks. In addition, our liability insurance may not be sufficient in type or amount to coverus against claims related to security breaches, cyberattacks and other related breaches.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thelegislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing amountof focus on privacy and data protection issues with the potential to affect our business, including compliance with the HealthInsurance Portability and Accountability Act of 1996 and recently enacted laws in a majority of states requiring security breachnotification. The collection and use of personal health data of individuals in the European Union is also governed by strict dataprotection laws. In addition to existing laws, since May 25, 2018, the General Data Protection Regulation (“GDPR”)has imposed new obligations with respect to European Union data and substantial fines for breaches of the data protection rules.It will increase our responsibility and potential liability in relation to personal data that we process, and we will be requiredto put in place additional mechanisms ensuring compliance with the new European Union data protection rules. There is significantuncertainty related to the manner in which data protection authorities will seek to enforce compliance with GDPR. For example,it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authoritieswill wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and thecosts associated with ensuring GDPR compliance may be onerous and adversely affect our business, operating results, prospectsand financial condition.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Additionally,California recently enacted legislation that has been dubbed the first “GDPR-like” law in the United States. Knownas the California Consumer Privacy Act (“CCPA”), it creates new individual privacy rights for consumers (as that wordis broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumersor households. The CCPA, which went into effect on January 1, 2020, requires covered companies to provide new disclosures to Californiaconsumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of actionfor data breaches. The CCPA may significantly impact our business activities and require substantial compliance costs that adverselyaffect business, operating results, prospects and financial condition.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thus,any access, disclosure or other loss of information, including our data being breached at our partners or third-party providers,could result in legal claims or proceedings and liability under laws that protect the privacy of personal information, disruptour operations and damage our reputation, which could adversely affect our business.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Wedo not intend to pay dividends on our common stock so any returns on our common stock will be limited to the value of our commonstock.
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wehave never declared dividends on our common stock, and currently do not plan to declare dividends on shares of our common stockin the foreseeable future. Pursuant to the terms of our Series C-3, E and G Convertible Preferred Stock, we may not declare orpay any dividends or make any distributions on any of our shares or other equity securities as long as any of those preferredshares remain outstanding. We currently expect to retain future earnings, if any, for use in the operation and expansion of ourbusiness. The payment of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will dependupon such factors as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevantby our Board of Directors. Any return to holders of our common stock will be limited to the value of their common stock.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 45; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      43
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 13.2pt">
    </p>
    <div>
    </div>
    <div>
     <a id="a_004">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                                         1B.
         </b>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Unresolved                                         Staff Comments
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      None.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_005">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                                         2.
         </b>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Properties
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InMarch 2020, we entered into a seven-year operating lease agreement for an office space at 300 Connell Drive, Berkeley Heights,New Jersey 07922. The lease agreement, with a monthly average cost of approximately $17,000, commenced on September 16, 2020.Our sublease from our previous premises terminated on November 30, 2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Oursubsidiary leases its offices in Fulda, Germany pursuant to a three-month lease agreement which commenced in June 2017, renewableevery three months for a base monthly payment of €400.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Webelieve that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces willbe available in the future on commercially reasonable terms.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_006">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                                         3.
         </b>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Legal                                         Proceedings
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnSeptember 9, 2014, we filed in the District Court of Mannheim, Germany a patent infringement action against TauroPharm GmbH andTauro-Implant GmbH as well as their respective CEOs, referred to as the Defendants, claiming infringement of our European PatentEP 1 814 562 B1, which was granted by the EPO on January 8, 2014, or the Prosl European Patent. The Prosl European Patent coversa low dose heparin catheter lock solution for maintaining patency and preventing infection in a hemodialysis catheter. In thisaction, we claim that the Defendants infringe on the Prosl European Patent by manufacturing and distributing catheter lockingsolutions to the extent they are covered by the claims of the Prosl European Patent. We believe that our patent is sound and areseeking injunctive relief and raising claims for information, rendering of accounts, calling back, destruction and damages. Separately,TauroPharm has filed an opposition with the EPO against the Prosl European Patent alleging that it lacks novelty and inventivestep. We cannot predict the ultimate outcome of either of these related matters. At present, the EPO has revoked the Prosl EuropeanPatent as invalid, and we have filed an appeal, which is currently pending.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe same complaint against the same Defendants, we also alleged an infringement (requesting the same remedies) of NDP’sutility model DE 20 2005 022 124 U1, referred to as the Utility Model, which we believe is fundamentally identical to the ProslEuropean Patent in its main aspects and claims. The Court separated the two proceedings and the Prosl European Patent and theUtility Model claims were tried separately. TauroPharm has filed a cancellation action against the Utility Model before the GermanPatent and Trademark Office, or German PTO based on the similar arguments as those in the opposition against the Prosl EuropeanPatent.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheCourt issued its decisions on May 8, 2015, staying both proceedings. In its decisions, the Court found that the commercializationby TauroPharm in Germany of its TauroLock catheter lock solutions Hep100 and Hep500 infringes both the Prosl European Patent andthe Utility Model and further that there is no prior use right that would allow TauroPharm to continue to make, use or sell itsproduct in Germany. However, the Court declined to issue an injunction in favor of us that would preclude the continued commercializationby TauroPharm based upon its finding that there is a sufficient likelihood that the EPO, in the case of the Prosl European Patent,or the German PTO, in the case of the Utility Model, may find that such patent or utility model is invalid. Specifically, theCourt noted the possible publication of certain instructions for product use that may be deemed to constitute prior art. As such,the District Court determined that it will defer any consideration of the request by us for injunctive and other relief untilsuch time as the EPO or the German PTO made a final decision on the underlying validity of the Prosl European Patent and the UtilityModel.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 46; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      44
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theopposition proceeding against the Prosl European Patent before the EPO is ongoing. Oral proceedings before the Opposition Divisionat the EPO were held on November 25, 2015, at which the three-judge patent examiner panel considered arguments related to thevalidity of the Prosl European Patent. The hearing was adjourned due to the fact that the panel was of the view that Claus Herdeis,one of the managing directors of TauroPharm, had to be heard as a witness in a further hearing in order to close some gaps inthe documentation presented by TauroPharm as regards the publication of prior art.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheGerman PTO held a hearing in the validity proceedings relating to the Utility Model on June 29, 2016, at which the panel affirmedits preliminary finding that the Utility Model was invalid based upon prior publication of a reference to the benefits that maybe associated with adding heparin to a taurolidine based solution. We filed an appeal against the ruling on September 7, 2016.An oral hearing was held on September 17, 2019 in which the German Federal Patent Court affirmed the first instance decision thatthe Utility Model was invalid. The decision has only a declaratory effect, as the Utility Model had expired in November 2015.On April 28, 2020, we filed a withdrawal of the complaint on the German utility model, thereby waiving our claims on these proceedings.During the year ended December 31, 2020, costs in connection with the utility model infringement proceedings of approximately$30,000 was reimbursed to TauroPharm
      <b>
       .
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnNovember 22, 2017, the EPO in Munich, Germany held a further oral hearing in this matter. At the hearing, the panel held thatthe Prosl European Patent would be invalidated because it did not meet the requirements of novelty based on a technical aspectof the European intellectual property law. We disagree with this decision and have appealed the decision. We continue to believethat the Prosl European Patent is indeed novel and that its validity should be maintained. There can be no assurance that we willprevail in this matter. In addition, the ongoing Unfair Competition litigation against TauroPharm is not affected and will continue.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnJanuary 16, 2015, we filed a complaint against TauroPharm GmbH and its managing directors in the District Court of Cologne, Germany.In the complaint, we allege violation of the German Unfair Competition Act by TauroPharm for the unauthorized use of our proprietaryinformation obtained in confidence by TauroPharm. We allege that TauroPharm is improperly and unfairly using our proprietary informationrelating to the composition and manufacture of Neutrolin, in the manufacture and sale of TauroPharm’s products TauroLockTM,TauroLock-HEP100 and TauroLock-HEP500. We seek a cease and desist order against TauroPharm from continuing to manufacture andsell any product containing taurolidine (the API of Neutrolin) and citric acid in addition to possible other components, damagesfor any sales in the past and the removal of all such products from the market. An initial hearing in the District Court of Cologne,Germany was held on November 19, 2015 to consider our claims. On January 14, 2016, the Court issued an interim decision in theform of a court order outlining several issues of concern that relate primarily to the court’s interest in clarifying thefacts and reviewing any and all available documentation, in particular with regard to the question which specific know-how wasprovided to TauroPharm by whom and when. A further oral hearing in this matter was held on November 15, 2016. In this hearing,the Court heard arguments from CorMedix and TauroPharm concerning the allegations of unfair competition. On March 7, 2017, theCourt issued another interim decision in the form of a court order outlining again several issues relating to the argumentationof both sides in the proceedings. Both parties have submitted further writs in this matter and the Court had scheduled a furtherhearing for May 8, 2018. After having been rescheduled several times, the hearing took place on November 20, 2018. A decisionwas rendered by the Court on December 11, 2018, dismissing the complaint in its entirety. However, we intend to continue to pursuethis matter, and still believe firmly that our claims are well-founded. We have therefore appealed in January 2019 and filed ourgrounds of appeal in March 2019. An oral hearing was held on September 6, 2019 in which our legal counsel brought forward furtherarguments for the fact that the manufacturing process of the respective catheter locking solution is indeed protectable as a tradesecret. In view of these new arguments, the Court issued an evidentiary order on September 27, 2019 ordering an expert opinion.The expert opinion was not in our favor, but we have filed a response to the expert opinion in reaction to which the Court askedthe expert to supplement his opinion to address the issues brought forward in our submission. In the supplementary expert opinion,the expert confirmed his view. We have filed another response and an oral hearing has been scheduled for February 5, 2021 butwas postponed to June 18, 2021 due to the COVID-19 situation in Germany.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_007">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0%">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                                         4.
         </b>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Mine                                         Safety Disclosures
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Notapplicable.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 47; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      45
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_008">
     </a>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      PARTII
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_009">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          5.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Market                                         for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases                                         of Equity Securities
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Marketfor Common Equity
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourcommon stock trades on the Nasdaq Global Market under the symbol “CRMD.”
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Based upon informationfurnished by our transfer agent, at March 25, 2021, we had approximately 272 holders of record of our common stock.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Acomparison of the performance of our common stock is found in Item 12 of the report under the heading “Stock PerformanceGraph.”
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       DividendPolicy
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wehave never declared dividends on our equity securities, and currently do not plan to declare dividends on shares of our commonstock in the foreseeable future. We expect to retain our future earnings, if any, for use in the operation and expansion of ourbusiness. Further, pursuant to the terms of our Series C-3, E and G Non-Voting Convertible Preferred Stock, we may not declareor pay any dividends or make any distributions on any of our shares or other equity securities as long as any of those preferredshares remain outstanding. Subject to the foregoing, the payment of cash dividends in the future, if any, will be at the discretionof our Board of Directors and will depend upon such factors as earnings levels, capital requirements, our overall financial conditionand any other factors deemed relevant by our Board of Directors.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      EquityCompensation Plan Information
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table provides information as of December 31, 2020 about our common stock that may be issued upon the exercise of options,warrants and rights under all of our existing equity compensation plans (including individual arrangements):
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">
        Plan Category
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Number of securities to be issued upon exercise of outstanding options, warrants and rights
        <br/>
        (a)
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Weighted-average exercise price of outstanding options, warrants and rights
        <br/>
        (b)
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Number of
        <br/>
        securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)
        <br/>
        (c)
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="width: 23%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Equity compensation plans approved by security holders
         <sup>
          (1)
         </sup>
        </span>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 23%; text-align: right">
        2,447,687
       </td>
       <td style="width: 1%; text-align: left">
        <sup>
         (2)
        </sup>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 23%; text-align: right">
        7.22
       </td>
       <td style="width: 1%; text-align: left">
        <sup>
         (3)
        </sup>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 22%; text-align: right">
        <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
         2,490,903
        </p>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (1)
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Our                                         Amended and Restated 2006 Stock Incentive Plan was approved by our stockholders on February                                         19, 2010. Our 2013 Stock Incentive Plan was approved by our stockholders on July 30,                                         2013. Our 2019 Omnibus Stock Incentive Plan was approved by our stockholders on November                                         26, 2019.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (2)
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consist                                         of underlying stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (3)
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Applicable                                         to shares underlying outstanding stock options only.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_010">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          6.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Selected                                         Financial Data
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Notapplicable.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 48; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      46
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_011">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          7.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Management’s                                         Discussion and Analysis of Financial Condition and Results of Operations
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     <i>
      You should readthe following discussion and analysis together with our audited consolidated financial statements and the accompanying notes containedelsewhere in this report. This discussion contains forward-looking statements, within the meaning of Section 27A of SecuritiesAct, Section 21E of the Exchange Act, and the Private Securities Litigation Reform Act of 1995, including statements
     </i>
     regarding
     <i>
      our expected financial condition, business and financing plans. These statements involve risks and uncertainties. Our actualresults could differ materially from the results described in or implied by these forward-looking statements as a result of variousfactors, including those discussed below and elsewhere in this report, particularly under the heading “Risk Factors.”
     </i>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Overview
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      CorMedixInc., together with our wholly owned subsidiaries, (collectively referred to herein as “we,” “us,” “our”and the “Company”), is a biopharmaceutical company focused on developing and commercializing therapeutic productsfor the prevention and treatment of infectious and inflammatory diseases. In May 2020, we formed a wholly-owned Spanish subsidiary,CorMedix Spain, S.L.U.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Our primary focus ison the development of our lead product candidate, DefenCath™, for potential commercialization in the United States, or U.S.,and other key markets as a catheter lock solution, or CLS. We have in-licensed the worldwide rights to develop and commercializeDefenCath and Neutrolin®. The name DefenCath is the U.S. proprietary name conditionally approved by the U.S. Food and DrugAdministration, or FDA, while the name Neutrolin® is currently used in the European Union, or EU, and other territories wherewe received CE-Mark approval for the commercial distribution of Neutrolin as a CLS regulated as a medical device. DefenCath/Neutrolinis a novel anti-infective solution (a formulation of taurolidine 1.35% and heparin 1000 u/ml) intended for the reduction and preventionof catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis,total parenteral nutrition, and oncology. Infection and thrombosis represent key complications among hemodialysis, total parenteralnutrition and cancer patients with central venous catheters. These complications can lead to treatment delays and increased coststo the healthcare system when they occur due to hospitalizations, need for intravenous, or IV, antibiotic treatment, long-termanticoagulation therapy, removal/replacement of the central venous catheter, related treatment costs and increased mortality. Webelieve DefenCath addresses a significant unmet medical need and a potential large market opportunity.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In January 2015, theFDA designated DefenCath as a Qualified Infectious Disease Product, or QIDP, for prevention of catheter-related blood stream infectionsin patients with end stage renal disease receiving hemodialysis through a central venous catheter. Catheter-related blood streaminfections and clotting can be life-threatening. The QIDP designation provides five years of market exclusivity in addition tothe five years granted for a New Chemical Entity upon approval of a New Drug Application, or NDA. In addition, in January 2015,the FDA granted Fast Track designation to DefenCath Catheter Lock Solution, a designation intended to facilitate development andexpedite review of drugs that treat serious and life-threatening conditions so that the approved drug can reach the market expeditiously.The Fast Track designation of DefenCath provides us with the opportunity to meet with the FDA on a more frequent basis during thedevelopment process, and also ensures eligibility to request priority review of the marketing application.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InDecember 2015, we launched our Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to DemonstrateSafety &amp; Effectiveness of DefenCath/Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysisfor End Stage Renal Disease, or LOCK-IT-100, in patients with hemodialysis catheters in the U.S. The clinical trial was designedto demonstrate the safety and effectiveness of DefenCath compared to the standard of care CLS, Heparin, in preventing CRBSIs.The primary endpoint for the trial assessed the incidence of CRBSI and time to CRBSI for each study subject. Secondary endpointswere catheter patency, which was defined as required use of tPA, or removal of catheter due to dysfunction, and removal of catheterfor any reason.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Aspreviously agreed with the FDA, an interim efficacy analysis was performed when the first 28 potential CRBSI cases were identifiedin our LOCK-IT-100 study that occurred through early December 2017. Based on these first 28 cases, there was a highly statisticallysignificant 72% reduction in CRBSI by DefenCath relative to the active control of heparin (p=0.0034). Because the pre-specifiedlevel of statistical significance was reached for the primary endpoint and efficacy had been demonstrated with no safety concerns,the LOCK-IT-100 study was terminated early. The study continued enrolling and treating subjects until study termination, and thefinal analysis was based on a total of 795 subjects. In a total of 41 cases, there was a 71% reduction in CRBSI by DefenCath relativeto heparin, which was highly statistically significant (p=0.0006), with a good safety profile.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 49; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      47
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     The FDA granted ourrequest for a rolling submission and review of the NDA which is designed to expedite the approval process for products being developedto address an unmet medical need. Although the FDA usually requires two pivotal clinical trials to provide substantial evidenceof safety and effectiveness for approval of an NDA, the FDA will in some cases accept one adequate and well-controlled trial, whereit is a large multicenter trial with a broad range of subjects and study sites that has demonstrated a clinically meaningful andstatistically very persuasive effect on a disease with potentially serious outcome.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In March 2020, webegan the modular submission process for the NDA for DefenCath for the prevention of CRBSI in hemodialysis patients, and in August2020, the FDA accepted for filing the DefenCath NDA. The FDA also granted our request for priority review, which provides fora six-month review period instead of the standard ten-month review period. As we announced in March 2021, the FDA has informedus that it will not approve the NDA for DefenCath in its present form. The FDA noted concerns at the third-party manufacturingfacility after a review of records requested by the FDA and provided by the manufacturing facility. We are working with the manufacturingfacility to develop plans for resolution of the deficiencies. Additionally, the FDA is requiring a manual extraction study todemonstrate that the labeled volume can be consistently withdrawn from the vials despite an existing in-process control to demonstratefill volume within specifications. We expect to be able to complete this requirement expeditiously. Satisfactory resolution ofthese issues is required for approval of the DefenCath NDA by a pre-approval inspection and/or adequate manufacturing facilityresponses addressing these concerns. If an inspection is required, we may encounter delays in obtaining FDA approval because theFDA is currently facing a backlog due to the pandemic and is actively working to define an approach for scheduling outstandinginspections once safe travel may resume. We will request a meeting with the FDA, which we estimate will occur in mid-April, toobtain agreement with the FDA on the proposed resolutions of the deficiencies.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA did not request additional clinical data and did not identify any deficiencies related to the data submitted on the efficacyor safety of DefenCath from LOCK-IT-100. In draft labeling discussed with the FDA, the FDA added that the initial approval willbe for the limited population of patients with kidney failure receiving chronic hemodialysis through a central venous catheter.This is consistent with our request for approval pursuant to the Limited Population Pathway for Antibacterial and Antifungal Drugs,or LPAD. LPAD, passed as part of the 21st Century Cures Act, is a new program intended to expedite the development and approvalof certain antibacterial and antifungal drugs to treat serious or life-threatening infections in limited populations of patientswith unmet needs. LPAD provides for a streamlined clinical development program involving smaller, shorter, or fewer clinical trialsand is intended to encourage the development of safe and effective products that address unmet medical needs of patients withserious bacterial and fungal infections. We believe that LPAD will provide additional flexibility for the FDA to approve DefenCathto prevent CRBSIs in the limited population of patients with kidney failure receiving hemodialysis through a central venous catheter.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weintend to pursue additional indications for DefenCath use as a CLS in populations with an unmet medical need that also representa significant market opportunity. For example, we intend to pursue marketing authorization in the U.S. for use as a CLS to reduceCRBSIs in oncology and total parenteral nutrition patients using a central venous catheter.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     In addition to DefenCath,we are sponsoring a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare orphan pediatrictumors. In February 2018, the FDA granted orphan drug designation to taurolidine for the treatment of neuroblastoma in children.We may seek one or more strategic partners or other sources of capital to help us develop and commercialize taurolidine for thetreatment of neuroblastoma in children. We are also evaluating opportunities for the possible expansion of taurolidine as a platformcompound for use in certain medical devices. Patent applications have been filed in several indications, including wound closure,surgical meshes, and wound management. Based on initial feasibility work, we are advancing pre-clinical studies for taurolidine-infusedsurgical meshes, suture materials and hydrogels. We will seek to establish development/commercial partnerships as these programsadvance.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wewere granted a deferral by the FDA under the Pediatric Research Equity Act, or PREA, that requires sponsors to conduct pediatricstudies for NDAs for a new active ingredient, such as taurolidine in DefenCath, unless a waiver or deferral is obtained from theFDA. A deferral acknowledges that a pediatric assessment is required but permits the applicant to submit the pediatric assessmentafter the submission of an NDA. We have made a commitment to conduct the pediatric study after approval of the NDA for use inadult hemodialysis patients. Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity,which if granted would provide an additional six months of marketing exclusivity. DefenCath would then have the potential to receivea total marketing exclusivity period of 10.5 years, including exclusivity pursuant to NCE and QIDP.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 50; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      48
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheFDA regards taurolidine as a new chemical entity and therefore an unapproved new drug. Consequently, there is no appropriate predicatemedical device currently marketed in the U.S. on which a 510(k) approval process could be based. As a result, we will be requiredto submit a premarket approval application, or PMA, for marketing authorization for any medical device indications that we maypursue. In the event that an NDA for DefenCath is approved by the FDA, the regulatory pathway for these medical device productcandidates may be revisited with the FDA. Although there may be no appropriate predicate, de novo Class II designation can beproposed, based on a risk assessment and a reasonable assurance of safety and effectiveness.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe European Union, or EU, Neutrolin is regulated as a Class 3 medical device. In July 2013, we received CE Mark approval forNeutrolin. In December 2013, we commercially launched Neutrolin in Germany for the prevention of CRBSI, and maintenance of catheterpatency in hemodialysis patients using a tunneled, cuffed central venous catheter for vascular access. To date, Neutrolin is registeredand may be sold in certain European Union and Middle Eastern countries for such treatment.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InSeptember 2014, the TUV-SUD and The Medicines Evaluation Board of the Netherlands, or MEB, granted a label expansion for Neutrolinto include use in oncology patients receiving chemotherapy, intravenous, or IV, hydration and IV medications via CVC for the EU.In December 2014, we received approval from the Hessian District President in Germany to expand the label for these same expandedindications. The expansion also adds patients receiving medication and IV fluids via CVC in intensive or critical care units (cardiaccare unit, surgical care unit, neonatal critical care unit, and urgent care centers). An indication for use in total parenteralnutrition was also approved.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InSeptember 2019, our registration with the Saudi Arabia Food and Drug Administration, or the SFDA, expired. As a result, we cannotsell Neutrolin in Saudi Arabia. We intend to complete the documentation required to renew our registration with the SFDA, however,we cannot predict how long the renewal process will take. There is no assurance that the registration will be renewed by the SFDA.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thenovel coronavirus has been declared a pandemic and has spread to multiple global regions. The outbreak and government measurestaken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortageshave occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goodsand services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, hasfallen. In response to the COVID-19 outbreak, “shelter in place” orders and other public health guidance measureshave been implemented across much of the United States, Europe and Asia, including in the locations of our offices, clinical trialsites, key vendors and partners. Our program timelines may be negatively affected by COVID-19, which could materially and adverselyaffect its business, financial conditions and results of operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Sinceour inception, our operations have been primarily limited to conducting clinical trials and establishing manufacturing for ourproduct candidates, licensing product candidates, business and financial planning, research and development, seeking regulatoryapproval for our products, initial commercialization activities for DefenCath in the U.S. and Neutrolin in the EU and other foreignmarkets, and maintaining and improving our patent portfolio. We have funded our operations primarily through debt and equity financings.We have generated significant losses to date, and we expect to use substantial amounts of cash for our operations as we prepareour pre-launch commercial activities for DefenCath for the U.S. market and commercialize Neutrolin in the EU and other foreignmarkets, pursue business development activities, and incur additional legal costs to defend our intellectual property. As of December31, 2020, we had an accumulated deficit of approximately $217.4 million. We are unable to predict the extent of any future lossesor when we will become profitable, if ever.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      FinancialOperations Overview
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Revenue
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wehave not generated substantial revenue since our inception. Through December 31, 2020, we have funded our operations primarilythrough debt and equity financings.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 51; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      49
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Researchand Development Expense
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Research and development,or R&amp;D, expense consists of: (i) internal costs associated with our development activities; (ii) payments we make to thirdparty contract research organizations, contract manufacturers, investigative sites, and consultants; (iii) technology and intellectualproperty license costs; (iv) manufacturing development costs; (v) personnel related expenses, including salaries, stock–basedcompensation expense, benefits, travel and related costs for the personnel involved in drug development; (vi) activities relatingto regulatory filings and the advancement of our product candidates through pre-clinical studies and clinical trials; (vii) facilitiesand other allocated expenses, which include direct and allocated expenses for rent, facility maintenance, as well as laboratoryand other supplies; and (viii) costs related to the manufacturing of the product that could potentially be available to supportthe commercial launch prior to marketing approval. All R&amp;D is expensed as incurred.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Conducting a significantamount of development is central to our business model. Product candidates in later-stage clinical development generally have higherdevelopment costs than those in earlier stages of development, primarily due to the significantly increased size and duration ofthe clinical trials.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theprocess of conducting pre-clinical studies and clinical trials necessary to obtain regulatory approval is costly and time consuming.The probability of success for each product candidate and clinical trial may be affected by a variety of factors, including, amongothers, the quality of the product candidate’s early clinical data, investment in the program, competition, manufacturingcapabilities and commercial viability. As a result of the uncertainties associated with clinical trial enrollments and the risksinherent in the development process, we are unable to determine the duration and completion costs of current or future clinicalstages of our product candidates or when, or to what extent, we will generate revenues from the commercialization and sale ofany of our product candidates.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Development timelines,probability of success and development costs vary widely. We are currently focused on securing the marketing approval for DefenCathin the U.S. as well as on continuing sales in foreign markets where Neutrolin is approved. In December 2015, we signed an agreementwith a clinical research organization, or CRO, to help us conduct our LOCK-IT-100 Phase 3 clinical trial in hemodialysis patientswith central venous catheters to demonstrate the efficacy and safety of DefenCath in preventing catheter-related bloodstream infectionsand blood clotting in subjects receiving hemodialysis therapy as treatment for end stage renal disease. Our LOCK-IT-100 study wascompleted and all costs related to the agreement with the CRO has been paid.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weare pursuing additional opportunities to generate value from taurolidine, an active component of DefenCath. Based on initial feasibilitywork, we have completed an initial round of pre-clinical studies for taurolidine-infused surgical meshes, suture materials, andhydrogels, which require a PMA regulatory pathway for approval. We are also involved in a pre-clinical research collaborationfor the use of taurolidine as a possible treatment for rare orphan pediatric tumors. In February 2018, the FDA granted orphandrug designation to taurolidine for the treatment of neuroblastoma in children. We may seek one or more strategic partners orother sources of capital to help us develop and commercialize taurolidine for the treatment of neuroblastoma in children.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Selling,General and Administrative Expense
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Selling,general and administrative, or SG&amp;A, expense includes costs related to commercial personnel, medical education professionals,marketing and advertising, salaries and other related costs, including stock-based compensation expense, for persons serving inour executive, sales, finance and accounting functions. Other SG&amp;A expense includes facility-related costs not included inR&amp;D expense, promotional expenses, costs associated with industry and trade shows, and professional fees for legal servicesand accounting services.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 52; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      50
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        ForeignCurrency Exchange Transaction Gain (Loss)
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Foreigncurrency exchange transaction gain (loss) is the result of re-measuring transactions denominated in a currency other than ourfunctional currency and is reported in the consolidated statement of operations as a separate line item within other income (expense).The intercompany loans outstanding between our company based in New Jersey and our subsidiary based in Germany are not expectedto be repaid in the foreseeable future and the nature of the funding advanced is of a long-term investment nature. As such, unrealizedforeign exchange movements related to long-term intercompany loans are recorded in other comprehensive income (loss).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        InterestIncome
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Interestincome consists of interest earned on our cash equivalents and short-term investments.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        InterestExpense
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Interestexpense consists of interest incurred on our convertible debt, amortization of debt discount and on financing of expenditures.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Resultsof Operations
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Comparisonof the Years Ended December 31, 2020 and 2019
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing is a tabular presentation of our consolidated operating results for the years ended December 31, 2020 and 2019
      <i>
       (inthousands)
      </i>
      :
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         2020
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         2019
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         % of
         <br/>
         Change
         <br/>
         Increase
         <br/>
         (Decrease)
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 64%; text-align: left">
        Revenue
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        239
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        283
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        (16
       </td>
       <td style="width: 1%; text-align: left">
        )%
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Cost of sales
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (205
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (373
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        (45
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )%
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Gross profit (loss)
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        34
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (90
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        (138
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )%
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Operating Expenses:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Research and development
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (13,377
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (11,053
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        21
       </td>
       <td style="text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Selling, general and administrative
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (13,878
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (9,865
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        41
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Total operating expenses
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (27,255
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (20,918
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        30
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Loss from operations
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (27,221
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (21,008
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        30
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Interest income
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        116
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        322
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (64
       </td>
       <td style="text-align: left">
        )%
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Foreign exchange transaction loss
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (59
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (21
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        180
       </td>
       <td style="text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Interest expense, including amortization of debt discount
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (33
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (787
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        (96
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )%
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Total other income (expense)
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        24
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (486
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        (105
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )%
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Loss before income taxes
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (27,197
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (21,494
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        27
       </td>
       <td style="text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Tax benefit
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        5,169
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        5,061
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        2
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Net loss
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (22,028
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (16,433
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        34
       </td>
       <td style="text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        Other comprehensive income (loss)
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        5
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        1
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
        547
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">
        Comprehensive loss
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (22,023
       </td>
       <td style="padding-bottom: 4pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (16,432
       </td>
       <td style="padding-bottom: 4pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="padding-bottom: 4pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt; text-align: right">
        34
       </td>
       <td style="padding-bottom: 4pt; text-align: left">
        %
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     <i>
      Revenue.
     </i>
     Revenuefor the year ended December 31, 2020 was $239,000 as compared to $283,000 for the same period in 2019, a decrease of $44,000. Thedecrease was attributable to decreased sales in the Middle East of $146,000, partially offset by higher sales in the European Unionof $102,000. The sales decrease in the Middle East was mainly due to the expiration of our registration with the Saudi Arabia Foodand Drug Administration. We intend to renew the registration in order for us to resume selling in Saudi Arabia, however, we cannotpredict how long the renewal process will take.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 53; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      51
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     <i>
      Cost of Sales.
     </i>
     Costof sales for the year ended December 31, 2020 was $205,000 as compared to $373,000 for the same period in 2019, a decrease of $168,000.The decrease is attributable to a decrease in cost of materials of $106,000, mainly due to lower sales in the Middle East, a decreasein the cost related to replacement of products shipped under warranty of $40,000, and a decrease in the write-off of expired rawmaterials of $32,000, offset by an increase in inventory reserve of $17,000.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       Researchand Development Expense
      </i>
      . R&amp;D expense for the year ended December 31, 2020 was $13,377,000, an increase of $2,324,000 from$11,053,000 for the same period in 2019. The increase was primarily attributable to an increase in costs related to the purchaseof raw materials and manufacturing of DefenCath prior to its potential marketing approval that could potentially support the commerciallaunch of $3,345,000, an increase in personnel expenses of $1,391,000, primarily due to additional hires, offset by a reductionin clinical trial expenses of $2,299,000, attributable to the closing of our LOCK-IT-100 clinical trial and a decrease in consultingfees of $271,000.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       Selling,General and Administrative Expense
      </i>
      . SG&amp;A expense for the year ended December 31, 2020 was $13,878,000, an increase of$4,013,000 from $9,865,000 for the same period in 2019. The increase was primarily attributable to increases in personnel expensesof $1,422,000, primarily due to additional hires during the year ended December 31, 2020 and increases in costs related to marketingresearch studies in preparation for the potential marketing approval of DefenCath of $1,216,000. Additionally, there were alsoincreases in insurance expenses of $395,000 driven by higher directors and officers insurance premium consistent with increasesacross our industry, in board fees of $274,000 as a result of a change in compensation which has eliminated issuance of restrictedstock units as compensation, in dues and subscription and office expenses of $195,000, in recruitment fees of $184,000 in searchfor additional personnel, in consulting fees of $149,000, and in investor relations and business development activities of $87,000.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       InterestIncome
      </i>
      . Interest income for the year ended December 31, 2020 was $116,000, a decrease of $207,000 from $323,000 for the sameperiod in 2019. The decrease was attributable to lower average interest-bearing cash balances and short-term investments duringthe year ending December 31, 2020 as compared to the same period in 2019.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       ForeignExchange Transaction Gain (Loss)
      </i>
      . Foreign exchange transaction losses for the year ended December 31, 2020 and 2019 were dueto the re-measuring of transactions denominated in a currency other than our functional currency.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       InterestExpense
      </i>
      . Interest expense for the year ended December 31, 2020 was $33,000 as compared to $787,000 for the same period in2019. The decrease of $754,000 was due primarily to the amortization of debt discount and non-cash interest expense recognizedin connection with the senior secured convertible note which is no longer outstanding.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       TaxBenefit.
      </i>
      Tax benefit for the years ended December 31, 2020 of $5,169,000 and December 31, 2019 of $5,061,000, represents incometax benefits due to the sale of our unused NOL for state fiscal year 2020 and 2019, respectively, through the NJEDA TechnologyBusiness Tax Certificate Transfer program.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       OtherComprehensive Income (Loss)
      </i>
      . Unrealized foreign exchange movements related to long-term loans and the translation of the foreignaffiliate financial statements to U.S. dollars and unrealized movements related to short term investment are recorded in othercomprehensive income (loss) which resulted in gains of $6,000 and $1,000 for the years ended December 31, 2020 and 2019, respectively.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Liquidityand Capital Resources
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Sourcesof Liquidity
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     As a result of ourcost of sales, R&amp;D and SG&amp;A expenditures and the lack of substantial product sales revenue, our ongoing operations havenot been profitable since our inception. During the year ended December 31, 2020, we received net proceeds of $18,433,000 fromthe issuance of 2,687,646 shares of common stock under our ATM program and $412,000 from the exercise of warrants. Additionally,in July 2020, we completed an underwritten public offering of our common stock, which yielded net proceeds of approximately $21,255,000.The public offering was made pursuant to an underwriting agreement with the underwriters thereto, relating to the issuance andsale of an aggregate of 5,111,110 shares of common stock, including 666,666 shares of common stock pursuant to the full exerciseof the Underwriters’ option to purchase additional shares, at a public offering price of $4.50 per share. We will continueto be reliant on external sources of cash for the foreseeable future until we are able to generate revenue.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 54; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      52
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InApril 2020, we received approximately $5,169,000, net of expenses, from the sale of most of our remaining unused New Jersey netoperating losses (“NOL”) eligible for sale under the State of New Jersey’s Economic Development Authority’sNew Jersey Technology Business Tax Certificate Transfer program (“NJEDA Program”). The NJEDA Program allowed us tosell approximately $5,529,000 of our total $6,018,000 in available NOL tax benefits for the state fiscal year 2019.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     As previously announced,the NJEDA has approved our application to participate in the NJEDA Program for the state fiscal year 2020.  The approval willallow us to sell approximately $1.3 million of the total $1.3 million in available tax benefits to an unrelated, profitable NewJersey corporation in return for approximately $1.3 million in cash. Closing is subject to NJEDA’s typical closing conditions,which are in process of completion.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     During January andFebruary 2021, we raised approximately $41,478,000 through the use of our ATM program. We currently have no available balance underour ATM program and we have $50.0 million available under our current shelf registration for the issuance of equity, debt or equity-linkedsecurities.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        NetCash Used in Operating Activities
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Net cash used in operatingactivities for the year ended December 31, 2020 was $21,968,000 as compared to $15,052,000 in 2019, an increase in net cash useof $6,916,000. The increase was mainly attributable to the increase in net loss of $5,595,000, primarily driven by an increasein operating expenses, due to the research and development expense related to the costs related to the manufacturing of DefenCathprior to its potential marketing approval and selling, general and administrative expense related to marketing research studiesin preparation for the potential marketing approval of DefenCath. In addition, the increase was also due to an increase in prepaidexpenses and other current assets for the year ended December 31, 2020 of $992,000, primarily due to a deposit on the equipment,compared to a $67,000 increase for the same period in 2019. There was also a decrease in accrued expenses of $1,883,000 for theyear ended December 31, 2020, as compared to a decrease of $363,000 for the same period in 2019, and an increase in accounts payableof $103,000 for the year ended December 31, 2020, as compared to a decrease of $1,564,000 for the same period in 2019.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        NetCash (Used in) Provided by Investing Activities
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Cashprovided by investing activities for the year ended December 31, 2020 was $7,426,000 as compared to $12,020,000 of cash usedin the same period in 2019. The increase in cash provided during the year ended December 31, 2020 as compared to the yearended December 31, 2019 was due to the maturity of short-term investments and a decline in purchases of short-terminvestments in 2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      NetCash Provided by Financing Activities
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Netcash provided by financing activities for the year ended December 31, 2020 was $40,100,000 as compared to $25,804,000 for thesame period in 2019. During the year ended December 31, 2020, we generated net proceeds of $21,255,000 from the public offeringof our common stock, $18,433,000 from the sale of our common stock in our at-the-market, or ATM program, and $412,000 from theexercise of warrants. In comparison to the same period in 2019, the net proceeds we generated in the amount of $15,235,000 wasfrom the sale of our common stock in our ATM program, gross proceeds of $8,674,000 and $123,000 from the exercise of warrantsand stock options, respectively, and gross proceeds from an exchange agreement of $2,000,000, respectively.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      FundingRequirements and Liquidity
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Our total cash andcash equivalents and short-term investments as of December 31, 2020 and 2019, excluding restricted cash of $0.2 million in eachfiscal year was $46.3 million and $28.3 million, respectively. During the year ended December 31, 2020, we realized net proceedsof $21.3 million from the public offering of 5,111,110 shares of our common stock and we sold 2,687,646 shares of common stockunder our ATM program at the weighted average price of $7.13 per share and realized net proceeds of approximately $18.4 million.At December 31, 2020, we had approximately $17.8 million available under our current ATM program and $75.0 million available underour current shelf registration for the issuance of equity, debt or equity-linked securities.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     On February 5, 2021,we allocated to our ATM program an additional $25.0 million of the remaining $75.0 million available under our shelf registrationstatement. Giving effect to the additional $25.0 million, plus the $17.8 million available at December 31, 2020, we had a totalof $42.8 million available under the ATM program. During January and February 2021, we sold an aggregate of 3,737,862 shares ofour common stock under the ATM program and realized net proceeds of approximately $41.5 million. As of the filing of this AnnualReport on Form 10-K, we have no available balance under our ATM program and we have $50.0 million available under our current shelfregistration for the issuance of equity, debt or equity-linked securities.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Becauseour business has not generated positive operating cash flow, we will need to raise additional capital in order to continue tofund our research and development activities, as well as to fund operations generally. Our continued operations are focused primarilyin activities leading to the pre-launch and commercialization for DefenCath and will depend on our ability to raise sufficientfunds through various potential sources, such as equity, debt financings, and/or strategic relationships and potential strategictransactions. We can provide no assurances that financing or strategic relationships will be available on acceptable terms, orat all.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 55; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      53
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weexpect to continue to fund operations from cash on hand and through capital raising sources as previously described, which maybe dilutive to existing stockholders, through revenues from the licensing of our products, or through strategic alliances. Weexpect to continue to utilize our ATM program, if conditions allow, to support our ongoing funding requirements. Additionally,we may seek to sell additional equity or debt securities through one or more discrete transactions, or enter into a strategicalliance arrangement, but can provide no assurances that any such financing or strategic alliance arrangement will be availableon acceptable terms, or at all. Moreover, the incurrence of indebtedness would result in increased fixed obligations and couldcontain covenants that would restrict our operations. Raising additional funds through strategic alliance arrangements with thirdparties may require significant time to complete and could force us to relinquish valuable rights to our technologies, futurerevenue streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us or ourstockholders. Our actual cash requirements may vary materially from those now planned due to a number of factors, any change inthe focus and direction of our research and development programs, any acquisition or pursuit of development of new product candidates,competitive and technical advances, the costs of commercializing any of our product candidates, and costs of filing, prosecuting,defending and enforcing any patent claims and any other intellectual property rights.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Sales of Neutrolinoutside the U.S. are not expected to generate significant product revenues for the foreseeable future, and we expect to grow productsales for DefenCath in the U.S., should we receive FDA approval. In the absence of significant revenue, we are likely to continuegenerating operating cash flow deficits. We will continue to use cash as we increase other activities leading to the commercializationof DefenCath upon approval, pursue business development activities, and incur additional legal costs to defend our intellectualproperty.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We currently estimatethat as of December 31, 2020 we have sufficient cash on hand to fund operations at least into the second half of 2022, after takinginto consideration the net proceeds received from the ATM program after December 31, 2020 and including the costs for the initialpreparations for the commercial launch of DefenCath, when the NDA is approved by FDA. Additional financing may be required to buildout our commercial infrastructure and to continue our operations should we decide to market and sell Defencath in the U.S. on ourown. If we are unable to raise additional funds when needed, we may be forced to slow or discontinue our preparations for the commerciallaunch of DefenCath. We may also be required to delay, scale back or eliminate some or all of our research and development programs.Each of these alternatives would likely have a material adverse effect on our business.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       ContractualObligations
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weentered into a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights,New Jersey 07922. The lease agreement, with a monthly average cost of approximately $17,000, commenced on September 16, 2020.Our sublease on our previous premises at 400 Connell Drive, Berkeley Heights, New Jersey 07922 terminated on November 30,2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="18" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <b>
         Payments Due in Period
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         Total
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         Within
         <br/>
         1 Year
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         Years 2-3
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         Years 4-5
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid">
        <b>
         More Than
         <br/>
         5 Years
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 40%; padding-bottom: 4pt; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Leases
        </span>
       </td>
       <td style="width: 1%; padding-bottom: 4pt">
       </td>
       <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
        1,393,000
       </td>
       <td style="width: 1%; padding-bottom: 4pt; text-align: left">
       </td>
       <td style="width: 1%; padding-bottom: 4pt">
       </td>
       <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
        198,000
       </td>
       <td style="width: 1%; padding-bottom: 4pt; text-align: left">
       </td>
       <td style="width: 1%; padding-bottom: 4pt">
       </td>
       <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
        402,000
       </td>
       <td style="width: 1%; padding-bottom: 4pt; text-align: left">
       </td>
       <td style="width: 1%; padding-bottom: 4pt">
       </td>
       <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
        413,000
       </td>
       <td style="width: 1%; padding-bottom: 4pt; text-align: left">
       </td>
       <td style="width: 1%; padding-bottom: 4pt">
       </td>
       <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
        380,000
       </td>
       <td style="width: 1%; padding-bottom: 4pt; text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      CriticalAccounting Estimates
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Our management’sdiscussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparationof these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets,liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments, including those described below. We baseour estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances.These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that arenot readily apparent from other sources. Actual results and experiences may differ materially from these estimates.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 56; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      54
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Whileour significant accounting policies are more fully described in Note 3 to our financial statements included with this report,we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reportedfinancial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Stock-BasedCompensation
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weaccount for stock options according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification(“ASC”) No. 718, “Compensation — Stock Compensation” (“ASC 718”). Share-based compensationcost is measured at grant date, based on the estimated fair value of the award using a Black-Scholes option pricing model foroptions with service or performance-based conditions. Stock-based compensation cost is recognized as expense, over the requisiteservice period on a straight-line basis.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Valuationsincorporate several variables, including expected term, expected volatility, expected dividend yield and a risk-free interestrate. We estimate the expected term of the options granted based on anticipated exercises in future periods. The expected stockprice volatility for the Company’s stock options is calculated based on the historical volatility of the Company’scommon stock. The expected dividend yield reflects our current and expected future policy for dividends on our common stock. Todetermine the risk-free interest rate, we utilize the U.S. Treasury yield curve in effect at the time of grant with a term consistentwith the expected term of our awards which is 5 years for employees and 10 years for non-employees.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        RevenueRecognition
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weadopted the new revenue recognition, ASC 606, “
      <i>
       Revenue from Contracts with Customers”
      </i>
      , as of January 1, 2018using the modified retrospective method. ASC 606 prescribes a five-step model for recognizing revenue which includes (i) identifyingcontracts with customers; (ii) identifying performance obligations; (iii) determining the transaction price; (iv) allocating thetransaction price; and (v) recognizing revenue.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourproduct Neutrolin received its CE Mark in Europe in July 2013 and shipment of product to the dialysis centers began in December2013. We recognize net sales upon shipment of product to the dialysis centers and upon meeting the five-step model prescribedby ASC 606 outlined above.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        InventoryValuation
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weengage third parties to manufacture and package inventory held for sale and warehouse such goods until packaged for final distributionand sale. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis.Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on sales activity, both projected andhistorical, as well as product shelf-life. In evaluating the recoverability of our inventories, we consider the probability thatrevenue will be obtained from the future sale of the related inventory and, if required, will write down inventory quantitiesin excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of product salesin our consolidated statements of operations.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weanalyze our inventory levels to identify inventory that may expire prior to sale, inventory that has a cost basis in excess ofits estimated realizable value, or inventory in excess of expected sales requirements. Although the manufacturing of our productsis subject to strict quality controls, certain batches or units of product may no longer meet quality specifications or may expire,which would require adjustments to our inventory values.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inthe future, reduced demand, quality issues or excess supply beyond those anticipated by management may result in an adjustmentto inventory levels, which would be recorded as an increase to cost of product sales. The determination of whether or not inventorycosts will be realizable requires estimates by our management. A critical input in this determination is future expected inventoryrequirements based on our internal sales forecasts which we then compare to the expiry dates of inventory on hand. To the extentthat inventory is expected to expire prior to being sold, we will write down the value of inventory. If actual results differfrom those estimates, additional inventory write-offs may be required.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 57; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      55
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        Short-TermInvestments
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wedetermine the appropriate classification of marketable securities at the time of purchase and reevaluate such designation asof each balance sheet date. Investments in marketable debt and equity securities classified as available-for-sale arereported at fair value. Fair values of our investments are determined using quoted market prices in active markets foridentical assets or liabilities or quoted prices for similar assets or liabilities or other inputs that are observable or canbe corroborated by observable market data for substantially the full term of the assets or liabilities. Our marketablesecurities are highly liquid and consist of U.S. government agency securities, high-grade corporate obligations andcommercial paper with maturities of more than 90 days but less than 12 months. Changes in fair value that are consideredtemporary are reported net of tax in other comprehensive income (loss). Realized gains and losses, amortization of premiumsand discounts and interest and dividends earned are included in income (expense) on the consolidated statements of operationsand comprehensive income (loss). The cost of investments for purposes of computing realized and unrealized gains and lossesis based on the specific identification method. Investments with maturities beyond one year, if any, are classified asshort-term based on management’s intent to fund current operations with these securities or to make them available forcurrent operations. For declines, if any, in the fair value of equity securities that are considered other-than-temporary,impairment losses are charged to other (income) expense, net. We consider available evidence in evaluating potentialimpairments of our investments, including the duration and extent to which fair value is less than cost and, for equitysecurities, our ability and intent to hold the investments.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        FairValue Measurements
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wecategorize our financial instruments into a three-level fair value hierarchy that prioritize the inputs to valuation techniquesused to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identicalassets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure fair value fall withindifferent levels of the hierarchy, the category level is based on the lowest priority level input that is significant to the fairvalue measurement of the instrument. Financial assets recorded at fair value on our consolidated balance sheets are categorizedas follows:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0.5in">
       </td>
       <td style="width: 0.25in; text-align: left">
        ●
       </td>
       <td style="text-align: justify">
        Level 1 inputs—Observable inputs that reflectquoted prices (unadjusted) for identical assets or liabilities in active markets.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0.5in">
       </td>
       <td style="width: 0.25in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Level2 inputs— Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices foridentical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interestrate and yield curves, and market-corroborated inputs).
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0.5in">
       </td>
       <td style="width: 0.25in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Level3 inputs—Unobservable inputs for the asset or liability, which are supported by little or no market activity and are valuedbased on management’s estimates of assumptions that market participants would use in pricing the asset or liability.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        RecentAuthoritative Pronouncements:
       </i>
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InDecember 2019, the FASB issued new guidance which removes certain exceptions to the general principles of the accounting for incometaxes and also improves consistent application of and simplification of other areas when accounting for income taxes. The guidanceis effective for us beginning in the first quarter of fiscal year 2021. Early adoption is permitted. We are assessing the impactof adopting this guidance on our consolidated financial statements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Off-BalanceSheet Arrangements
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wedo not have any off-balance sheet arrangements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_012">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          7A.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Quantitative                                         and Qualitative Disclosures About Market Risk
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Notapplicable.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_013">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          8.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Financial                                         Statements and Supplementary Data
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Seethe financial statements included at the end of this report beginning on page F-1.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 58; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      56
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_014">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          9.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Changes                                         in and Disagreements With Accountants on Accounting and Financial Disclosure
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Notapplicable.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_015">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          9A.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Controls                                         and Procedures
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Asof the end of the period covered by this Annual Report on Form 10-K, we carried out an evaluation, under the supervision and withthe participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectivenessof the design and operation of our disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e))(the “Exchange Act”). Based on the foregoing evaluation, our Chief Executive Officer and Chief Financial Officer haveconcluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by usin the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periodsspecified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, includingour Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Changesin Internal Control Over Financial Reporting
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Therewere no changes in our internal control over financial reporting during our fourth quarter ended December 31, 2020, or in otherfactors that could significantly affect these controls, that materially affected, or are reasonably likely to materially affect,our internal control over financial reporting.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Management’sAnnual Report on Internal Controls Over Financial Reporting
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ourmanagement is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessmentof the effectiveness of internal control over financial reporting. As defined by the Securities and Exchange Commission, internalcontrol over financial reporting is a process designed by, or under the supervision of, our principal executive and principalfinancial officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regardingthe reliability of financial reporting and the preparation of the consolidated financial statements in accordance with U.S. generallyaccepted accounting principles.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Our internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance ofrecords that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets; (2) providereasonable assurance that transactions are recorded as necessary to permit preparation of the consolidated financial statementsin accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordancewith authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detectionof unauthorized acquisition, use or disposition of our assets that could have a material effect on the consolidated financialstatements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Becauseof its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projectionsof any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changesin conditions, or that the degree of compliance with the policies or procedures may deteriorate.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inconnection with the preparation of our annual consolidated financial statements, management, including, our Principal Executiveand Financial Officer, has undertaken an assessment of the effectiveness of our internal control over financial reporting as ofDecember 31, 2020, based on the criterial established in Internal Control—Integrated Framework (2013) issued by the Committeeof Sponsoring Organizations of the Treadway Commission (COSO). Management’s assessment included an evaluation of the designof our internal control over financial reporting and testing of the operational effectiveness of those controls.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Basedon this evaluation, management has concluded that our internal control over financial reporting was effective as of December 31,2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <div>
     <a id="a_016">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          9B.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Other                                         Information
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Notapplicable.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 59; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      57
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <div>
     <a id="a_017">
     </a>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      PARTIII
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_018">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                          10.
         </b>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Directors,                                         Executive Officers, and Corporate Governance
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wehave adopted a written Code of Conduct and Ethics that applies to our directors, executive officers and all employees. We intendto disclose any amendments to, or waivers from, our code of ethics and business conduct that are required to be publicly disclosedpursuant to rules of the SEC by filing such amendment or waiver with the SEC. This code of ethics and business conduct can befound in the “Investors - Corporate Governance” section of our website,
      <i>
       www.cormedix.com
      </i>
      .
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       DelinquentSection 16(a) Reports
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Section16(a) of the Exchange Act requires our directors, executive officers and holders of more than 10% of our common stock to filewith the SEC initial reports of ownership and reports of changes in the ownership of our common stock and other equity securities.Such persons are required to furnish us copies of all Section 16(a) filings. Based solely upon a review of the copies of the formsfurnished to us, we believe that our officers, directors and holders of more than 10% of our common stock complied with all applicablefiling requirements during the fiscal year ended December 31, 2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Directors
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table sets forth the name, age and position of each of our directors as of December 31, 2020:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid; vertical-align: bottom">
        Name
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; vertical-align: bottom">
        Age
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; vertical-align: bottom">
        Director Since
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
        Position(s) with CorMedix
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="width: 30%; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">
        Khoso Baluch
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 9%; text-align: center">
        63
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 20%; text-align: center">
        October 2016
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 38%; text-align: left">
        Director and Chief Executive Officer
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">
        Paulo Costa
       </td>
       <td>
       </td>
       <td style="text-align: center">
        70
       </td>
       <td>
       </td>
       <td style="text-align: center">
        September 2020
       </td>
       <td>
       </td>
       <td style="text-align: left">
        Director
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">
        Janet M. Dillione
       </td>
       <td>
       </td>
       <td style="text-align: center">
        62
       </td>
       <td>
       </td>
       <td style="text-align: center">
        August 2015
       </td>
       <td>
       </td>
       <td style="text-align: left">
        Director
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">
        Greg Duncan
       </td>
       <td>
       </td>
       <td style="text-align: center">
        56
       </td>
       <td>
       </td>
       <td style="text-align: center">
        November 2020
       </td>
       <td>
       </td>
       <td style="text-align: left">
        Director
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">
        Alan Dunton
       </td>
       <td>
       </td>
       <td style="text-align: center">
        66
       </td>
       <td>
       </td>
       <td style="text-align: center">
        February 2019
       </td>
       <td>
       </td>
       <td style="text-align: left">
        Director
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">
        Myron Kaplan
       </td>
       <td>
       </td>
       <td style="text-align: center">
        75
       </td>
       <td>
       </td>
       <td style="text-align: center">
        April 2016
       </td>
       <td>
       </td>
       <td style="text-align: left">
        Director and Chairman of the Board
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">
        Steven Lefkowitz
       </td>
       <td>
       </td>
       <td style="text-align: center">
        65
       </td>
       <td>
       </td>
       <td style="text-align: center">
        June 2017
       </td>
       <td>
       </td>
       <td style="text-align: left">
        Director
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 12.3pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        KhosoBaluch
       </i>
      </b>
      joined our Board in October 2016 upon his appointment as our Chief Executive Officer. Mr. Baluch previously servedas Senior Vice President and President Europe, Middle East &amp; Africa of UCB, SA, or UCB, from January 2015 to April 2016, SeniorVice President and President of the European Region of UCB from February 2013 to December 2014, and Senior Vice President andChief Marketing Officer of UCB from January 2010 to February 2013. Prior to joining UCB, Mr. Baluch worked for Eli Lilly and Companyfor 24 years, holding international positions spanning Europe, the Middle East and the United States in general management, businessdevelopment, market access and product leadership. He has served as an independent director of Poxel SA, a French publicly tradedbiotech company, since 2013, and chairs its compensation committee. He also serves as a member of the business development andscientific committees of Poxel SA. Mr. Baluch holds a BSc in Aeronautical Engineering from City University London and a Mastersof Business Administration from Cranfield School of Management. Among other qualifications, attributes and skills, Mr. Baluch’sbusiness expertise and significant executive management experience in the pharmaceutical industry led to the conclusion of ourBoard that he should serve as a director of our Company in light of our business and structure.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        PauloF. Costa
       </i>
      </b>
      has been a director of CorMedix since September 2020. Mr. Costa previously served as President and Chief ExecutiveOfficer of Novartis U.S. Corporation, from October 2005 to August 2008. Prior to his work at Novartis U.S. Corporation, Mr. Costawas President and Chief Executive Officer of Novartis Pharmaceuticals, U.S. from July 1999 to September 2005. Prior to joiningNovartis, Mr. Costa spent 30 years at Johnson &amp; Johnson, including as President of Janssen Pharmaceutica, Inc. From August2009 to August 2012, Mr. Costa served as Chairman of the Board of Amylin Pharmaceuticals Inc, a commercial stage biopharma company,until its sale to Bristol-Myers Squibb and AstraZeneca in a $7 billion transaction in 2012. Mr. Costa currently serves as Chairmanof the Board of MacroGenics, Inc., a public late stage biopharma company focused on oncology, and as a director of two privatelyheld life science companies. Mr. Costa received his undergraduate degree from São Paulo School of Business Administrationand earned a master’s degree in business administration from Harvard Business School. Among other experience, qualifications,attributes and skills, Mr. Costa’s significant depth of experience in the pharmaceutical industry, including service asa director and executive of pharmaceutical companies, led to the conclusion of our Board that he should serve as a director ofour Company in light of our business and structure.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 60; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      58
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     <b>
      <i>
       JanetDillione
      </i>
     </b>
     has been a director of CorMedix since August 2015. Since November 2020, Ms. Dillione currently serves as theChief Executive Officer of Contact America, a nationally recognized leader in comprehensive telehealth and remote patientmonitoring solutions. Prior to joining Contact America, she served as Chief Executive Officer of Bernoulli Enterprise, Inc.since May 2014, a real-time connected healthcare information technology company. Previously, she was at NuanceCommunications, Inc., a leading provider of voice and language solutions for businesses and consumers around the world,having joined Nuance in April 2010 as Executive Vice President and General Manager of the Healthcare Division and serving asan executive officer from March 2010 until May 2014. From June 2000 to March 2010, Ms. Dillione held several senior levelmanagement positions at Siemens Medical Solutions, a global leader in medical imaging, laboratory diagnostics, and healthcareinformation technology, including President and CEO of the global healthcare IT division. Ms. Dillione received her B.A. fromBrown University in 1981 and completed the Executive Program at The Wharton School of Business of the University ofPennsylvania in 1998. She has over 25 years of experience leading global teams in the development and delivery of healthcaretechnology and services. She is a member of the board of CortiCare, a private U.S. based company. Among other qualifications,attributes and skills, Ms. Dillione’s financial expertise and significant executive management experience with medicaldevice and healthcare companies led to the conclusion of our Board that she should serve as a director of our Company inlight of our business and structure.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        GregDuncan
       </i>
      </b>
      has been a director of CorMedix since November 2020. Mr. Duncan currently serves as the Chairman and CEO of ViriosTherapeutics, a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treatdiseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM), and has served since April 2020.From 2014 and prior to joining his current company earlier this year, Mr. Duncan served as President and CEO of Celtaxsys, a privatelyheld biotechnology company focused on cystic fibrosis and other rare, inflammatory diseases. Mr. Duncan has spent the majorityof his career in senior leadership roles in commercial stage pharmaceutical companies. From 2007 to 2013, he served as a seniorexecutive at UCB, including as President of its North America business. Prior to his roles with UCB, Mr. Duncan spent approximately18 years at Pfizer where he gained significant experience across sales and marketing functions including serving as SVP of USMarketing and later as President of Pfizer’s Latin America business from 2005 to 2007. Mr. Duncan received his undergraduatedegree from the State University of New York, Albany, and earned an MBA degree from Emory University. Among other experience,qualifications, attributes and skills, Mr. Duncan’s significant depth of experience in the pharmaceutical industry led tothe conclusion of our Board that he should serve as a director of our Company in light of our business and structure.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        AlanW. Dunton, M.D.
       </i>
      </b>
      has been a director of CorMedix since March 2019. In 2006, Dr. Dunton founded Danerius, LLC, a biotechnologyand pharmaceutical consulting business. From November 2015 through March 2018, Dr. Dunton was the Head/Senior Vice President ofResearch, Development and Regulatory Affairs of Purdue Pharma L.P., a private pharmaceutical company. From January 2007 throughMarch 2009, Dr. Dunton served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc. From 2003 until 2006,Dr. Dunton was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc., until it merged with ActivBiotics.He was also President and Managing Director of the Janssen Research Foundation, the research and development and regulatory armof the pharmaceuticals division at Johnson &amp; Johnson. Dr. Dunton received his Bachelor of Science degree in biochemistry,magna cum laude, from State University of New York at Buffalo, and received his M.D. from New York University School of Medicine.In addition to CorMedix, Dr. Dunton currently serves on the boards of two public companies, Palatin Technologies, Inc. and Oragenics,Inc. and chairs the compensation committees of both companies. He also serves as a member of the audit committees of these companies.Additionally, Dr. Dunton is a member of the board of Cytogel Pharma LLC, a private bio-pharmaceutical development company focusedon acquiring promising early-stage programs, and Regeneus, Ltd., an Austrian public company listed on the ASX. Among other qualifications,Dr. Dunton’s significant depth of experience in the pharmaceutical industry, including service as a director of public pharmaceuticalcompanies, led to the conclusion of our Board that he should serve as a director of our Company in light of our business and structure.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        MyronKaplan
       </i>
      </b>
      became a director of CorMedix in April 2016. He is a founding partner of Kleinberg, Kaplan, Wolff &amp; Cohen,P.C., a New York City general practice law firm, where he has practiced corporate and securities law for more than forty years.In 2012, Mr. Kaplan became a trustee of the Lehman Brothers Plan Holding Trust. Previously, he served as a member of the boardof directors of SAirGroup Finance (USA) Inc., a subsidiary of SAirGroup that had publicly issued debt securities, Trans WorldAirlines, Inc. and Kitty Hawk, Inc. Among his business and civic involvements, Mr. Kaplan currently serves on the boards of directorsof a number of private companies and has been active for many years on the boards of trustees and various board committees ofThe Children’s Museum of Manhattan and JBI International (formerly The Jewish Braille Institute of America). Mr. Kaplangraduated from Columbia College and holds a Juris Doctor from Harvard Law School. Among other experience, qualifications, attributesand skills, Mr. Kaplan’s experience in a broad range of corporate and securities matters and service as a director of publiccompanies led to the conclusion of our Board that he should serve as a director of our Company in light of our business and structure.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 61; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      59
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        StevenLefkowitz
       </i>
      </b>
      was a director of CorMedix from August 2011 to June 2016. He was reappointed to the Board in June 2017. He alsoserved as our acting Chief Financial Officer from August 2013 to July 2014. Mr. Lefkowitz has been the President and Founder ofWade Capital Corporation, a financial advisory services company, since June 1990. Mr. Lefkowitz has been a director of both publicand private companies. Mr. Lefkowitz received his A.B. from Dartmouth College in 1977 and his M.B.A. from Columbia Universityin 1985. Among other experience, qualifications, attributes and skills, Mr. Lefkowitz’s education, experience and financialexpertise led to the conclusion of our Board that he should serve as a director of our Company in light of our business and structure.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 12.3pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       BoardIndependence
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Our Board has undertakena review of the independence of our directors and has determined that (i) all current directors except Khoso Baluch are independentwithin the meaning of Section 5605(b) of the Nasdaq Marketplace Rules, (ii) all members of our Audit Committee meet the additionaltest for independence for audit committee members imposed by SEC regulation and Section 5605(c) of the Nasdaq Marketplace Rules,(iii) all of the members of our Compensation Committee are independent within the meaning of Section 5605(d) of the Nasdaq MarketplaceRules, and (iv) all of the members of our Nominating and Governance Committee are independent within the meaning of Section 5605(e)of the Nasdaq Marketplace Rules.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       BoardCommittees
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Our Board hasestablished an Audit Committee, Compensation Committee and Nominating and Governance Committee. OurAudit Committee currently consists of Mr. Lefkowitz (Chair), Dr. Dunton and Mr. Duncan. Our Compensation Committee currentlyconsists of Ms. Dillione (Chair), Dr. Dunton and Mr. Duncan. Our Nominating and Governance Committee currently consists ofMr. Costa (Chair), Mr. Kaplan and Ms. Dillione. The membership of these Committees may be changed after our next annualmeeting.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Eachof the above-referenced committees operates pursuant to a formal written charter. The charters for each committee, which havebeen adopted by our Board, contain a detailed description of the respective committee’s duties and responsibilities andare available on our website at www.cormedix.com under the “Investor Relations—Corporate Governance” tab.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       AuditCommittee
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheAudit Committee monitors our corporate financial statements and reporting and our external audits, including, among other things,our internal controls and audit functions, the results and scope of the annual audit and other services provided by our independentregistered public accounting firm and our compliance with legal matters that have a significant impact on our financial statements.The Audit Committee also consults with our management and our independent registered public accounting firm prior to the presentationof financial statements to stockholders and, as appropriate, initiates inquiries into aspects of our financial affairs. The AuditCommittee is responsible for establishing procedures for the receipt, retention and treatment of complaints regarding accounting,internal accounting controls or auditing matters, and for the confidential, anonymous submission by our employees of concernsregarding questionable accounting or auditing matters. In addition, the Audit Committee is directly responsible for the appointment,retention, compensation and oversight of the work of our independent registered public accounting firm, including approving servicesand fee arrangements. All related party transactions will be approved by the Audit Committee before we enter into them.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Bothour independent registered public accounting firm and internal financial personnel regularly meet with, and have unrestrictedaccess to, the Audit Committee.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheBoard has determined that each of Mr. Lefkowitz, Dr. Dunton and Mr. Duncan qualifies as an “audit committee financial expert”as that term is defined in the rules and regulations of the SEC. The designation of each of Mr. Lefkowitz, Dr. Dunton and Mr.Duncan as an “audit committee financial expert” does not impose on them any duties, obligations or liability thatare greater than those that are generally imposed on them as a member of the Audit Committee and the Board, and their designationas an “audit committee financial expert” pursuant to this SEC requirement does not affect the duties, obligationsor liability of any other member of the Audit Committee or the Board.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 62; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      60
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       CompensationCommittee
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheCompensation Committee reviews and approves our compensation policies and all forms of compensation to be provided to our executiveofficers and directors, including, among other things, annual salaries, bonuses, and other incentive compensation arrangements.In addition, the Compensation Committee administers our stock option and employee stock purchase plans, including granting stockoptions to our executive officers and directors. The Compensation Committee also reviews and approves employment agreements withexecutive officers and other compensation policies and matters.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Since 2016, we haveperiodically engaged Frederic W. Cook &amp; Co., an independent compensation consultant, for input on the compensation of ourNamed Executive Officers and directors. The Compensation Committee assessed the independence of Frederic W. Cook &amp; Co., consideringthe factors required by the Nasdaq Marketplace Rules and concluded that no conflict of interest exists that would prevent FredericW. Cook &amp; Co. from independently representing our Company. In the future, we, or the Compensation Committee, may engage orseek the advice of Frederic W. Cook &amp; Co., or another compensation consultant.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Eachmember of the Compensation Committee is a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the ExchangeAct, and an outside director, as defined pursuant to Section 162(m) of the Internal Revenue of 1986, as amended (the “Code”).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Nominatingand Governance Committee
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      TheNominating and Governance Committee identifies, evaluates and recommends nominees to the Board and committees of the Board, conductssearches for appropriate directors and evaluates the performance of the Board and of individual directors. The Nominating andGovernance Committee also is responsible for reviewing developments in corporate governance practices, evaluating the adequacyof our corporate governance practices and reporting and making recommendations to the Board concerning corporate governance matters.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       ExecutiveOfficers
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table sets forth information concerning our current executive officers:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="width: 25%; border-bottom: black 1.5pt solid">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Name
         </b>
        </span>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Age
         </b>
        </span>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 64%; border-bottom: black 1.5pt solid; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Position(s) with CorMedix
         </b>
        </span>
       </td>
      </tr>
      <tr style="background-color: #CCEEFF">
       <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Khoso Baluch
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         63
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Chief Executive Officer
        </span>
       </td>
      </tr>
      <tr>
       <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Matthew David
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         43
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Executive Vice President and Chief Financial Officer
        </span>
       </td>
      </tr>
      <tr style="background-color: #CCEEFF">
       <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Phoebe Mounts
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         71
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal
        </span>
       </td>
      </tr>
      <tr>
       <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         John Armstrong
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         77
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Executive Vice President for Technical Operations
        </span>
       </td>
      </tr>
      <tr style="background-color: #CCEEFF">
       <td style="vertical-align: top; padding-left: 9pt; text-indent: -9pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Elizabeth Masson-Hurlburt
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         42
        </span>
       </td>
       <td style="text-align: justify">
       </td>
       <td>
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Executive Vice President and Head of Clinical Operations
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Seethe biography for
      <b>
       <i>
        Khoso Baluch
       </i>
      </b>
      under “Directors.”
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        MatthewDavid, M.D.
       </i>
      </b>
      became our Executive Vice President and Chief Financial Officer in May 2020. Dr. David joins CorMedix afterserving as Head of Strategy at Ovid Therapeutics Inc, a late-stage clinical biopharmaceutical company focused on developing treatmentsfor rare neurological disorders, where he was responsible for financing strategy and investor relations, and joined in October2018. Prior to Ovid, Dr. David was a Strategic Advisor to Frequency Therapeutics, advising on financing, investor relations andstrategic initiatives from 2017 to early 2019. Prior to Frequency, Dr. David spent the majority of his career as an investmentbanker specialized in the life sciences sectors, including at Piper Jaffray, Thomas Weisel Partners, Ferghana Partners and mostrecently at Bank of America Merrill Lynch. As part of his experience as an investment banker, Dr. David has advised on a broadrange of capital raising and strategic transactions. Earlier in his career, Dr. David was part of the equity research team atLehman Brothers, focusing on Large Pharma. Dr. David began his career as a surgical resident at Beth Israel Hospital, after receivingan M.D. from NYU School of Medicine. Dr. David earned his Bachelor of Arts degree in Chemistry, magna cum laude, from DartmouthCollege.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 63; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      61
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        PhoebeMounts, PhD, Esq.
       </i>
      </b>
      became our Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legalin May 2019. Prior to her employment with us, Dr. Mounts was a partner at Morgan, Lewis &amp; Bockius LLP, where she providedlegal counsel to life sciences companies for over 20 years. As part of her work at Morgan Lewis, Dr. Mounts had been providingus legal services as outside counsel since 2013, with responsibility for developing our FDA regulatory strategies for Neutrolin.Prior to graduating from Georgetown University Law Center, Dr. Mounts was on the faculty of the Johns Hopkins University Schoolof Public Health for 16 years, specializing in molecular biology and infectious disease. She received her Ph.D. in molecular biologyfrom the University of Edinburgh in Scotland.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        JohnArmstrong
       </i>
      </b>
      became our Executive Vice President for Technical Operations in March 2017. Prior to that, he was employed byus as a consultant beginning in November 2014, performing the same services that he now performs as our Executive Vice Presidentfor Technical Operations. Jack has over 45 years’ experience in the pharmaceutical industry with broad senior level crossfunctional experience and has held a number of general management positions. Most recently, from August 2010 to January 2013,he was President, Operations for Correvio, a private pharmaceutical company supplying product to over 50 countries, and priorpositions include President/CEO of Genaera Corporation, Sr. Vice President of Urocor Corporation, CEO of Mills Biopharma, Presidentof Oread CMO, President of Endo Laboratories (subsidiary of DuPont Merck), President of World-wide Manufacturing for DuPont MerckPharmaceuticals, Vice President Operations for Marion/ Marion Merrill Dow, and he has held varied roles in manufacturing, qualityassurance, and integrated business systems development for three companies, as well as having expertise in business development.Mr. Armstrong holds a B.S. from Juniata College and an executive M.B.A. from Century University. He is also a CPIM (Certifiedin Production and Inventory Management).
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       <i>
        ElizabethMasson-Hurlburt
       </i>
      </b>
      became our Executive Vice President and Head of Clinical Operations in March 2018. Prior to her employment,Ms. Masson-Hurlburt had been providing us clinical operations expertise as a consultant since late November 2017. Before she beganher consulting career, she held several progressive management roles in clinical operations, most recently at Gemphire Therapeutics,as a Senior Director, Clinical Operations from April 2015 to October 2016, then as Vice President, Clinical Operations from October2016 to March 2018. Ms. Masson-Hurlburt received her B.A. in Leadership and Organizational Management from Bay Path College.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 64; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      62
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_019">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                          11.
         </b>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Executive                                         Compensation
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       DIRECTORCOMPENSATION
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       DirectorCompensation in Fiscal 2020
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table shows the compensation earned by each non-employee director of our company for the year ended December 31, 2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; font-weight: bold; text-align: left">
        <b>
         Name
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Fees                                         Earned
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Option
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Awards
           <sup>
            (1) (2)
           </sup>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Restricted
          <br/>
          Stock Units
          <br/>
          Awards
          <sup>
           (1)
          </sup>
          <br/>
          ($)
         </b>
        </span>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Total
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 52%; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Paulo Costa
         <sup>
          (3)
         </sup>
        </span>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        16,042
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        82,365
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        -
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        98,407
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Janet M. Dillione
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        83,000
       </td>
       <td style="text-align: left">
        <sup>
         (4)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        63,885
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        146,885
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Greg Duncan
         <sup>
          (5)
         </sup>
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        9,167
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        84,983
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        94,150
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Alan Dunton
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        72,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        63,885
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        135,885
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Myron Kaplan
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        115,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        63,885
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        178,885
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Mehmood Khan
         <sup>
          (6)
         </sup>
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        57,500
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        63,885
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        121,385
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
        Steven Lefkowitz
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        95,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        63,885
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        158,885
       </td>
       <td style="text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (1)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        Theamounts included in this column are the dollar amounts representing the full grant date fair value of each stock option awardor restricted stock unit award calculated in accordance with FASB ASC Topic 718 and do not represent the actual value that maybe recognized by the directors upon option exercise or payment of restricted stock units. For information on the valuation assumptionsused in calculating these amounts, see Note 8 to our audited financial statements included in this Annual Report on Form 10-K.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (2)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         As                                         of December 31, 2020, the number of shares underlying options held by each non-employee                                         director was as follows: 23,750 shares for Mr. Costa; 75,000 shares for Ms. Dillione;                                         22,500 for Mr. Duncan; 42,500 shares for Dr. Dunton; 56,000 shares for Mr. Kaplan; and                                         53,000 shares for Mr. Lefkowitz.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (3)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Mr.                                         Costa became a director on September 15, 2020.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (4)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Includes                                         fees of $62,250 for Ms. Dillione that were deferred. See “Director Compensation                                         Plan” below for a description of the deferral plan pursuant to which the deferrals                                         were made.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (5)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Mr.                                         Duncan became a director on November 2, 2020.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (6)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Dr. Khan resigned as a director on October 30, 2020 and unvested stock options as of his resignation date with respect to 5,000 shares were forfeited.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       DirectorCompensation Plan
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InJuly 2014, we adopted a Deferred Compensation Plan for Directors, pursuant to which our non-employee directors may defer all oftheir cash director fees and restricted stock units. Any cash fees due a participating director will be converted into a numberof shares of our common stock by dividing the dollar amount of fees payable by the closing price of our common stock on the datesuch fees would be payable, and the director’s unfunded account would be credited with the shares. The shares that accumulatein a director’s account will be paid to the director on the tenth business day in January following the year in which thedirector’s service terminates for whatever reason, other than death, in which case the account will be paid within 30 daysof the date of death to the designated beneficiaries, if any. If there are no designated beneficiaries, the account will be paidout the same as with any other termination of service. In the event of a change in control of our Company, the director wouldreceive cash in an amount equal to the number of shares in the account multiplied by the fair market value of our common stockon the change in control date, and the payment would be accelerated to five business days after the effective date of the changein control.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 65; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      63
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Inlate 2018, with the assistance of Frederic W. Cook &amp; Co., the Compensation Committee reviewed a peer group of 14 public companies,which group was used by Frederic W. Cook &amp; Co. to conduct a compensation study for purposes of establishing director compensation.The composition of the peer group was based on the following criteria: (i) companies operating in a similar industry sector, (ii)publicly traded companies, (iii) companies of similar size, and (iv) companies of similar business operation and stage of researchand development. The Compensation Committee also used this data in various combinations in an effort to establish director compensationthat reflects our particular facts and circumstances. We continue to grant stock options to our non-employee directors.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      InDecember 2018, as a result of the 2018 compensation study provided by Frederic W. Cook &amp; Co., we determined that our non-employeedirector compensation program was significantly below market. Accordingly, we increased compensation levels effective January1, 2019 to bring non-employee director compensation closer to our peer group. Effective as of July 1, 2019, we implemented Boardcommittee fees (differentiating fees between heads of committees and committee members) to recognize the substantial work doneby our Board committees. As of January 1, 2020, we discontinued granting restricted stock units to non-employee directors andcorrespondingly increased the cash retainers, in order to bring the compensation more in line with the forms of payment providedby peer companies and to minimize dilution. Each of the 2020 and 2021 compensation programs are set forth below in the table.All equity awards are subject to continued service on the Board through the vesting date. The exercise price per share of eachstock option granted to our non-employee directors is equal to the fair market value of our common stock as determined in goodfaith by our Board on the date of the grant.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="white-space: nowrap; font-weight: bold; text-align: left">
       </td>
       <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Effective January 1, 2020
       </td>
       <td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Effective January 1, 2021
       </td>
       <td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="font-weight: bold; text-align: left">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Cash
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Stock
        <br/>
        Options
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Cash
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Stock
        <br/>
        Options
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="width: 52%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Annual Fee
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        55,000
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        55,000
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        First Election to Board
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        20,000
       </td>
       <td style="text-align: left">
        (1)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        25,000
       </td>
       <td style="text-align: left">
        (1)
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Annual Grant, Prorated in First Year Following Election to the Board
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        15,000
       </td>
       <td style="text-align: left">
        (2)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        20,000
       </td>
       <td style="text-align: left">
        (2)
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee - Board Chair
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        45,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        45,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee - Audit Chair
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        23,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        23,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee - Compensation Chair
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        18,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        18,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee - Nomination and Governance Chair
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        14,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        14,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee - Audit Committee Non-Chair Members
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        10,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        10,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee - Compensation Committee Non-Chair Members
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        7,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        7,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee – Nomination and Governance Committee Non-Chair Members
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        5,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        5,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee – Strategic Committee Members
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        15,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">
        Additional Annual Fee – Strategic Finance Committee Two Co-Chairs
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        20,000
       </td>
       <td style="text-align: left">
        (3)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (1)
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Vest one third each    on the date of grant and the first and second anniversary date of grant.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (2)
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Vest monthly over    one year after the grant date.
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (3)
        </span>
       </td>
       <td style="text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          ThroughJune 30, 2020.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 66; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      64
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       EXECUTIVECOMPENSATION
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Componentsof Compensation
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thekey components of our executive compensation package are cash compensation (salary and annual bonuses), long-term equity incentiveawards and change in control and other severance agreements. These components are administered with the goal of providing totalcompensation that recognizes meaningful differences in individual performance, is competitive, varies the opportunity based onindividual and corporate performance, and is valued by our Named Executive Officers. For 2020, our Named Executive Officers wereKhoso Baluch, Phoebe Mounts, John Armstrong and Elizabeth Masson-Hurlburt. In addition, Robert W. Cook served as our Chief FinancialOfficer until January 31, 2020, and Matthew David served as our Chief Financial Officer starting May 11, 2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       BaseSalary
      </i>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Itis the Compensation Committee’s objective to set a competitive rate of annual base salary for each Named Executive Officer.The Compensation Committee believes competitive base salaries are necessary to attract and retain top quality executives, sinceit is common practice for public companies to provide their named executive officers with a guaranteed annual component of compensationthat is not subject to performance risk. The Compensation Committee, on its own or with outside consultants, may establish salaryranges for the Named Executive Officers, with minimum to maximum opportunities that cover the normal range of market variability.The actual base salary for each Named Executive Officer is then derived from those salary ranges based on his or her responsibility,tenure and past performance and market comparability. Annual base salaries for the Named Executive Officers are reviewed and approvedby the Compensation Committee in the first quarter following the end of the previous performance year. Changes in base salaryare based on the scope of an individual’s current job responsibilities, individual performance in the previous performanceyear, target pay position relative to the peer group, and our salary budget guidelines. The Compensation Committee reviews establishedgoals and objectives, and determines an individual’s achievement of those goals and objectives and considers the recommendationsprovided by the Chief Executive Officer to assist it in determining appropriate salaries for the Named Executive Officers otherthan the Chief Executive Officer. For the year ended December 31, 2020 and the three month period ended March 31, 2021, with theadvice of outside consultants, including Frederic W. Cook &amp; Co., the Compensation Committee increased the salaries of certainof our Named Executive Officers, to account for adjustments in the market.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     The base salary informationfor our Named Executive Officers for 2019 and 2020 is set forth in the Summary Compensation Table below. In September 2019, February2017, May 2020, March 2019, April 2020 and March 2021, respectively, we entered into an employment agreement with each of KhosoBaluch, our Chief Executive Officer, Robert Cook, our Chief Financial Officer (at such time), Matthew David, our Executive VicePresident and Chief Financial Officer, Phoebe Mounts, our Executive Vice President and General Counsel and Head of Regulatory,Compliance and Legal, John Armstrong, our Executive Vice President for Technical Operations, and Elizabeth Masson-Hurlburt, ourExecutive Vice President and Head of Clinical Operations. These agreements provide for a salary for each Named Executive Officerand are described under the caption “Employment Agreements.”
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       AnnualBonuses
      </i>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Aspart of their compensation package, our Named Executive Officers generally have the opportunity to earn annual non-equity incentivebonuses. Annual non-equity bonuses are designed to reward superior executive performance while reinforcing our short-term strategicoperating goals. The Compensation Committee establishes each year a corporate target award for the Named Executive Officers basedon a percentage of base salary and any applicable terms in any individual employment agreements. Annual bonus targets as a percentageof salary increase with executive rank so that for the more senior executives, a greater proportion of their total cash compensationis contingent upon annual performance.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Atthe beginning of the performance year, the Named Executive Officers, in conjunction with the Chief Executive Officer, establishannual corporate goals and objectives. Actual bonus awards for each Named Executive Officer are based on the achievement of thepre-established corporate goals. For any given performance year, proposed annual bonuses may range from 0% to 100% of target,or higher under certain circumstances, based solely on the achievement of corporate objectives. Corporate performance has a significantimpact on the annual bonus amounts because the Compensation Committee believes it is a precise measure of how the Named ExecutiveOfficer contributed to business results.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 67; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      65
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Pursuantto their respective employment agreements, Messrs. Baluch and Armstrong, Dr. David, Dr. Mounts and Ms. Masson-Hurlburt are eacheligible for an annual bonus, which may equal up to 80%, 35%, 30%, 30% and 30%, respectively, of his or her base salary then ineffect, as determined by our Board or Compensation Committee. In determining such bonus, our Board or Compensation Committee willtake into consideration the achievement of specified Company objectives, predetermined by the Board in consultation with the ChiefExecutive Officer.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       Long-TermIncentive Equity Awards
      </i>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     We believe that long-term performance is achieved through anownership culture that encourages high performance by our Named Executive Officers through the use of stock-based awards. Our long-termincentive plans were established to provide our employees, including our Named Executive Officers, with incentives to help alignemployees’ interests with the interests of our stockholders. The Compensation Committee believes that the use of stock-basedawards offers the best approach to achieving our compensation goals. We have historically elected to use stock options as the primarylong-term equity incentive vehicle; however, the Compensation Committee has used restricted stock in the past and may in the futureutilize restricted stock or other forms of equity grant as part of our long-term incentive program. We have selected the Black-Scholesmethod of valuation for share-based compensation. Due to the early stage of our business and our desire to preserve cash, we mayprovide a greater portion of total compensation to our Named Executive Officers through stock options and other equity grants thanthrough cash-based compensation. The Compensation Committee generally oversees the administration of our equity plans.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       StockOptions
      </i>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Our 2019 Omnibus Stock Incentive Plan (the 2019 Plan), whichwas approved by the shareholders on November 26, 2019 authorizes us to grant options to purchase shares of common stock and otherequity awards to our employees, directors and consultants. In 2020, we granted stock options to the Named Executive Officers.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      The Compensation Committee reviews and approves stock optionawards to Named Executive Officers based upon a review of competitive compensation data, its assessment of individual performance,a review of each Named Executive Officer’s existing long-term incentives, and retention considerations. Periodic stock optiongrants are made at the discretion of the Compensation Committee to eligible employees and, in appropriate circumstances, the CompensationCommittee considers the recommendations of our Chief Executive Officer. Stock option grants made to Named Executive Officers areapproved by the Board, based on the Compensation Committee’s recommendation.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Stockoptions granted to employees have an exercise price equal to the fair market value of our common stock on the day of grant,typically vest over a time period or upon the achievement of certain performance-based milestones and are based uponcontinued employment, and generally expire 10 years after the date of grant. The fair value of the options granted to theNamed Executive Officers in the Summary Compensation Table is determined in accordance with the Black-Scholes method ofvaluation for share-based compensation. Incentive stock options also include certain other terms necessary to ensurecompliance with the Code.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Weexpect to continue to use stock options as a long-term incentive vehicle because:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.5in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Stock                                         options align the interests of our Named Executive Officers with those of our stockholders,                                         supporting a pay-for performance culture, foster employee stock ownership, and focus                                         the management team on increasing value for our stockholders.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.5in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Stock                                         options are performance-based. All of the value received by the recipient of a stock                                         option is based on the growth of the stock price. In addition, stock options can be issued                                         with vesting based on the achievement of specified milestones.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.5in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Stock                                         options help to provide balance to the overall executive compensation program as base                                         salary and annual bonuses focus on short-term compensation, while the vesting of stock                                         options increases stockholder value over the longer term.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.5in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         The                                         vesting period of stock options encourages executive retention and the preservation of                                         stockholder value. In determining the number of stock options to be granted to our Named                                         Executive Officers, we take into account the individual’s position, scope of responsibility,                                         ability to affect profits and stockholder value and the individual’s historic and                                         recent performance and the value of stock options in relation to other elements of the                                         individual Named Executive Officer’s total compensation.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 68; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      66
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       ExecutiveBenefits and Perquisites
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OurNamed Executive Officers are parties to employment agreements as described below. In addition, consistent with our compensationphilosophy, we intend to continue to maintain our current benefits for our Named Executive Officers, including medical, dentaland life insurance and the ability to contribute to a 401(k) plan; however, the Compensation Committee in its discretion may revise,amend, or add to the officer’s executive benefits if it deems it advisable. We believe these benefits are currently comparableto benefit levels for comparable companies.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       EmploymentAgreements
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <i>
       EmploymentAgreements with Current Named Executive Officers
      </i>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     On September 27, 2016,we entered into an employment agreement with Khoso Baluch, our Chief Executive Officer, which, upon its expiration in September2019, was replaced with a new agreement, dated September 26, 2019, that is nearly identical to the old agreement (except as notedbelow). On March 1, 2017, we entered into an employment agreement with John Armstrong to serve as our Executive Vice Presidentfor Technical Operations, which upon its expiration in March 2020, was replaced with a new agreement dated April 17, 2020. OnMarch 19, 2018, we entered into an employment agreement with Elizabeth Masson-Hurlburt to serve as our Executive Vice Presidentand Head of Clinical Operations, which upon its expiration in March 2021, was replaced with a new agreement dated March 10, 2021. On March 19, 2019, we entered into an employment agreement with Phoebe Mounts to serve as our Executive Vice President and GeneralCounsel effective May 1, 2019. On May 11, 2020 we entered into an employment agreement with Matthew David to serve as our ChiefFinancial Officer. After the initial three-year term of each employment agreement, the agreement will automatically renew foradditional successive one-year periods, unless either party notifies the other in writing at least 90 days before the expirationof the then current term that the agreement will not be renewed.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     Pursuantto their respective agreements, Mr. Baluch receives an annual salary of $425,000, Mr. Armstrong an annual salary of $325,000,Ms. Masson-Hurlburt an annual salary of $315,000 (effective March 2021), Dr. Mounts an annual salary of $350,000 (amended to$375,000 in January 2021) and Dr. David an annual salary of $330,000, which cannot be decreased unless all officers and/ormembers of our executive management team experience an equal or greater percentage reduction in base salary and/or totalcompensation, provided that any reduction in an executive’s salary may be no greater than 25%. Each executive will beeligible for an annual bonus, which may equal up to 80% for Mr. Baluch (the target amount is 80%, but the bonus may exceedthat amount), up to 35% for Mr. Armstrong, up to 30% for Ms. Masson-Hurlburt, up to 30% for Dr. Mounts and up to 30% for Dr.David, of his or her base salary then in effect, as determined by our Board or the Compensation Committee. In determiningsuch bonus, our Board or the Compensation Committee will take into consideration the achievement of specified Companyobjectives, predetermined by our Board or the Compensation Committee and Chief Executive Officer, and such other factors asour Board or the Compensation Committee deems appropriate, and approved by the Board or the Compensation Committee. Eachexecutive must be employed through December 31 of a given year to be eligible to earn that year’s annual bonus.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     On January 30, 2017,we entered into an employment agreement, effective February 1, 2017, with Robert Cook to serve as our Chief Financial Officer.On November 6, 2019, Mr. Cook and the Company mutually agreed not to renew his employment agreement, which expired on January 31,2020. Mr. Cook and the Company entered into a consulting agreement.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing provisions of the employment agreements with Messrs. Baluch, Armstrong, Ms. Masson-Hurlburt, Dr. Mounts and Dr. Davidare identical except where noted.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     If we terminate the executive’s employment for Cause (asdefined below), the executive will be entitled to receive only the accrued compensation due to him or her as of the date of suchtermination, rights to indemnification and directors’ and officers’ liability insurance, and as otherwise requiredby law. All unvested equity awards then held by the executive in the case of Mr. Baluch, Mr. Armstrong, Dr. David and Ms. Masson-Hurlburt,any vested equity awards granted after September 26, 2019, April 17, 2020, May 11, 2020 and March 20, 2021, respectively, willbe forfeited to us as of such date.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 69; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      67
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     If we terminate theexecutive’s employment other than for Cause, death, or disability, other than by notice of nonrenewal, or if the executiveresigns for Good Reason (as defined below), including in each case within 24 months of a Corporation Transaction (as defined inthe agreement, which is the same definition as in our 2019 Plan), the executive will receive the following benefits: (i) paymentof any accrued compensation and any unpaid bonus for the prior year, as well as rights to indemnification and directors’and officers’ liability insurance and any rights or privilege otherwise required by law; (ii) we will continue to pay hisor her base salary and benefits for a period of twelve months in the case of Mr. Baluch and nine months for the other executivesfollowing the effective date of the termination of employment; (iii) payment on a prorated basis for any target bonus for the yearof termination based on the actual achievement of the specified bonus objectives; (iv) if the executive timely elects continuedhealth insurance coverage under COBRA, then we will pay the premium to continue such coverage for him or her and his or her eligibledependents in an amount equal to the portion paid for by us during the executive’s employment until the conclusion of thetime when he or she is receiving continuation of base salary payments or until he or she becomes eligible for group health insurancecoverage under another employer’s plan, whichever occurs first, provided however that we have the right to terminate suchpayment of COBRA premiums on behalf of the executive and instead pay him or her a lump sum amount equal to the COBRA premium timesthe number of months remaining in the specified period if we determine in our discretion that continued payment of the COBRA premiumsis or may be discriminatory under Section 105(h) of the Code; (v) unvested equity awards that are scheduled to vest on or beforethe next succeeding anniversary of the date of termination shall be accelerated and deemed to have vested as of the terminationdate; provided that any performance based equity awards or stock options whose vesting requirements have not been successfullymet as of the date of termination of employment or resignation with Good Reason will not accelerate; and (vi) in the event of aCorporate Transaction all equity awards and stock options shall become fully vested and exercisable; and (vii) vested stock optionswill remain exercisable for a specified period of time following termination or resignation or, if earlier, the expiration dateof the stock option. The separation benefits set forth above are conditioned upon the executive executing a release of claims againstus, our parents, subsidiaries, and affiliates, and each such entities’ officers, directors, employees, agents, successors,and assigns in a form acceptable to us, within a time specified therein, which release is not revoked within any time period allowedfor revocation under applicable law.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      For purposes of the agreement, “Cause” is definedas: (i) the willful failure, disregard, or refusal by the executive to perform his or her material duties or obligations underthe agreement (other than as a result of executive’s mental incapacity or illness, (ii) any willful, intentional, or grosslynegligent act by the executive having the effect of materially injuring (whether financially or otherwise) our business or reputationor any of our affiliates; (iii) executive’s conviction of any felony involving moral turpitude (including entry of a guiltyor nolo contendere plea); (iv) the executive’s qualification as a “bad actor,” as defined by 17 CFR 230.506(a);(v) the good faith determination by the Board, after a reasonable and good-faith investigation by us that the executive engagedin some form of harassment or discrimination prohibited by law (including, without limitation, harassment on the basis of age,sex or race) unless the executive’s actions were specifically directed by the Board; (vi) any material misappropriation orembezzlement by the executive of our or our affiliates’ property (whether or not a misdemeanor or felony); or (vii) materialbreach by the executive of the agreement that is not cured, to the extent subject to cure, by executive to our reasonable satisfaction.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      For purposes of the agreement, “Good Reason” isdefined as: (i) any material breach of the agreement by us; (ii) any material diminution by us of the executive’s duties,responsibilities, or authority; (iii) a material reduction in the executive’s annual base salary unless all officers and/ormembers of our executive management team experience an equal or greater percentage reduction in annual base salary and/or totalcompensation, provided that any reduction may be no greater than 25%; or (iv) a material reduction in the executive’s targetbonus level unless all officers and/or members of our executive management team experience an equal or greater percentage reductionrelated to target bonus levels, provided that any reduction may be no greater than 25%.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 70; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      68
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifthe executive terminates his or her employment by written notice of termination or if the executive or we terminate his or heremployment by providing a notice of nonrenewal at least 90 days before the agreement is set to expire, the executive will notbe entitled to receive any payments or benefits other than any accrued compensation, any unpaid prior year’s bonus, rightsto indemnification and directors’ and officers’ liability insurance, and as otherwise required by law.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifthe executive’s employment is terminated as a result of his or her death or disability, we will pay him or her or his orher estate, as applicable, any accrued compensation and any unpaid prior year’s bonus.
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Our agreements with Messrs. Baluch, Armstrong, Ms. Masson-Hurlburt,Dr. Mounts and Dr. David each contain a non-compete provision that provides that during the term of each agreement and the 12-monthperiod immediately following the executive’s separation from employment for any reason, the executive is prohibited fromengaging in any business involving the development or commercialization of a preventive anti-infective product that would be adirect competitor of Neutrolin or a product containing taurolidine or any other product being actively developed or produced byus within the United States and the European Union (in the case of Mr. Baluch, Dr. David, Ms. Masson-Hurlburt and Mr. Armstrong,worldwide) on the date of termination of his or her employment.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Taxand Accounting Considerations
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      U.S.federal income tax generally limits the tax deductibility of compensation we pay to our Named Executive Officers and certainother officers to $1.0 million each in the year the compensation becomes taxable to the executive officers. Althoughdeductibility of compensation is preferred, tax deductibility is not a primary objective of our compensation programs.Rather, we seek to maintain flexibility in how we compensate our executive officers so as to meet a broader set of corporateand strategic goals and the needs of stockholders, and as such, we may be limited in our ability to deduct amounts ofcompensation from time to time. Accounting rules require us to expense the cost of our stock option grants. Because of optionexpensing and the impact of dilution on our stockholders, we pay close attention to, among other factors, the type of equityawards we grant and the number and value of the shares underlying such awards.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       PensionBenefits
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wedo not maintain any qualified or non-qualified defined benefit pension plans. As a result, none of our Named ExecutiveOfficers participate in or have benefits under qualified or non-qualified defined benefit pension plans sponsored by us. OurCompensation Committee may elect to adopt qualified or non-qualified defined benefit plans in the future if it determinesthat doing so is in our best interests.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       NonqualifiedDeferred Compensation
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     None of our Named ExecutiveOfficers participate in nonqualified defined contribution plans or other non-qualified deferred compensation plans maintainedby us. Our Compensation Committee may elect to provide our officers and other employees with non-qualified defined contributionor other non-qualified deferred compensation benefits in the future if it determines that doing so is in our best interests.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 71; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      69
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       SummaryCompensation Table
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table sets forth information with respect to compensation earned by our Named Executive Officers in the years endedDecember 31, 2020 and 2019:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">
        Name and Principal Position
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        Year
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Salary
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Option
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Awards (1)
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           RestrictedStock Units Awards (1)
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Non-equityIncentive Plan Compensation
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        All Other Compensation ($)
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Total
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($)
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 31%; text-align: left">
        Khoso Baluch
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 7%; text-align: center">
        2020
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 7%; text-align: right">
        425,000
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 7%; text-align: right">
        428,583
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 7%; text-align: right">
        --
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 7%; text-align: right">
        340,000
       </td>
       <td style="width: 1%; text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 7%; text-align: right">
        40,088
       </td>
       <td style="width: 1%; text-align: left">
        <sup>
         (6)
        </sup>
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 7%; text-align: right">
        1,233,671
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: left; padding-left: 0.25in">
        Chief Executive Officer
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2019
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        387,885
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1,133,600
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        248,000
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        26,344
       </td>
       <td style="text-align: left">
        <sup>
         (6)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1,795,829
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Matthew David
         <sup>
          (2)
         </sup>
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2020
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        209,423
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        768,386
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        99,000
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        20,866
       </td>
       <td style="text-align: left">
        <sup>
         (7)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1,097,675
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: left; padding-left: 0.25in">
        Chief Financial Officer
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Phoebe Mounts
         <sup>
          (3)
         </sup>
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2020
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        350,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        408,070
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        163,333
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        9,745
       </td>
       <td style="text-align: left">
        <sup>
         (7)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        931,148
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: left; padding-left: 0.25in">
        Executive Vice President and General Counsel and Head of Regulatory, Compliance and Legal
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2019
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        232,885
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        426,790
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        84,000
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        2,479
       </td>
       <td style="text-align: left">
        <sup>
         (7)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        746,154
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        John Armstrong
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2020
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        322,635
       </td>
       <td style="text-align: left">
        <sup>
         (4)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        332,420
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        112,875
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        19,388
       </td>
       <td style="text-align: left">
        <sup>
         (8)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        787,318
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: left; padding-left: 0.25in">
        Executive Vice President for Technical Operations
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2019
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        310,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        57,195
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        86,800
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        11,001
       </td>
       <td style="text-align: left">
        <sup>
         (8)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        464,996
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Elizabeth Masson-Hurlburt
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2020
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        291,792
       </td>
       <td style="text-align: left">
        <sup>
         (4)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        332,420
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        136,500
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        35,561
       </td>
       <td style="text-align: left">
        <sup>
         (7)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        796,273
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; padding-left: 0.25in; text-align: left">
        Executive Vice President and Head of Clinical Operations
       </td>
       <td>
       </td>
       <td style="text-align: center">
        2019
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        280,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        298,504
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        67,200
       </td>
       <td style="text-align: left">
        <sup>
         (5)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        25,734
       </td>
       <td style="text-align: left">
        <sup>
         (7)
        </sup>
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        671,438
       </td>
       <td style="text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (1)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         The                                         amounts included in this column are the dollar amounts representing the full grant date                                         fair value of each award calculated in accordance with FASB ASC Topic 718 and do not                                         represent the actual value that may be recognized by the Named Executive Officers upon                                         option exercise.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (2)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Dr.                                         David became our Executive Vice President and Chief Financial Officer on May 11, 2020.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (3)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Dr.                                         Mounts became our Executive Vice President and General Counsel and Head of Regulatory,                                         Compliance and Legal on May 1, 2019.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0in">
       </td>
       <td style="width: 0.25in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (4)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Basesalary increases effective February 25, 2020.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (5)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         The                                         non-equity incentive plan bonuses reflected in 2020 were for the performance for the                                         year 2020 which were accrued in 2020 but will be paid in 2021. The non-equity incentive                                         bonuses reflected in 2019 were for the performance for the year 2019 which were accrued                                         in 2019 and paid in 2020.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (6)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists                                         of health benefits, 401(k) employer match, and reimbursed commuter expenses.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (7)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists                                         of health benefits and 401(k) employer match.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (8)
         </sup>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists                                         of health benefits.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 72; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      70
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       OutstandingEquity Awards at Fiscal Year-End 2020
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table contains certain information concerning unexercised options for the Named Executive Officers as of December 31,2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">
        Name
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Number of Shares Underlying Unexercised Options (#) – Exercisable
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Number    of Shares Underlying Unexercised Options (#) – Unexercisable
        <sup>
         (1)
        </sup>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Equity    Incentive Plan Awards: Number of Shares Underlying Unexercised Unearned Options #
        <sup>
         (2)
        </sup>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Option Exercise Price ($)
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
        Option Expiration Date
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 26%; text-align: left">
        Khoso Baluch
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 12%; text-align: right">
        310,000
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 12%; text-align: right">
        --
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 12%; text-align: right">
        --
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 12%; text-align: right">
        12.60
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 12%; text-align: right">
        10/03/2026
       </td>
       <td style="width: 1%">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        55,600
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        14,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        8.30
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        01/10/2029
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        30,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        90,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        6.82
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        09/26/2029
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        25,157
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        75,473
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        02/25/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Matthew David
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        22,167
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        83,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        19,833
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        22,167
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        83,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        19,833
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        4.08
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Phoebe Mounts
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        28,500
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        31,500
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        10,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        7.92
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/01/2029
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        6,191
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        18,573
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        02/25/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        12,500
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        37,500
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        4.08
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        12,500
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        37,500
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        John Armstrong
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        2,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        7.60
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        11/14/2024
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        3,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        16.25
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        7/28/2025
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        40,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        12.55
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        3/08/2026
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        6,600
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        10.90
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        3/01/2027
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        6,255
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1,575
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        8.30
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        01/10/2029
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        6,191
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        18,573
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        02/25/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        9,375
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        28,125
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        4.08
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        9,375
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        28,125
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Elizabeth Masson-Hurlburt
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        35,400
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        18,600
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1.45
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        3/19/2028
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        16,680
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        4,200
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        8.30
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        01/10/2029
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        6,191
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        18,573
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        02/25/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        9,375
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        28,125
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        4.08
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        9,375
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        28,125
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        --
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        5.63
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: right">
        05/11/2030
       </td>
       <td>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 0pt; width: 25%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0">
       </td>
       <td style="width: 0.25in; text-align: left">
        (1)
       </td>
       <td style="text-align: justify">
        Options vest based on continued employment over three orfour years.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0">
       </td>
       <td style="width: 0.25in; text-align: left">
        (2)
       </td>
       <td style="text-align: justify">
        Options vest based on achievement of specific milestonesand continued employment, and become exercisable if and when a milestone is achieved.
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 73; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      71
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       OptionRepricings
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Wedid not engage in any repricings or other modifications to any of our Named Executive Officers’ outstanding optionsduring the year ended December 31, 2020.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       PotentialPayments on a Qualifying Termination
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Ifthe severance payments called for in our employment agreements for Mr. Baluch, Dr. David, Dr. Mounts, Mr. Armstrong and Ms.Masson-Hurlburt had been triggered on December 31, 2020, we would have been obligated to make the followingpayments:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">
        Name
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Cash                                                                                                         Severance Payment
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($per month) and
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           (#of months paid)
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Severance                                                                                                         Benefits
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($per month) and
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           (#                               of months paid)
           <sup>
            (1)
           </sup>
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
       <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Numberof Options
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           (#that would vest) and
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           ($market value)
           <sup>
            (2)
           </sup>
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">
        Khoso Baluch
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         35,417
         <sup>
          (3)
         </sup>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         12 mos.
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        2,952
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         12 mos.
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        179,473
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        190,751
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Matthew David
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         27,500
         <sup>
          (4)
         </sup>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        3,711
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        166,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        427,450
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Phoebe Mounts
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         29,167
         <sup>
          (5)
         </sup>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        936
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        125,073
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        226,556
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        John Armstrong
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         27,083
         <sup>
          (6)
         </sup>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        2,186
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        76,398
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        178,275
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Elizabeth Masson-Hurlburt
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         24,500
         <sup>
          (7)
         </sup>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        3,720
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9 mos.
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        97,623
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        289,503
       </td>
       <td style="text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (1)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of COBRA and 401(k) employer match.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (2)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         The market value equals the difference between the fair market value of the shares that could be acquired based on the closing sale price per share of our common stock on the NYSE American on December 31, 2020, which was $7.43, and the exercise prices of the applicable stock options.
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (3)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Represents severance based on monthly base salary, payable for 12 months. Any bonus for the year of termination based on performance would also be paid.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (4)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Represents severance based on monthly base salary, payable for 9 months. Any bonus for the year of termination based on performance would also be paid.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (5)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Represents severance based on monthly base salary, payable for 9 months. Any bonus for the year of termination based on performance would also be paid.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (6)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Represents severance based on monthly base salary, payable for 9 months. Any bonus for the year of termination based on performance would also be paid.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <sup>
          (7)
         </sup>
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Represents severance based on monthly base salary, payable for 9 months. Any bonus for the year of termination based on performance would also be paid.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 74; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      72
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_020">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                          12.
         </b>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Security                                         Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       PrincipalStockholders
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table shows the number of shares of our common stock beneficially owned as of March 15, 2021 by:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0.5in">
       </td>
       <td style="width: 0.25in; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         each    person known by us to own beneficially more than 5% of the outstanding shares of our common stock;
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="text-align: justify">
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         each director;
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="text-align: justify">
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         each of our Named    Executive Officers and our current executive officers; and
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td>
       </td>
       <td style="text-align: justify">
       </td>
       <td style="text-align: justify">
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ●
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         all of our current    directors and executive officers as a group.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     This table is basedupon the information supplied by our Named Executive Officers, directors and principal stockholders and from Schedules 13D and13G filed with the SEC. Except as indicated in footnotes to this table, the persons named in this table have sole voting and investmentpower with respect to all shares of common stock shown, and their address is c/o CorMedix Inc., 300 Connell Drive, Suite 4200,Berkeley Heights, New Jersey 07922. As March 15, 2021, we had 38,024,194 shares of common stock outstanding. Beneficial ownershipin each case also includes shares issuable upon exercise of outstanding options that can be exercised within 60 days after March15, 2021 for purposes of computing the percentage of common stock owned by the person named. Options owned by a person are notincluded for purposes of computing the percentage owned by any other person.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td>
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <b>
          Common Stock
         </b>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
         <b>
          Beneficially Owned
         </b>
         (1)
        </p>
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="font-weight: bold; border-bottom: Black 1.5pt solid">
        Name and Address of Beneficial Owner
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        Shares
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        %
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="font-weight: bold; font-style: italic; border-bottom: Black 1.5pt solid">
        5% or Greater Stockholders
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="text-align: right">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="text-align: right">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Elliott Associates, L.P. (2)
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        1,303,411
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: right">
        4.99
       </td>
       <td style="width: 1%; text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        BlackRock, Inc. (3)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1,995,193
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        6.2
       </td>
       <td style="text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-indent: -9pt; padding-left: 0.25in">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">
        Directors and Named Executive Officers:
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: right">
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Khoso Baluch (4)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        553,820
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1.4
       </td>
       <td style="text-align: left">
        %
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Matthew David (5)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        96,984
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Phoebe Mounts (6)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        126,082
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        John Armstrong (7)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        222,902
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Elizabeth Masson-Hurlburt (8)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        138,862
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Paulo Costa (9)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        15,516
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Janet M. Dillione (10)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        138,473
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Greg Duncan (11)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        14,580
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Alan Dunton (12)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        58,750
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Myron Kaplan (13)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        216,034
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">
        Steven Lefkowitz (14)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        155,650
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="font-style: italic; text-align: left; text-indent: -9pt; padding-left: 0.25in">
        All executive officers and directors as a group (11 persons) (1.5)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        1,737,653
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        4.4
       </td>
       <td style="text-align: left">
        %
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
       <td style="font: 10pt Times New Roman, Times, Serif; width: 0in">
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <i>
          *
         </i>
        </span>
       </td>
       <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <i>
          Lessthan 1%
         </i>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0in">
       </td>
       <td style="width: 0.35in; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (1)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Based upon 38,024,194 shares of our common stock outstanding on March 15, 2021 and, with respect to each individual holder, rights to acquire our common stock exercisable within 60 days of March 15, 2021.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 75; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      73
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (2)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Based solely on information contained in Amendment No. 1 to the Statement on Schedule 13D filed with the SEC on February 11, 2021 by Elliott Associates, L.P. (“Elliott Associates”), Elliott International, L.P. (“Elliott International”) and Elliott International Capital Advisors Inc. (“Elliott International Capital Advisors”, and together with Elliott Associates and Elliott International, the “Elliott Reporting Entities”), the investment manager of Elliott International, and other information known to us. Due to the Ownership Limitation (as defined below), the Elliott Reporting Entities may be deemed to collectively beneficially own 1,303,411 shares of our common stock through securities held by Elliott Associates and Elliott International. Elliott Associates beneficially holds: (i) 464,706 shares of our common stock, (ii) 32,383 shares of Series G preferred stock convertible into 1,800,539 shares of our common stock (subject to the Ownership Limitation) and (iii) 89,623 shares of our Series E preferred stock convertible into 391,953 shares of our common stock (subject to the Ownership Limitation). Elliott International beneficially holds (i) 368,668 shares of our common stock and (ii) 67,617 shares of Series G preferred stock convertible into 3,759,599 shares of our common stock (subject to the Ownership Limitation. In accordance with Rule 13d-4 under the Exchange Act, the number of shares of our common stock into which the Series E and Series G preferred stock are convertible into, as applicable, are limited pursuant to the terms of the convertible securities to that number of shares of our common stock which would result in the Elliott Reporting Entities having aggregate beneficial ownership of not more than 4.99% of the total issued and outstanding shares of our common stock (the “Ownership Limitation”). The Elliott Reporting Entities disclaim beneficial ownership of any and all shares of our common stock issuable upon any conversion of the convertible securities if such conversion would cause the Elliott Reporting Entities aggregate beneficial ownership of our common stock to exceed or remain above the Ownership Limitation (as is currently the case). Therefore, the Elliott Reporting Entities disclaim beneficial ownership of any shares of our common stock, issuable upon any conversion of the Series E preferred stock and the Series G preferred stock, which conversion would be prohibited by the Ownership Limitation. The Ownership Limitation does not prevent the Elliott Reporting Entities or their affiliates from voting the shares of Series E and Series G preferred stock held by Elliott Associates and Elliott International. Accordingly, the shares of Series E preferred stock and Series G preferred stock, as of the record date, will be entitled to an aggregate of 2,918,776 votes. The business address of Elliott Associates is 40 West 57th Street, 30th Floor, New York, New York 10019. The business address of Elliott International is c/o Maples &amp; Calder, P.O. Box 309, Ugland House, South Church Street, George Town, Cayman Islands, British West Indies.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (3)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Based solely on information contained in Amendment No. 1 to the Statement on Schedule 13G filed with the SEC on January 29, 2021 by BlackRock, Inc. BlackRock, Inc. has the sole voting power with respect to 1,969,743 shares of our common stock and the sole dispositive power with respect to 1,995,193 shares of our common stock. The business address of BlackRock, Inc. is 55 East 52
         <sup>
          nd
         </sup>
         Street, New York, New York 10055.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (4)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 60,905 shares of our common stock, and (ii) 492,915 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (5)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 1,150 shares of our common stock, and (ii) 95,834 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (6)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 7,200 shares of our common stock, and (ii) 118,882shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (7)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 96,878 shares of our common stock, and (ii) 126,024 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (8)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 8,000 shares of our common stock, and (ii) 130,862 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (9)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of 15,516 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (10)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 53,473 shares of our common stock, and (ii) 85,000 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (11)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of 14,580 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (12)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 6,250 shares of our common stock, and (ii) 52,500 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (13)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 150,034 shares of our common stock, and (ii) 66,000 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 76; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      74
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (14)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of (i) 60,498 shares of our common stock held directly, (ii) 2,000 shares of our common stock held by Mr. Lefkowitz’s wife, (iv) 30,152 shares of our common stock held by Wade Capital Corporation Money Purchase Plan, an entity for which Mr. Lefkowitz has voting and investment control, and (v) 63,000 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 0px">
       </td>
       <td style="width: 34px; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (15)
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Consists of the following held by our directors and executiveofficers (A) 476,540 shares of our common stock, and (B) 1,261,113 shares of our common stock issuable upon exercise of stock options.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       StockPerformance Graph
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing performance graph shall not be deemed to be “soliciting material” or “filed” or incorporatedby reference in future filings with the SEC, or subject to the liabilities of Section 18 of the Exchange Act except as shall beexpressly set forth by specific reference in such filing. The performance graph compares the performance of our common stock tothe NASDAQ Composite Index and the NASDAQ Biotechnology Index. The graph covers the most recent five-year period ended December31, 2020. The graph assumes that the value of the investment in our common stock and each index was $100.00 at December 31, 2015,and that all dividends are reinvested.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1410098/000121390021018684/img_001.jpg" src="https://www.sec.gov/Archives/edgar/data/1410098/000121390021018684/img_001.jpg" style="height: 372px; width: 700px"/>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 77; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      75
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">
        <b>
        </b>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <b>
        </b>
       </td>
       <td colspan="21" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Cumulative                                         Total Return
         </b>
        </span>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <b>
        </b>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 28%; text-align: left; padding-bottom: 1.5pt">
        <b>
        </b>
       </td>
       <td style="text-align: center; width: 1%; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 1%; text-align: center">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center">
        <b>
         12/2015
        </b>
       </td>
       <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center">
       </td>
       <td style="text-align: center; width: 1%; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 1%; text-align: center">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center">
        <b>
         12/2016
        </b>
       </td>
       <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center">
       </td>
       <td style="text-align: center; width: 1%; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 1%; text-align: center">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center">
        <b>
         12/2017
        </b>
       </td>
       <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center">
       </td>
       <td style="text-align: center; width: 1%; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 1%; text-align: center">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center">
        <b>
         12/2018
        </b>
       </td>
       <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center">
       </td>
       <td style="text-align: center; width: 1%; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 1%; text-align: center">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center">
        <b>
         12/2019
        </b>
       </td>
       <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center">
       </td>
       <td style="text-align: center; width: 1%; padding-bottom: 1.5pt; vertical-align: bottom">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 1%; text-align: center">
        <b>
        </b>
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center">
        <b>
         12/2020
        </b>
       </td>
       <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        CorMedix Inc.
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        100.00
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        75.37
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        24.73
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        63.55
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        71.72
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        73.20
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        Russell 2000
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        100.00
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        121.31
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        139.08
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        123.76
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        155.35
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        186.36
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
        NASDAQ Biotechnology
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        100.00
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        78.65
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        95.67
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        87.19
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        109.08
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        137.90
       </td>
       <td style="text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin: 0">
    </p>
    <div>
    </div>
    <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     Copyright© 2021 Russell Investment Group. All rights reserved.
    </p>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <div>
     <a id="a_021">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0%">
       </td>
       <td style="text-align: justify; width: 0.75in">
        <p style="margin-top: 0; margin-bottom: 0">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
          </b>
         </span>
        </p>
        <p style="margin-top: 0; margin-bottom: 0">
         <span style="font: 10pt Times New Roman, Times, Serif">
          <b>
           Item 13.
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Certain                                         Relationships and Related Transactions and Director Independence
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       RelatedParty Transactions
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      OnSeptember 6, 2019, we consummated a securities exchange agreement (the “Exchange Agreement”), dated as of August 14,2019, with Elliott Associates, Elliott International, and Manchester Securities Corp. (together “Elliott”), pursuantto which we exchanged certain of our outstanding securities (the “Exchanged Securities”) together with an aggregatecash payment of $2,000,000 for 100,000 shares of Series G Preferred Stock. The Exchanged Securities, which in the aggregate wereexercisable or convertible for 5,017,769 shares of common stock, consisted of (i) all of the shares of our Series C-2 PreferredStock, Series D Preferred Stock and Series F Preferred Stock held by Elliott, (ii) all of the warrants held by Elliott, and (iii)all of the 10% Senior Secured Convertible Notes issued on December 31, 2018 held by Elliott, with an aggregate principal amountof $7,879,688, including accrued interest compounded quarterly of $379,688. The Exchanged Securities, other than the Series EWarrants, were cancelled upon delivery of such Exchanged Securities to us and the issuance of the Series G Preferred Stock tothe holders. No shares of Series G Preferred Stock were issued in exchange for the surrender and cancellation of the Series EWarrants owned by Elliott, which were cancelled upon delivery to the Company. Additionally, our Series E Preferred Stock, whichis owned by Elliott, was amended to conform certain of the restrictive covenants to those in the Series G Preferred Stock, andto provide the shares of Series E Preferred Stock with similar rights to vote on an as-converted basis.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
     Additionally, on September6, 2019, in connection with the closing of the transactions under the Exchange Agreement, we also amended and restated the RegistrationRights Agreement, dated as of November 9, 2017, by and between us and Elliott, in order to include the shares of common stock currentlyheld by Elliott, and the shares of common stock issuable upon conversion of the Series G Preferred Stock and the Series E PreferredStock as registrable securities thereunder.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       Proceduresfor Review and Approval of Transactions with Related Persons
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Pursuantto the Audit Committee Charter, the Audit Committee is responsible for reviewing and approving all related party transactionsas defined under Item 404 of Regulation S-K, after reviewing each such transaction for potential conflicts of interests and otherimproprieties. Our policies and procedures for review and approval of transactions with related persons are in writing in ourCode of Conduct and Ethics available on our website at www.cormedix.com under the “Investor Relations—Corporate Governance”tab.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theinformation on Board independence is found in Item 10 of this Report under the heading “Board Independence.”
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 78; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      76
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_022">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                          14.
         </b>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Principal                                         Accounting Fees and Services
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       FeesPaid to the Independent Registered Public Accounting Firm
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing table sets forth fees billed to us by Friedman LLP, our independent registered public accounting firm for the yearsended December 31, 2020 and 2019, for services relating to: auditing our annual financial statements; reviewing our financialstatements included in our quarterly reports on Form 10-Q; reviewing registration statements during 2020 and 2019; financing activitiesin 2020 and 2019; and services rendered in connection with tax compliance, tax advice and tax planning, and all other fees forservices rendered.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td>
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2020
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2019
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">
        Audit Fees
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        153,000
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        188,790
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">
        Audit Related Fees
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        37,000
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">
        Tax Fees
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        -
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">
        All Other Fees
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        -
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        -
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">
        Total
       </td>
       <td style="font-weight: bold; padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">
        190,000
       </td>
       <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">
       </td>
       <td style="font-weight: bold; padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">
        188,790
       </td>
       <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       AuditCommittee Pre-Approval Policies and Procedures
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Pursuantto its charter, the Audit Committee is responsible for reviewing and approving in advance any audit and any permissible non-auditengagement or relationship between us and our independent registered public accounting firm. The Audit Committee may delegateto one or more designated members of the Audit Committee the authority to grant pre-approvals, provided such approvals are presentedto the Audit Committee at a subsequent meeting. If the Audit Committee elects to establish pre-approval policies and proceduresregarding non-audit services, the Audit Committee must be informed of each non-audit service provided by our independent registeredpublic accounting firm. Audit Committee pre-approval of audit and non-audit services will not be required if the engagement forthe services is entered into pursuant to pre-approval policies and procedures, provided the policies and procedures are detailedas to the particular service, the Audit Committee is informed of each service provided and such policies and procedures do notinclude delegation of the Audit Committee’s responsibilities under the Exchange Act to our management. Audit Committee pre-approvalof non-audit services (other than review and attestation services) also will not be required if such services fall within availableexceptions established by the SEC. All services performed by our independent registered public accounting firm during 2020 werepre-approved by the Audit Committee.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 79; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      77
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_023">
     </a>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      PARTIV
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <div>
     <a id="a_024">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Item                                         15.
         </b>
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <b>
          Exhibits,                                         Financial Statement Schedules
         </b>
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0in">
       </td>
       <td style="width: 0.5in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (a)
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Listof documents filed as part of this report:
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0in">
       </td>
       <td style="width: 0.5in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         1.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         FinancialStatements:
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefinancial statements of the Company and the related reports of the Company’s independent registered public accounting firmsthereon have been filed under Item 8 hereof.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0in">
       </td>
       <td style="width: 0.5in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         2.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         FinancialStatement Schedules:
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      None.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 80; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      78
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
     <tbody>
      <tr style="vertical-align: top; text-align: justify">
       <td style="width: 0in">
       </td>
       <td style="width: 0.5in; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         ExhibitIndex
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Thefollowing is a list of exhibits filed as part of this Form 10-K:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold">
        Exhibit Number
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
         <b>
         </b>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
         <b>
          Description of Document
         </b>
        </p>
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">
        Registrant’s Form
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">
        Dated
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">
        Exhibit Number
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">
        Filed Herewith
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; width: 8%; text-align: center">
        1.1
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 50%; text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495418002365/crmd_ex11.htm" tabindex="18">
         At Market Issuance Sales Agreement, dated March 9, 2018, between CorMedix Inc. and B. Riley FBR, Inc.
        </a>
       </td>
       <td style="width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
        S-3
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 9%; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/09/2018
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 9%; text-align: center">
        1.1
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="text-align: center; width: 9%">
       </td>
       <td style="width: 1%">
       </td>
      </tr>
      <tr>
       <td style="vertical-align: top; text-align: center; width: 8%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         1.2
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: justify; width: 50%">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390020039648/ea130607ex1-1_cormedix.htm" tabindex="18">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Amended and Restated At Market Issuance Sales Agreement, dated November 27, 2020, by and among CorMedix Inc., B. Riley Securities, Inc. and Needham &amp; Company LLC
         </span>
        </a>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         8-K
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         11/27/2020
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         1.1
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center; width: 8%">
        3.1
       </td>
       <td style="text-align: left; width: 1%">
       </td>
       <td style="text-align: justify; width: 50%">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420410010806/v173445_ex3-3.htm" tabindex="18">
         Form of Amended and Restated Certificate of Incorporation.
        </a>
       </td>
       <td style="width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
        S-1/A
       </td>
       <td style="width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/01/2010
        </span>
       </td>
       <td style="text-align: left; width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
        3.3
       </td>
       <td style="text-align: left; width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
       </td>
       <td style="width: 1%">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        3.2
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420410014550/v177841_ex3-5.htm" tabindex="18">
         Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated February 24, 2010.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        S-1/A
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/19/2010
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.5
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        3.3
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390020031268/ea128136ex3-1_cormedixinc.htm" tabindex="18">
         Second Amended and Restated Bylaws as amended October 8, 2020.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         10/14/2020
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        3.4
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420413017913/v338013_ex3-3.htm" tabindex="18">
         Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated December 3, 2012.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        10-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/27/2013
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.3
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        3.5
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495417007240/crmd_ex31.htm" tabindex="18">
         Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated August 9, 2017.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         8/10/2017
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        3.6
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495419003255/crmd_ex31.htm" tabindex="18">
         Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated March 25, 2019
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/25/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        3.7
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000135448814004657/crmd_ex316.htm" tabindex="18">
         Amended and Restated Certificate of Designation of Series C-3 Non-Voting Convertible Preferred Stock of CorMedix Inc., filed with the Delaware Secretary of State on September 15, 2014.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9/16/2014
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.16
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        3.8
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390019017759/f8k090519ex3-2_cormedixinc.htm" tabindex="18">
         Second Amended and Restated Certificate of Designation of Series E Convertible Preferred Stock of CorMedix Inc., filed with the Delaware Secretary of State on September 5, 2019.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9/11/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.2
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        3.9
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390019017759/f8k090519ex3-1_cormedixinc.htm" tabindex="18">
         Certificate of Designation of Series G Convertible Preferred Stock of CorMedix Inc., filed with the Delaware Secretary of State on September 5, 2019
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9/11/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        3.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        4.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420410014550/v177841_ex4-1.htm" tabindex="18">
         Specimen of Common Stock Certificate.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        S-1/A
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/19/2010
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        4.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        4.2
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000135448814000106/crmd_ex423.htm" tabindex="18">
         Form of Warrant issued on January 8, 2014.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         1/09/2014
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        4.23
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        4.3
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495417004015/crmd_ex42.htm" tabindex="18">
         Form of Series B Warrant to Purchase Common Stock of CorMedix Inc. issued on May 3, 2017.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         5/03/2017
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        4.2
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        4.4
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495417004015/crmd_ex43.htm" tabindex="18">
         Form of Underwriter’s Warrant to Purchase Common Stock of CorMedix Inc., issued May 3, 2017.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         5/03/2017
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        4.3
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        4.5
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390020006521/f10k2019ex4-5_cormed.htm" tabindex="18">
         Description of Capital Stock of CorMedix Inc.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        10-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        3/16/2020
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        4.5
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.1*
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420409067091/v169969_ex10-5.htm" tabindex="18">
         License and Assignment Agreement, dated as of January 30, 2008, between the Company and ND Partners LLC.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        S-1/A
       </td>
       <td>
       </td>
       <td style="text-align: center">
        12/31/2009
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.5
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.2
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420409062141/v167363_ex10-6.htm" tabindex="18">
         Escrow Agreement, dated as of January 30, 2008, among the Company, ND Partners LLC and the Secretary of the Company, as Escrow Agent.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        S-1
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         11/25/2009
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.6
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.3
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420409062141/v167363_ex10-12.htm" tabindex="18">
         Consulting Agreement, dated as of January 30, 2008, between the Company and Frank Prosl.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        S-1
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         11/25/2009
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.12
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.4+
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420410010806/v173445_ex10-8.htm" tabindex="18">
         Amended and Restated 2006 Stock Incentive Plan.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        S-1/A
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/01/2010
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.8
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.5+
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420410010806/v173445_ex10-17.htm" tabindex="18">
         Form of Indemnification Agreement between the Company and each of its directors and executive officers.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        S-1/A
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/01/2010
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.17
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.6+
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420413017913/v338013_ex10-27.htm" tabindex="18">
         2013 Stock Incentive Plan
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        10-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/27/2013
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.27
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.7
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000135448815003601/crmd_ex101.htm" tabindex="18">
         Preliminary Services Agreement dated April 8, 2015, between CorMedix Inc. and [RC]2 Pharma Connect LLC.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        10-Q
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         8/06/2015
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.8
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000135448816006585/crmd_ex1016.htm" tabindex="18">
         Release of Claims and Severance Modification, dated July 17, 2015, between Randy Milby and CorMedix Inc.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        10-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/15/2016
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.16
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.9+
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390019019400/f8k0919ex10-1_cormedixinc.htm" tabindex="18">
         Executive Employment Agreement, dated as of September 26, 2019, between CorMedix Inc. and Khoso Baluch
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         10/01/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr>
       <td style="vertical-align: top; text-align: center; width: 8%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         10.10**+
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: justify; width: 50%">
        <a href="https://www.sec.gov/Archives/edgar/data/1410098/000121390021018684/f10k2020ex10-10_cormedixinc.htm" tabindex="18">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Executive Employment Agreement, dated and effective May 11, 2020, between CorMedix Inc. and Matthew David.
         </span>
        </a>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         10-K
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         10.10
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         X
        </span>
       </td>
       <td style="vertical-align: bottom; width: 1%">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 81; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      79
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; font-weight: bold; width: 8%">
        Exhibit Number
       </td>
       <td style="font-weight: bold; width: 1%">
       </td>
       <td style="border-bottom: Black 1.5pt solid; width: 50%; text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
         <b>
         </b>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
         <b>
          Description of Document
         </b>
        </p>
       </td>
       <td style="font-weight: bold; width: 1%">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; width: 9%">
        Registrant’s Form
       </td>
       <td style="font-weight: bold; width: 1%">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; width: 9%">
        Dated
       </td>
       <td style="font-weight: bold; width: 1%">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; width: 9%">
        Exhibit Number
       </td>
       <td style="font-weight: bold; width: 1%">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold; width: 9%">
        Filed Herewith
       </td>
       <td style="width: 1%">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center; width: 8%">
        10.11**+
       </td>
       <td style="text-align: left; width: 1%">
       </td>
       <td style="text-align: justify; width: 50%">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390020009879/ea120863-8kex101_cormedix.htm" tabindex="18">
         Executive Employment Agreement, dated and effective April 17, 2020, between CorMedix Inc. and John Armstrong.
        </a>
       </td>
       <td style="width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
        8-K
       </td>
       <td style="width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         4/23/2020
        </span>
       </td>
       <td style="text-align: left; width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
        10.1
       </td>
       <td style="text-align: left; width: 1%">
       </td>
       <td style="text-align: center; width: 9%">
       </td>
       <td style="width: 1%">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.12
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495417010405/crmd_ex101.htm" tabindex="18">
         Form of Securities Purchase Agreement, dated November 17, 2017, between CorMedix Inc. and the investors signatory thereto.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         11/13/2017
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.13
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495417010405/crmd_ex102.htm" tabindex="18">
         Backstop Agreement, dated November 9, 2017, between CorMedix Inc. and the investor named therein.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         11/13/2017
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.2
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.14
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495417010405/crmd_ex103.htm" tabindex="18">
         Form of Registration Rights Agreement, dated November 9, 2017, by and between CorMedix Inc. and the investor named therein.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         11/13/2017
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.3
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.15
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495417011458/crmd_ex101.htm" tabindex="18">
         Amendment No. 1, dated as of December 11, 2017, to Registration Rights Agreement, dated November 9, 2017, by and between CorMedix Inc. and the investor named therein.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         12/11/2017
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.16**+
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390021015144/ea137602ex10-1_cormedixinc.htm" tabindex="18">
         Executive Employment Agreement, dated and effective March 10, 2021, between CorMedix Inc. and Elizabeth Masson-Hurlburt
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/12/2021
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.17
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495419000082/crmd_ex101.htm" tabindex="18">
         Securities Purchase Agreement, dated December 31, 2018, between CorMedix Inc. and the investor named therein.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         1/03/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.18*
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000165495419005790/crmd_ex101.htm" tabindex="18">
         Employment Agreement, dated as of March 19, 2019, between CorMedix Inc. and Phoebe Mounts
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        10-Q
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         5/13/19
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.19
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390019015932/f8k081419ex10-1_cormedixinc.htm" tabindex="18">
         Securities Exchange Agreement, dated August 14, 2019, by and among CorMedix Inc. and the Existing Security holders listed on the Schedule of Holders thereto.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         8/15/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        10.20
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390019017759/f8k090519ex10-1_cormedixinc.htm" tabindex="18">
         Amended and Restated Registration Rights Agreement, dated as of September 6, 2019, by and among CorMedix Inc. and Manchester Securities Corp., and Elliot International, L.P. and Elliot Associates, L.P.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         9/11/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        10.21
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000121390019024927/f8k112619ex10-1_cormedix.htm" tabindex="18">
         2019 Omnibus Stock Incentive Plan
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        8-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         11/27/2019
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        10.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        21.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="http://www.sec.gov/Archives/edgar/data/1410098/000114420413017913/v338013_ex21-1.htm" tabindex="18">
         List of Subsidiaries.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
        10-K
       </td>
       <td>
       </td>
       <td style="text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         3/27/2013
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        21.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        23.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="https://www.sec.gov/Archives/edgar/data/1410098/000121390021018684/f10k2020ex23-1_cormedixinc.htm" tabindex="18">
         Consent of Independent Registered Public Accounting Firm.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        X
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        31.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="https://www.sec.gov/Archives/edgar/data/1410098/000121390021018684/f10k2020ex31-1_cormedixinc.htm" tabindex="18">
         Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        X
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="vertical-align: top; text-align: center">
        32.1
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <a href="https://www.sec.gov/Archives/edgar/data/1410098/000121390021018684/f10k2020ex32-1_cormedixinc.htm" tabindex="18">
         Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
        </a>
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        X
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="vertical-align: top; text-align: center">
        101
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: justify">
        <p style="margin: 0pt 0">
         The following materials from CorMedix Inc. Form 10-K for the year ended December 31, 2020, formattedin Extensible Business Reporting Language (XBRL): (i) Balance Sheets at December 31, 2020 and 2019, (ii) Statements of Operationsfor the years ended December 31, 2020 and 2019, (iii) Statements of Changes in Stockholders’ Equity for the years endedDecember 31, 2020 and 2019, (iv) Statements of Cash Flows for the years ended December 31, 2020 and 2019 and (v) Notes to theFinancial Statements.
        </p>
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td>
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: center">
        X
       </td>
       <td>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Rule-Page -->
    <div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%">
     <div style="font-size: 1pt; border-top: Black 1.5pt solid">
     </div>
    </div>
    <!-- Field: /Rule-Page -->
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0.25in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         *
        </span>
       </td>
       <td style="text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Confidentialtreatment has been granted for portions of this document. The omitted portions of this document have been filed separately withthe SEC.
         </span>
        </p>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="vertical-align: top">
       <td style="width: 24px; text-align: justify; font-size: 10pt">
        <span style="font-size: 10pt">
         **
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Portions of the exhibit have been omitted in reliance on Item 601(b)(10)(iv) of Regulation S-K.
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         +
        </span>
       </td>
       <td style="text-align: justify; font-size: 10pt">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Indicates management contract or compensation plan.
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <div>
     <a id="a_025">
     </a>
    </div>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
     <tbody>
      <tr style="vertical-align: top">
       <td style="text-align: justify; width: 0in">
       </td>
       <td style="text-align: justify; width: 0.75in">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Item                          16.
        </span>
       </td>
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Form                                         10-K Summary
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Notapplicable.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 82; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      80
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      SIGNATURES
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Pursuantto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalfby the undersigned thereunto duly authorized.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td colspan="2" style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         CORMEDIX    INC.
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td colspan="2" style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         By:
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Khoso Baluch
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; width: 60%; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; width: 4%; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; width: 36%; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Khoso    Baluch
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Chief                                    Executive Officer
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          (Principal        Executive Officer)
         </span>
        </p>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         By:
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Matthew David
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Matthew David
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Chief                                    Financial Officer
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          (Principal        Financial and Accounting Officer)
         </span>
        </p>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Pursuantto the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalfof the Registrant and in the capacities and on the dates indicated:
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="vertical-align: top">
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 40%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Signature
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; width: 1%; vertical-align: bottom">
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 40%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Title
          </b>
         </span>
        </p>
       </td>
       <td style="text-align: center; width: 1%; vertical-align: bottom">
       </td>
       <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 18%">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           Date
          </b>
         </span>
        </p>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Khoso    Baluch
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Chief Executive Officer and Director
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Khoso Baluch
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (Principal Executive Officer)
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Matthew    David
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Chief Financial Officer
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Matthew David
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         (Principal Financial and Accounting Officer)
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Myron    Kaplan
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Director and Chairman of the Board
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Myron Kaplan
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Paulo    Costa
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Director
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Paulo Costa
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Janet    Dillione
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Director
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Janet Dillione
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Greg    Duncan
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Director
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Greg Duncan
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/ Alan    Dunton
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Director
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Alan Dunton
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="vertical-align: top; text-align: center">
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         /s/    Steven Lefkowitz
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: bottom; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Director
        </span>
       </td>
       <td style="text-align: left; vertical-align: bottom">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         March 30, 2021
        </span>
       </td>
      </tr>
      <tr style="vertical-align: top">
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         Steven Lefkowitz
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: left">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td style="text-align: left; vertical-align: top">
       </td>
       <td style="vertical-align: top; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 83; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      81
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       CORMEDIXINC. AND SUBSIDIARIES
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       FINANCIALSTATEMENTS
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       FinancialStatements Index
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
     <tbody>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: justify; width: 90%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#b_001" tabindex="18">
          Report of Independent Registered Public Accounting Firm
         </a>
        </span>
       </td>
       <td style="width: 1%">
       </td>
       <td style="vertical-align: bottom; text-align: center; width: 9%">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         F-2
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#b_002" tabindex="18">
          Consolidated Balance Sheets as of December 31, 2020 and 2019
         </a>
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         F-3
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; margin-left: 0.125in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <a href="#b_003" tabindex="18">
           Consolidated Statements of Operations and Comprehensive Income (Loss) Years Ended December 31, 2020 and 2019
          </a>
         </span>
        </p>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         F-4
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; margin-left: 0.125in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <a href="#b_004" tabindex="18">
           Consolidated Statements of Changes in Stockholders’ Equity Years Ended December 31, 2020 and 2019
          </a>
         </span>
        </p>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         F-5
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: justify">
        <p style="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; margin-left: 0.125in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <a href="#b_005" tabindex="18">
           Consolidated                                    Statements of Cash Flows Years Ended December 31, 2020 and 2019
          </a>
         </span>
        </p>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         F-6
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: justify">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         <a href="#b_006" tabindex="18">
          Notes to Consolidated Financial Statements
         </a>
        </span>
       </td>
       <td>
       </td>
       <td style="vertical-align: bottom; text-align: center">
        <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         F-7
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 84; Options: NewSection; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      1
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <div>
     <a id="b_001">
     </a>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      REPORTOF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
     To the Board of Directors and
     <br/>
     Stockholders of CorMedix Inc.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <b>
      Opinion on the Consolidated FinancialStatements
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     We have audited the accompanying consolidatedbalance sheets of CorMedix Inc. and Subsidiaries (the “Company”) as of December 31, 2020 and 2019, and the relatedconsolidated statements of operations and comprehensive income (loss), changes in stockholders’ equity, and cash flows foreach of the years in the two-year period ended December 31, 2020, and the related notes (collectively referred to as the “consolidatedfinancial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, thefinancial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for eachof the years in the two-year period ended December 31, 2020, in conformity with accounting principles generally accepted in theUnited States of America.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <b>
      Basis for Opinion
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     These consolidated financial statementsare the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidatedfinancial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting OversightBoard (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federalsecurities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     We conducted our audits in accordance withthe standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whetherthe consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not requiredto have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we arerequired to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinionon the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     Our audits included performing proceduresto assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performingprocedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts anddisclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significantestimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believethat our audits provide a reasonable basis for our opinion.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <b>
      Critical Audit Matter
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     The critical audit matters communicatedbelow are matters arising from the current period audit of the consolidated financial statements that were communicated or requiredto be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidatedfinancial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of criticalaudit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not,by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accountsor disclosures to which they relate.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">
     <i>
      Critical Audit MatterDescription
     </i>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">
     Stock
     <span style="font-size: 10pt">
      BasedCompensation
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">
     During the year ended December31, 2020, the Company recorded stock-based compensation expense of $2.5 million. As discussed in Note 8 to the consolidated financialstatements, the Company issues various types of equity awards, including stock options and restricted stock units.
    </p>
    <div>
    </div>
    <p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">
     Auditing the Company’s accountingfor stock-based compensation required complex auditor judgment due to the number and variety of equity awards outstanding, theinclusion of performance vesting criteria in certain awards, and the subjectivity of assumptions used to value stock-based awards.In particular, judgment was required to evaluate the nature of the performance conditions, as well as to assess the satisfactionof the performance targets.
    </p>
    <div>
    </div>
    <p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">
     <i>
      How We Addressedthe Matter in Our Audit
     </i>
    </p>
    <div>
    </div>
    <p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">
     To test stock based compensationexpense, we performed audit procedures that included, among others, obtaining an understanding of the Company’s controlsover stock-based compensation, assessing the completeness of the awards granted and evaluating the methodologies used to estimatethe fair value of these awards. We also tested the accuracy of the data used in measuring the awards by agreeing the underlyinginputs, such as grant date, grant price, performance targets and vesting terms, among others, back to source documents, such ascompensation meeting minutes or award letters and testing the clerical accuracy of the calculation of the expense recorded. Wedetermined whether milestone targets were satisfied in accordance with the contractual conditions and recalculated grant date fairvalue. We also evaluated the adequacy of the Company’s stock-based compensation disclosures included in Note 8 in relationto these matters.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     /s/ Friedman LLP
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     We have served as the Company’s auditor since 2014.
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     <span style="font-size: 6pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     Marlton, NJ
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">
     March 30, 2021
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 85; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      2
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <div>
     <a id="b_002">
     </a>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">
      CorMedixInc. And Subsidiaries
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      CONSOLIDATEDBALANCE SHEETS
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       December31, 2020 and 2019
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        December 31,
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2020
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2019
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        ASSETS
       </td>
       <td>
       </td>
       <td colspan="2" style="text-align: center">
       </td>
       <td>
       </td>
       <td>
       </td>
       <td colspan="2" style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        Current assets
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">
        Cash and cash equivalents
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-30" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          41,905,469
         </ix:nonfraction>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-31" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          16,350,237
         </ix:nonfraction>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Restricted cash
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-32" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCashCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          191,314
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-33" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCashCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          174,950
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Short-term investments
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-34" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShortTermInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          4,444,072
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-35" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShortTermInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          11,984,157
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Trade receivables, net
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-36" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsReceivableNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          3,357
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-37" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsReceivableNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          35
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Inventories, net
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-38" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          143,564
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-39" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          338,465
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Prepaid research and development expenses
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-40" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          62,210
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-41" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          34,831
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Security deposit
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-42" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepositsAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          20,000
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-43" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DepositsAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          20,000
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Other prepaid expenses and current assets
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-44" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,412,183
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-45" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          446,415
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Total current assets
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-46" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          48,182,169
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-47" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AssetsCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          29,349,090
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        Property and equipment, net
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-48" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          111,499
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-49" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          122,130
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Operating lease right-of-use assets
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-50" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseRightOfUseAsset" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,014,635
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-51" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseRightOfUseAsset" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          4,690
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        TOTAL ASSETS
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-52" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          49,308,303
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-53" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          29,475,910
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        LIABILITIES AND STOCKHOLDERS’ EQUITY
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        Current liabilities
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Accounts payable
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-54" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,128,104
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-55" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccountsPayableCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,024,280
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Accrued expenses
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-56" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,924,351
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-57" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          4,798,475
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Operating lease liabilities, short-term
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-58" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          109,128
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-59" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,011
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Deferred revenue
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        -
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-60" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredRevenueCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,206
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Total current liabilities
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-61" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          4,161,583
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-62" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          5,826,972
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Operating lease liabilities, net of current portion
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-63" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          923,708
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-64" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiabilityNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,678
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">
        TOTAL LIABILITIES
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-65" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          5,085,291
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-66" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Liabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          5,829,650
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        COMMITMENTS AND CONTINGENCIES (Note 7)
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-1">
         <span>
          <ix:nonfraction contextref="c3" continued-taxonomy="false" data-original-id="hidden-fact-1" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-67" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommitmentsAndContingencies" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-2">
         <span>
          <ix:nonfraction contextref="c4" continued-taxonomy="false" data-original-id="hidden-fact-2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-68" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommitmentsAndContingencies" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        STOCKHOLDERS’ EQUITY
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Preferred stock - $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-69" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-70" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
            0.001
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        par value:
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-71" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-72" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
            2,000,000
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        shares authorized;
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-73" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-74" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-75" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-76" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                241,623
               </ix:nonfraction>
              </span>
             </ix:nonfraction>
            </span>
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        shares issued and outstanding at December 31, 2020 and 2019
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-77" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          242
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-78" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          242
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Common stock - $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-79" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-80" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
            0.001
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        par value:
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-81" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-82" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
            160,000,000
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        shares authorized at December 31, 2020 and 2019;
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-83" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          <span>
           <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-84" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
            33,558,096
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        and
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-85" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-86" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
            25,665,350
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        shares issued and outstanding at December 31, 2020 and 2019, respectively
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-87" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          33,558
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-88" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          25,665
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Accumulated other comprehensive gain
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-89" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          102,006
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-90" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          97,257
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Additional paid-in capital
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-91" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdditionalPaidInCapital" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          261,536,061
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-92" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdditionalPaidInCapital" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          218,944,268
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Accumulated deficit
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-93" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:RetainedEarningsAccumulatedDeficit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          217,448,855
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-94" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:RetainedEarningsAccumulatedDeficit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          195,421,172
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">
        TOTAL STOCKHOLDERS’ EQUITY
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-95" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          44,223,012
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-96" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          23,646,260
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-97" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesAndStockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          49,308,303
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-98" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LiabilitiesAndStockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          29,475,910
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theaccompanying notes are integral part of these consolidated financial statements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 86; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      3
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <div>
     <a id="b_003">
     </a>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">
      CorMedixInc. and Subsidiaries
     </span>
    </p>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      CONSOLIDATEDSTATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       YearsEnded December 31, 2020 and 2019
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: normal; text-align: center">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        December 31,
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: normal; text-align: center">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2020
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2019
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Revenue:
       </td>
       <td>
       </td>
       <td colspan="2" style="text-align: center">
       </td>
       <td>
       </td>
       <td>
       </td>
       <td colspan="2" style="text-align: center">
       </td>
       <td>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">
        Net sales
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-99" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Revenues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          239,231
         </ix:nonfraction>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-100" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Revenues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          283,266
         </ix:nonfraction>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Cost of sales
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-101" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CostOfRevenue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          204,846
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-102" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CostOfRevenue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          373,234
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Gross profit
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-103" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:GrossProfit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          34,385
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-104" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:GrossProfit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          89,968
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Operating Expenses:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Research and development
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-105" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ResearchAndDevelopmentExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          13,377,193
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-106" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ResearchAndDevelopmentExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          11,052,903
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Selling, general and administrative
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-107" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SellingGeneralAndAdministrativeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          13,877,944
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-108" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SellingGeneralAndAdministrativeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          9,865,005
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Total operating expenses
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-109" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          27,255,137
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-110" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          20,917,908
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Loss From Operations
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-111" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          27,220,752
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-112" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OperatingIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          21,007,876
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Other Income (Expense):
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Interest income
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-113" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InvestmentIncomeInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          116,065
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-114" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InvestmentIncomeInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          322,668
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Foreign exchange transaction loss
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-115" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          59,165
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-116" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          21,156
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Interest expense including amortization of debt discount
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-117" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          33,226
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-118" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          787,488
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Total other income (expense)
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-119" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherNonoperatingIncomeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          23,674
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-120" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherNonoperatingIncomeExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          485,976
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Net Loss Before Income Taxes
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-121" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          27,197,078
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-122" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          21,493,852
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Tax benefit
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-123" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          5,169,395
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-124" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          5,060,778
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">
        Net Loss
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-125" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          22,027,683
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-126" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          16,433,074
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Other Comprehensive Income (Loss):
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Unrealized gain (loss) from investments
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-127" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,271
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-128" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetTransitionAssetObligationNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          268
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Foreign currency translation gain
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-129" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          6,020
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-130" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          467
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Total other comprehensive income
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-131" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          4,749
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-132" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          735
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        Comprehensive Loss
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-133" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          22,022,934
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-134" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ComprehensiveIncomeNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          16,432,339
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Net Loss
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-135" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          22,027,683
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
        $
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-136" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:ProfitLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          16,433,074
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Deemed dividend as a result of warrant modification
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-3">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-137" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:DeemedDividendResultOfWarrantModification" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-138" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:DeemedDividendResultOfWarrantModification" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          369,500
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Deemed dividend as a result of exchange of convertible note and Series C-2, Series D and Series F preferred stock, related party
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        -
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-139" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:DeemedDividend" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          26,733,098
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        Net Loss Attributable to Common Shareholders
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-140" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          22,027,683
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-141" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          43,535,672
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font-weight: bold; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        Net Loss Per Common Share – Basic and Diluted
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-142" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usdPershares">
          0.77
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-143" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usdPershares">
          1.80
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="font-weight: bold; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        Weighted Average Common Shares Outstanding – Basic and Diluted
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-144" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          28,561,963
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-145" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          24,152,088
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theaccompanying notes are integral part of these consolidated financial statements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 87; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      4
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <div>
     <a id="b_004">
     </a>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       CORMEDIXINC. AND SUBSIDIARIES
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font: 10pt Times New Roman, Times, Serif">
      <b>
       CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font: 10pt Times New Roman, Times, Serif">
      <b>
       Years Ended December 31, 2020 and 2019
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Common                                         Stock
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Preferred                                         Stock – Series C-2, C-3, Series D, Series E, Series F and Series G
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td colspan="2" style="vertical-align: bottom; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Accumulated                                         Other Comprehen-sive Gain
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Additional
           <br/>
           Paid-in
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Accumulated
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Total
           <br/>
           Stockholders’
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: center; padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Shares
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Amount
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Shares
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">
          <b>
           Amount
          </b>
         </span>
        </p>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <span style="font-size: 8pt">
         <b>
          (Loss)
         </b>
        </span>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <span style="font-size: 8pt">
         <b>
          Capital
         </b>
        </span>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <span style="font-size: 8pt">
         <b>
          Deficit
         </b>
        </span>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
       <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
        <span style="font-size: 8pt">
         <b>
          Equity
         </b>
        </span>
       </td>
       <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: center">
        <span style="font-size: 8pt">
         <b>
         </b>
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; width: 36%; font-weight: bold; text-align: left">
        <span style="font-size: 8pt">
         Balance    at December 31, 2018
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c6" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-146" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           21,775,173
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c6" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-147" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           21,775
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c7" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-148" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           419,585
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c7" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-149" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           420
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c8" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-150" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           96,522
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c9" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-151" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           183,803,636
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c10" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-152" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           178,988,098
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td style="width: 1%">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="width: 5%; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c11" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-153" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           4,934,255
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock issued in connection    with ATM sale of common stock, net
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-154" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           1,768,012
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-155" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           1,768
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-156" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           15,232,761
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-157" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           15,234,529
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock issue in connection    with warrants exercised
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-158" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedInConnectionWithWarrantsExercisedinShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           1,948,207
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-159" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           1,948
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-4">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-160" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedInConnectionWithWarrantsExercisedinShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-5">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-161" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-6">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-162" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-163" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           8,672,036
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-7">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-164" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-165" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           8,673,984
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Exchange of convertible    note for Series G preferred stock, net, related party
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-8">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-166" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodValueOfExchangeConvertibleNotesOfRelatedParty" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-9">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-167" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodValueOfExchangeConvertibleNotesOfRelatedParty" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-10">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-10" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-168" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodValueOfExchangeConvertibleNotesOfRelatedParty" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-169" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodValueOfExchangeConvertibleNotesOfRelatedParty" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           8,673,509
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-11">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-11" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-170" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodValueOfExchangeConvertibleNotesOfRelatedParty" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-171" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodValueOfExchangeConvertibleNotesOfRelatedParty" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           8,673,509
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Exchange of Series    C-2, Series D and Series F preferred stock for Series G preferred stock, related party
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-12">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-12" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-172" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-13">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-13" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-173" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-174" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="shares">
           225,962
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-175" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           226
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-14">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-14" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-176" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-177" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           226
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-15">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-15" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-178" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Issuance of Series    G preferred stock, related party
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-16">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-16" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-179" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIsssuedDuringPeriodSharesOfIssuanceOfPreferredStockRelatedPartyinShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-17">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-17" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-180" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-181" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIsssuedDuringPeriodSharesOfIssuanceOfPreferredStockRelatedPartyinShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           100,000
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-182" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           100
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-18">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-18" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-183" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-184" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           100
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-19">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-19" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-185" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock issued in connection    with stock options exercised
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-186" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           38,090
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-187" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           38
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-20">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-20" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-188" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-21">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-21" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-189" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-22">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-22" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-190" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-191" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           122,666
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-23">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-23" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-192" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-193" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           122,704
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Conversion of Series    C-3 non-voting preferred stock to common stock
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-194" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           104,000
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-195" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           104
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-196" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="shares">
           52,000
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-197" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           52
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-24">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-24" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-198" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-199" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           52
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-25">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-25" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-200" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-26">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" data-original-id="hidden-fact-26" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-201" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConversionOfSeriesC3NonvotingPreferredStockToCommonStockAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Issuance of vested    restricted stock
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-202" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           25,346
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-203" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           25
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-27">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-27" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-204" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-28">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-28" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-205" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-29">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-29" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-206" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-207" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           25
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-30">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-30" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-208" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-31">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" data-original-id="hidden-fact-31" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-209" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Issuance of common    stock as a result of reverse stock split rounding
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-210" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           6,522
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-211" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodReverseStockSplitsAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           7
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-212" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringPeriodReverseStockSplitsAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           7
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock-based compensation
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-32">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-32" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-213" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-33">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-33" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-214" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-34">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-34" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-215" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-216" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           2,439,618
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-35">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-35" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-217" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-218" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           2,439,618
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Other comprehensive    loss
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-36">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-36" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-219" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-37">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-37" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-220" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-221" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           735
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-38">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" data-original-id="hidden-fact-38" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-222" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-39">
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" data-original-id="hidden-fact-39" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-223" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-224" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           735
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
         Net    loss
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-40">
         <span>
          <ix:nonfraction contextref="c12" continued-taxonomy="false" data-original-id="hidden-fact-40" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-225" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-41">
         <span>
          <ix:nonfraction contextref="c14" continued-taxonomy="false" data-original-id="hidden-fact-41" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-226" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-42">
         <span>
          <ix:nonfraction contextref="c15" continued-taxonomy="false" data-original-id="hidden-fact-42" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-227" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-43">
         <span>
          <ix:nonfraction contextref="c13" continued-taxonomy="false" data-original-id="hidden-fact-43" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-228" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c16" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-229" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           16,433,074
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-230" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           16,433,074
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        <span style="font-size: 8pt">
         Balance    at December 31, 2019
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c17" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-231" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           25,665,350
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c17" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-232" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           25,665
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c18" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-233" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           241,623
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c18" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-234" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           242
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c19" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-235" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           97,257
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c20" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-236" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           218,944,268
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c21" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-237" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           195,421,172
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-238" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           23,646,260
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock issued in connection    with public offering, net
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-239" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           5,111,110
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-240" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           5,111
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-44">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-44" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-241" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-45">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-45" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-242" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-46">
         <span>
          <ix:nonfraction contextref="c24" continued-taxonomy="false" data-original-id="hidden-fact-46" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-243" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c25" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-244" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           21,250,059
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-47">
         <span>
          <ix:nonfraction contextref="c26" continued-taxonomy="false" data-original-id="hidden-fact-47" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-245" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-246" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           21,255,170
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock issued in connection    with ATM sale of common stock, net
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-247" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           2,687,646
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-248" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           2,688
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-48">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-48" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-249" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-49">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-49" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-250" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-50">
         <span>
          <ix:nonfraction contextref="c24" continued-taxonomy="false" data-original-id="hidden-fact-50" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-251" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c25" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-252" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           18,430,257
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-51">
         <span>
          <ix:nonfraction contextref="c26" continued-taxonomy="false" data-original-id="hidden-fact-51" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-253" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-254" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           18,432,945
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock issue in connection    with warrants exercised
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-255" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedInConnectionWithWarrantsExercisedinShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           91,500
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-256" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           92
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-52">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-52" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-257" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedInConnectionWithWarrantsExercisedinShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-53">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-53" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-258" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-54">
         <span>
          <ix:nonfraction contextref="c24" continued-taxonomy="false" data-original-id="hidden-fact-54" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-259" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c25" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-260" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           411,659
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-55">
         <span>
          <ix:nonfraction contextref="c26" continued-taxonomy="false" data-original-id="hidden-fact-55" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-261" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-262" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedDuringperiodValueInConnectionWithWarrantsExercisedAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           411,751
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Issuance of vested    restricted stock
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-263" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           2,490
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-264" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           2
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-56">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-56" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-265" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-57">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-57" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-266" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-58">
         <span>
          <ix:nonfraction contextref="c24" continued-taxonomy="false" data-original-id="hidden-fact-58" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-267" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c25" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-268" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           2
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-59">
         <span>
          <ix:nonfraction contextref="c26" continued-taxonomy="false" data-original-id="hidden-fact-59" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-269" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Stock-based compensation
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-60">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" data-original-id="hidden-fact-60" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-270" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-61">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-61" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-271" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-62">
         <span>
          <ix:nonfraction contextref="c24" continued-taxonomy="false" data-original-id="hidden-fact-62" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-272" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c25" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-273" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           2,499,820
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-63">
         <span>
          <ix:nonfraction contextref="c26" continued-taxonomy="false" data-original-id="hidden-fact-63" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-274" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-275" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           2,499,820
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
        <span style="font-size: 8pt">
         Other comprehensive    income
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c24" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-276" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           4,749
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td>
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-277" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           4,749
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
         Net    loss
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-64">
         <span>
          <ix:nonfraction contextref="c22" continued-taxonomy="false" data-original-id="hidden-fact-64" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-278" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         -
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-65">
         <span>
          <ix:nonfraction contextref="c23" continued-taxonomy="false" data-original-id="hidden-fact-65" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-279" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-66">
         <span>
          <ix:nonfraction contextref="c24" continued-taxonomy="false" data-original-id="hidden-fact-66" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-280" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-67">
         <span>
          <ix:nonfraction contextref="c25" continued-taxonomy="false" data-original-id="hidden-fact-67" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-281" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           <span style="font-size: 8pt">
            -
           </span>
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c26" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-282" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           22,027,683
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td style="padding-bottom: 1.5pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-283" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           22,027,683
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        <span style="font-size: 8pt">
         Balance    at December 31, 2020
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c27" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-284" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           33,558,096
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c27" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-285" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           33,558
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c28" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-286" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
           241,623
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c28" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-287" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           242
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c29" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-288" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           102,006
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c30" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-289" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           261,536,061
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         (
         <span>
          <ix:nonfraction contextref="c31" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-290" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
           217,448,855
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
         )
        </span>
       </td>
       <td style="padding-bottom: 4pt">
        <span style="font-size: 8pt">
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        <span style="font-size: 8pt">
         $
        </span>
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span style="font-size: 8pt">
         <span>
          <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-291" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:StockholdersEquity" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           44,223,012
          </ix:nonfraction>
         </span>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        <span style="font-size: 8pt">
        </span>
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theaccompanying notes are integral part of these consolidated financial statements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 88; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      5
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <div>
     <a id="b_005">
     </a>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       CORMEDIXINC. AND SUBSIDIARIES
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font: 10pt Times New Roman, Times, Serif">
      <b>
       CONSOLIDATED STATEMENTS OF CASH FLOWS
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      <b>
       YearsEnded December 31, 2020 and 2019
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
     <tbody>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        December 31,
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2020
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
       <td style="font-weight: bold; padding-bottom: 1.5pt">
       </td>
       <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
        2019
       </td>
       <td style="padding-bottom: 1.5pt; font-weight: bold">
       </td>
      </tr>
      <tr style="vertical-align: bottom">
       <td style="font-weight: bold; text-align: left">
        CASH FLOWS FROM OPERATING ACTIVITIES:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">
        Net loss
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-292" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          22,027,683
         </ix:nonfraction>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        )
       </td>
       <td style="width: 1%">
       </td>
       <td style="width: 1%; text-align: left">
        $
       </td>
       <td style="width: 9%; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-293" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetIncomeLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          16,433,074
         </ix:nonfraction>
        </span>
       </td>
       <td style="width: 1%; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">
        Adjustments to reconcile net loss to net cash used in operating activities:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Stock-based compensation
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-294" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,499,820
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-295" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,439,618
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Amortization of debt discount
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-68">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-68" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-296" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AmortizationOfDebtDiscountPremium" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-297" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AmortizationOfDebtDiscountPremium" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          313,097
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Non-cash interest expense
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-69">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-69" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-298" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NoncashInterestExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-299" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NoncashInterestExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          461,839
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Non-cash lease expense
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-300" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NoncashLeaseExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          15,523
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-70">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" data-original-id="hidden-fact-70" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-301" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NoncashLeaseExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Inventory reserve
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-302" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInMaterialsAndSupplies" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          44,006
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-303" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInMaterialsAndSupplies" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          27,163
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Depreciation
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-304" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Depreciation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          127,964
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-305" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Depreciation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          73,286
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Changes in operating assets and liabilities:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.5in; text-indent: -0.125in; text-align: left">
        (Increase) decrease in trade receivables
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-306" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInReceivables" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          3,089
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-307" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInReceivables" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          10,631
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.5in; text-indent: -0.125in; text-align: left">
        Decrease in inventory
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-308" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInInventories" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          149,597
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-309" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInInventories" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          59,285
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.5in; text-indent: -0.125in; text-align: left">
        Increase in prepaid expenses and other current assets
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-310" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          991,754
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-311" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          67,385
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.5in; text-indent: -0.125in; text-align: left">
        Increase (decrease) in accounts payable
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-312" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          103,333
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-313" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          1,564,381
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.5in; text-indent: -0.125in; text-align: left">
        Decrease in accrued expenses
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-314" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:IncreaseDecreaseInAccruedExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,883,149
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-315" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:IncreaseDecreaseInAccruedExpenses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          363,280
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.5in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Decrease in deferred revenue
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-316" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,206
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-317" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          8,823
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Net cash used in operating activities
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-318" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          21,967,638
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-319" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          15,052,024
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        CASH FLOWS FROM INVESTING ACTIVITIES:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Purchase of short-term investments
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-320" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForProceedsFromInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          8,549,758
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-321" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForProceedsFromInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          14,106,369
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Maturity of short-term investments
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-322" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          16,088,572
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-323" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,122,481
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Purchase of equipment
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-324" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          112,638
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-325" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          36,571
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Net cash provided by (used in) investing activities
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-326" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          7,426,176
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-327" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          12,020,459
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        CASH FLOWS FROM FINANCING ACTIVITIES:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Proceeds from sale of common stock from at-the-market program, net
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-328" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          18,432,945
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-329" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          15,234,529
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Proceeds from the public offering, net
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-330" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          21,255,170
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-71">
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" data-original-id="hidden-fact-71" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-331" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Proceeds from exchange agreement, related party
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-72">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-72" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-332" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromRelatedPartyDebt" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-333" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromRelatedPartyDebt" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,000,000
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Proceeds from exercise of warrants
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-334" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromWarrantExercises" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          411,751
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-335" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromWarrantExercises" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          8,673,984
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">
        Proceeds from exercise of stock options
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-73">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-73" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-336" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-337" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          122,704
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Payment of financing fees
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-74">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-74" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-338" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-339" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          226,855
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Net cash provided by financing activities
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-340" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          40,099,866
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-341" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          25,804,362
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
        Foreign exchange effects on cash
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-342" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          13,192
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-343" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          2,015
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-344" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          25,571,596
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-345" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          1,270,136
         </ix:nonfraction>
        </span>
       </td>
       <td style="text-align: left">
        )
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">
        CASH AND CASH EQUIVALENTS AND RESTRICTED CASH – BEGINNING OF YEAR
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-346" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          16,525,187
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
       <td style="padding-bottom: 1.5pt">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: left">
       </td>
       <td style="border-bottom: Black 1.5pt solid; text-align: right">
        <span>
         <ix:nonfraction contextref="c11" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-347" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          17,795,323
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 1.5pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">
        CASH AND CASH EQUIVALENTS AND RESTRICTED CASH – END OF YEAR
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-348" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          42,096,783
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-349" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          16,525,187
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Cash paid for interest
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-350" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestPaidNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          33,226
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-351" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestPaidNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          12,552
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">
        Supplemental Disclosure of Non-Cash Financing and Investing Activities:
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
       <td>
       </td>
       <td style="text-align: left">
       </td>
       <td style="text-align: right">
       </td>
       <td style="text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Deemed dividend as a result of warrant modification
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-75">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-75" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-352" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:DeemedDividendAsAResultOfWarrantModification" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-353" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:DeemedDividendAsAResultOfWarrantModification" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          369,500
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Deemed dividend as a result of exchange of convertible note, Series C-2, Series D and Series F convertible preferred shares, related party
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-76">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-76" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-354" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:DeemedDividendExchangeOfConvertibleNote" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-355" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:DeemedDividendExchangeOfConvertibleNote" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          26,733,098
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Issuance of common stock for vested restricted stock units
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-356" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:IssuanceOfCommonStockForVestedRestrictedStockUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-357" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:IssuanceOfCommonStockForVestedRestrictedStockUnits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          25
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Right-of-use asset and lease liability recognized under ASC 842
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-358" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:RightofuseAssetAndLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,015,000
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-359" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:RightofuseAssetAndLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          5,000
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Unrealized gain (loss) from investments
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        (
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-360" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:UnrealizedGainlossFromInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          1,270
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
        )
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-361" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:UnrealizedGainlossFromInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          268
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; ">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Conversion of preferred stock to common stock
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-77">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-77" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-362" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConversionOfPreferredStockToCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-363" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConversionOfPreferredStockToCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          52
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
      <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
       <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
        Write-off of fully depreciated computer equipment
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <div style="-sec-ix-hidden: hidden-fact-78">
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-78" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-364" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:WriteoffOfFullyDepreciatedComputerEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
           -
          </ix:nonfraction>
         </span>
        </div>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
       <td style="padding-bottom: 4pt">
       </td>
       <td style="border-bottom: Black 4pt double; text-align: left">
        $
       </td>
       <td style="border-bottom: Black 4pt double; text-align: right">
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-365" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:WriteoffOfFullyDepreciatedComputerEquipment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          47,850
         </ix:nonfraction>
        </span>
       </td>
       <td style="padding-bottom: 2pt; text-align: left">
       </td>
      </tr>
     </tbody>
    </table>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
      Theaccompanying notes are integral part of these consolidated financial statements.
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 89; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      6
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <div>
     <a id="b_006">
     </a>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <b>
      CORMEDIX INC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <b>
      NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-366" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note1 — Organization, Business and Basis of Presentation:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Organizationand Business:
       </span>
      </p>
      <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        CorMedixInc. (“CorMedix” or the “Company”) was incorporated in the State of Delaware on July 28, 2006. The Companyis a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatmentof infectious and inflammatory diseases. In 2013, the Company formed a wholly-owned subsidiary, CorMedix Europe GmbH and in May2020, the Company formed a wholly-owned Spanish subsidiary, CorMedix Spain, S.L.U.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The Company’sprimary focus is to develop its lead product candidate, DefenCath™, for potential commercialization in the United States(“U.S.”) and other key markets.
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-370" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:OrganizationAndBusinessDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         The Company has in-licensed the worldwide rights to develop and commercialize DefenCath/Neutrolin®,which is a novel anti-infective solution (a formulation of taurolidine 1.35% and heparin 1000 u/ml) intended for the reductionand prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settingssuch as hemodialysis, total parenteral nutrition, and oncology. The name DefenCath is the U.S. proprietary name conditionally approvedby the U.S. Food and Drug Administration (“FDA”), while the name Neutrolin is currently used in the European Union(“EU”) and other territories where the Company has received CE-Mark approval for the commercial distribution of Neutrolinas a catheter lock solution (“CLS”) regulated as a medical device.
        </ix:nonnumeric>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        InJanuary 2015, the FDA designated DefenCath as a Qualified Infectious Disease Product (“QIDP”) for prevention of catheter-relatedblood stream infections in patients with end stage renal disease receiving hemodialysis through a central venous catheter. Catheter-relatedblood stream infections and clotting can be life-threatening. The QIDP designation provides five years of market exclusivity inaddition to the five years granted for a New Chemical Entity upon approval of a New Drug Application (“NDA”). In addition,in January 2015, the FDA granted Fast Track designation to DefenCath Catheter Lock Solution, a designation intended to facilitatedevelopment and expedite review of drugs that treat serious and life-threatening conditions so that the approved drug can reachthe market expeditiously. The Fast Track designation of DefenCath provides us with the opportunity to meet with the FDA on a morefrequent basis during the development process, and also ensures eligibility to request priority review of the marketing application.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        InDecember 2015, the Company launched its Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to DemonstrateSafety &amp; Effectiveness of DefenCath/Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysisfor End Stage Renal Disease (“LOCK-IT-100”), in patients with hemodialysis catheters in the U.S. The clinical trialwas designed to demonstrate the safety and effectiveness of DefenCath compared to the standard of care CLS, Heparin, in preventingCRBSIs. The primary endpoint for the trial assessed the incidence of CRBSI and time to CRBSI for each study subject. Secondaryendpoints were catheter patency, which was defined as required use of tissue plasminogen activating factor, or tPA, or removalof catheter due to dysfunction, and removal of catheter for any reason.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-373" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:DefencathRelativeToTheActiveControlDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Aspreviously agreed with the FDA, an interim efficacy analysis was performed when the first 28 potential CRBSI cases were identifiedin our LOCK-IT-100 study that occurred through early December 2017. Based on these first 28 cases, there was a highly statisticallysignificant 72% reduction in CRBSI by DefenCath relative to the active control of heparin (p=0.0034). Because the pre-specifiedlevel of statistical significance was reached for the primary endpoint and efficacy had been demonstrated with no safety concerns,the LOCK-IT-100 study was terminated early. The study continued enrolling and treating subjects until study termination, and thefinal analysis was based on a total of 795 subjects. In a total of 41 cases, there was a 71% reduction in CRBSI by DefenCath relativeto heparin, which was highly statistically significant (p=0.0006), with a good safety profile.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The FDA granted theCompany’s request for a rolling submission and review of the NDA which is designed to expedite the approval process for productsbeing developed to address an unmet medical need. Although the FDA usually requires two pivotal clinical trials to provide substantialevidence of safety and effectiveness for approval of an NDA, the FDA will in some cases accept one adequate and well-controlledtrial, where it is a large multicenter trial with a broad range of subjects and investigation sites with procedures to includetrial quality that has demonstrated a clinically meaningful and statistically very persuasive effect on prevention of a diseasewith potentially serious outcome.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       In March 2020,the Company began the modular submission process for the NDA for DefenCath for the prevention of CRBSI in hemodialysispatients, and in August 2020, the FDA accepted for filing the DefenCath NDA. The FDA also granted the Company’s requestfor priority review, which provides for a six-month review period instead of the standard ten-month review period. As theCompany announced in March 2021, the FDA informed the Company that it will not approve the NDA for DefenCath in its presentform. The FDA noted concerns at the third-party manufacturing facility after a review of records requested by the FDA andprovided by the manufacturing facility. The Company is working with the manufacturing facility to develop plans forresolution of the deficiencies. Additionally, the FDA is requiring a manual extraction study to demonstrate that the labeledvolume can be consistently withdrawn from the vials despite an existing in-process control to demonstrate fill volume withinspecifications. The Company expects to be able to complete this requirement expeditiously. Satisfactory resolution of theseissues is required for approval of the DefenCath NDA by a pre-approval inspection and/or adequate manufacturing facilityresponses addressing these concerns. If an inspection is required, the Company may encounter delays in obtaining FDA approvalbecause the FDA is currently facing a backlog due to the pandemic and is actively working to define an approach forscheduling outstanding inspections once safe travel may resume. The Company will request a meeting with the FDA, which theCompany estimates will occur in mid-April, to obtain agreement with the FDA on the proposed resolutions of thedeficiencies.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 90; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      7
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        TheFDA did not request additional clinical data and did not identify any deficiencies related to the data submitted on the efficacyor safety of DefenCath from LOCK-IT-100. In draft labeling discussed with the FDA, the FDA added that the initial approval willbe for the limited population of patients with kidney failure receiving chronic hemodialysis through a central venous catheter.This is consistent with our request for approval pursuant to the Limited Population Pathway for Antibacterial and Antifungal Drugs(“LPAD”). LPAD, passed as part of the 21
        <sup>
         st
        </sup>
        Century Cures Act, is a new program intended to expedite thedevelopment and approval of certain antibacterial and antifungal drugs to treat serious or life-threatening infections in limitedpopulations of patients with unmet needs. LPAD provides for a streamlined clinical development program involving smaller, shorter,or fewer clinical trials and is intended to encourage the development of safe and effective products that address unmet medicalneeds of patients with serious bacterial and fungal infections. We believe that LPAD will provide additional flexibility for theFDA to approve DefenCath to reduce CRBSIs in the limited population of patients with kidney failure receiving hemodialysis througha central venous catheter.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The Company intendsto pursue additional indications for DefenCath use as a CLS in populations with an unmet medical need that also represent a significantmarket opportunity. For example, the Company intends to pursue marketing authorization in the U.S. for use as a CLS to reduce CRBSIsin oncology and total parenteral nutrition patients using a central venous catheter.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Inaddition to DefenCath, the Company is sponsoring a pre-clinical research collaboration for the use of taurolidine as a possibletreatment for rare orphan pediatric tumors. In February 2018, the FDA granted orphan drug designation to taurolidine for the treatmentof neuroblastoma in children. The Company may seek one or more strategic partners or other sources of capital to help developand commercialize taurolidine for the treatment of neuroblastoma in children. The Company is also evaluating opportunities forthe possible expansion of taurolidine as a platform compound for use in certain medical devices. Patent applications have beenfiled in several indications, including wound closure, surgical meshes, and wound management.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The Company was granteda deferral by the FDA under the Pediatric Research Equity Act (“PREA”), that requires sponsors to conduct pediatricstudies for NDAs for a new active ingredient, such as taurolidine in DefenCath, unless a waiver or deferral is obtained from theFDA. A deferral acknowledges that a pediatric assessment is required but permits the applicant to submit the pediatric assessmentafter the submission of an NDA. The Company has made a commitment to conduct the pediatric study after approval of the NDA foruse in adult hemodialysis patients.
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-381" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:PediatricResearchEquityActDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         Pediatric studies for an approved product conducted under PREA may qualify for pediatric exclusivity,which if granted would provide an additional six months of marketing exclusivity. DefenCath would then have the potential to receivea total marketing exclusivity period of 10.5 years, including exclusivity pursuant to NCE and QIDP.
        </ix:nonnumeric>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_14" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheFDA regards taurolidine as a new chemical entity and therefore, it is currently an unapproved new drug. The Company might in thefuture pursue product candidates that would involve devices impregnated with taurolidine, and the Company believes that at thecurrent time such products would be combination products subject to device premarket submission requirements (while subject also,under review by the FDA, to the standards for drug approvability). Consequently, given that there is no appropriate predicatemedical device currently marketed in the U.S. on which a 510(k) approval process could be based and that taurolidine is not yetapproved in any application, the Company anticipates that it would be required to submit a premarket approval application (“PMA”)for marketing authorization for any medical device indications that we may pursue for devices containing taurolidine. In the eventthat an NDA for DefenCath is approved by the FDA, the regulatory pathway for these medical device product candidates may be revisitedwith the FDA. Although there may be no appropriate predicate, de novo Class II designation can be proposed, based on a risk assessmentand a reasonable assurance of safety and effectiveness.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_15" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_14" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       In the European Union(“EU”), Neutrolin is regulated as a Class 3 medical device. In July 2013, the Company received CE Mark approval forNeutrolin. In December 2013, the Company commercially launched Neutrolin in Germany for the prevention of CRBSI, and maintenanceof catheter patency in hemodialysis patients using a tunneled, cuffed central venous catheter for vascular access. To date, Neutrolinis registered and may be sold in certain European Union and Middle Eastern countries for such treatment.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_16" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_15" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       In September 2014,the TUV-SUD and The Medicines Evaluation Board of the Netherlands (“MEB”), granted a label expansion for Neutrolinto include use in oncology patients receiving chemotherapy, intravenous (“IV”) hydration and IV medications via CVCfor the EU. In December 2014, the Company received approval from the Hessian District President in Germany to expand the labelfor these same expanded indications. The expansion also adds patients receiving medication and IV fluids via CVC in intensive orcritical care units (cardiac care unit, surgical care unit, neonatal critical care unit, and urgent care centers). An indicationfor use in total parenteral nutrition was also approved.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_17" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_16" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       In September 2019,the Company’s registration with the Saudi Arabia Food and Drug Administration, or the SFDA, expired. As a result, the Companycannot sell Neutrolin in Saudi Arabia. The Company intends to complete the documentation required to renew its registration withthe SFDA, however, the Company cannot predict how long the renewal process will take. There is no assurance that the registrationwill be renewed by the SFDA.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 91; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      8
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_18" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_17" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       OnMarch 26, 2019,
       <span>
        <ix:nonnumeric contextref="c32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-387" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:StockholdersEquityReverseStockSplit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         the Company effected a 1-for-5 reverse stock split of its issued and outstanding shares of common stock, par value$0.001, per share (“Common Stock”), by combining, reclassifying and changing each authorized and outstanding fiveshares of “old” common stock into one share of “new” common stock. No fractional shares were issued, and,in lieu thereof, where applicable, one whole share was issued. To reflect the reverse stock split, reclassification, combinationand change, proportional adjustments were also made to the number of shares of our common stock issuable upon conversion of outstandingpreferred shares and the convertible note payable, warrants and options and other equity awards. The reverse stock split did notaffect the par value per share of our common stock (which remains at $0.001 per share) or the total number of shares of commonstock that are authorized to be issued pursuant to our Amended and Restated Certificate of Incorporation, as amended, which remainsat 160 million shares.
        </ix:nonnumeric>
       </span>
       All issued and outstanding share and per share amounts included in the accompanying consolidated financialstatements and in this report have been adjusted to reflect the reverse stock split, reclassification, combination and changefor all periods presented.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_19" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_18" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany is using its current cash resources for certain pre-launch activities. Commercial preparations are dependent on the Company’sability to raise sufficient additional funds through various potential sources, such as equity, debt financings, and/or strategicrelationships and potential strategic transactions. The Company can provide no assurances that financing or strategic relationshipswill be available on acceptable terms, or at all, to complete its clinical development program for DefenCath.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_19" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The novel coronavirushas been declared a pandemic and has spread to multiple global regions. The outbreak and government measures taken in responsehave also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supplychains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medicalservices and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. In response to the COVID-19outbreak, “shelter in place” orders and other public health guidance measures have been implemented across much ofthe United States, Europe and Asia, including in the locations of the Company’s offices, clinical trial sites, key vendorsand partners. The Company’s program timelines may be negatively affected by COVID-19, which could materially and adverselyaffect its business, financial conditions and results of operations.
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_LiquidityAndUncertaintiesTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-390" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:LiquidityAndUncertaintiesTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note2 — Liquidity and Uncertainties:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LiquidityAndUncertaintiesTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LiquidityAndUncertaintiesTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The consolidated financialstatements have been prepared in conformity with generally accepted accounting principles which contemplate continuation of theCompany as a going concern. To date, the Company’s commercial operations have not generated sufficient revenues to enableprofitability. As of December 31, 2020, the Company had an accumulated deficit of $
       <span>
        <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-392" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:RetainedEarningsAccumulatedDeficits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="usd">
         217.4
        </ix:nonfraction>
       </span>
       million, and incurred net losses of $
       <span>
        <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-393" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NetIncomeLosses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="usd">
         22.0
        </ix:nonfraction>
       </span>
       million and $
       <span>
        <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-394" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NetIncomeLosses" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="usd">
         16.4
        </ix:nonfraction>
       </span>
       million for the years ended December 31, 2020 and 2019, respectively. Based on the Company’s current developmentplans for DefenCath/Neutrolin in both the U.S. and foreign markets and its other operating requirements, the Company’s existingcash and cash equivalents and short-term investments at December 31, 2020 are expected to fund its operations for at least twelvemonths after the filing date of this report after taking into consideration the $
       <span>
        <ix:nonfraction contextref="c33" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-395" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:FundNetProceeds" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="usd">
         41.5
        </ix:nonfraction>
       </span>
       million of net proceeds received in Januaryand February 2021 from the At-the-Market Issuance Sales Agreement (the “ATM program”) (see Note 11) and the costsfor the initial preparations for the commercial launch for DefenCath.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LiquidityAndUncertaintiesTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LiquidityAndUncertaintiesTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The Company’scontinued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/ordebt financings, strategic relationships, potential strategic transactions or out-licensing of its products in order to commerciallylaunch DefenCath upon NDA approval and until profitability is achieved, if ever. Management can provide no assurances that suchfinancing or strategic relationships will be available on acceptable terms, or at all.
       <span>
        <ix:nonnumeric contextref="c33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-397" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:NewAtmAgreementDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         As of the filing date of this Annual Reporton Form 10-K, the Company has no available balance under its ATM program and has $50.0 million available under its current shelfregistration for the issuance of equity, debt or equity-linked securities (see Note 8).
        </ix:nonnumeric>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LiquidityAndUncertaintiesTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany’s operations are subject to a number of other factors that can affect its operating results and financial condition.Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s productcandidates; the ability to obtain regulatory approval to market the Company’s products; ability to manufacture successfully;competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company products;the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products;and the Company’s ability to raise capital to support its operations.
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 92; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      9
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-399" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note3 — Summary of Significant Accounting Policies:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_UseOfEstimates-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-401" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:UseOfEstimates" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Useof Estimates
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_UseOfEstimates-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Thepreparation of financial statements in conformity with accounting principles generally accepted in the United States of Americarequires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosureof contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses duringthe reporting period. Actual results could differ from those estimates.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_ConsolidationPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-405" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ConsolidationPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           <i>
            Basisof Consolidation
           </i>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_ConsolidationPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Theconsolidated financial statements include the accounts of the Company, CorMedix Europe GmbH and CorMedix Spain, S.L.U. its whollyowned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-409" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          FinancialInstruments
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Financialinstruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalentsand short-term investments. The Company maintains its cash and cash equivalents in bank deposit and other interest-bearing accounts,the balances of which, at times, may exceed federally insured limits.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Thefollowing table is the reconciliation of the accounting standard that modifies certain aspects of the recognition, measurement,presentation and disclosure of financial instruments as shown on the Company’s consolidated statement of cash flows:
         </span>
        </p>
        <p style="margin: 0">
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-415" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" continuedat="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">
              <b>
               December 31,
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
              <b>
               2020
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
              <b>
               2019
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">
              Cash and cash equivalents
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-417" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                41,905,469
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-418" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                16,350,237
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Restricted cash
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-419" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCashAndCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                191,314
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-420" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCashAndCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                174,950
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total cash, cash equivalents and restricted cash
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-421" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                42,096,783
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-422" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                16,525,187
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
           </tbody>
          </table>
          <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_10" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Theappropriate classification of marketable securities is determined at the time of purchase and reevaluated as of each balance sheetdate. Investments in marketable debt and equity securities classified as available-for-sale are reported at fair value. Fair valueis determined using quoted market prices in active markets for identical assets or liabilities or quoted prices for similar assetsor liabilities or other inputs that are observable or can be corroborated by observable market data for substantially the fullterm of the assets or liabilities. Changes in fair value that are considered temporary are reported net of tax in other comprehensiveincome (loss). Realized gains and losses, amortization of premiums and discounts and interest and dividends earned are includedin income (expense). For declines in the fair value of equity securities that are considered other-than-temporary, impairmentlosses are charged to other (income) expense, net. The Company considers available evidence in evaluating potential impairmentsof its investments, including the duration and extent to which fair value is less than cost. There were no deemed permanent impairmentsat December 31, 2020 or 2019.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_11" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueOfFinancialInstrumentsPolicy-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          TheCompany’s marketable securities are highly liquid and consist of U.S. government agency securities, high-grade corporateobligations and commercial paper with original maturities of more than 90 days. As of December 31, 2020 and 2019, all of the Company’sinvestments had contractual maturities which were less than one year. The following table summarizes the amortized cost, unrealizedgains and losses and the fair value at December 31, 2020 and 2019:
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 93; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      10
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_12" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-428" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:MarketableSecuritiesTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueOfFinancialInstrumentsPolicy-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: left">
              <span style="text-decoration:underline">
              </span>
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
             <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Amortized
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Cost
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
              </p>
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
             <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Gross
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Unrealized
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Losses
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               </span>
              </p>
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
             <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Gross Unrealized
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Gains
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               </span>
              </p>
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
             <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center">
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                <b>
                 Fair Value
                </b>
               </span>
              </p>
              <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
               <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               </span>
              </p>
             </td>
             <td style="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: bottom; text-align: left">
              <span style="text-decoration:underline">
               December 31, 2020:
              </span>
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
             <td colspan="2" style="vertical-align: bottom; text-align: center">
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
             <td colspan="2" style="vertical-align: bottom; text-align: center">
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
             <td colspan="2" style="vertical-align: bottom; text-align: center">
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
             <td colspan="2" style="vertical-align: bottom; text-align: center">
             </td>
             <td style="text-align: center; vertical-align: bottom">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">
              Money Market Funds and Cash Equivalents
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c38" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-430" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,182,762
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c39" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-431" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                81
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
              )
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c39" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-432" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                8
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c38" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-433" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,182,689
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Corporate Securities
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c40" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-434" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,565,501
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c41" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-435" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,005
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
              )
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c41" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-436" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c40" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-437" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,564,499
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Commercial Paper
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c42" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-438" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                879,501
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-79">
               <span>
                <ix:nonfraction contextref="c43" continued-taxonomy="false" data-original-id="hidden-fact-79" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-439" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c43" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-440" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                72
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c42" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-441" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                879,573
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Subtotal
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c44" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-442" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                4,445,002
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c45" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-443" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,005
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
              )
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c45" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-444" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                75
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c44" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-445" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                4,444,072
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total December 31, 2020
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-446" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                7,627,764
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-447" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,086
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
              )
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-448" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                83
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-449" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                7,626,761
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; text-align: left">
              December 31, 2019:
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Money Market Funds and Cash Equivalents
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c46" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-450" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,472,043
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-80">
               <span>
                <ix:nonfraction contextref="c47" continued-taxonomy="false" data-original-id="hidden-fact-80" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-451" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c47" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-452" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                51
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c46" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-453" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,472,094
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              U.S. Government Agency Securities
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c48" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-454" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,691,091
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c49" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-455" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                42
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
              )
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c49" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-456" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                869
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c48" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-457" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,691,918
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Corporate Securities
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c50" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-458" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                6,058,265
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c51" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-459" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,438
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
              )
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c51" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-460" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                440
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c50" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-461" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                6,057,267
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Commercial Paper
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c52" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-462" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,234,583
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c53" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-463" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                16
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
              )
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c53" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-464" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                405
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c52" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-465" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,234,972
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Subtotal
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c54" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-466" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                11,983,939
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c55" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-467" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,496
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
              )
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c55" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-468" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,714
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c54" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-469" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                11,984,157
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total December 31, 2019
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-470" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                15,455,982
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-471" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedLoss" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,496
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
              )
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-472" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesGrossUnrealizedGain" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,765
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-473" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleEquitySecuritiesAmortizedCostBasis" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                15,456,251
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
           </tbody>
          </table>
          <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_13" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-475" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           <i>
            FairValue Measurements
           </i>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_14" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          TheCompany’s financial instruments recorded in the consolidated balance sheets include cash and cash equivalents, accountsreceivable, investment securities, accounts payable and accrued expenses. The carrying value of certain financial instruments,primarily cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their estimated fairvalues based upon the short-term nature of their maturity dates. The Company’s senior secured convertible note (prior toits extinguishment in August 2019) falls into the Level 3 category within the fair value level hierarchy. The fair value was determinedusing market data for valuation.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_15" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          TheCompany categorizes its financial instruments into a three-level fair value hierarchy that prioritizes the inputs to valuationtechniques used to measure fair value, which is set out below. The fair value hierarchy gives the highest priority to quoted pricesin active markets for identical assets (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs usedto measure fair value fall within different levels of the hierarchy, the category level is based on the lowest priority levelinput that is significant to the fair value measurement of the instrument.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_16" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
         <tbody>
          <tr style="vertical-align: top; text-align: justify">
           <td style="width: 0.5in">
           </td>
           <td style="width: 0.25in; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             ●
            </span>
           </td>
           <td style="text-align: justify">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Level1 inputs—Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.
            </span>
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_17" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
         <tbody>
          <tr style="vertical-align: top; text-align: justify">
           <td style="width: 0.5in">
           </td>
           <td style="width: 0.25in; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             ●
            </span>
           </td>
           <td style="text-align: justify">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Level2 inputs— Significant other observable inputs (e.g., quoted prices for similar items in active markets, quoted prices foridentical or similar items in markets that are not active, inputs other than quoted prices that are observable such as interestrate and yield curves, and market-corroborated inputs).
            </span>
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_18" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
         <tbody>
          <tr style="vertical-align: top; text-align: justify">
           <td style="width: 0.5in">
           </td>
           <td style="width: 0.25in; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             ●
            </span>
           </td>
           <td style="text-align: justify">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Level3 inputs—Unobservable inputs for the asset or liability, which are supported by little or no market activity and are valuedbased on management’s estimates of assumptions that market participants would use in pricing the asset or liability.
            </span>
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 94; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      11
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_19" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Thefollowing table provides the carrying value and fair value of the Company’s financial assets measured at fair value as ofDecember 31, 2020 and 2019:
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_20" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-489" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
             </td>
             <td style="font-weight: bold; padding-bottom: 1.5pt">
             </td>
             <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
              Carrying Value
             </td>
             <td style="padding-bottom: 1.5pt; font-weight: bold">
             </td>
             <td style="font-weight: bold; padding-bottom: 1.5pt">
             </td>
             <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
              Level 1
             </td>
             <td style="padding-bottom: 1.5pt; font-weight: bold">
             </td>
             <td style="font-weight: bold; padding-bottom: 1.5pt">
             </td>
             <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
              Level 2
             </td>
             <td style="padding-bottom: 1.5pt; font-weight: bold">
             </td>
             <td style="font-weight: bold; padding-bottom: 1.5pt">
             </td>
             <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
              Level 3
             </td>
             <td style="padding-bottom: 1.5pt; font-weight: bold">
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; text-align: left">
              December 31, 2020:
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt">
              Money Market Funds and Cash Equivalents
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c38" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-491" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,182,689
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c56" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-492" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,182,689
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-81">
               <span>
                <ix:nonfraction contextref="c57" continued-taxonomy="false" data-original-id="hidden-fact-81" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-493" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt">
             </td>
             <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-82">
               <span>
                <ix:nonfraction contextref="c58" continued-taxonomy="false" data-original-id="hidden-fact-82" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-494" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Corporate Securities
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c40" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-495" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,564,499
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-83">
               <span>
                <ix:nonfraction contextref="c59" continued-taxonomy="false" data-original-id="hidden-fact-83" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-496" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c60" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-497" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,564,499
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-84">
               <span>
                <ix:nonfraction contextref="c61" continued-taxonomy="false" data-original-id="hidden-fact-84" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-498" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Commercial Paper
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c42" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-499" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                879,573
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-85">
               <span>
                <ix:nonfraction contextref="c62" continued-taxonomy="false" data-original-id="hidden-fact-85" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-500" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c63" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-501" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                879,573
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-86">
               <span>
                <ix:nonfraction contextref="c64" continued-taxonomy="false" data-original-id="hidden-fact-86" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-502" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Subtotal
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c44" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-503" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                4,444,072
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-87">
               <span>
                <ix:nonfraction contextref="c65" continued-taxonomy="false" data-original-id="hidden-fact-87" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-504" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c66" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-505" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                4,444,072
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-88">
               <span>
                <ix:nonfraction contextref="c67" continued-taxonomy="false" data-original-id="hidden-fact-88" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-506" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total December 31, 2020
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-507" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                7,626,761
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c68" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-508" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,182,689
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c69" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-509" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                4,444,072
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-89">
               <span>
                <ix:nonfraction contextref="c70" continued-taxonomy="false" data-original-id="hidden-fact-89" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-510" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-decoration: underline; text-align: left">
              December 31, 2019:
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Money Market Funds and Cash    Equivalents
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c46" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-511" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,472,094
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c71" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-512" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,472,094
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-90">
               <span>
                <ix:nonfraction contextref="c72" continued-taxonomy="false" data-original-id="hidden-fact-90" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-513" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-91">
               <span>
                <ix:nonfraction contextref="c73" continued-taxonomy="false" data-original-id="hidden-fact-91" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-514" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              U.S. Government Agency Securities
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c48" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-515" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,691,918
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c74" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-516" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,691,918
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-92">
               <span>
                <ix:nonfraction contextref="c75" continued-taxonomy="false" data-original-id="hidden-fact-92" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-517" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-93">
               <span>
                <ix:nonfraction contextref="c76" continued-taxonomy="false" data-original-id="hidden-fact-93" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-518" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Corporate Securities
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c50" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-519" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                6,057,267
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-94">
               <span>
                <ix:nonfraction contextref="c77" continued-taxonomy="false" data-original-id="hidden-fact-94" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-520" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c78" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-521" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                6,057,267
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-95">
               <span>
                <ix:nonfraction contextref="c79" continued-taxonomy="false" data-original-id="hidden-fact-95" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-522" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Commercial Paper
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c52" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-523" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,234,972
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-96">
               <span>
                <ix:nonfraction contextref="c80" continued-taxonomy="false" data-original-id="hidden-fact-96" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-524" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c81" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-525" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                3,234,972
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-97">
               <span>
                <ix:nonfraction contextref="c82" continued-taxonomy="false" data-original-id="hidden-fact-97" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-526" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Subtotal
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c54" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-527" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                11,984,157
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c83" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-528" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,691,918
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c84" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-529" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                9,292,239
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-98">
               <span>
                <ix:nonfraction contextref="c85" continued-taxonomy="false" data-original-id="hidden-fact-98" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-530" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total December 31, 2019
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-531" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                15,456,251
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c86" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-532" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                6,164,012
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c87" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-533" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                9,292,239
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-99">
               <span>
                <ix:nonfraction contextref="c88" continued-taxonomy="false" data-original-id="hidden-fact-99" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-534" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AvailableForSaleSecurities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
           </tbody>
          </table>
          <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_21" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-536" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           <i>
            ForeignCurrency Translation and Transactions
           </i>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_22" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
         The consolidated financialstatements are presented in U.S. Dollars (USD), the reporting currency of the Company. For the financial statements of the Company’sforeign subsidiaries, whose functional currency is the EURO, foreign currency asset and liability amounts, if any, are translatedinto USD at end-of-period exchange rates. Foreign currency income and expenses are translated at average exchange rates in effectduring the year. Translation gains and losses are included in other comprehensive income (loss). The Company had a foreign currencytranslation gain of $
         <span>
          <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-539" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           6,020
          </ix:nonfraction>
         </span>
         in 2020 and a gain of $
         <span>
          <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-540" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           467
          </ix:nonfraction>
         </span>
         in 2019.
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_23" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Foreigncurrency exchange transaction gain (loss) is the result of re-measuring transactions denominated in a currency other than thefunctional currency of the entity recording the transaction.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_24" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-544" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          GeographicInformation
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_25" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Thefollowing table summarizes the geographic information:
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_26" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-548" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               December 31,
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2020
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2019
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">
              Reported revenues
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-550" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Revenues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                239,231
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-551" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Revenues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                283,266
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Revenues attributable to European and Mideast operations, which are based in Germany
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c89" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-552" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Revenues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                237,025
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c90" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-553" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Revenues" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                274,443
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Total assets
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-554" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                49,308,303
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-555" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                29,475,910
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Total assets located in the United States, with the remainder in the European Union
             </td>
             <td>
             </td>
             <td style="text-align: left">
              $
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c91" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-556" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                48,928,244
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
              $
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c92" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-557" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Assets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                28,919,276
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
           </tbody>
          </table>
          <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 95; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      12
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_27" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-559" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          RestrictedCash
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_28" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          As of December 31, 2020, and 2019 the Company has restrictedcash in connection with the patent and utility model infringement proceedings against TauroPharm (see Note 7). The Company wasrequired by the District Court Mannheim to provide a security deposit of approximately $
          <span>
           <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-562" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            135,000
           </ix:nonfraction>
          </span>
          (€
          <span>
           <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-563" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SecurityDeposit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="eur">
            110,000
           </ix:nonfraction>
          </span>
          ) to cover legalfees in the event TauroPharm is entitled to reimbursement of these costs. The Company furthermore had to provide a deposit in theamount of $
          <span>
           <ix:nonfraction contextref="c34" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-564" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:TimeDeposits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            44,000
           </ix:nonfraction>
          </span>
          (€
          <span>
           <ix:nonfraction contextref="c34" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-565" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:TimeDeposits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="eur">
            36,000
           </ix:nonfraction>
          </span>
          ) and $
          <span>
           <ix:nonfraction contextref="c35" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-566" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:TimeDeposits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            12,000
           </ix:nonfraction>
          </span>
          (€
          <span>
           <ix:nonfraction contextref="c35" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-567" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:TimeDeposits" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="eur">
            10,000
           </ix:nonfraction>
          </span>
          ) for the first and second instances, respectively, in connection withthe unfair competition proceedings in Cologne. During the year ended December 31, 2020, the Company reimbursed TauroPharm approximately$
          <span>
           <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-568" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:CashReimbursed" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            30,000
           </ix:nonfraction>
          </span>
          for the costs in connection with the utility model infringement proceedings. In January 2021, approximately $
          <span>
           <ix:nonfraction contextref="c36" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-569" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCash" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            48,000
           </ix:nonfraction>
          </span>
          (€
          <span>
           <ix:nonfraction contextref="c36" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-570" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCash" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="eur">
            40,000
           </ix:nonfraction>
          </span>
          )was released by the court to the Company’s account which will be deducted from the restricted cash.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_29" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_PrepaidExpensesPolicyTextblock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-572" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:PrepaidExpensesPolicyTextblock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          PrepaidResearch and Development and Other Prepaid Expenses
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_30" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_PrepaidExpensesPolicyTextblock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Prepaidexpenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, manufacturing,pre-clinical development and insurance policies. These advanced payments are amortized to expense either as services are performedor over the relevant service period using the straight-line method.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_31" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_InventoryPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-576" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:InventoryPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Inventories,net
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_32" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_InventoryPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_InventoryPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Inventoriesare valued at the lower of cost or net realizable value on a first in, first out basis. Inventories consist of raw materials (includinglabeling and packaging), work-in-process, and finished goods, if any, for the DefenCath product. Inventories consist of the following:
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_33" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-580" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_InventoryPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               December 31,
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2020
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2019
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">
              Raw materials
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-100">
               <span>
                <ix:nonfraction contextref="c3" continued-taxonomy="false" data-original-id="hidden-fact-100" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-582" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryRawMaterials" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-583" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryRawMaterials" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                6,893
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Finished goods
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-584" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryFinishedGoods" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                317,733
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-585" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryFinishedGoods" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                461,735
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Inventory reserve
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-586" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryLIFOReserve" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                174,169
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
              )
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              (
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-587" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryLIFOReserve" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                130,163
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
              )
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-588" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                143,564
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-589" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InventoryNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                338,465
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
           </tbody>
          </table>
          <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_34" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-591" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Propertyand Equipment
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_35" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Propertyand equipment consist primarily of furnishings, fixtures, leasehold improvements, office equipment and computer equipment allof which are recorded at cost. Depreciation is provided for by the straight-line method over the estimated useful lives of therelated assets. Leasehold improvements are amortized using the straight-line method over the remaining lease term or the lifeof the asset, whichever is shorter. Property and equipment, as of December 31, 2020 and 2019 were $
          <span>
           <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-594" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            111,499
           </ix:nonfraction>
          </span>
          and $
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-595" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentNet" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            122,130
           </ix:nonfraction>
          </span>
          , respectively,net of accumulated depreciation of $
          <span>
           <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-596" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            303,279
           </ix:nonfraction>
          </span>
          and $
          <span>
           <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-597" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            244,328
           </ix:nonfraction>
          </span>
          , respectively. Depreciation and amortization of property and equipmentis included in selling, general and administrative expenses.
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_36" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-599" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; width: 80%">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               <b>
                Description
               </b>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; width: 1%">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
             <td style="border-bottom: Black 1.5pt solid; width: 18%; text-align: center">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               <b>
                Estimated    Useful Life
               </b>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; width: 1%">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               Office equipment and furniture
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
             <td style="text-align: center">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               <span>
                <ix:nonnumeric contextref="c93" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-601" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
                 5
                </ix:nonnumeric>
               </span>
               years
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               Leasehold improvements
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
             <td style="text-align: center">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               <span>
                <ix:nonnumeric contextref="c94" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-602" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
                 7
                </ix:nonnumeric>
               </span>
               years
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               Computer equipment
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
             <td style="text-align: center">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               <span>
                <ix:nonnumeric contextref="c95" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-603" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
                 5
                </ix:nonnumeric>
               </span>
               years
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               Computer software
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
             <td style="text-align: center">
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
               <span>
                <ix:nonnumeric contextref="c96" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-604" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
                 3
                </ix:nonnumeric>
               </span>
               years
              </span>
             </td>
             <td>
              <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
              </span>
             </td>
            </tr>
           </tbody>
          </table>
          <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 96; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      13
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_37" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_LesseeLeasesPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-606" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LesseeLeasesPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Leases
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_38" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_LesseeLeasesPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LesseeLeasesPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
         The Company determinesif an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets,current portion of operating lease liabilities (included in accrued expenses), and operating lease liabilities, net of currentportion, on the consolidated balance sheet (see Note 10).
        </p>
        <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_39" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_LesseeLeasesPolicyTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LesseeLeasesPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Operatinglease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease paymentsover the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company uses itsincremental borrowing rate based on the information available at commencement date in determining the present value of futurepayments. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain thatthe Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over thelease term.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_40" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_LesseeLeasesPolicyTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LesseeLeasesPolicyTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">
          TheCompany has elected, as an accounting policy, not to apply the recognition requirements in ASC 842 to short-term leases.
          <span>
           <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-613" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:ShorttermLeasesTermDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
            Short-termleases are leases that have a term of 12 months or less and do not include an option to purchase the underlying asset that theCompany is reasonably certain to exercise. The Company recognizes the lease payments for short-term leases on a straight-linebasis over the lease term.
           </ix:nonnumeric>
          </span>
         </span>
        </p>
        <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_41" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LesseeLeasesPolicyTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">
          TheCompany has also elected, as a practical expedient, by underlying class of asset, not to separate lease components from non-leasecomponents and, instead, account for them as a single component.
         </span>
        </p>
        <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_42" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_AccruedExpensesPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-617" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:AccruedExpensesPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          AccruedExpenses
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_43" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_AccruedExpensesPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_AccruedExpensesPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Accruedexpenses consist of the following:
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_44" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-621" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_AccruedExpensesPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               December 31,
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2020
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2019
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">
              Professional and consulting fees
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-623" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedProfessionalFeesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                146,129
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
              $
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-624" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedProfessionalFeesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                214,777
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Accrued payroll and payroll taxes
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-625" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,490,441
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-626" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                1,287,047
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Clinical trial related
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-627" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AccruedClinicalTrial" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,187
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-628" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AccruedClinicalTrial" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,435,953
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Manufacturing development related
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-629" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AccruedManufacturingDevelopment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                143,780
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-630" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AccruedManufacturingDevelopment" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                806,032
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Other
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-631" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                141,814
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-632" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherAccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                54,666
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-633" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                2,924,351
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
              $
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-634" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AccruedLiabilitiesCurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
                4,798,475
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
           </tbody>
          </table>
          <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
           <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
           </span>
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 97; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      14
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_45" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_RevenueRecognitionPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-636" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:RevenueRecognitionPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           <i>
            RevenueRecognition
           </i>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_46" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_RevenueRecognitionPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          TheCompany uses Accounting Standards Codification (“ASC”) 606, “
          <i>
           Revenue from Contracts with Customers,”
          </i>
          issued by the Financial Accounting Standards Board (“FASB”), that prescribes a five-step model for recognizingrevenue which includes (i) identifying contracts with customers; (ii) identifying performance obligations; (iii) determining thetransaction price; (iv) allocating the transaction price; and (v) recognizing revenue.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_47" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          TheCompany recognizes net sales upon shipment of product to the dialysis centers and upon meeting the five-step model prescribedby ASC 606 outlined above.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_48" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_RevenueRecognitionDeferredRevenue-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-642" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:RevenueRecognitionDeferredRevenue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           <i>
            DeferredRevenue
           </i>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_49" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_RevenueRecognitionDeferredRevenue-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
         In August 2014, theCompany entered into an exclusive distribution agreement (the “Wonik Agreement”) with Wonik Corporation, a South Koreancompany, to market, sell and distribute Neutrolin for hemodialysis and oncolytic patients upon receipt of regulatory approval inSouth Korea. Upon execution, Wonik paid the Company a non-refundable $
         <span>
          <ix:nonfraction contextref="c37" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-645" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredRevenueRefundPayments1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           50,000
          </ix:nonfraction>
         </span>
         payment and will pay an additional $
         <span>
          <ix:nonfraction contextref="c37" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-646" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredRevenueAdditions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
           50,000
          </ix:nonfraction>
         </span>
         upon receiptof the product registration necessary to sell Neutrolin in South Korea (the “Territory”). The term of the Wonik Agreementcommenced on August 8, 2014 and will continue for three years after the first commercial sale of Neutrolin in the Territory. Thenon-refundable up-front payment has been recorded as deferred revenue and will be recognized as revenue on a straight-line basisover the contractual term of the Agreement. Deferred revenue related to this agreement was fully amortized at December 31, 2020.
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_50" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-648" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:EarningsPerSharePolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          LossPer Common Share
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_51" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_EarningsPerSharePolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Basicloss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstandingduring the period. Diluted loss per common share reflects the potential dilution that could occur if securities or other contractsto issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then sharedin the earnings of the entity.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_52" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_EarningsPerSharePolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          TheCompany’s outstanding shares of Series E preferred stock entitle the holders to receive dividends on a basis equivalentto the dividends paid to holders of common stock. As a result, the Series E preferred stock meet the definition of participatingsecurities requiring the application of the two-class method. Under the two-class method, earnings available to common shareholders,including both distributed and undistributed earnings, are allocated to each class of common stock and participating securitiesaccording to dividends declared and participating rights in undistributed earnings, which may cause diluted earnings per shareto be more dilutive than the calculation using the treasury stock method. No loss has been allocated to these participating securitiessince they do not have contractual obligations that require participation in the Company’s losses.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_53" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_EarningsPerSharePolicyTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Sincethe Company has only incurred losses, basic and diluted loss per share are the same as potentially dilutive shares have been excludedfrom the calculation of diluted net loss per share as their effect would be anti-dilutive. The shares outstanding at the end ofthe respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutiveeffect:
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_54" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-656" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <span>
         <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_EarningsPerSharePolicyTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
           <tbody>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="6" style="text-align: center">
              <b>
               Number of Shares of Common Stock Issuable    At
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               December 31,
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2020
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
             <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">
              <b>
               2019
              </b>
             </td>
             <td style="padding-bottom: 1.5pt">
              <b>
              </b>
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">
              Series C non-voting preferred stock
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c97" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-658" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                104,000
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
             <td style="width: 1%">
             </td>
             <td style="width: 1%; text-align: left">
             </td>
             <td style="width: 9%; text-align: right">
              <span>
               <ix:nonfraction contextref="c98" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-659" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                104,000
               </ix:nonfraction>
              </span>
             </td>
             <td style="width: 1%; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Series E voting preferred stock
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c99" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-660" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                391,953
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c100" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-661" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                391,953
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Series G voting preferred stock
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c101" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-662" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                5,560,137
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c102" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-663" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                5,560,137
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Restricted stock units
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <div style="-sec-ix-hidden: hidden-fact-101">
               <span>
                <ix:nonfraction contextref="c103" continued-taxonomy="false" data-original-id="hidden-fact-101" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-664" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="shares" xsi:nil="true">
                 -
                </ix:nonfraction>
               </span>
              </div>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c104" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-665" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                2,490
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Shares issuable for payment of deferred board compensation
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c105" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-666" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                48,909
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c106" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-667" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                33,597
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">
              Shares underlying outstanding warrants
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c107" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-668" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                183,148
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
             <td>
             </td>
             <td style="text-align: left">
             </td>
             <td style="text-align: right">
              <span>
               <ix:nonfraction contextref="c108" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-669" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                341,328
               </ix:nonfraction>
              </span>
             </td>
             <td style="text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">
              Shares underlying outstanding stock options
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c109" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-670" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                2,447,687
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
             <td style="padding-bottom: 1.5pt">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: left">
             </td>
             <td style="border-bottom: Black 1.5pt solid; text-align: right">
              <span>
               <ix:nonfraction contextref="c110" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-671" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                1,376,394
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 1.5pt; text-align: left">
             </td>
            </tr>
            <tr style="vertical-align: bottom; ">
             <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">
              Total potentially dilutive shares
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-672" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                8,735,834
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
             <td style="padding-bottom: 4pt">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: left">
             </td>
             <td style="border-bottom: Black 4pt double; text-align: right">
              <span>
               <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-673" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
                7,809,899
               </ix:nonfraction>
              </span>
             </td>
             <td style="padding-bottom: 2pt; text-align: left">
             </td>
            </tr>
           </tbody>
          </table>
          <p style="margin-top: 0; margin-bottom: 0">
          </p>
         </ix:continuation>
        </span>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 98; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      15
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="margin-top: 0; margin-bottom: 0">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_55" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-675" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <i>
           Stock-BasedCompensation
          </i>
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_56" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Share-basedcompensation cost is measured at grant date, based on the estimated fair value of the award using the Black-Scholes option pricingmodel for options with service or performance-based conditions. Stock-based compensation is recognized as expense over the requisiteservice period on a straight-line basis or when the achievement of the performance condition is probable.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_57" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-679" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Researchand Development
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_58" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          Researchand development costs are charged to expense as incurred. Research and development include fees associated with operational consultants,contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory researchorganizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilitiesexpenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial andthe invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in theperiod when actual costs become known. Costs related to the acquisition of technology rights and patents for which developmentwork is still in process are charged to operations as incurred and considered a component of research and development expense.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_59" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_IncomeTaxPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-683" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:IncomeTaxPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          IncomeTaxes
         </span>
        </p>
        <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_60" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">
          Deferredtax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financialstatement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilitiesare measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences areexpected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognizedin income in the period that includes the enactment date. Valuation allowances are established when it is more likely than notthat some or all of the deferred tax assets will not be realized.
         </span>
        </p>
        <p style="font: italic 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_61" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-687" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           <i>
            RecentlyAdopted Authoritative Pronouncements
           </i>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_62" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          InJune 2016, the Financial Accounting Standards Board (“FASB”) issued new guidance which replaces the incurred lossimpairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of abroader range of reasonable and supportable information to inform credit loss estimates. This adoption on January 1, 2020 didnot have a material impact on the Company’s consolidated financial statements.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_63" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          InAugust 2018, the FASB issued new guidance which modifies the disclosure requirements on fair value measurements. The guidancewas effective for the Company beginning in the first quarter of fiscal year 2020. This adoption on January 1, 2020 did not havea material impact on the Company’s consolidated financial statements.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_64" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          InNovember 2018, the FASB issued new guidance to clarify the interaction between the authoritative guidance for collaborative arrangementsand revenue from contracts with customers. The new guidance clarifies that, when the collaborative arrangement participant isa customer in the context of a unit-of-account, revenue from contracts with customers guidance should be applied, adds unit-of-accountguidance to collaborative arrangements guidance, and, in a transaction with a collaborative arrangement participant who is nota customer, precludes presenting the transaction together with revenue recognized under contracts with customers. The guidancewas effective for the Company beginning in the first quarter of fiscal year 2020. This adoption on January 1, 2020 did not havea material impact on the Company’s consolidated financial statements.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 99; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      16
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_65" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          InNovember 2019, the FASB issued new guidance which requires that an entity measure and classify share-based payment awards grantedto a customer by applying the guidance in FASB ASC 718. The guidance was effective for the Company beginning in the first quarterof fiscal year 2020. This adoption on January 1, 2020 did not have a material impact on the Company’s consolidated financialstatements.
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_66" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_RecentAuthoritativePronouncementsPolicyTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-697" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:RecentAuthoritativePronouncementsPolicyTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          <b>
           <i>
            RecentAuthoritative Pronouncements
           </i>
          </b>
         </span>
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_RecentAuthoritativePronouncementsPolicyTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
          InDecember 2019, the FASB issued new guidance which removes certain exceptions to the general principles of the accounting for incometaxes and also improves consistent application of and simplification of other areas when accounting for income taxes. The guidanceis effective for the company beginning in the first quarter of fiscal year 2021. Early adoption is permitted. The Company is assessingthe impact of adopting this guidance on its consolidated financial statements.
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-700" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note4 — Related Party Transactions:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnAugust 14, 2019,
        <span>
         <ix:nonnumeric contextref="c111" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-702" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:DeconsolidationRelatedPartyDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the Company entered into an exchange agreement (the “Exchange Agreement”) with Manchester SecuritiesCorp. (“Manchester”), an existing institutional investor and a wholly owned subsidiary of Elliott Associates, L.P.(together with Manchester, “Elliott”), who collectively beneficially own the largest portion of the Company’scommon stock, pursuant to which Elliott agreed to exchange all of its outstanding warrants, its 10% senior secured convertiblenote and its shares of Series C-2 preferred stock, Series D preferred stock and Series F preferred stock, and make a cash paymentof $2.0 million to the Company, for 100,000 shares of Series G preferred stock (see Notes 6 and 8).
         </ix:nonnumeric>
        </span>
        On September 6, 2019, theCompany completed the transactions contemplated by the Exchange Agreement.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnDecember 31, 2018, the Company entered into a securities purchase agreement with Elliott, for the purchase and sale of a
        <span>
         <ix:nonfraction contextref="c112" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-704" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % seniorsecured convertible note in the aggregate principal amount of $
        <span>
         <ix:nonfraction contextref="c112" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-705" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          7,500,000
         </ix:nonfraction>
        </span>
        and a warrant to purchase up to an aggregate of
        <span>
         <ix:nonfraction contextref="c112" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-706" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          90,000
         </ix:nonfraction>
        </span>
        shares of the Company’s common stock, for gross proceeds of $
        <span>
         <ix:nonfraction contextref="c112" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-707" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          7,500,000
         </ix:nonfraction>
        </span>
        (see Note 6).
        <span>
         <ix:nonnumeric contextref="c112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-708" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SaleOfStockDescriptionOfTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          The warrant with a grant date fairvalue of $
          <span>
           <ix:nonfraction contextref="c113" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-709" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WarrantsAndRightsOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
            433,365
           </ix:nonfraction>
          </span>
          , is immediately exercisable, has an exercise price of $
          <span>
           <ix:nonfraction contextref="c113" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-710" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
            7.50
           </ix:nonfraction>
          </span>
          per share, subject to adjustment in the event ofstock dividends and distributions, stock splits, stock combinations, or reclassifications affecting our common stock, and hasa term of five years. The note has a conversion price of $7.50 per share.
         </ix:nonnumeric>
        </span>
        The conversion price is subject to appropriate adjustmentin the event of stock dividends and distributions, stock splits, stock combinations, or reclassifications affecting our commonstock. As of December 31, 2019, this note is no longer outstanding as a result of the Exchange Agreement (see Notes 6 and 8).
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        InMay 2013, the Company issued a warrant to purchase up to
        <span>
         <ix:nonfraction contextref="c114" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-712" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:WarrantIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          100,000
         </ix:nonfraction>
        </span>
        shares of the Company’s common stock to Elliott.
        <span>
         <ix:nonnumeric contextref="c115" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-713" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SaleOfStockDescriptionOfTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          The warranthad an expiration date of May 30, 2019. In May 2019, to allow the Company and Elliott time to discuss and possibly conclude theExchange Agreement, the Company extended the expiration date of the warrant to July 1, 2019, which was subsequently extended toAugust 16, 2019.
         </ix:nonnumeric>
        </span>
        The warrant, which was canceled in connection with the terms of the Exchange Agreement, had an exercise priceof $
        <span>
         <ix:nonfraction contextref="c115" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-714" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WarrantExercisePriceIncrease" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          0.005
         </ix:nonfraction>
        </span>
        (see Note 6). The incremental value of the warrant extended was immaterial.
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-715" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:IncomeTaxDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <b>
         Note5 — Income Taxes:
        </b>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany’s U.S. and foreign loss before income taxes are set forth below:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-718" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-align: center">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            December 31,
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom">
           <td style="text-align: center">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            2020
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            2019
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="width: 76%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">
            United States
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c117" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-719" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              20,605,821
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
            )
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c118" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-720" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              20,943,703
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
            )
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in">
            Foreign
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c119" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-721" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              591,257
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c120" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-722" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              550,149
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-align: left; padding-bottom: 2pt; text-indent: -0.125in; padding-left: 0.25in">
            Total
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-723" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              27,197,078
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
            )
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-724" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              21,493,852
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
            )
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 100; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      17
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Therewere no current or deferred income tax provision for the years ended December 31, 2020 and 2019 because the Company has incurredoperating losses since inception.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany’s deferred tax assets consist of the following:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-728" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            December 31,
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            2020
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            2019
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">
            Net operating loss carryforwards – Federal
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-729" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              38,986,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-730" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              33,494,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Net operating loss carryforwards – State
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-731" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              2,958,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-732" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              6,171,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Net operating loss carryforwards – Foreign
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-733" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              2,455,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-734" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              2,128,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Capitalized licensing fees
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-735" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:DeferredTaxAssetsCapitalizedLicensingFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              600,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-736" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:DeferredTaxAssetsCapitalizedLicensingFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              757,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Stock-based compensation
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-737" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              3,358,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-738" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              2,892,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Accrued compensation
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-739" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              102,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-740" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              349,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">
            Other
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-741" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              21,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-742" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOther" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              24,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">
            Totals
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-743" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              48,480,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-744" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              45,815,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">
            Less valuation allowance
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-745" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:IncomeTaxReconciliationChangesInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              48,480,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-746" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:IncomeTaxReconciliationChangesInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              45,815,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">
            Deferred tax assets
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <div style="-sec-ix-hidden: hidden-fact-102">
             <span>
              <ix:nonfraction contextref="c3" continued-taxonomy="false" data-original-id="hidden-fact-102" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-747" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
               -
              </ix:nonfraction>
             </span>
            </div>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <div style="-sec-ix-hidden: hidden-fact-103">
             <span>
              <ix:nonfraction contextref="c4" continued-taxonomy="false" data-original-id="hidden-fact-103" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-748" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" ishiddenelement="true" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usd" xsi:nil="true">
               -
              </ix:nonfraction>
             </span>
            </div>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany had the following potentially utilizable net operating loss tax carryforwards:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-751" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            December 31,
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            2020
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            2019
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 75%; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Federal
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c121" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-752" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              185,650,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c122" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-753" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              155,400,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             State
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c123" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-754" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              41,600,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c124" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-755" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              82,700,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Foreign
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c125" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-756" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              8,185,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c126" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-757" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLossCarryforwards" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              7,091,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_8" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The net operating lossesgenerated will start to expire in 2026 for Federal purposes whereas the operating losses for state purposes will begin expiringin 2038. The Tax Cuts and Jobs Act of 2017 (the “Act”) limits the net operating loss deduction to
       <span>
        <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-759" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
         80
        </ix:nonfraction>
       </span>
       % of taxable incomefor losses arising in tax years beginning after December 31, 2017. However, the net operating losses now have an indefinite carryforwardas opposed to the former 20-year carryforward. The foreign net operating loss tax carryforwards do not expire. Our federal andstate operating loss carryforwards include windfall tax deductions from stock option exercises.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_10" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_9" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Theutilization of the Company’s net operating losses may be subject to a substantial limitation due to the “change ofownership provisions” under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may resultin the expiration of the net operating loss carryforwards before their utilization.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_11" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_10" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany’s foreign earnings are derived from its German subsidiary. The Company does not expect any foreign earnings to berepatriated in the U.S. in the near future.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 101; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      18
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_12" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_11" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany’s effective tax rate varied from the statutory rate as follows:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_13" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_12" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-764" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">
            <b>
            </b>
           </td>
           <td colspan="6" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
            <b>
             December 31,
            </b>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: center; vertical-align: bottom">
            <b>
            </b>
           </td>
          </tr>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
            <b>
             2020
            </b>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">
            <b>
             2019
            </b>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold; vertical-align: bottom">
            <b>
            </b>
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">
            Statutory federal tax rate
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-765" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              21.0
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
            %
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-766" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              21.0
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
            %
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            State income tax rate (net of federal)
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-767" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              4.3
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-768" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              7.2
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Effect of foreign operations
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-769" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0.7
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-770" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0.8
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Federal deferred tax rate change
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-771" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0.5
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-772" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0.1
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            NJ NOL adjustment
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-773" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              2.9
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-774" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              6.2
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Other permanent differences
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-775" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="pure">
              0.6
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            )%
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-776" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="pure">
              0.4
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            )%
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">
            Effect of valuation allowance
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-777" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="pure">
              9.8
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )%
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-778" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" sign="-" tabindex="18" unitref="pure">
              11.3
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )%
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">
            Effective tax rate
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-779" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              19.0
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
            %
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-780" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              23.6
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
            %
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_14" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_13" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Inassessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portionor all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon thegeneration of future taxable income of the appropriate character during the periods in which those temporary differences becomedeductible and the loss carryforwards are available to reduce taxable income. In making its assessment, the Company consideredall sources of taxable income including carryback potential, future reversals of existing deferred tax liabilities, prudent andfeasible tax planning strategies, and lastly, objectively verifiable projections of future taxable income exclusive of reversingtemporary differences and carryforwards. At December 31, 2020 and 2019, the Company maintained a full valuation allowance againstits net deferred tax assets. The Company will continue to assess all available evidence during future periods to evaluate therealization of its deferred tax assets.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_15" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_14" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Thefollowing table presents the changes in the deferred tax asset valuation allowance for the periods indicated:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_16" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_15" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-784" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:ScheduleOfTheChangesInTheDeferredTaxAssetValuationAllowanceTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">
            Year Ended
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Balance at Beginning of Year
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Increase (Decrease) Charged (Credited) to Income Taxes (Benefit)
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Increase (Decrease) Charged (Credited) to OCI
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Balance at End of Year
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="width: 52%; padding-bottom: 2pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             December 31, 2020
            </span>
           </td>
           <td style="width: 1%; padding-bottom: 2pt; text-align: left">
           </td>
           <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-785" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              45,815,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; padding-bottom: 2pt; text-align: left">
           </td>
           <td style="width: 1%; padding-bottom: 4pt">
           </td>
           <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-786" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              2,696,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; padding-bottom: 2pt; text-align: left">
           </td>
           <td style="width: 1%; padding-bottom: 4pt">
           </td>
           <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-787" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:IncreaseDecreaseChargedCreditedToOCI" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              31,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; padding-bottom: 2pt; text-align: left">
            )
           </td>
           <td style="width: 1%; padding-bottom: 4pt">
           </td>
           <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="width: 9%; border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-788" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              48,480,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="padding-bottom: 2pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             December 31, 2019
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c11" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-789" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              43,396,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-790" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              2,449,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-791" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="true" isstandardonly="false" istextonly="false" name="crmd:IncreaseDecreaseChargedCreditedToOCI" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
              30,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
            )
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-792" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DeferredTaxAssetsValuationAllowance" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              45,815,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_17" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_16" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Accountingfor uncertainty in income taxes requires uncertain tax positions to be classified as non-current income tax liabilities unlessthey are expected to be paid within one year. The Company has concluded that there are no uncertain tax positions requiring recognitionin its consolidated financial statements as of December 31, 2020 and 2019. The Company recognizes interest and penalties relatedto uncertain tax positions if any as a component of income tax expense.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_18" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_17" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany files income tax returns in the U.S. federal, state and foreign jurisdictions. Tax years 2014 to 2018 remain open to examinationfor both the U.S. federal and state jurisdictions. Tax years 2015 to 2018 remain open for Germany.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_IncomeTaxDisclosureTextBlock-c0_cont_18" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Duringthe years ended December 31, 2020 and 2019, the Company received net proceeds of $
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-796" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          5,169,395
         </ix:nonfraction>
        </span>
        and $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-797" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="true" isstandardonly="true" istextonly="false" name="us-gaap:IncomeTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" sign="-" tabindex="18" unitref="usd">
          5,060,778
         </ix:nonfraction>
        </span>
        , respectively, fromthe sale of most of its remaining unused New Jersey net operating losses (“NOL”) eligible for sale under the Stateof New Jersey’s Economic Development Authority’s New Jersey Technology Business Tax Certificate Transfer program (“NJEDAProgram”). The NJEDA Program allowed the Company to sell $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-798" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:OtherSales" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          5,529,000
         </ix:nonfraction>
        </span>
        of its total $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-799" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          6,018,000
         </ix:nonfraction>
        </span>
        in available NOL tax benefitsfor the state fiscal year 2019 and $
        <span>
         <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-800" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:OtherSales" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          5,413,000
         </ix:nonfraction>
        </span>
        of its total $
        <span>
         <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-801" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherTaxExpenseBenefit" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          6,085,000
         </ix:nonfraction>
        </span>
        for the state fiscal year 2018.
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 102; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      19
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-802" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:DebtDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <b>
         Note6 — Senior Secured Convertible Note, Related Party:
        </b>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       On December 31, 2018,the Company entered into a securities purchase agreement with Elliott for the purchase and sale of a
       <span>
        <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-804" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:PercentageOfSecuredConvertibleNote" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
         10
        </ix:nonfraction>
       </span>
       % senior secured convertiblenote in the aggregate principal amount of $
       <span>
        <ix:nonfraction contextref="c11" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-805" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DebtInstrumentFaceAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         7,500,000
        </ix:nonfraction>
       </span>
       and a warrant to purchase up to an aggregate of
       <span>
        <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-806" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:WarrantPurchase" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
         90,000
        </ix:nonfraction>
       </span>
       shares of the Company’scommon stock, for gross proceeds of $
       <span>
        <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-807" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:GrossProceeds" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         7,500,000
        </ix:nonfraction>
       </span>
       . For year ended December 31, 2019, $
       <span>
        <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-808" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:InterestAndDebtExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         462,000
        </ix:nonfraction>
       </span>
       was recognized as interest expense onthe consolidated statement of operations and comprehensive loss. The senior secured convertible note, including accrued interest,and warrant to purchase up to an aggregate of
       <span>
        <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-809" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:WarrantPurchase" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
         90,000
        </ix:nonfraction>
       </span>
       shares of the Company’s common stock were cancelled in connection withthe terms of the Exchange Agreement.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Onthe same date, and in connection with the sale of the note and warrant,
        <span>
         <ix:nonnumeric contextref="c116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-811" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:WarrantsIssuedDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the Company amended and restated the following warrantsheld by Elliott and its affiliates to reduce the exercise price of each warrant to $0.005 per share: warrants issued in May 2013to purchase up to an aggregate of 100,000 shares of the Company’s common stock with a pre-amendment exercise price of $3.25per share and an expiration date of May 30, 2019, which was subsequently extended to August 16, 2019 (the “May 30, 2019Warrants”), (see Note 4); and warrants issued in October 2013 to purchase up to an aggregate of 150,000 shares of the Company’scommon stock with a pre-amendment exercise price of $4.50 per share and an expiration date of October 22, 2019 (the “October22, 2019 Warrants”).
         </ix:nonnumeric>
        </span>
        These warrants were subsequently cancelled in connection with the Exchange Agreement, (see Note 8).
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Alsoin conjunction with the December 2018 securities purchase agreement, the Company and Elliott and certain of its affiliates thathold shares of various series of the Company’s preferred stock and warrants to purchase shares of the Company’s commonstock agreed to waive any rights of conversion or exercise for all of the shares of its Series C-2, D, E and F preferred stockand shares issuable upon the exercise of certain warrants (collectively with the shares of Series C-2, D, E, and F preferred stock,the “Elliott Derivative Securities”), until the earliest to occur of (i) the effective date on which the Company’sCertificate of Incorporation is amended to increase the number of authorized shares of common stock, (ii) the effective date onwhich the Company effects a reverse stock split of its common stock, (iii) one business day immediately prior to the consummationof a fundamental transaction (as defined in the instruments governing the applicable Elliott Derivative Securities), and (iv)April 30, 2019. The 1-for-5 reverse stock split that was effective on March 26, 2019 satisfied this condition, however, with theexception of the Series E preferred stock, the Elliot Derivative Securities were cancelled in connection with the Exchange Agreement.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 103; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      20
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany was required to have a majority of the Series C-2, Series D, Series E and Series F non-voting preferred stock consentto any indebtedness other than trade payables incurred in the ordinary course of business consistent with past practice, and lettersof credit incurred in an aggregate amount of $
        <span>
         <ix:nonfraction contextref="c11" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-814" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LettersOfCreditOutstandingAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          3,000,000
         </ix:nonfraction>
        </span>
        at any point in time. At the time of the securities purchase agreement,Elliott was the holder of all of the shares of the Series C-2, Series D, Series E and Series F non-voting preferred stock andimplicitly consented to the convertible note financing. Elliott is currently the holder of all of the shares of the Series E andSeries G preferred stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        The$
        <span>
         <ix:nonfraction contextref="c127" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-816" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:GrossProceeds" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          7,500,000
         </ix:nonfraction>
        </span>
        in gross proceeds, along with the legal fees of approximately $
        <span>
         <ix:nonfraction contextref="c127" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-817" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:LegalFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          267,000
         </ix:nonfraction>
        </span>
        , were allocated between the senior secured convertiblenote and warrants based on their relative fair values. The portion of the proceeds allocated to the warrants of approximately$
        <span>
         <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-818" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          396,000
         </ix:nonfraction>
        </span>
        , net of allocated fees of approximately $
        <span>
         <ix:nonfraction contextref="c11" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-819" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AdditionalsPaidInCapital" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          6,000
         </ix:nonfraction>
        </span>
        , was accounted for as additional paid-in capital. The remainder of theproceeds of approximately $
        <span>
         <ix:nonfraction contextref="c127" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-820" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NetAllocatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          7,000,000
         </ix:nonfraction>
        </span>
        , net of allocated fees of approximately $
        <span>
         <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-821" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NetAllocatedFees" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          103,000
         </ix:nonfraction>
        </span>
        was allocated to the senior convertiblenote, with the fair value of the warrants resulting in a debt discount. In addition, the incremental cost of approximately $
        <span>
         <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-822" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:IncrementalCostOfApproximately" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          710,000
         </ix:nonfraction>
        </span>
        associated with the warrant modification was recorded as a debt discount. An additional debt discount of approximately $
        <span>
         <ix:nonfraction contextref="c127" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-823" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AmortizationOfDebtDiscountsPremium" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          143,000
         </ix:nonfraction>
        </span>
        was recorded as a beneficial conversion feature as the stock price was greater than the effective conversion price (after allocationof the total proceeds) on the measurement date.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Thedebt discount was being amortized to interest expense using the effective interest method in accordance with ASC 835 over theterm of the agreement. For the year ended December 31, 2019, approximately $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-825" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AmortizationOfDebtDiscountsPremium" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          313,000
         </ix:nonfraction>
        </span>
        was recognized as amortization of debt discountand is included in interest expense on the consolidated statement of operations and comprehensive loss.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany used a hybrid valuation model to determine the fair value of the senior secured convertible note. The hybrid model incorporatedboth a present value analysis and the use of the Black Scholes option pricing model to reflect the senior secured convertiblenote’s conversion feature. The Black-Scholes option pricing model was also used to determine the fair value of the warrantsin order to allocate the gross proceeds based on relative fair values (see Note 1). ASC 820,
        <i>
         “Fair Value Measurements,”
        </i>
        states that the reporting entity should use the valuation technique(s) appropriate for the measurement, considering the availabilityof data with which to develop inputs that represent the assumptions that market participants would use when pricing the assetor liability. Market participants price options based on expected volatility, not historical volatility. In estimating the expectedvolatility of the Company’s common stock, the Company followed the guidance of ASC 820 and considered a number of factors- including the implied volatility of put and call options on the Company’s common stock that are traded over the counter.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_8" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Asummary of the assumptions used in the Black Scholes pricing model are as follows:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_DebtDisclosureTextBlock-c0_cont_10" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_9" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-829" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfDebtTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
            Conversion Option
            <br/>
            At Issuance Date
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
            New Warrants
            <br/>
            At Issuance Date
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 78%; text-align: left">
            Expected term (months)
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 9%; text-align: center">
            <span>
             <ix:nonnumeric contextref="c128" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:durmonth" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-830" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              36
             </ix:nonnumeric>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 9%; text-align: center">
            <span>
             <ix:nonnumeric contextref="c107" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:durmonth" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-831" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              60
             </ix:nonnumeric>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Volatility
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span>
             <ix:nonfraction contextref="c128" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-832" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              161.5
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span>
             <ix:nonfraction contextref="c107" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-833" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              161.5
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Dividend yield
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span>
             <ix:nonfraction contextref="c128" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-834" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span>
             <ix:nonfraction contextref="c107" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-835" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExpectedDividendRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Risk-free interest rate
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span>
             <ix:nonfraction contextref="c128" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-836" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentsAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              2.43
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span>
             <ix:nonfraction contextref="c107" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-837" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentsAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              2.48
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 104; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      21
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_DebtDisclosureTextBlock-c0_cont_10" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">
        Aspart of
        <span>
         <ix:nonnumeric contextref="c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-839" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:ExpectedTermDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the Exchange Agreement, the senior secured convertible note, along with certain warrants and the Series C-2, Series Dand Series F preferred stock, and the payment of $2,000,000, was exchanged for 100,000 shares of Series G preferred stock. Asa result of this transaction, the Company recognized a deemed dividend of $26,733,098 on its consolidated statement of operationsand comprehensive loss for the year ended December 31, 2019 (see Note 8).
         </ix:nonnumeric>
        </span>
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-840" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note7 — Commitments and Contingencies:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">
        <i>
         ContingencyMatters
        </i>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnSeptember 9, 2014, the Company filed in the District Court of Mannheim, Germany, a patent infringement action against TauroPharmGmbH and Tauro-Implant GmbH as well as their respective CEOs (the “Defendants”) claiming infringement of the Company’sEuropean Patent EP 1 814 562 B1, which was granted by the European Patent Office (the “EPO”) on January 8, 2014 (the“Prosl European Patent”). The Prosl European Patent covers the formulation of taurolidine and citrate with low doseheparin in a catheter lock solution for maintaining patency and preventing infection in hemodialysis catheters. In this action,the Company claims that the Defendants infringe on the Prosl European Patent by manufacturing and distributing catheter lockingsolutions to the extent they are covered by the claims of the Prosl European Patent. The Company believes that its patent is soundand is seeking injunctive relief and raising claims for information, rendering of accounts, calling back, destruction and damages.Separately, TauroPharm has filed an opposition with the EPO against the Prosl European Patent alleging that it lacks novelty andinventive step. The Company cannot predict the ultimate outcome of either of these related matters. At present, the EPO has revokedthe Prosl European Patent as invalid, and the Company has filed an appeal, which is currently pending.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Inthe same complaint against the same Defendants, the Company also alleged an infringement (requesting the same remedies) of NDPartners’ utility model DE 20 2005 022 124 U1 (the “Utility Model”), which the Company believes is fundamentallyidentical to the Prosl European Patent in its main aspects and claims. The Court separated the two proceedings and the Prosl EuropeanPatent and the Utility Model claims were tried separately. TauroPharm has filed a cancellation action against the Utility Modelbefore the German Patent and Trademark Office (the “German PTO”) based on the similar arguments as those in the oppositionagainst the Prosl European Patent.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCourt issued its decisions on May 8, 2015, staying both proceedings. In its decisions, the Court found that the commercializationby TauroPharm in Germany of its TauroLock catheter lock solutions Hep100 and Hep500 infringes both the Prosl European Patent andthe Utility Model and further that there is no prior use right that would allow TauroPharm to continue to make, use or sell itsproduct in Germany. However, the Court declined to issue an injunction in favor of the Company that would preclude the continuedcommercialization by TauroPharm based upon its finding that there is a sufficient likelihood that the EPO, in the case of theProsl European Patent, or the German PTO, in the case of the Utility Model, may find that such patent or utility model is invalid.Specifically, the Court noted the possible publication of certain instructions for product use that may be deemed to constituteprior art. As such, the District Court determined that it will defer any consideration of the request by the Company for injunctiveand other relief until such time as the EPO or the German PTO made a final decision on the underlying validity of the Prosl EuropeanPatent and the Utility Model.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Theopposition proceeding against the Prosl European Patent before the EPO is ongoing. The EPO held a hearing in the opposition proceedingon November 25, 2015. However, the EPO did not issue a decision at the end of the hearing but adjourned the matter due to thefact that the panel was of the view that Claus Herdeis, one of the managing directors of TauroPharm, had to be heard as a witnessin a further hearing in order to close some gaps in the documentation presented by TauroPharm as regards the publication of theprior art.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 105; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      22
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheGerman PTO held a hearing in the validity proceedings relating to the Utility Model on June 29, 2016, at which the panel affirmedits preliminary finding that the Utility Model was invalid based upon prior publication of a reference to the benefits that maybe associated with adding heparin to a taurolidine based solution. The Company filed an appeal against the ruling on September7, 2016. An oral hearing was held on September 17, 2019 in which the German Federal Patent Court affirmed the first instance decisionthat the Utility Model was invalid. The decision has only a declaratory effect, as the Utility Model had expired in November 2015.On April 28, 2020, the Company filed a withdrawal of the complaint on the German utility model, thereby waiving its claims onthese proceedings.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnNovember 22, 2017, the EPO in Munich, Germany held a further oral hearing in this matter. At the hearing, the panel held thatthe Prosl European Patent would be invalidated because it did not meet the requirements of novelty based on a technical aspectof the European intellectual property law. The Company disagrees with this decision and has appealed the decision. The Companycontinues to believe that the Prosl European Patent is indeed novel and that its validity should be maintained. There can be noassurance that the Company will prevail in this matter. In addition, the ongoing Unfair Competition litigation brought by theCompany against TauroPharm is not affected and will continue.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnJanuary 16, 2015, the Company filed a complaint against TauroPharm GmbH and its managing directors in the District Court of Cologne,Germany. In the complaint, the Company alleges violation of the German Unfair Competition Act by TauroPharm for the unauthorizeduse of its proprietary information obtained in confidence by TauroPharm. The Company alleges that TauroPharm is improperly andunfairly using its proprietary information relating to the composition and manufacture of Neutrolin, in the manufacture and saleof TauroPharm’s products TauroLock
        <sup>
         TM
        </sup>
        , TauroLock-HEP100 and TauroLock-HEP500. The Company seeks a cease and desistorder against TauroPharm from continuing to manufacture and sell any product containing taurolidine (the active pharmaceuticalingredient (“API”) of Neutrolin) and citric acid in addition to possible other components, damages for any sales inthe past and the removal of all such products from the market. An initial hearing in the District Court of Cologne, Germany washeld on November 19, 2015 to consider the Company’s claims. In this hearing, the presiding judge explained that the courtneeded more information with regard to several aspects of the case. As a consequence, the Court issued an interim decision inthe form of a court order outlining several issues of concern that relate primarily to the court’s interest in clarifyingthe facts and reviewing any and all available documentation, in particular with regard to the question which specific know-howwas provided to TauroPharm by whom and when. A further oral hearing in this matter was held on November 15, 2016. In this hearing,the court heard arguments from CorMedix and TauroPharm concerning the allegations of unfair competition. On March 7, 2017, theCourt issued another interim decision in the form of a court order outlining again several issues relating to the argumentationof both sides in the proceedings. Both parties have submitted further writs in this matter and the Court scheduled a further hearingon May 8, 2018. After having been rescheduled several times, the hearing took place on November 20, 2018. A decision was renderedby the court on December 11, 2018, dismissing the complaint in its entirety. However, the Company intends to continue to pursuethis matter, and still believes firmly that its claims are well-founded. The Company therefore appealed in January 2019 and filedits grounds of appeal in March 2019. An oral hearing was held on September 6, 2019 in which the legal counsel of the Company broughtforward further arguments for the fact that the manufacturing process of the respective catheter locking solution is indeed protectableas a trade secret. In view of these new arguments, the Court issued an evidentiary order on September 27, 2019 ordering an expertopinion. The expert opinion was not in the Company’s favor but the Company has filed a response to the expert opinion inreaction to which the Court asked the expert to supplement his opinion to address the issues brought forward in the Company’ssubmission. In the supplementary expert opinion, the expert confirmed his view. The Company has filed a response and an oral hearinghas been scheduled for February 5, 2021 but was postponed to June 18, 2021 due to the COVID19 situation in Germany.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Inconnection with the aforementioned patent and utility model infringement and unfair competition proceedings against TauroPharm,the Company was required by the District Courts of Mannheim and Cologne to provide security deposits to cover legal fees in theevent TauroPharm is entitled to reimbursement of these costs. As of December 31, 2020, the aggregate deposit was approximately$
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-850" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AggregateDepositAmount" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          191,000
         </ix:nonfraction>
        </span>
        , which the Company recorded as restricted cash on the consolidated balance sheets. During the year ended December 31,2020, costs in connection with the utility model infringement proceedings of approximately $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-851" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:CashReimbursed" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          30,000
         </ix:nonfraction>
        </span>
        was reimbursed to TauroPharm
        <b>
         .
        </b>
        In January 2021, approximately $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-852" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:RestrictedCashNoncurrent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          48,000
         </ix:nonfraction>
        </span>
        was released by the court to the Company’s account which will be deducted fromrestricted cash.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 106; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      23
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <b>
         <i>
          Commitments
         </i>
        </b>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <span style="text-decoration:underline">
         In-Licensing
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        In2008, the Company entered into a License and Assignment Agreement (the “NDP License Agreement”) with ND Partners,LLP (“NDP”). Pursuant to the NDP License Agreement, NDP granted the Company exclusive, worldwide licenses for certainantimicrobial catheter lock solutions, processes for treating and inhibiting infections, a biocidal lock system and a taurolidinedelivery apparatus, and the corresponding United States and foreign patents and applications (the “NDP Technology”).The Company acquired such licenses and patents through its assignment and assumption of NDP’s rights under certain separatelicense agreements by and between NDP and Dr. Hans-Dietrich Polaschegg, Dr. Klaus Sodemann and Dr. Johannes Reinmueller. As considerationin part for the rights to the NDP Technology, the Company paid NDP an initial licensing fee of $
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-856" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:AmountOfInitialLicensingFee" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          325,000
         </ix:nonfraction>
        </span>
        and granted NDP a
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-857" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:PercentageOfEquityInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          5
         </ix:nonfraction>
        </span>
        % equityinterest in the Company, consisting of
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-858" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:SharesOfEquityOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          7,996
         </ix:nonfraction>
        </span>
        shares of the Company’s common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany is required to make payments to NDP upon the achievement of certain regulatory and sales-based milestones. Certain ofthe milestone payments are to be made in the form of shares of common stock currently held in escrow for NDP, and other milestonepayments are to be paid in cash. The maximum aggregate number of shares issuable upon achievement of milestones is
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-860" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          29,109
         </ix:nonfraction>
        </span>
        shares.In 2014, a certain milestone was achieved resulting in the release of
        <span>
         <ix:nonfraction contextref="c129" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-861" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NumberOfSharesReleasedInEscrow" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          7,277
         </ix:nonfraction>
        </span>
        shares held in escrow. The number of shares held inescrow as of December 31, 2020 is
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-862" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NumberOfShareHeldInEscrowOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          21,832
         </ix:nonfraction>
        </span>
        shares of common stock. The maximum aggregate amount of cash payments due upon achievementof milestones is $
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-863" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:MaximumAggregateAmountOfCashPaymentsDue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          3,000,000
         </ix:nonfraction>
        </span>
        with the balance being $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-864" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:MaximumAggregateAmountOfCashPaymentsDue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,500,000
         </ix:nonfraction>
        </span>
        as of December 31, 2020 and 2019. Events that trigger milestonepayments include but are not limited to the reaching of various stages of regulatory approval and upon achieving certain worldwidenet sales amounts. There were no milestones achieved during the years ended December 31, 2020 and 2019.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheNDP License Agreement may be terminated by the Company on a country-by-country basis upon 60 days prior written notice. If theNDP License Agreement is terminated by either party, the Company’s rights to the NDP Technology will revert back to NDP.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <span style="text-decoration:underline">
         Other
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       The Company enteredinto a seven-year operating lease agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights, New Jersey07922. The lease agreement, with a monthly average of approximately $
       <span>
        <ix:nonfraction contextref="c130" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-868" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForLeasingCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         17,000
        </ix:nonfraction>
       </span>
       commenced on September 16, 2020. The Company’ssublease on its previous premises at 400 Connell Drive, Berkeley Heights, New Jersey 07922 terminated on November 30, 2020 (seeNote 10).
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-869" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note8 — Stockholders’ Equity:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        CommonStock:
       </span>
      </p>
      <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       On July 30, 2020, theCompany completed an underwritten public offering of its common stock, par value $
       <span>
        <ix:nonfraction contextref="c131" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-872" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
         0.001
        </ix:nonfraction>
       </span>
       per share, which yielded net proceeds ofapproximately $
       <span>
        <ix:nonfraction contextref="c132" continued-taxonomy="false" decimals="-5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-873" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="usd">
         21.3
        </ix:nonfraction>
       </span>
       million. The public offering was made pursuant to an underwriting agreement with SunTrust Robinson Humphrey,Inc. and JMP Securities LLC (collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of
       <span>
        <ix:nonfraction contextref="c133" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-874" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:CommonStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
         5,111,110
        </ix:nonfraction>
       </span>
       shares of common stock, including
       <span>
        <ix:nonfraction contextref="c133" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-875" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:CommonStockShareIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
         666,666
        </ix:nonfraction>
       </span>
       shares of common stock pursuant to the full exercise of the Underwriters’option to purchase additional shares, at a public offering price of $
       <span>
        <ix:nonfraction contextref="c131" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-876" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockPricePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
         4.50
        </ix:nonfraction>
       </span>
       per share. The offering was made pursuant to the Company’seffective registration statement on Form S-3 Registration Statement No. 333-223562 previously filed with and declared effectiveby the SEC and a prospectus supplement and accompanying prospectus filed with the SEC.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 107; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      24
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:nonnumeric contextref="c134" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-877" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:NewAtmAgreementDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
         The Company had a prior sales agreement with FBR Securities, Inc., (formerly known as B. Riley FBR, Inc.) (“B. Riley”)for its ATM program, which expired on April 16, 2018, under which the Company could issue and sell up to an aggregate of $60.0million of shares of its common stock. On March 9, 2018, the Company entered into a new agreement with B. Riley for the sale ofup to $14.7 million of the Company’s common stock under the ATM program, pursuant to a registration statement filed on March9, 2018 for an aggregate of $70 million of the Company’s securities, which became effective on April 16, 2018. This new ATMagreement replaced a prior sales agreement with B. Riley that expired on April 16, 2018. The ATM program amount was increased by$25.0 million in November 2018. Under the ATM program, the Company may issue and sell common stock from time to time through B.Riley acting as agent, subject to limitations imposed by the Company and subject to B. Riley’s acceptance, such as the numberor dollar amount of shares registered under the registration statement to which the offering relates. B. Riley is entitled to acommission of up to 3% of the gross proceeds from the sale of common stock sold under the ATM program. During the years ended December31, 2020 and 2019, the Company sold 1,854,970 and 1,768,012 shares of common stock under the new and expired ATM programs, respectively,and realized net proceeds of approximately $11.4 million and $15.2 million during the years ended December 31, 2020 and 2019, respectively.At December 31, 2020, this current ATM program and the current shelf registration for the issuance of equity, debt or equity-linkedsecurities has been exhausted.
        </p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
         <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
         </span>
        </p>
       </ix:continuation>
      </span>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        InNovember 2020,
        <span>
         <ix:nonnumeric contextref="c135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-880" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:NewAtmAgreementDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the Company filed a new registration statement, under which the Company could issue and sell up to an aggregateof $100.0 million of shares of its common stock, $0.001 par value per share. On November 27, 2020, the Company entered into anAmended and Restated At Market Issuance Sales Agreement (“Amended Sales Agreement”) with B. Riley and Needham &amp;Company, LLC (“Needham”), together with B. Riley, acting as sales agents (“Sales Agent”). The AmendedSales Agreement relates to the sale of shares of up to $25.0 million of the Company’s common stock under its ATM program, of which the Companymay issue and sell common stock from time to time through the Sales Agent, subject to limitations imposed by the Company and subjectto Sales Agent’s acceptance, such as the number or dollar amount of shares registered under the registration statement towhich the offering relates. Sales Agent is entitled to a commission of up to 3% of the gross proceeds from the sale of commonstock sold under the ATM program. During the year ended December 31, 2020, the Company sold 832,676 shares of common stock underthe Amended Sales Agreement at the weighted average price of $8.69 per share and realized net proceeds of approximately $7.0 million.At December 31, 2020, the Company had approximately $17.8 million available under the Amended Sales Agreement and $75.0 millionavailable under its current shelf registration for the issuance of equity, debt or equity-linked securities unrelated to the AmendedSales Agreement.
         </ix:nonnumeric>
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <b>
         <i>
          RestrictedStock Units
         </i>
        </b>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       During the year endedDecember 31, 2020 the Company did not grant any restricted stock units (“RSUs”) and granted an aggregate of
       <span>
        <ix:nonfraction contextref="c136" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-883" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:RestrictedStockUnitsIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
         24,850
        </ix:nonfraction>
       </span>
       RSUs during the year ended December 31, 2019 to its officers and directors under its 2013 Stock Incentive Plan with a weightedaverage grant date fair value of $
       <span>
        <ix:nonfraction contextref="c136" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-884" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:WeightedAverageGrantDateFairValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
         8.33
        </ix:nonfraction>
       </span>
       per share. The fair value of each RSU was estimated to be the closing price of the Company’scommon stock on each date of grant. These RSUs vest monthly over one year after grant date, subject to continued service on theboard through the vesting date. During the year ended December 31, 2020 and 2019, compensation expense recorded for these RSUswas $
       <span>
        <ix:nonfraction contextref="c137" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-885" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         11,000
        </ix:nonfraction>
       </span>
       and $
       <span>
        <ix:nonfraction contextref="c138" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-886" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         198,000
        </ix:nonfraction>
       </span>
       , respectively. There was no unrecognized compensation expense as of December 31, 2020 as all RSU’soutstanding had vested. At December 31, 2020, there are no RSUs outstanding.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Duringthe years ended December 31, 2020 and 2019, the Company issued an aggregate of
        <span>
         <ix:nonfraction contextref="c136" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-888" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:IssuanceOfVestedRestrictedStockShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          2,490
         </ix:nonfraction>
        </span>
        and
        <span>
         <ix:nonfraction contextref="c139" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-889" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:IssuanceOfVestedRestrictedStockShares" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          25,346
         </ix:nonfraction>
        </span>
        shares of its common stock uponthe vesting of restricted stock units issued to the Company’s board of directors, respectively.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 108; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      25
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
      </b>
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <b>
         <i>
          PreferredStock
         </i>
        </b>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
        TheCompany is authorized to issue up to
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-892" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          2,000,000
         </ix:nonfraction>
        </span>
        shares of preferred stock in one or more series without stockholder approval. TheCompany’s board of directors has the discretion to determine the rights, preferences, privileges and restrictions, includingvoting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferredstock. Of the
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-893" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesAuthorized" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          2,000,000
         </ix:nonfraction>
        </span>
        shares of preferred stock authorized, the Company’s board of directors has designated (all withpar value of $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-894" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          0.001
         </ix:nonfraction>
        </span>
        per share) the following:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font: 10pt Times New Roman, Times, Serif">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-896" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfPreferredUnitsTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">
            <b>
             As of December 31, 2020
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="10" style="text-align: center; border-bottom: Black 1.5pt solid">
            <b>
             As of December 31, 2019
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
          </tr>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: center">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <b>
              Preferred    Shares Outstanding
             </b>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <b>
              Liquidation    Preference
              <br/>
              (Per Share)
             </b>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <b>
              Total    Liquidation Preference
             </b>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <b>
              Preferred    Shares Outstanding
             </b>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <b>
              Liquidation    Preference
              <br/>
              (Per Share)
             </b>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
           <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <b>
              Total    Liquidation Preference
             </b>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt">
            <b>
            </b>
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 28%; text-align: left">
            Series C-3
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c166" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-897" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              52,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c166" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-898" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreference" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              10.00
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c166" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-899" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              520,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c167" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-900" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              52,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c167" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-901" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreference" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              10.00
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c167" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-902" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              520,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Series E
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c150" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-903" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              89,623
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c150" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-904" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreference" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              49.20
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c150" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-905" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              4,409,452
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c168" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-906" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              89,623
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c168" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-907" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreference" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              49.20
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c168" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-908" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              4,409,452
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">
            Series G
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            <span>
             <ix:nonfraction contextref="c169" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-909" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              100,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            $
           </td>
           <td style="padding-bottom: 1.5pt; text-align: right">
            <span>
             <ix:nonfraction contextref="c169" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-910" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreference" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              187.36
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            <span>
             <ix:nonfraction contextref="c169" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-911" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              18,736,452
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            <span>
             <ix:nonfraction contextref="c170" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-912" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              100,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            $
           </td>
           <td style="padding-bottom: 1.5pt; text-align: right">
            <span>
             <ix:nonfraction contextref="c170" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-913" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreference" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              187.36
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            <span>
             <ix:nonfraction contextref="c170" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-914" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              18,736,452
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">
            Total
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-915" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              241,623
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 2pt; text-align: right">
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-916" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              23,665,904
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-917" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockSharesOutstanding" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              241,623
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 2pt; text-align: right">
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-918" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockLiquidationPreferenceValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              23,665,904
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       On November 9, 2017,the Company entered into a securities purchase agreement which, on November 16, 2017, resulted in the Company selling $
       <span>
        <ix:nonfraction contextref="c140" continued-taxonomy="false" decimals="-6" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-920" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="usd">
         2
        </ix:nonfraction>
       </span>
       .0 millionof its Series F preferred stock (“Series F Stock”) at $
       <span>
        <ix:nonfraction contextref="c140" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-921" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:EarningsPerShareBasic" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
         1,000
        </ix:nonfraction>
       </span>
       per share. All outstanding shares of Series F Stock werecancelled in connection with the terms of the Exchange Agreement, as described below.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnAugust 14, 2019, the Company entered into the Exchange Agreement with Elliott, pursuant to which Elliott agreed to exchange allof its outstanding warrants, its
        <span>
         <ix:nonfraction contextref="c111" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-923" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % senior secured convertible note and its shares of Series C-2 preferred stock, Series D preferredstock and Series F preferred stock, and make a cash payment of $
        <span>
         <ix:nonfraction contextref="c141" continued-taxonomy="false" decimals="-6" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-924" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:Cash" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="6" selected-taxonomy="false" tabindex="18" unitref="usd">
          2
         </ix:nonfraction>
        </span>
        .0 million to the Company, for
        <span>
         <ix:nonfraction contextref="c142" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-925" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          100,000
         </ix:nonfraction>
        </span>
        shares of Series G preferredstock, with an aggregate liquidation preference of $
        <span>
         <ix:nonfraction contextref="c142" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-926" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ProceedsFromIssuanceOfCommonStock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          18,736,452
         </ix:nonfraction>
        </span>
        , which are convertible into an aggregate of
        <span>
         <ix:nonfraction contextref="c141" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-927" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConvertibleCommonStockSharesIssuedUponConversion" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          5,560,138
         </ix:nonfraction>
        </span>
        shares ofthe Company’s common stock at a conversion price of $
        <span>
         <ix:nonfraction contextref="c141" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-928" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConvertiblePerSharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          3.37
         </ix:nonfraction>
        </span>
        per share. Elliott retained the shares of the Company’scommon stock and Series E preferred stock that it held at the time of the consummation of the Exchange Agreement. Other than withrespect to conversion price and liquidation preference, the Series G preferred stock has substantially the same terms as the Company’soutstanding Series E preferred stock, including the restrictive covenants contained therein as modified as set forth in the ExchangeAgreement. However, Elliott is prohibited from converting the Series G preferred stock into shares of the Company’s commonstock to the extent that, as a result of such conversion, Elliott would own more than
        <span>
         <ix:nonfraction contextref="c143" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-929" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          4.99
         </ix:nonfraction>
        </span>
        % of the total number of shares of theCompany’s common stock then issued and outstanding. The shares of Series G preferred stock are entitled to vote on an as-convertedbasis with respect to the number of shares of common stock into which they are convertible, based upon an assumed conversion price,solely for the purpose of the voting rights, equal to $
        <span>
         <ix:nonfraction contextref="c144" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-930" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:CommonStockPerSharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          7.93
         </ix:nonfraction>
        </span>
        , the closing price of the Company’s common stock on August 14,2019, and the Series E preferred stock was modified to provide for similar rights to vote on an as-converted basis. The Companyfiled the Certificate of Designation of the Series G preferred stock and the Second Amended and Restated Certificate of Designationof the Series E preferred stock with the Secretary of State of the State of Delaware on September 5, 2019. On September 6, 2019,the Company closed this transaction and issued the Series G preferred stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Pursuantto the terms of the Exchange Agreement, the exchange of the Series C-2 preferred stock, Series D preferred stock, Series F preferredstock and the
        <span>
         <ix:nonfraction contextref="c145" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-932" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:seniorSecuredConvertibleNote" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % senior secured convertible note was considered an extinguishment. As a result, the difference between the fairvalue allocated to the Series G preferred stock and the carrying value of the Series C-2 preferred stock, Series D preferred stock,Series F preferred stock and the
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-933" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:seniorSecuredConvertibleNote" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % senior secured convertible note is being treated as a deemed dividend and is added to netloss to arrive at loss available to common stockholders.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheSeries G preferred stock was valued using the Black Scholes option pricing model. The Black-Scholes option pricing model was alsoused to determine the fair value of the warrants and the Series C-2 preferred stock, Series D preferred stock and Series F preferredstock. These fair values, along with the fair value of the
        <span>
         <ix:nonfraction contextref="c142" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-935" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % senior secured convertible note were utilized to allocate the fairvalue of the Series G preferred stock based on relative fair values. ASC 820, Fair Value Measurements, states that the reportingentity should use the valuation technique(s) appropriate for the measurement, considering the availability of data with whichto develop inputs that represent the assumptions that market participants would use when pricing the asset or liability. Marketparticipants price options based on expected volatility, not historical volatility. In estimating the expected volatility of theCompany’s common stock, the Company followed the guidance of ASC 820 and considered a number of factors - including theimplied volatility of the Company’s listed warrant contracts.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 109; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      26
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Asummary of the assumptions used in the Black Scholes pricing model are as follows:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-938" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 89%; text-align: left">
            Expected term, years
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-939" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:PreferredStockExpectedTerm" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              3.0
             </ix:nonnumeric>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Volatility
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-940" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:PreferredStockExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              93.3
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Dividend yield
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-941" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:PreferredStockExpectedDividendRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0.0
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            Risk-free interest rate
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-942" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:PreferredStockRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              1.53
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            %
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Asa result of the Exchange Agreement, the Company recognized a deemed dividend of $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-944" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherInterestAndDividendIncome" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          26,733,098
         </ix:nonfraction>
        </span>
        .
        <span>
         <ix:nonnumeric contextref="c146" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-945" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:ExchangeAgreementDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          The deemed dividend was comprisedof (1) a beneficial conversion related to the 10% secured senior convertible note recognized at extinguishment; (2) the differencebetween the allocated fair value of the Series G Preferred Stock issued and the carrying values of the 10% secured senior convertiblenote, the Series C-2 Preferred Stock, Series D Preferred Stock and Series F Preferred Stock; (3) the difference between the fairvalue of the exchanged warrants before and after the Exchange Agreement; and (4) the difference between the fair value and thecarrying value of Series E Preferred Stock, less the fair value of the Series E warrants that were cancelled as part of the ExchangeAgreement.
         </ix:nonnumeric>
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Thefollowing rights, privileges, terms and condition apply to the outstanding preferred stock at December 31, 2020:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <span style="text-decoration:underline">
         SeriesC-3 Non-Voting Preferred Stock
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Rank.
        </i>
        The Series C-3 non-voting preferred stock will rank senior to our common stock; senior to any class or series of capital stockcreated after the issuance of the Series C-3 non-voting preferred stock; and junior to the Series E voting convertible preferredstock in each case, as to dividends or distributions of assets upon our liquidation, dissolution or winding up whether voluntarilyor involuntarily.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Conversion.
        </i>
        Each share of Series C-3 preferred stock is convertible into
        <span>
         <ix:nonfraction contextref="c147" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-950" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          2
         </ix:nonfraction>
        </span>
        shares of our common stock (subject to adjustment in the eventof stock dividends and distributions, stock splits, stock combinations, or reclassifications affecting our common stock) at aper share price of $
        <span>
         <ix:nonfraction contextref="c148" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-951" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConvertiblePerSharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          5.00
         </ix:nonfraction>
        </span>
        at any time at the option of the holder, except that a holder will be prohibited from converting sharesof Series C-3 preferred stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates,would beneficially own more than
        <span>
         <ix:nonfraction contextref="c149" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-952" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          9.99
         </ix:nonfraction>
        </span>
        % of the total number of shares of our common stock then issued and outstanding.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         LiquidationPreference.
        </i>
        In the event of our liquidation, dissolution or winding up, holders of Series C-3 preferred stock will receivea payment equal to $
        <span>
         <ix:nonfraction contextref="c148" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-954" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          10.00
         </ix:nonfraction>
        </span>
        per share of Series C-3 preferred stock before any proceeds are distributed to the holders of our commonstock. After the payment of this preferential amount, and subject to the rights of holders of any class or series of our capitalstock hereafter created specifically ranking by its terms senior to the Series C-3 preferred stock and holders of Series C-3 preferredstock will participate ratably in the distribution of any remaining assets with the common stock and any other class or seriesof our capital stock hereafter created that participates with the common stock in such distributions.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         VotingRights.
        </i>
        Shares of Series C-3 preferred stock will generally have no voting rights, except as required by law and except thatthe consent of holders of two thirds of the outstanding Series C-3 preferred Stock will be required to amend the terms of theSeries C-3 preferred stock or the certificate of designation for the Series C-3 preferred stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         <span style="text-decoration:underline">
          Dividends
         </span>
         .
        </i>
        Holders of Series C-3 preferred stock are entitled to receive, and we are required to pay, dividends on shares of the SeriesC-3 preferred stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividendsin the form of common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividendsin the form of common stock) are paid on shares of the common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         <span style="text-decoration:underline">
          Redemption
         </span>
         .
        </i>
        We are not obligated to redeem or repurchase any shares of Series C-3 preferred stock. Shares of Series C-3 preferred stockare not otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 110; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      27
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         <span style="text-decoration:underline">
          Listing
         </span>
         .
        </i>
        There is no established public trading market for the Series C-3 preferred stock, and we do not expect a market to develop.In addition, we do not intend to apply for listing of the Series C-3 preferred stock on any national securities exchange or tradingsystem.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         <span style="text-decoration:underline">
          FundamentalTransactions
         </span>
         .
        </i>
        If, at any time that shares of Series C-3 preferred stock are outstanding, we effect a merger or other changeof control transaction, as described in the certificate of designation and referred to as a fundamental transaction, then a holderwill have the right to receive, upon any subsequent conversion of a share of Series C-3 preferred stock (in lieu of conversionshares) for each issuable conversion share, the same kind and amount of securities, cash or property as such holder would havebeen entitled to receive upon the occurrence of such fundamental transaction if such holder had been, immediately prior to suchfundamental transaction, the holder of a share of common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <span style="text-decoration:underline">
         SeriesE Voting Convertible Preferred Stock
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Rank.
        </i>
        The Series E voting preferred stock will rank senior to our common stock; senior to any class or series of capital stock createdafter the issuance of the Series E voting convertible preferred stock; senior to the Series C-3 non-voting convertible preferredstock; and on parity with the Series G voting convertible preferred stock in each case, as to dividends or distributions of assetsupon our liquidation, dissolution or winding up whether voluntarily or involuntarily.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Conversion.
        </i>
        Each share of Series E preferred stock is convertible into
        <span>
         <ix:nonfraction contextref="c150" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-963" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          4.3733
         </ix:nonfraction>
        </span>
        shares of our common stock (subject to adjustment as providedin the certificates of designation for the Series E preferred stock) at a per share price of $
        <span>
         <ix:nonfraction contextref="c150" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-964" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          3.75
         </ix:nonfraction>
        </span>
        at any time at the option ofthe holder, except that a holder will be prohibited from converting shares of Series E preferred stock into shares of common stockif, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than
        <span>
         <ix:nonfraction contextref="c151" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-965" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          4.99
         </ix:nonfraction>
        </span>
        % of the totalnumber of shares of our common stock then issued and outstanding.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         LiquidationPreference.
        </i>
        In the event of our liquidation, dissolution or winding up, holders of Series E preferred stock will receive apayment equal to $
        <span>
         <ix:nonfraction contextref="c151" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-967" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          49.20
         </ix:nonfraction>
        </span>
        per share of Series E preferred stock on parity with the payment of the liquidation preference due theSeries G preferred stock, but before any proceeds are distributed to the holders of common stock, and the Series C-3 non-votingconvertible preferred stock. After the payment of this preferential amount, holders of Series E preferred stock will participateratably in the distribution of any remaining assets with the common stock and any other class or series of our capital stock thatparticipates with the common stock in such distributions.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         VotingRights.
        </i>
        Shares of Series E preferred stock are entitled to vote on an as-converted basis, based upon an assumed conversionprice of $
        <span>
         <ix:nonfraction contextref="c150" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-969" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConvertiblePerSharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          7.93
         </ix:nonfraction>
        </span>
        .
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_33" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Dividends.
        </i>
        Holders of Series E preferred stock are entitled to receive, and we are required to pay, dividends on shares of the SeriesE preferred stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividendsin the form of common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividendsin the form of common stock) are paid on shares of the common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_35" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_34" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Redemption.
        </i>
        We are not obligated to redeem or repurchase any shares of Series E preferred stock. Shares of Series E preferred stock arenot otherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_36" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_35" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Listing.
        </i>
        There is no established public trading market for the Series E preferred stock, and we do not expect a market to develop.In addition, we do not intend to apply for listing of the Series E preferred stock on any national securities exchange or tradingsystem.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_37" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_36" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         FundamentalTransactions.
        </i>
        If, at any time that shares of Series E preferred stock are outstanding, we effect a merger or other changeof control transaction, as described in the certificate of designation and referred to as a fundamental transaction, then a holderwill have the right to receive, upon any subsequent conversion of a share of Series E preferred stock (in lieu of conversion shares)for each issuable conversion share, the same kind and amount of securities, cash or property as such holder would have been entitledto receive upon the occurrence of such fundamental transaction if such holder had been, immediately prior to such fundamentaltransaction, the holder of a share of common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 111; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      28
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_38" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_37" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         DebtRestriction.
        </i>
        As long as any of the Series E preferred stock is outstanding, we cannot create, incur, guarantee, assume orsuffer to exist any indebtedness, other than (i) trade payables incurred in the ordinary course of business consistent with pastpractice, and (ii) up to $10 million aggregate principal amount of indebtedness with a maturity less than twelve months outstandingat any time, which amount may include up to $5 million of letters of credit outstanding at any time.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_39" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_38" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         OtherCovenants.
        </i>
        In addition to the debt restrictions above, as long as any of the Series E preferred stock is outstanding, we cannot,among others things: create, incur, assume or suffer to exist any encumbrances on any of our assets or property; redeem, repurchaseor pay any cash dividend or distribution on any of our capital stock (other than as permitted, which includes the dividends onthe Series E preferred stock and Series G preferred stock); redeem, repurchase or prepay any indebtedness (other than as permitted);or engage in any material line of business substantially different from our current lines of business.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_40" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_39" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         PurchaseRights.
        </i>
        In the event we issue any options, convertible securities or rights to purchase stock or other securities pro ratato the holders of common stock, then a holder of Series E preferred stock will be entitled to acquire, upon the same terms a prorata amount of such stock or securities as if the Series E preferred stock had been converted to common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_41" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_40" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <span style="text-decoration:underline">
         SeriesG Voting Convertible Preferred Stock
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_42" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_41" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Rank
        </i>
        .The Series G voting convertible preferred stock will rank senior to our common stock; senior to any class or series of capitalstock created after the issuance of the Series G voting convertible preferred stock; junior to the Series C-3 non-voting convertiblepreferred stock, pending the consent of the holders of such series to the subordination thereof; and on parity with the SeriesE voting convertible preferred stock in each case, as to dividends or distributions of assets upon our liquidation, dissolutionor winding up whether voluntarily or involuntarily.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_43" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_42" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Conversion
        </i>
        .Each share of Series G preferred stock is convertible into approximately
        <span>
         <ix:nonfraction contextref="c152" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-980" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          55.5978
         </ix:nonfraction>
        </span>
        shares of our common stock (subject to adjustmentas provided in the certificate of designation for the Series G preferred stock) at a per share price of $
        <span>
         <ix:nonfraction contextref="c152" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-981" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockParOrStatedValuePerShare" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          3.37
         </ix:nonfraction>
        </span>
        at any time at theoption of the holder, except that a holder will be prohibited from converting shares of Series G preferred stock into shares ofcommon stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than
        <span>
         <ix:nonfraction contextref="c153" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-982" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          4.99
         </ix:nonfraction>
        </span>
        %of the total number of shares of our common stock then issued and outstanding.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_44" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_43" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         LiquidationPreference
        </i>
        . In the event of our liquidation, dissolution or winding up, holders of Series E preferred stock will receive apayment equal to $
        <span>
         <ix:nonfraction contextref="c153" continued-taxonomy="false" decimals="5" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-984" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          187.36452
         </ix:nonfraction>
        </span>
        per share of Series G preferred stock on parity with the payment of the liquidation preference duethe Series E preferred stock, but before any proceeds are distributed to the holders of Series C-3 preferred stock (pending theconsent of the holders of such series to the subordination thereof) and any proceeds are distributed to the holders of commonstock. After the payment of this preferential amount, holders of Series G preferred stock will participate ratably in the distributionof any remaining assets with the common stock and any other class or series of our capital stock that participates with the commonstock in such distributions.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_45" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_44" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         VotingRights
        </i>
        . Shares of Series G preferred stock are entitled to vote on an as-converted basis, based upon an assumed conversionprice of $
        <span>
         <ix:nonfraction contextref="c152" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-986" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ConvertiblePerSharePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          7.93
         </ix:nonfraction>
        </span>
        .
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_46" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_45" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Dividends
        </i>
        .Holders of Series G Preferred stock are entitled to receive, and we are required to pay, dividends on shares of the Series G preferredstock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the formof common stock) actually paid on shares of the common stock when, as and if such dividends (other than dividends in the formof common stock) are paid on shares of the common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_47" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_46" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Redemption
        </i>
        .We are not obligated to redeem or repurchase any shares of Series G preferred stock. Shares of Series G preferred stock are nototherwise entitled to any redemption rights, or mandatory sinking fund or analogous fund provisions.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_48" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_47" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         Listing
        </i>
        .There is no established public trading market for the Series G preferred stock, and we do not expect a market to develop. In addition,we do not intend to apply for listing of the Series G preferred stock on any national securities exchange or trading system.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 112; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      29
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_49" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_48" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         FundamentalTransactions
        </i>
        . If, at any time that shares of Series G preferred stock are outstanding, we effect a merger or other changeof control transaction, as described in the certificate of designation and referred to as a fundamental transaction, then a holderwill have the right to receive, upon any subsequent conversion of a share of Series G preferred stock (in lieu of conversion shares)for each issuable conversion share, the same kind and amount of securities, cash or property as such holder would have been entitledto receive upon the occurrence of such fundamental transaction if such holder had been, immediately prior to such fundamentaltransaction, the holder of a share of common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_50" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_49" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         DebtRestriction
        </i>
        . As long as any of the Series G preferred stock is outstanding, we cannot create, incur, guarantee, assume orsuffer to exist any indebtedness, other than (i) trade payables incurred in the ordinary course of business consistent with pastpractice, and (ii) up to $10 million aggregate principal amount of indebtedness with a maturity less than twelve months outstandingat any time, which amount may include up to $5 million of letters of credit outstanding at any time.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_51" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_50" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         OtherCovenants
        </i>
        . In addition to the debt restrictions above, as long as any of the Series G preferred stock is outstanding, we cannot,among others things: create, incur, assume or suffer to exist any encumbrances on any of our assets or property; redeem, repurchaseor pay any cash dividend or distribution on any of our capital stock (other than as permitted, which includes the dividends onthe Series E preferred stock and the Series G preferred stock); redeem, repurchase or prepay any indebtedness (other than as permitted);or engage in any material line of business substantially different from our current lines of business.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_52" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_51" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <i>
         PurchaseRights
        </i>
        . In the event we issue any options, convertible securities or rights to purchase stock or other securities pro ratato the holders of common stock, then a holder of Series G preferred stock will be entitled to acquire, upon the same terms a prorata amount of such stock or securities as if the Series G preferred stock had been converted to common stock.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_53" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_52" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        StockOptions:
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_54" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_53" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
       On November 26, 2019, the Company’sshareholders approved the CorMedix Inc. 2019 Omnibus Stock Incentive Plan (the “2019 Plan”). Pursuant to the 2019 Plan andsubject to certain adjustments as described below, the Company may issue up to
       <span>
        <ix:nonfraction contextref="c154" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-996" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
         3,000,000
        </ix:nonfraction>
       </span>
       shares of its common stock, plus any shares thatremain available for grant under its 2013 Stock Incentive Plan (the “2013 Plan”) as of the effective date (up to a maximumcarry-forward of
       <span>
        <ix:nonfraction contextref="c154" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-997" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:MaximumNumberOfSharesCarryForward" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
         522,606
        </ix:nonfraction>
       </span>
       shares plus any outstanding options under the 2013 Plan that were canceled, forfeited and expired after the approvalof the 2019 Plan), as long-term equity incentives to the Company’s employees, consultants, and directors. The long-term incentivesmay be in the form of stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights,or other rights or benefits (collectively, stock rights) to employees, consultants, and directors of the Company or a related entity (collectively,participants). The Company believes that the effective use of long- term equity incentives is essential to attract, motivate, and retainemployees, consultants and directors, to further align participants’ interests with those of the Company’s stockholders, andto provide participants incentive compensation opportunities that are competitive with those offered by other companies in the same industryand locations as the Company.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_55" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_54" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
       The 2019 Plan is a new equitycompensation plan for the Company’s employees, consultants, and directors which replaced the 2013 Plan. The 2013 Plan and the Amendedand Restated 2006 Stock Incentive Plan are referred to collectively as the “Prior Plans”. No further awards will be grantedunder the Prior Plans after the approval of the 2019 Plan. Awards outstanding under the Prior Plans will remain outstanding in accordancewith their terms and the Prior Plans.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_56" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_55" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Duringthe year ended December 31, 2020, the Company granted ten-year qualified and non-qualified stock options to its officers, directors,employees and consultants covering an aggregate of
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1000" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ExcessStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          1,111,984
         </ix:nonfraction>
        </span>
        shares of the Company’s common stock under the 2019 Plan. Theweighted average exercise price of these options is $
        <span>
         <ix:nonfraction contextref="c155" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1001" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          5.11
         </ix:nonfraction>
        </span>
        per share.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 113; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      30
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_57" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_56" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Duringthe year ended December 31, 2019, the Company granted ten-year qualified and non-qualified stock options to its officers, directors,employees and consultants covering an aggregate of
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1003" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ExcessStockSharesIssued" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          496,300
         </ix:nonfraction>
        </span>
        shares of the Company’s common stock under the 2013 Plan. Theweighted average exercise price of these options is $
        <span>
         <ix:nonfraction contextref="c156" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1004" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          7.64
         </ix:nonfraction>
        </span>
        per share.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_58" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_57" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1006" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:ExchangeAgreementDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         During the years ended December 31, 2020 and 2019, total compensationexpense for stock options issued to employees, directors, officers and consultants was $2,489,000 and $2,242,000, respectively.
        </ix:nonnumeric>
       </span>
       As of December 31, 2020, there was $
       <span>
        <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1007" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OtherGeneralExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         3,284,000
        </ix:nonfraction>
       </span>
       total unrecognized compensation expense related to unvested stock options grantedwhich expense is expected to be recognized over an expected remaining weighted average period of
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1008" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         1.7
        </ix:nonnumeric>
       </span>
       years. All share-based awardsare recognized on a straight-line method, assuming all awards granted will vest. Forfeitures of share-based awards are recognizedin the period in which they occur.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_59" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_58" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Thefair value at grants dates of the grants issued subject to service and performance-based vesting conditions were determined usingthe Black-Scholes option pricing model with the following assumptions:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_60" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_59" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c171" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1011" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="4" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Year Ended December 31,
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
            2020
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">
            2019
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            Risk-free interest rate
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c172" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1012" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               0.27
              </ix:nonfraction>
             </span>
             % -
             <span>
              <ix:nonfraction contextref="c149" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1013" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               1.67
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c173" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1014" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               1.51
              </ix:nonfraction>
             </span>
             % -
             <span>
              <ix:nonfraction contextref="c174" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1015" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               2.74
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            Expected volatility
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c172" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1016" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               102.7
              </ix:nonfraction>
             </span>
             % -
             <span>
              <ix:nonfraction contextref="c149" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1017" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               107.9
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c173" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1018" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               103
              </ix:nonfraction>
             </span>
             % -
             <span>
              <ix:nonfraction contextref="c174" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1019" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               110
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            Expected term (years)
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonnumeric contextref="c172" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1020" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               5
              </ix:nonnumeric>
             </span>
             –
             <span>
              <ix:nonnumeric contextref="c149" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1021" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               10
              </ix:nonnumeric>
             </span>
             years
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonnumeric contextref="c173" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1022" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               5
              </ix:nonnumeric>
             </span>
             -
             <span>
              <ix:nonnumeric contextref="c174" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1023" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               10
              </ix:nonnumeric>
             </span>
             years
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 66%; text-align: left; vertical-align: top">
            Expected dividend yield
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 15%; text-align: center">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1024" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0.0
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 15%; text-align: center">
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1025" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
              0.0
             </ix:nonfraction>
            </span>
            %
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            Weighted-average grant date fair value of options granted during the period
           </td>
           <td>
           </td>
           <td style="text-align: center">
            $
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1026" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              3.59
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: center">
            $
            <span>
             <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1027" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              6.11
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_61" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_60" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany estimated the expected term of the stock options granted based on anticipated exercises in future periods. The expectedterm of the stock options granted to consultants is based upon the full term of the respective option agreements. The expectedstock price volatility for the Company’s stock options is calculated based on the historical volatility since the initialpublic offering of the Company’s common stock in March 2010. The expected dividend yield of
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1029" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:FairValueOfDividendYield" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          0.0
         </ix:nonfraction>
        </span>
        % reflects the Company’scurrent and expected future policy for dividends on the Company’s common stock. To determine the risk-free interest rate,the Company utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected termof the Company’s awards which is
        <span>
         <ix:nonnumeric contextref="c157" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1030" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          5
         </ix:nonnumeric>
        </span>
        years for employees and
        <span>
         <ix:nonnumeric contextref="c158" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1031" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          10
         </ix:nonnumeric>
        </span>
        years for non-employees.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_62" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_61" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Thefollowing table summarizes the Company’s stock options activity and related information for the year ended December 31,2020:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_63" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_62" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c171" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1034" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">
           </td>
           <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
           </td>
           <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Shares Underlying Stock Options
           </td>
           <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
           </td>
           <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
           </td>
           <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Weighted-
            <br/>
            Average
            <br/>
            Exercise
            <br/>
            Price
           </td>
           <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
           </td>
           <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
           </td>
           <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Weighted-
            <br/>
            Average
            <br/>
            Remaining Contractual Term (Years)
           </td>
           <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
           </td>
           <td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">
           </td>
           <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Aggregate Intrinsic Value
           </td>
           <td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left; vertical-align: top">
            Outstanding at beginning of year
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1035" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              1,376,394
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1036" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              8.98
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1037" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              6.8
             </ix:nonnumeric>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1038" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              1,232,545
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            Granted
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1039" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              1,111,984
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1040" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              5.11
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1041" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              2,585,172
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            Expired/Canceled
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1042" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              6,891
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
            )
           </td>
           <td>
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1043" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              12.53
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <div style="-sec-ix-hidden: hidden-fact-104">
             <span>
              <ix:nonfraction contextref="c0" continued-taxonomy="false" data-original-id="hidden-fact-104" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1044" inside-table="true" isadditionalitemsonly="true" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" ishiddenelement="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" unitref="usdPershares" xsi:nil="true">
               -
              </ix:nonfraction>
             </span>
            </div>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; vertical-align: top">
            Forfeited
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1045" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              33,800
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            $
           </td>
           <td style="padding-bottom: 1.5pt; text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1046" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              8.51
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: right">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1047" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              9,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; vertical-align: top">
            Outstanding at end of year
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1048" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              2,447,687
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1049" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              7.22
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1050" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              7.1
             </ix:nonnumeric>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1051" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              3,872,092
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; vertical-align: top">
            Vested at end of year
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1052" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              1,418,990
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1053" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              8.56
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1054" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermVested" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              5.6
             </ix:nonnumeric>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1055" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              1,683,965
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt; vertical-align: top">
            Expected to vest in the future
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1056" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              1,028,697
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1057" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              5.36
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1058" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              9.1
             </ix:nonnumeric>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1059" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              2,188,127
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_64" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_63" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       No stock options were exercised during the year ended December31, 2020 and for the year ended December 31, 2019, the total intrinsic value of stock options exercised was $
       <span>
        <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1061" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementIntrinsicValue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
         154,589
        </ix:nonfraction>
       </span>
       . The aggregateintrinsic value is calculated as the difference between the exercise prices of the underlying options and the quoted closing priceof the common stock of the Company at the end of the reporting period for those options that have an exercise price below the quotedclosing price.
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 114; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      31
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_65" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_64" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Warrants:
       </span>
      </p>
      <p style="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_66" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_65" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Thefollowing table is the summary of warrant activities:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_67" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_66" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c175" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1065" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Shares Underlying Warrants
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Weighted
            <br/>
            Average
            <br/>
            Exercise
            <br/>
            Price
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
           <td style="font-weight: bold; padding-bottom: 1.5pt">
           </td>
           <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">
            Weighted Average Remaining Contractual Life
           </td>
           <td style="padding-bottom: 1.5pt; font-weight: bold">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 63%; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Outstanding at December 31, 2019
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1066" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              341,328
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1067" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              6.24
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1068" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:WeightedAverageRemainingContractualLifeOutstandingWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              1.42
             </ix:nonnumeric>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Exercised
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1069" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              91,500
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1070" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              4.50
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            -
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Expired
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1071" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              66,680
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="text-align: left">
            $
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1072" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsWeightedAverageExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              12.13
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            -
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2pt; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Outstanding at December 31, 2020
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1073" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
              183,148
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1074" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
              4.96
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1075" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:WeightedAverageRemainingContractualLifeWarrantsGranted" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
              1.61
             </ix:nonnumeric>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_68" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_67" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnDecember 31, 2018,
        <span>
         <ix:nonnumeric contextref="c159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1077" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:WarrantsIssuedDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the Company sold to Elliott a senior secured convertible note in the aggregate principal amount of $7,500,000and a warrant to purchase up to an aggregate of 90,000 shares of common stock, for gross proceeds of $7,500,000. The warrant isimmediately exercisable, has an exercise price of $7.50 per share, subject to adjustment in the event of stock dividends and distributions,stock splits, stock combinations, or reclassifications affecting the Company’s common stock, and has a term of five years(see Note 6). On December 31, 2018, the Company amended and restated the following warrants held by Elliott and its affiliatesto reduce the exercise price of each warrant to $0.001 per share: warrants issued in May 2013 to purchase up to an aggregate of100,000 shares of the Company’s common stock with a pre-amendment exercise price of $3.25 per share and an expiration dateof May 30, 2019 (the “May 30, 2019 Warrants”); and warrants issued in October 2013 to purchase up to an aggregateof 150,000 shares of common stock with a pre-amendment exercise price of $4.50 per share and an expiration date of October 22,2019 (the “October 22, 2019 Warrants”). The incremental cost of approximately $710,000 associated with the warrantmodification was recorded as a debt discount. The senior secured convertible note and warrant to purchase up to an aggregate of90,000 shares of the Company’s common stock were cancelled in connection with the terms of the Exchange Agreement.
         </ix:nonnumeric>
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_69" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_68" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Thefair value of the warrant was determined using a Black-Scholes option pricing model using the following assumptions at the grantdate of the warrant:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_70" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_69" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c175" continued-main-taxonomy="true" continuedat="_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock-c175_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1080" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
         <tbody>
          <tr style="background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top; width: 90%">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Expected    Term
            </span>
           </td>
           <td style="text-align: justify; vertical-align: top; width: 1%">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            </span>
           </td>
           <td style="vertical-align: bottom; width: 9%; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonnumeric contextref="c116" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1081" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:SharebasedCompensationArrangementBySharebasedPaymentsAwardFairValueAssumptionExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               5.0
              </ix:nonnumeric>
             </span>
             years
            </span>
           </td>
          </tr>
          <tr>
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Volatility
            </span>
           </td>
           <td style="text-align: justify; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            </span>
           </td>
           <td style="vertical-align: bottom; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1082" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentsAwardFairValuesAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               102.85
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
          </tr>
          <tr style="background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Dividend yield
            </span>
           </td>
           <td style="text-align: justify; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            </span>
           </td>
           <td style="vertical-align: bottom; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1083" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               0.0
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
          </tr>
          <tr>
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Exercise Price
            </span>
           </td>
           <td style="text-align: justify; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            </span>
           </td>
           <td style="vertical-align: bottom; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             $
             <span>
              <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1084" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:WarrantsExercisePrice" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
               1.50
              </ix:nonfraction>
             </span>
            </span>
           </td>
          </tr>
          <tr style="background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Risk-free interest    rate
            </span>
           </td>
           <td style="text-align: justify; vertical-align: top">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
            </span>
           </td>
           <td style="vertical-align: bottom; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c116" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1085" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestsRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               2.51
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
        </p>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_71" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_70" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        OnSeptember 25, 2019, the Company entered into Letter Agreements with Holders of Series B Warrants. Pursuant to each Letter Agreement,the Company agreed to reduce the exercise price of each Holder’s Series B Warrants from $
        <span>
         <ix:nonfraction contextref="c160" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1087" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WarrantExercisePriceDecrease" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          5.25
         </ix:nonfraction>
        </span>
        to $
        <span>
         <ix:nonfraction contextref="c161" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1088" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WarrantExercisePriceDecrease" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          4.00
         </ix:nonfraction>
        </span>
        , provided that theHolder exercised its Warrant for cash at the time of entry into such Letter Agreement. Each Holder exercised its Series B Warrantsin full and the Company issued an aggregate of
        <span>
         <ix:nonfraction contextref="c162" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1089" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:CommonStockShareIssue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          1,224,263
         </ix:nonfraction>
        </span>
        shares of Common Stock to them. The Company received net proceeds ofapproximately $
        <span>
         <ix:nonfraction contextref="c163" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1090" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:NetProceedsValueOfStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          4,900,000
         </ix:nonfraction>
        </span>
        . As a result of the modification of the exercise price of these warrants, the Company recognized an incrementalvalue of $
        <span>
         <ix:nonfraction contextref="c163" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1091" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          369,500
         </ix:nonfraction>
        </span>
        , which was recorded as a deemed dividend on the consolidated statement of operations and comprehensive lossfor the year ended December 31, 2019, using the Black-Scholes pricing model with the following assumptions:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_72" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_71" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span>
       <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock-c175_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
        <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
         <tbody>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; width: 90%">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Expected term
            </span>
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 9%; text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonnumeric contextref="c163" continued-taxonomy="false" enabled-taxonomy="true" format="ixt-sec:duryear" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1094" inside-table="true" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:SharebasedCompensationArrangementBySharebasedPaymentsAwardFairValueAssumptionExpectedTerm1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
               2.88
              </ix:nonnumeric>
             </span>
             years
            </span>
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Volatility
            </span>
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c163" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1095" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentsAwardFairValuesAssumptionsExpectedVolatilityRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               111.5
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Dividend yield
            </span>
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c163" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1096" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPercentage" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               0.0
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Risk-free interest rate
            </span>
           </td>
           <td>
           </td>
           <td style="text-align: center">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             <span>
              <ix:nonfraction contextref="c163" continued-taxonomy="false" decimals="4" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1097" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionRiskFreeInterestsRate" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
               1.62
              </ix:nonfraction>
             </span>
             %
            </span>
           </td>
          </tr>
         </tbody>
        </table>
        <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
        </p>
       </ix:continuation>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 115; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      32
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued
      </b>
     </span>
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       )
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_73" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_72" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Duringthe year ended December 31, 2019,
        <span>
         <ix:nonnumeric contextref="c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1099" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:WarrantsIssuedDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the expiration date of a warrant to purchase up to 100,000 shares of the Company’s commonstock was extended from May 30, 2019 to August 16, 2019
         </ix:nonnumeric>
        </span>
        , then subsequently canceled in connection with the Exchange Agreementtransaction (see Note 6). The warrant had an exercise price of $
        <span>
         <ix:nonfraction contextref="c164" continued-taxonomy="false" decimals="3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1100" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:WarrantExercisePriceDecrease" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usdPershares">
          0.005
         </ix:nonfraction>
        </span>
        . The incremental value of the warrant extended was immaterial.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_74" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_73" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Duringthe year ended December 31, 2020, the Company issued an aggregate of
        <span>
         <ix:nonfraction contextref="c165" continued-taxonomy="false" decimals="INF" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1102" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:StockIssuedInConnectionWithStockOptionsExercised" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="shares">
          91,500
         </ix:nonfraction>
        </span>
        shares of its common stock upon exercise of warrants,resulting in net proceeds of approximately $
        <span>
         <ix:nonfraction contextref="c165" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1103" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ValueOfStockIssuedInConnectionWithUponExerciseOfWarrants" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          412,000
         </ix:nonfraction>
        </span>
        .
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_75" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_74" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <b>
         <i>
          Stock-basedDeferred Compensation Plan for Non-Employee Directors
         </i>
        </b>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_75" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        In2014, the Company established an unfunded stock-based deferred compensation plan, providing non-employee directors the opportunityto defer up to one hundred percent of fees and compensation, including restricted stock units. The amount of fees and compensationdeferred by a non-employee director is converted into stock units, the number of which is determined based on the closing priceof the Company’s common stock on the date such compensation would have otherwise been payable. At all times, the plan participantsare one hundred percent vested in their respective deferred compensation accounts. On the tenth business day of January in theyear following a director’s termination of service, the director will receive a number of common shares equal to the numberof stock units accumulated in the director’s deferred compensation account. The Company accounts for this plan as stock-basedcompensation under ASC 718. During the year ended December 31, 2020 and 2019, the amount of compensation that was deferred underthis plan was $
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1106" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInDeferredCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          62,250
         </ix:nonfraction>
        </span>
        and $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1107" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:IncreaseDecreaseInDeferredCompensation" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          36,500
         </ix:nonfraction>
        </span>
        , respectively.
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1108" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note9 — Concentrations:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_ConcentrationRiskDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        AtDecember 31, 2020 and 2019, one customer exceeded
        <span>
         <ix:nonfraction contextref="c176" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1110" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          <span>
           <ix:nonfraction contextref="c177" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1111" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
            10
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        % of the Company’s accounts receivable (
        <span>
         <ix:nonfraction contextref="c178" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1112" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          <span>
           <ix:nonfraction contextref="c179" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1113" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
            95
           </ix:nonfraction>
          </span>
         </ix:nonfraction>
        </span>
        %) and at December 31, 2019,no customer exceeded
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1114" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % of the Company’s accounts receivable. During the year ended December 31, 2020, the Company hadrevenue from two customers that exceeded
        <span>
         <ix:nonfraction contextref="c180" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1115" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % of its total sales (
        <span>
         <ix:nonfraction contextref="c181" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1116" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          58
         </ix:nonfraction>
        </span>
        % and
        <span>
         <ix:nonfraction contextref="c182" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1117" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          12
         </ix:nonfraction>
        </span>
        %) and the Company had revenue from four customersthat exceeded
        <span>
         <ix:nonfraction contextref="c183" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1118" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          10
         </ix:nonfraction>
        </span>
        % of its total sales (
        <span>
         <ix:nonfraction contextref="c184" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1119" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          42
         </ix:nonfraction>
        </span>
        %,
        <span>
         <ix:nonfraction contextref="c185" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1120" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          18
         </ix:nonfraction>
        </span>
        %,
        <span>
         <ix:nonfraction contextref="c186" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1121" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          17
         </ix:nonfraction>
        </span>
        % and
        <span>
         <ix:nonfraction contextref="c187" continued-taxonomy="false" decimals="2" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1122" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:ConcentrationRiskPercentage1" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="-2" selected-taxonomy="false" tabindex="18" unitref="pure">
          12
         </ix:nonfraction>
        </span>
        %) for the year ended December 31, 2019.
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1123" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        <b>
         Note10 — Leases:
        </b>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany entered into a
        <span>
         <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1125" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LessorOperatingLeaseDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          seven-year operating lease
         </ix:nonnumeric>
        </span>
        agreement in March 2020 for an office space at 300 Connell Drive, Berkeley Heights,New Jersey 07922. The lease agreement, with a monthly average cost of approximately $
        <span>
         <ix:nonfraction contextref="c130" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1126" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:PaymentsForLeasingCosts" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          17,000
         </ix:nonfraction>
        </span>
        commenced on September 16, 2020.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany’s sublease on its previous premises at 400 Connell Drive, Berkeley Heights, New Jersey 07922 terminated on November30, 2020.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        TheCompany entered into an operating lease for office space in Germany that began in July 2017. The rental agreement has a three-monthterm which automatically renews and includes a monthly cost of 400 Euros. The Company elected to apply the short-term practicalexpedient to the office lease. The Company also has an operating lease for office equipment.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_5" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Operatinglease expense in the Company’s consolidated statements of operations and comprehensive loss for the year ended December31, 2020 and 2019 was approximately $
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1130" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          66,000
         </ix:nonfraction>
        </span>
        and $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1131" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseExpense" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          6,000
         </ix:nonfraction>
        </span>
        , respectively, which includes costs associated with leases for which ROUassets have been recognized as well as short-term leases.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_6" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_5" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        AtDecember 31, 2020 and 2019, the Company has a total operating lease liability of $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1133" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,033,000
         </ix:nonfraction>
        </span>
        and $
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1134" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          4,000
         </ix:nonfraction>
        </span>
        , respectively. At December31, 2020, approximately $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1135" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ClassifiedOperatingLeaseLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          109,000
         </ix:nonfraction>
        </span>
        and $
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1136" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShorttermLeases" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          924,000
         </ix:nonfraction>
        </span>
        were classified as operating lease liabilities, short-term and operating lease liabilities,net of current portion, respectively, on the consolidated balance sheet. At December 31, 2019, approximately $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1137" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:ShorttermLeases" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          2,000
         </ix:nonfraction>
        </span>
        was includedin each operating lease liabilities, short-term and operating lease liabilities, net of current portion on the consolidated balancesheet. Operating ROU assets as of December 31, 2020 and 2019 are $
        <span>
         <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1138" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:OperatingLeaseRightOfUseAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          1,015,000
         </ix:nonfraction>
        </span>
        and $
        <span>
         <ix:nonfraction contextref="c4" continued-taxonomy="false" decimals="-3" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1139" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:OperatingLeaseRightOfUseAssets" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          5,000
         </ix:nonfraction>
        </span>
        , respectively.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 116; Value: 1 -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      33
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">
     <p style="margin: 0pt">
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font: 10pt Times New Roman, Times, Serif">
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">
     <b>
      CORMEDIXINC. AND SUBSIDIARIES
     </b>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
     <span style="font-family: Times New Roman, Times, Serif">
      <b>
       NOTESTO CONSOLIDATED FINANCIAL STATEMENTS, (Continued)
      </b>
     </span>
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_7" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_6" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Forthe year ended December 31, 2020 and 2019, cash paid for amounts included in the measurement of lease liabilities in operatingcash flows from operating leases was $
        <span>
         <ix:nonfraction contextref="c0" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1141" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:MeasurementLeaseLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          48,000
         </ix:nonfraction>
        </span>
        and $
        <span>
         <ix:nonfraction contextref="c5" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1142" inside-table="false" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="false" name="crmd:MeasurementLeaseLiabilities" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
          6,000
         </ix:nonfraction>
        </span>
        , respectively.
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_8" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_7" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Asof December 31, 2020 and 2019,
        <span>
         <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1144" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:WeightedAverageRemainingDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
          the weighted average remaining lease term were 6.8 years and 2.8 years, respectively and the weightedaverage discount rate of 9% and 10% at December 31, 2020 and 2019, respectively.
         </ix:nonnumeric>
        </span>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_LeasesOfLesseeDisclosureTextBlock-c0_cont_9" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_8" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Asof December 31, 2020, maturities of lease liabilities were as follows:
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_LeasesOfLesseeDisclosureTextBlock-c0_cont_9" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
      </span>
      <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
      </span>
      <span>
       <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1147" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18" text-block-taxonomy="true">
        <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
         <tbody>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; width: 87%; text-align: left">
            2021
           </td>
           <td style="width: 1%; text-align: left">
           </td>
           <td style="width: 1%">
           </td>
           <td style="width: 1%; text-align: left">
            $
           </td>
           <td style="width: 9%; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1148" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              198,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="width: 1%; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            2022
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1149" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              200,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            2023
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1150" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              202,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            2024
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1151" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              205,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            2025
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1152" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              208,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             2026 and thereafter
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1153" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              380,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Total future minimum lease payments
            </span>
           </td>
           <td style="text-align: left">
           </td>
           <td>
           </td>
           <td style="text-align: left">
           </td>
           <td style="text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1154" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              1,393,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="text-align: left">
           </td>
          </tr>
          <tr style="vertical-align: bottom; ">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Less imputed interest
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
           </td>
           <td style="padding-bottom: 1.5pt">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: left">
           </td>
           <td style="border-bottom: Black 1.5pt solid; text-align: right">
            (
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1155" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:UnrecordedUnconditionalPurchaseObligationImputedInterest" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              360,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 1.5pt; text-align: left">
            )
           </td>
          </tr>
          <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
           <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2pt; text-align: left">
            <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
             Total
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
           <td style="padding-bottom: 4pt">
           </td>
           <td style="border-bottom: Black 4pt double; text-align: left">
            $
           </td>
           <td style="border-bottom: Black 4pt double; text-align: right">
            <span>
             <ix:nonfraction contextref="c3" continued-taxonomy="false" decimals="0" enabled-taxonomy="true" format="ixt:numdotdecimal" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1156" inside-table="true" isadditionalitemsonly="false" isamountsonly="true" iscalculationsonly="true" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="false" name="us-gaap:OperatingLeaseLiability" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" scale="0" selected-taxonomy="false" tabindex="18" unitref="usd">
              1,033,000
             </ix:nonfraction>
            </span>
           </td>
           <td style="padding-bottom: 2pt; text-align: left">
           </td>
          </tr>
         </tbody>
        </table>
       </ix:nonnumeric>
      </span>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
    </p>
    <div>
    </div>
    <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol.">
    </span>
    <span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol.">
    </span>
    <span>
     <ix:nonnumeric contextref="c0" continued-main-taxonomy="true" continuedat="_SubsequentEventsTextBlock-c0_cont_1" enabled-taxonomy="true" escape="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1157" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SubsequentEventsTextBlock" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
        Note11 — Subsequent Events:
       </span>
      </p>
      <p style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">
       <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
       </span>
      </p>
     </ix:nonnumeric>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SubsequentEventsTextBlock-c0_cont_2" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SubsequentEventsTextBlock-c0_cont_1" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       On February 5, 2021,
       <span>
        <ix:nonnumeric contextref="c188" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1159" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SubsequentEventDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         the Company allocated to its ATM program an additional $25.0 million of the remaining $75.0 million available under its shelfregistration statement. Giving effect to the additional $25.0 million, plus the $17.8 million available at December 31, 2020,the Company had a total of $42.8 million available under the ATM program. During January and February 2021, the Company sold anaggregate of 3,737,862 shares of its common stock under the ATM program and realized net proceeds of approximately $41.5 million.As of the filing of this Annual Report on Form 10-K, the Company has no available balance under its ATM program and it has $50.0million available under its current shelf registration for the issuance of equity, debt or equity-linked securities.
        </ix:nonnumeric>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SubsequentEventsTextBlock-c0_cont_3" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SubsequentEventsTextBlock-c0_cont_2" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
       During thefirst quarter of 2021,
       <span>
        <ix:nonnumeric contextref="c189" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1161" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:AggregateIssuedSharesDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         the Company issued an aggregate of 92,167 shares of its common stock upon cashless exercise of 95,286 warrantsand cash exercise of 21,898 warrants, resulting in net proceeds of $115,000.
        </ix:nonnumeric>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" continuedat="_SubsequentEventsTextBlock-c0_cont_4" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SubsequentEventsTextBlock-c0_cont_3" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
       During the first quarter of 2021,
       <span>
        <ix:nonnumeric contextref="c190" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1163" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="true" isnegativesonly="false" isstandardonly="false" istextonly="true" name="crmd:AggregateIssuedSharesDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         the Company issued an aggregate of 656,069 shares of its common stock upon conversion of 10,001 Series G preferred shares by Elliott and50,000 Series C-3 preferred shares by an unrelated party.
        </ix:nonnumeric>
       </span>
      </p>
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <div>
    </div>
    <span>
     <ix:continuation continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="_SubsequentEventsTextBlock-c0_cont_4" inside-table="false" isadditionalitemsonly="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
      <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
       As previously announced, the NJEDAhas approved the Company’s application to participate in the NJEDA Program for the state fiscal year 2020.
       <span>
        <ix:nonnumeric contextref="c191" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1165" inside-table="false" isadditionalitemsonly="false" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="us-gaap:SubsequentEventDescription" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         The approval willallow the Company to sell approximately $1.3 million of the total $1.3 million in available tax benefits to an unrelated, profitable NewJersey corporation in return for approximately $1.3 million in cash. Closing is subject to NJEDA’s typical closing conditions, whichare in process of completion.
        </ix:nonnumeric>
       </span>
      </p>
     </ix:continuation>
    </span>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">
    </p>
    <div>
    </div>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
     <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
     </span>
    </p>
    <div>
    </div>
    <!-- Field: Page; Sequence: 117; Options: Last -->
    <div>
    </div>
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">
     <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">
      F-
      <!-- Field: Sequence; Type: Arabic; Name: PageNo -->
      34
      <!-- Field: /Sequence -->
     </p>
    </div>
    <div>
    </div>
    <!-- Field: /Page -->
    <div>
    </div>
    <div style="display: none">
     <ix:header>
      <ix:hidden>
       <ix:nonfraction decimals="0" id="hidden-fact-0" unitref="usd">
        208400000
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-1" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-2" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-3" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-4" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-5" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-6" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-7" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-8" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-9" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-10" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-11" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-12" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-13" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-14" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-15" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-16" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-17" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-18" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-19" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-20" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-21" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-22" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-23" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-24" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-25" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-26" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-27" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-28" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-29" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-30" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-31" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-32" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-33" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-34" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-35" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-36" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-37" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-38" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-39" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-40" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-41" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-42" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-43" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-44" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-45" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-46" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-47" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-48" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-49" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-50" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-51" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-52" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-53" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-54" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-55" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-56" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-57" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-58" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-59" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-60" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-61" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-62" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-63" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-64" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-65" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-66" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-67" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-68" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-69" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-70" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-71" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-72" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-73" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-74" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-75" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-76" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-77" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-78" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-79" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-80" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-81" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-82" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-83" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-84" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-85" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-86" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-87" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-88" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-89" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-90" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-91" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-92" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-93" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-94" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-95" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-96" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-97" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-98" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-99" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-100" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-101" unitref="shares" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-102" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-103" unitref="usd" xsi:nil="true">
       </ix:nonfraction>
       <ix:nonfraction id="hidden-fact-104" unitref="usdPershares" xsi:nil="true">
       </ix:nonfraction>
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1166" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:AmendmentFlag" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         false
        </ix:nonnumeric>
       </span>
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1167" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:DocumentFiscalPeriodFocus" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         FY
        </ix:nonnumeric>
       </span>
       <span>
        <ix:nonnumeric contextref="c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" hover-taxonomy="false" id="fact-identifier-1168" inside-table="false" isadditionalitemsonly="true" isamountsonly="false" iscalculationsonly="false" iscustomonly="false" isnegativesonly="false" isstandardonly="true" istextonly="true" name="dei:EntityCentralIndexKey" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" selected-taxonomy="false" tabindex="18">
         0001410098
        </ix:nonnumeric>
       </span>
      </ix:hidden>
      <ix:references>
       <link:schemaref xlink:href="crmd-20201231.xsd" xlink:type="simple">
       </link:schemaref>
      </ix:references>
      <ix:resources>
       <xbrli:context id="c0">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c1">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2021-03-25
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c2">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-06-30
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c3">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c4">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c5">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c6">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2018-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c7">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:PreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2018-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c8">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AccumulatedOtherComprehensiveIncomeMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2018-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c9">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AdditionalPaidInCapitalMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2018-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c10">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:RetainedEarningsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2018-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c11">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2018-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c12">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c13">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AdditionalPaidInCapitalMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c14">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:PreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c15">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AccumulatedOtherComprehensiveIncomeMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c16">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:RetainedEarningsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c17">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c18">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:PreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c19">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AccumulatedOtherComprehensiveIncomeMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c20">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AdditionalPaidInCapitalMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c21">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:RetainedEarningsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c22">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c23">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:PreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c24">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AccumulatedOtherComprehensiveIncomeMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c25">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AdditionalPaidInCapitalMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c26">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:RetainedEarningsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c27">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c28">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:PreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c29">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AccumulatedOtherComprehensiveIncomeMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c30">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:AdditionalPaidInCapitalMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c31">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:RetainedEarningsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c32">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-02-27
         </xbrli:startdate>
         <xbrli:enddate>
          2019-03-26
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c33">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
           us-gaap:SubsequentEventMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2021-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2021-03-30
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c34">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="crmd:TermDepositsAxis">
           crmd:FirstInstancesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c35">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="crmd:TermDepositsAxis">
           crmd:SecondInstancesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c36">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
           us-gaap:SubsequentEventMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2021-01-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c37">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2014-08-01
         </xbrli:startdate>
         <xbrli:enddate>
          2014-08-14
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c38">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c39">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c40">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c41">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c42">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c43">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c44">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c45">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c46">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c47">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c48">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:USGovernmentAgenciesDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c49">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:USGovernmentAgenciesDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c50">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c51">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c52">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c53">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c54">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c55">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c56">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c57">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c58">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c59">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c60">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c61">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c62">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c63">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c64">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c65">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c66">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c67">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c68">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c69">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c70">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c71">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c72">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c73">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:MoneyMarketFundsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c74">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:USGovernmentAgenciesDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c75">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:USGovernmentAgenciesDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c76">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:USGovernmentAgenciesDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c77">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c78">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c79">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CorporateDebtSecuritiesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c80">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c81">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c82">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           us-gaap:CommercialPaperMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c83">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c84">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c85">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">
           crmd:SubtotalsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c86">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel1Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c87">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel2Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c88">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
           us-gaap:FairValueInputsLevel3Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c89">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
           srt:EuropeMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c90">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
           srt:EuropeMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c91">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
           pf0:US
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c92">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">
           pf0:US
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbrOGNAJSScJOWK+JGY6rkutyMK1Kpa5ApAqQt9v6EqKMexjRUFUopfS9ulvXicMMXMhwk8+5L6YHhngoNqJnP1uRYZGlnQ5/7wdnFbXMijNK52NQT/VJaYRJGXV0ZZtNW1RCsxCXAhI3+DW0D6kTGCUSWRO/YNyEJt874pqeChsTfocgJw76KLMTmmYg4i7DM=] CSR-->
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c93">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
           us-gaap:FurnitureAndFixturesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c94">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
           us-gaap:LeaseholdImprovementsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c95">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
           us-gaap:ComputerEquipmentMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c96">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
           us-gaap:ComputerSoftwareIntangibleAssetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c97">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:SeriesCPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c98">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:SeriesCPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c99">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:SeriesEPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c100">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:SeriesEPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c101">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:SeriesGPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c102">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:SeriesGPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c103">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:RestrictedStockUnitsRSUMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c104">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:RestrictedStockUnitsRSUMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c105">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           crmd:SharesIssuableForPaymentOfDeferredBoardCompensationMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c106">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           crmd:SharesIssuableForPaymentOfDeferredBoardCompensationMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c107">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:WarrantMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c108">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:WarrantMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c109">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:StockOptionMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c110">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:StockOptionMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c111">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-08-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-08-14
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c112">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">
           crmd:SeniorSecuredConvertibleNoteMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2018-12-01
         </xbrli:startdate>
         <xbrli:enddate>
          2018-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c113">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">
           crmd:SeniorSecuredConvertibleNoteMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2018-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c114">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:WarrantMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2013-05-01
         </xbrli:startdate>
         <xbrli:enddate>
          2013-05-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c115">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ShortTermDebtTypeAxis">
           crmd:SeniorSecuredConvertibleNoteMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2013-05-01
         </xbrli:startdate>
         <xbrli:enddate>
          2013-05-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c116">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2018-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2018-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c117">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           pf0:US
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c118">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           pf0:US
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c119">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           us-gaap:ForeignCountryMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c120">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           us-gaap:ForeignCountryMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c121">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           crmd:FederalMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c122">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           crmd:FederalMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c123">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           crmd:StateMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c124">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           crmd:StateMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c125">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           us-gaap:ForeignCountryMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c126">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="dei:EntityByLocationAxis">
           us-gaap:ForeignCountryMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c127">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:WarrantMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2018-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2018-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c128">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
           us-gaap:ConvertibleDebtMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c129">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2014-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2014-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c130">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-09-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-09-16
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c131">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-07-30
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c132">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-07-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-07-30
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c133">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">
           crmd:underwritersMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-07-30
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c134">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2018-03-01
         </xbrli:startdate>
         <xbrli:enddate>
          2018-03-09
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c135">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-11-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-11-30
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c136">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
           us-gaap:RestrictedStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c137">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
           us-gaap:RestrictedStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c138">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
           us-gaap:RestrictedStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c139">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
           us-gaap:RestrictedStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c140">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
           crmd:SeriesFStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2017-11-01
         </xbrli:startdate>
         <xbrli:enddate>
          2017-11-09
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c141">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-08-14
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c142">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesGPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-08-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-08-14
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c143">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-08-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-08-14
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c144">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:CommonStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-08-14
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c145">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesFPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-08-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-08-14
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c146">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:ConvertiblePreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c147">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           crmd:SeriesC3NonVotingPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c148">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           crmd:SeriesC3PreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c149">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">
           srt:MaximumMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c150">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesEPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c151">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesEPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c152">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           crmd:SeriesGVotingConvertiblePreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c153">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           crmd:SeriesGVotingConvertiblePreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c154">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-11-26
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c155">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
           crmd:TwoThousandNineteenMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c156">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">
           crmd:TwoThousandThirteenPlanMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c157">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           crmd:EmployeesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c158">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           crmd:nonemployeesMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c159">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           crmd:WarrantsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2018-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2018-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c160">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">
           srt:MaximumMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-09-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-09-25
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c161">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">
           srt:MinimumMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-09-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-09-25
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c162">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-09-25
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c163">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-09-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-09-25
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c164">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-12-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c165">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">
           us-gaap:WarrantMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c166">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           crmd:SeriesC3Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c167">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           crmd:SeriesC3Member
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c168">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesEPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c169">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesGPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2020-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c170">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesGPreferredStockMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:instant>
          2019-12-31
         </xbrli:instant>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c171">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">
           us-gaap:OptionMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c172">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">
           srt:MinimumMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c173">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">
           srt:MinimumMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c174">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:RangeAxis">
           srt:MaximumMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c175">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">
           crmd:WarrantsMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c176">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersOneMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c177">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersOneMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c178">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">
           us-gaap:AccountsReceivableMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c179">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">
           us-gaap:AccountsReceivableMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c180">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c181">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersOneMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c182">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersTowMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2020-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2020-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c183">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c184">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersOneMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c185">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersTowMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c186">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersThreeMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c187">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="srt:MajorCustomersAxis">
           crmd:CustomersFourMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
           us-gaap:SalesRevenueNetMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2019-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2019-12-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c188">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
           us-gaap:SubsequentEventMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2021-02-01
         </xbrli:startdate>
         <xbrli:enddate>
          2021-02-05
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c189">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
           us-gaap:SubsequentEventMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2021-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2021-03-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c190">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">
           us-gaap:SeriesGPreferredStockMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
           us-gaap:SubsequentEventMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2021-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2021-03-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:context id="c191">
        <xbrli:entity>
         <xbrli:identifier scheme="http://www.sec.gov/CIK">
          0001410098
         </xbrli:identifier>
         <xbrli:segment>
          <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityNameAxis">
           us-gaap:NewJerseyDivisionOfTaxationMember
          </xbrldi:explicitmember>
          <xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">
           us-gaap:SubsequentEventMember
          </xbrldi:explicitmember>
         </xbrli:segment>
        </xbrli:entity>
        <xbrli:period>
         <xbrli:startdate>
          2021-01-01
         </xbrli:startdate>
         <xbrli:enddate>
          2021-03-31
         </xbrli:enddate>
        </xbrli:period>
       </xbrli:context>
       <xbrli:unit id="shares">
        <xbrli:measure>
         xbrli:shares
        </xbrli:measure>
       </xbrli:unit>
       <xbrli:unit id="usd">
        <xbrli:measure>
         iso4217:USD
        </xbrli:measure>
       </xbrli:unit>
       <xbrli:unit id="usdPershares">
        <xbrli:divide>
         <xbrli:unitnumerator>
          <xbrli:measure>
           iso4217:USD
          </xbrli:measure>
         </xbrli:unitnumerator>
         <xbrli:unitdenominator>
          <xbrli:measure>
           xbrli:shares
          </xbrli:measure>
         </xbrli:unitdenominator>
        </xbrli:divide>
       </xbrli:unit>
       <xbrli:unit id="eur">
        <xbrli:measure>
         iso4217:EUR
        </xbrli:measure>
       </xbrli:unit>
       <xbrli:unit id="pure">
        <xbrli:measure>
         xbrli:pure
        </xbrli:measure>
       </xbrli:unit>
      </ix:resources>
     </ix:header>
    </div>
   </div>
  </div>
 </div>
</body>